JP2019089711A - Oxadiazole compound and application thereof - Google Patents

Abstract

To provide an oxadiazole compound having excellent controlling activities against a pest.SOLUTION: There is provided a compound represented by the formula (I). [A represents a single bond, ORor O; m represents an integer of 0 to 3; X represents a single bond, CRR, NRor O; Rto Reach independently represent H, a substituted/unsubstituted alkyl, an alkoxy or the like; Rrepresents a substituted/unsubstituted alkyl, a phenyl, H or the like; n represents an integer of 0 to 2; Q represents O, NR, N-CN, N-NOor the like; Rrepresents a substituted/unsubstituted alkyl, H or the like; G represents a benzene ring, a furan ring or the like; Y represents a cycloalkyl, a phenyl, CRRRor the like; Rto Reach independently represent a substituted/unsubstituted alkyl, a heterocycle, H or the like.]SELECTED DRAWING: None

Description

  The present invention relates to oxadiazole compounds and their uses.

で示される化合物等が記載されている。 Patent Document 1 describes the following formula as a medical use

The compound etc. which are shown by are described.

International Publication No. 2013/008162

An object of the present invention is to provide a compound having excellent control activity against pests.

〔式中、
Ａは、単結合、ＮＲ¹又は酸素原子を表し、
ｍは、０〜３のいずれかを表し、
Ｒ¹は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基又は水素原子を表し、
Ｘは、単結合、ＣＲ⁴Ｒ⁵、ＮＲ⁶又は酸素原子を表し、
Ｒ²、Ｒ³、Ｒ⁴及びＲ⁵は、各々独立して、群Ａより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、群Ｂより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよいピリジル基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、水素原子、ハロゲン原子、若しくはシアノ基を表すか、又はＲ²及びＲ³は、それらが結合する炭素原子と一緒になって３−６員環を形成していてもよく（該３−６員環は群Ｄより選ばれる１以上の置換基を有していてもよい）、ｍが２又は３である場合、複数のＲ²及びＲ³は同一でも異なっていてもよく、
Ｒ⁶は、群Ａより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよい５員芳香族ヘテロ環基、群Ｄより選ばれる１以上の置換基を有していてもよい６員芳香族ヘテロ環基又は水素原子を表し、
ｎは、０、１又は２を表し、
Ｑは、酸素原子、ＮＲ⁷、Ｎ−ＣＮ、Ｎ−ＮＯ₂、Ｎ−Ｃ（Ｏ）Ｒ⁷、Ｎ−Ｃ（Ｏ）ＯＲ⁷又はＮ−Ｓ（Ｏ）₂Ｒ⁷を表し（ｎが２の場合、２つのＱは同一でも異なっていてもよい）
Ｒ⁷は、ハロゲン原子及びシアノ基からなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基又は水素原子を表し、
Ｇは、チオフェン環、フラン環、イミダゾール環、オキサゾール環、イソオキサゾール環、チアゾール環、オキサジアゾール環、チアジアゾール環、ピリジン環、ピラジン環、ピリダジン環、ピリミジン環又はベンゼン環｛該チオフェン環、該フラン環、該イミダゾール環、該オキサゾール環、該イソオキサゾール環、該チアゾール環、該ピリジン環、該ピラジン環、該ピリダジン環、及び該ピリミジン環は、群Ｄより選ばれる１以上の置換基を有していてもよい。また、ｎが０の場合、該ベンゼン環は群Ｉより選ばれる１以上の置換基を有していてもよく、ｎが１又は２の場合、該ベンゼン環は群Ｄより選ばれる１以上の置換基を有していてもよい｝を表し、
Ｙは、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよい５員芳香族ヘテロ環基、群Ｇより選ばれる１以上の置換基を有していてもよい６員芳香族ヘテロ環基、群Ｄより選ばれる１以上の置換基を有していてもよい３−６員非芳香族ヘテロ環基、ＣＲ⁸Ｒ⁹Ｒ¹⁰、ＮＲ¹¹Ｒ¹²又はＯＲ¹³を表し、
Ｒ⁸、Ｒ⁹及びＲ¹⁰は、各々独立して、群Ａ及び群Ｆからなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、群Ｂより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基、水素原子、ハロゲン原子又はシアノ基を表し、
Ｒ¹¹及びＲ¹²は、各々独立して、群Ｅ及び群Ｆからなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基若しくは水素原子を表すか、又はＲ¹¹とＲ¹²とは、互いに結合して３−８員ヘテロ環（該３−８員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）を形成していてもよく、
Ｒ¹³は、群Ａ及び群Ｆからなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｄより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基又は水素原子を表し、
ＸがＣＲ⁴Ｒ⁵であり、ＹがＣＲ⁸Ｒ⁹Ｒ¹⁰である場合、Ｒ⁴とＲ⁸とは、互いに結合して５−７員ヘテロ環を形成していてもよく（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）、
ＸがＣＲ⁴Ｒ⁵であり、ＹがＮＲ¹¹Ｒ¹²である場合、Ｒ⁴とＲ¹¹とは、互いに結合して５−７員ヘテロ環を形成していてもよく（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）、
ＸがＣＲ⁴Ｒ⁵であり、Ｙが、ＯＲ¹³である場合、Ｒ⁴とＲ¹³とは、互いに結合して５−７員ヘテロ環を形成していてもよく（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）、
ＸがＮＲ⁶であり、ＹがＣＲ⁸Ｒ⁹Ｒ¹⁰である場合、Ｒ⁶とＲ⁸とは、互いに結合して５−７員ヘテロ環を形成していてもよく（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）、
ＸがＮＲ⁶であり、ＹがＮＲ¹¹Ｒ¹²である場合、Ｒ⁶とＲ¹¹とは、互いに結合して５−７員ヘテロ環を形成していてもよく（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）、
ＸがＮＲ⁶であり、Ｙが、ＯＲ¹³である場合、Ｒ⁶とＲ¹³とは、互いに結合して５−７員ヘテロ環を形成していてもよい（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）。
群Ａ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｈより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基、ハロゲン原子、ニトロ基及びシアノ基からなる群。
群Ｂ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｈより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基、ハロゲン原子、ニトロ基及びシアノ基からなる群。
群Ｃ：ハロゲン原子、ニトロ基、及びシアノ基からなる群。
群Ｄ：群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニルオキシ基、ハロゲン原子、シアノ基、及びニトロ基からなる群。
群Ｅ：群Ｃより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｈより選ばれる１以上の置換基を有していてもよい５−６員芳香族ヘテロ環基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニルオキシ基及びハロゲン原子からなる群。
群Ｆ：群Ｃより選ばれる１以上の置換基を有していてもよいＣ２−Ｃ７アルキルカルボニルアミノ基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキルアミノカルボニル基、群Ｃより選ばれる１以上の置換基を有していてもよいジ（Ｃ１−Ｃ６アルキル）アミノカルボニル基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキルスルホニルアミノ基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキルアミノスルホニル基及び群Ｃより選ばれる１以上の置換基を有していてもよいジ（Ｃ１−Ｃ６アルキル）アミノスルホニル基からなる群。
群Ｇ：群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニルオキシ基、ハロゲン原子、及びニトロ基からなる群。
群Ｈ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、ハロゲン原子及びシアノ基からなる群。
群Ｉ：群Ｃより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、群Ｃより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルチオ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニルオキシ基、フッ素原子及びシアノ基からなる群。〕
で示される化合物（以下、本発明化合物と記す）。
〔２〕 Ａが単結合であり、ｍが０であり、
Ｇがベンゼン環又はピリジン環（該ベンゼン環及び該ピリジン環は１以上のフッ素原子を有していてもよい）であり、
Ｘが単結合又はＮＲ⁶であり、
Ｑが酸素原子、ＮＨ、Ｎ−ＣＮ、Ｎ−Ｃ（Ｏ）Ｒ⁷又はＮ−Ｃ（Ｏ）ＯＲ⁷であり、
Ｒ⁷がＣ１−Ｃ６アルキル基であり、
Ｙが１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、１以上のハロゲン原子を有していてもよいフェニル基、ＣＲ⁸Ｒ⁹Ｒ¹⁰又はＮＲ¹¹Ｒ¹²であり、
Ｒ⁶がＣ１−Ｃ６アルキル基（該Ｃ１−Ｃ６アルキル基は、ハロゲン原子、Ｃ１−Ｃ６アルコキシ基、Ｃ１−Ｃ６アルキルチオ基、Ｃ３−Ｃ６シクロアルキル基及びフェニル基からなる群より選ばれる１以上の置換基を有していてもよい）、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、フェニル基（該フェニル基はハロゲン原子、Ｃ１−Ｃ６アルキル基又はＣ１−Ｃ６アルコキシ基からなる群より選ばれる１以上の置換基を有していてもよい）又は水素原子であり、
Ｒ⁸、Ｒ⁹及びＲ¹⁰が、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、フェニル基、水素原子又はハロゲン原子であり、
Ｒ¹¹及びＲ¹²が、各々独立して、水素原子又はＣ１−Ｃ６アルキル基であり、
Ａが、Ｇにあたるベンゼン環又はピリジン環上で、オキサジアゾール環に対してパラ位に結合している〔１〕に記載の化合物。
〔３〕 Ａが単結合であり、ｍが０であり、
Ｇがベンゼン環又はピリジン環であり（該ベンゼン環及び該ピリジン環は１以上のフッ素原子を有していてもよい）、
Ｘが単結合又はＮＲ⁶であり、
Ｑが酸素原子、ＮＨ又はＮ−ＣＮであり、
Ｙが１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、ＣＲ⁸Ｒ⁹Ｒ¹⁰又はＮＲ¹¹Ｒ¹²であり、
Ｒ⁶が１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基又は水素原子であり、
Ｒ⁸、Ｒ⁹及びＲ¹⁰が、各々独立して１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基又は水素原子であり、
Ｒ¹¹及びＲ¹²が、各々独立してＣ１−Ｃ６アルキル基（該Ｃ１−Ｃ６アルキル基はハロゲン原子、Ｃ３−Ｃ６シクロアルキル基及びＣ１−Ｃ６アルコキシ基からなる群より選ばれる１以上の置換基を有していてもよい）、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基若しくは水素原子であるか、又はＲ¹¹とＲ¹²とが互いに結合して３−６員ヘテロ環（該３−６員ヘテロ環は１以上のハロゲン原子を有していてもよい）を形成している、〔１〕又は〔２〕に記載の化合物。
〔４〕 Ｇが１以上のフッ素原子を有していてもよいベンゼン環であり、
Ｙが１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基又はＣＲ⁸Ｒ⁹Ｒ¹⁰である、〔１〕〜〔３〕のいずれかに記載の化合物。
〔５〕 Ｇが１以上のフッ素原子を有していてもよいベンゼン環であり、Ｘが単結合であり、ＹがＣＲ⁸Ｒ⁹Ｒ¹⁰である、〔１〕〜〔４〕のいずれかに記載の化合物。
〔６〕 Ｇが１以上のフッ素原子を有していてもよいベンゼン環であり、ＸがＮＲ⁶であり、ｎが２であり、Ｑが酸素原子であり、ＹがＣＲ⁸Ｒ⁹Ｒ¹⁰又は１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基である、〔１〕〜〔４〕のいずれかに記載の化合物。
〔７〕 Ｇが１以上のフッ素原子を有していてもよいベンゼン環であり、Ｘが単結合であり、ｎが２であり、Ｑが酸素原子であり、ＹがＮＲ¹¹Ｒ¹²である、〔１〕〜〔３〕のいずれかに記載の化合物。
〔８〕 〔１〕〜〔７〕のいずれかに記載の化合物を含有する有害生物防除剤（以下、本発明防除剤とも記す）。
〔９〕 〔１〕〜〔７〕のいずれかに記載の化合物の有効量を植物又は土壌に処理することによる、有害生物の防除方法。
〔１０〕 有害生物を防除するための〔１〕〜〔７〕のいずれかに記載の化合物の使用。
〔１１〕 殺菌剤、殺虫剤、殺ダニ剤、殺センチュウ剤、植物成長調節剤及び共力剤からなる群より選ばれる１以上、並びに、〔１〕〜〔７〕いずれかに記載の化合物を含有する組成物。 As a result of examining to find a compound having an excellent controlling effect on pests, the present inventor has found that a compound represented by the following formula (I) has an excellent controlling effect on pests.
That is, the present invention is as follows.
[1] Formula (I)

[In the formula,
A represents a single bond, NR ¹ or an oxygen atom,
m represents any of 0 to 3;
R ¹ represents a C1-C6 alkyl group optionally having one or more halogen atoms or a hydrogen atom,
X represents a single bond, CR ⁴ R ⁵ , NR ⁶ or an oxygen atom,
R ² , R ³ , R ⁴ and R ⁵ are each independently a C 1 -C 6 alkyl group optionally having one or more substituents selected from group A, one or more substituents selected from group B A C1-C6 alkoxy group which may have a group, a phenyl group which may have one or more substituents selected from group D, and one or more substituents selected from group D A pyridyl group, a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, a hydrogen atom, a halogen atom, or a cyano group, or R ² and R ³ M may be taken together with the carbon atom to which it is attached to form a 3- to 6-membered ring (the 3- to 6-membered ring may have one or more substituents selected from Group D), m When is 2 or 3, the plurality of R ² and R ³ may be the same or different,
R ⁶ is a C 1 -C 6 alkyl group which may have one or more substituents selected from group A, a C 3 -C 6 alkenyl group which may have one or more halogen atoms, one or more halogen atoms C 3 -C 6 alkynyl group which may have one or more substituents, C 1 -C 6 alkoxy group which may have one or more halogen atoms, C 3-which may have one or more substituents selected from group D A C6 cycloalkyl group, a phenyl group optionally having one or more substituents selected from group D, a 5-membered aromatic heterocyclic group optionally having one or more substituents selected from group D, A 6-membered aromatic heterocyclic group or a hydrogen atom which may have one or more substituents selected from group D,
n represents 0, 1 or 2;
Q represents an oxygen atom, NR ⁷ , N-CN, N-NO ₂ , N-C (O) R ⁷ , N-C (O) OR ⁷ or N-S (O) ₂ R ⁷ (n is In the case of 2, two Q may be the same or different)
R ⁷ represents a C 1 -C 6 alkyl group optionally having one or more substituents selected from the group consisting of a halogen atom and a cyano group, or a hydrogen atom,
G is a thiophene ring, furan ring, imidazole ring, oxazole ring, isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine ring, pyrazine ring, pyridazine ring, pyrimidine ring or benzene ring {the thiophene ring, The furan ring, the imidazole ring, the oxazole ring, the isoxazole ring, the thiazole ring, the pyridine ring, the pyrazine ring, the pyridazine ring, and the pyrimidine ring have one or more substituents selected from group D. It may be done. In addition, when n is 0, the benzene ring may have one or more substituents selected from group I. When n is 1 or 2, the benzene ring is one or more selected from group D. Represents an optionally substituted substituent},
Y is a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, a phenyl group optionally having one or more substituents selected from group D, a group D 5-membered aromatic heterocyclic group optionally having one or more substituents selected, 6-membered aromatic heterocyclic group optionally having one or more substituents selected from group G, from group D Represents a 3- to 6-membered non-aromatic heterocyclic group optionally having one or more substituents, CR ⁸ R ⁹ R ¹⁰ , NR ¹¹ R ¹² or OR ¹³ ,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more substituents selected from the group consisting of Group A and Group F, and one or more halogen atoms C3-C6 alkenyl group which may have, C3-C6 alkynyl group which may have one or more halogen atoms, C1-C6 which may have one or more substituents selected from group B Alkoxy group, C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, phenyl group optionally having one or more substituents selected from group D, group D Represents a 5- to 6-membered aromatic heterocyclic group optionally having one or more substituents, a hydrogen atom, a halogen atom or a cyano group,
R ¹¹ and R ¹² each independently have a C 1 -C 6 alkyl group optionally having one or more substituents selected from the group consisting of Group E and Group F, and one or more halogen atoms A C3-C6 alkenyl group which may be, a C3-C6 alkynyl group which may have one or more halogen atoms, a C1-C6 alkoxy group which may have one or more halogen atoms, a group D C3-C6 cycloalkyl group which may have one or more substituents, phenyl group which may have one or more substituents selected from group D, one or more substituents selected from group D Represents a 5- to 6-membered aromatic heterocyclic group or hydrogen atom which may be possessed, or R ¹¹ and R ¹² are bonded to each other to form a 3- to 8-membered heterocyclic ring (the 3- to 8-membered heterocyclic ring is Form one or more substituents selected from group D) Even if well,
R ¹³ is a C1-C6 alkyl group optionally having one or more substituents selected from the group consisting of Group A and Group F, and a C3-C6 alkenyl group optionally having one or more halogen atoms A C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, one or more selected from group D Or a substituted or unsubstituted phenyl group, a 5-6 membered aromatic heterocyclic group optionally having one or more substituents selected from group D, or a hydrogen atom,
When X is CR ⁴ R ⁵ and Y is CR ⁸ R ⁹ R ¹⁰ , R ⁴ and R ⁸ may be combined with each other to form a 5-7 membered heterocyclic ring (the 7-membered heterocyclic ring may have one or more substituents selected from group D),
When X is CR ⁴ R ⁵ and Y is NR ¹¹ R ¹² , R ⁴ and R ¹¹ may be combined with each other to form a 5-7 membered heterocyclic ring (the 5-7 membered member) The heterocycle may have one or more substituents selected from group D),
When X is CR ⁴ R ⁵ and Y is OR ¹³ , R ⁴ and R ¹³ may be bonded to each other to form a 5-7 membered hetero ring (the 5-7 membered hetero ring) The ring may have one or more substituents selected from group D),
When X is NR ⁶ and Y is CR ⁸ R ⁹ R ¹⁰ , R ⁶ and R ⁸ may be combined with each other to form a 5-7 membered heterocyclic ring (the 5-7 membered member) The heterocycle may have one or more substituents selected from group D),
When X is NR ⁶ and Y is NR ¹¹ R ¹² , R ⁶ and R ¹¹ may be bonded to each other to form a 5- to 7-membered heterocyclic ring (the 5- to 7-membered heterocyclic ring) And may have one or more substituents selected from group D),
When X is NR ⁶ and Y is OR ¹³ , R ⁶ and R ¹³ may be bonded to each other to form a 5-7 membered heterocycle (the 5-7 membered heterocycle is It may have one or more substituents selected from group D).
Group A: C1-C6 alkoxy group optionally having one or more halogen atoms, C1-C6 alkylthio group optionally having one or more halogen atoms, one or more substituents selected from group C A C3-C6 cycloalkyl group which may have, a phenyl group which may have one or more substituents selected from group H, and one or more substituents selected from group H A group consisting of a 5- to 6-membered aromatic heterocyclic group, a halogen atom, a nitro group and a cyano group.
Group B: C1-C6 alkylthio group optionally having one or more halogen atoms, phenyl group optionally having one or more substituents selected from group H, one or more substituents selected from group H A group comprising a 5- to 6-membered aromatic heterocyclic group which may have a group, a halogen atom, a nitro group and a cyano group.
Group C: a group consisting of a halogen atom, a nitro group, and a cyano group.
Group D: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3 optionally having one or more halogen atoms -C6 alkynyloxy group, C1-C6 alkylthio group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, halogen atom, cyano group, And a nitro group.
Group E: C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A C1-C6 alkylthio group which may have one or more substituents, a phenyl group which may have one or more substituents selected from group H, and one or more substituents selected from group H 5-6 membered aromatic heterocyclic group, C1-C6 alkylsulfonyl group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, and halogen A group of atoms.
Group F: C2 to C7 alkylcarbonylamino group optionally having one or more substituents selected from group C, C1 to C6 alkylamino optionally having one or more substituents selected from group C A carbonyl group, a di (C 1 -C 6 alkyl) aminocarbonyl group optionally having one or more substituents selected from group C, a C 1-optionally having one or more substituents selected from group C A C6 alkylsulfonylamino group, a C1-C6 alkylaminosulfonyl group optionally having one or more substituents selected from group C, and one or more substituents optionally selected from group C The group which consists of a C1-C6 alkyl) aminosulfonyl group.
Group G: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3 optionally having one or more halogen atoms -C6 alkynyloxy group, C1-C6 alkylthio group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, halogen atom, and nitro group A group consisting of
Group H: a group consisting of a C1 to C6 alkyl group optionally having one or more halogen atoms, a C1 to C6 alkoxy group optionally having one or more halogen atoms, a halogen atom and a cyano group.
Group I: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3-C6 alkynyloxy group optionally having one or more halogen atoms, optionally having one or more halogen atoms A group consisting of a C1-C6 alkylthio group, a C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, a fluorine atom and a cyano group. ]
And a compound represented by (hereinafter, referred to as the present compound).
[2] A is a single bond, m is 0,
G is a benzene ring or a pyridine ring (the benzene ring and the pyridine ring may have one or more fluorine atoms),
X is a single bond or NR ⁶ ,
Q is an oxygen atom, NH, N-CN, a N-C (O) R ⁷ or ^{N-C (O) OR 7} ,
R ⁷ is a C1-C6 alkyl group,
Y is a C3-C6 cycloalkyl group which may have one or more halogen atoms, a phenyl group which may have one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² ,
R ⁶ is a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is one or more selected from the group consisting of a halogen atom, a C 1 -C 6 alkoxy group, a C 1 -C 6 alkylthio group, a C 3 -C 6 cycloalkyl group and a phenyl group Optionally substituted), C3-C6 alkynyl group optionally having one or more halogen atoms, C3-C6 cycloalkyl group optionally having one or more halogen atoms, phenyl group (The phenyl group may have one or more substituents selected from the group consisting of a halogen atom, a C1-C6 alkyl group or a C1-C6 alkoxy group) or a hydrogen atom,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more halogen atoms, a phenyl group, a hydrogen atom or a halogen atom,
R ¹¹ and R ¹² are each independently a hydrogen atom or a C 1 -C 6 alkyl group,
The compound according to [1], wherein A is bonded to the benzene ring or pyridine ring corresponding to G at a position para to the oxadiazole ring.
[3] A is a single bond, m is 0,
G is a benzene ring or a pyridine ring (the benzene ring and the pyridine ring may have one or more fluorine atoms),
X is a single bond or NR ⁶ ,
Q is an oxygen atom, NH or N-CN,
Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² ,
R ⁶ is a C 1 -C 6 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
Each of R ¹¹ and R ¹² independently represents a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is a halogen atom, a C 3 -C 6 cycloalkyl group, and a C 1 -C 6 alkoxy group) A C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or a hydrogen atom Or R ¹¹ and R ¹² are bonded to each other to form a 3- to 6-membered heterocyclic ring (the 3- to 6-membered heterocyclic ring may have one or more halogen atoms), [1 Or a compound described in [2].
[4] G is a benzene ring which may have one or more fluorine atoms,
The compound in any one of [1]-[3] whose Y is a C3-C6 cycloalkyl group or CR < ⁸ > R < ⁹ > R < ¹⁰ > which may have one or more halogen atoms.
[5] Any one of [1] to [4], wherein G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, and Y is CR ⁸ R ⁹ R ¹⁰ The compound as described in.
[6] G is a benzene ring which may have one or more fluorine atoms, X is NR ⁶ , n is 2 and Q is an oxygen atom, and Y is CR ⁸ R ⁹ R ¹⁰ Or the compound in any one of [1]-[4] which is the C3-C6 cycloalkyl group which may have one or more halogen atoms.
[7] G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² And the compound in any one of [1]-[3].
[8] A pest control agent containing the compound according to any one of [1] to [7] (hereinafter also referred to as the control agent of the present invention).
[9] A method for controlling a pest by treating a plant or soil with an effective amount of the compound according to any one of [1] to [7].
[10] Use of the compound according to any one of [1] to [7] for controlling pests.
[11] One or more members selected from the group consisting of fungicides, insecticides, acaricides, nematocides, plant growth regulators and synergists, and a compound according to any one of [1] to [7] Composition to contain.

  According to the present invention, pests can be controlled.

The substituents in the present specification will be described.
In the present specification,
When the substituent has two or more halogen atoms, those halogen atoms may be the same or different.
The notation "CX-CY" in the present specification means that the number of carbon atoms is X to Y. For example, the notation "C1-C6" means that the number of carbon atoms is 1 to 6.

The halogen atom represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
As the "alkyl group", for example, methyl group, ethyl group, propyl group, isopropyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, butyl group, isobutyl group, tert- Examples include butyl, pentyl and hexyl.
As the “alkenyl group”, for example, a vinyl group, 1-propenyl group, 2-propenyl group, 1-methyl-1-propenyl group, 1-methyl-2-propenyl group, 1,2-dimethyl-1-propenyl group, 1,1-dimethyl-2-propenyl group, 1-ethyl-1-propenyl group, 1-ethyl-2-propenyl group, 3-butenyl group, 4-pentenyl group and 5-hexenyl group can be mentioned.
As the “alkynyl group”, for example, ethynyl group, 1-propynyl group, 2-propynyl group, 1-methyl-2-propynyl group, 1,1-dimethyl-2-propynyl group, 1-ethyl-2-propynyl group, Examples include 2-butynyl group, 4-pentynyl group and 5-hexynyl group.
The “5-6 membered aromatic heterocyclic group” represents a 5-membered aromatic heterocyclic group or a 6-membered aromatic heterocyclic group, and the 5-membered aromatic heterocyclic group represents a pyrrolyl group, a furyl group, a thienyl group, Represents a pyrazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an oxadiazolyl group or a thiadiazolyl group, and the 6-membered aromatic heterocyclic group is a pyridyl group, a pyridazinyl group, a pyrimidinyl group or a pyrazinyl group Represents

In the compound of the present invention, a compound in which R ² and R ³ together with the carbon atom to which they are bonded form a 3- to 6-membered ring represents any of the structures shown in the following (ZA1 to ZA4).

In NR ¹¹ R ¹² , the 3-8 membered heterocyclic ring formed by combining R ¹¹ and R ¹² with each other represents any of the structures shown in (ZB 1 to ZB 21) below (● represents the bonding position: Represent).

In NR ¹¹ R ¹² , the 3- to 6-membered heterocyclic ring formed by combining R ¹¹ and R ¹² with each other represents any of the structures shown in the following (ZB 1 to ZB 4 and ZB 7 to ZB 21) (● Represents a bonding position).

When X is CR ⁴ R ⁵ and Y is CR ⁸ R ⁹ R ¹⁰ , the 5- to 7-membered heterocycle formed by bonding R ⁴ and R ⁸ to each other is the following (ZC1 to ZC3): Represents any of the structures shown in (where ● represents a bonding position).

When X is CR ⁴ R ⁵ and Y is NR ¹¹ R ¹² , the 5-7 membered heterocyclic ring formed by bonding R ⁴ and R ¹¹ to each other is represented by the following (ZD 1 to ZD 3) Represents any structure (● represents a bonding position).

When X is CR ⁴ R ⁵ and Y is OR ¹³ , the 5-7 membered heterocyclic ring formed by bonding R ⁴ and R ¹³ to each other is any of the following (ZE 1 to ZE 3): Represents the structure of the compound (● represents the bonding position).

When X is NR ⁶ and Y is CR ⁸ R ⁹ R ¹⁰ , the 5-7 membered heterocyclic ring formed by bonding R ⁶ and R ⁸ to each other is represented by the following (ZF 1 to ZF 3) Represents any structure (● represents a bonding position).

When X is NR ⁶ and Y is NR ¹¹ R ¹² , the 5-7 membered heterocyclic ring formed by bonding R ⁶ and R ¹¹ to each other is any one of the following (ZG 1 to ZG 4): Represents the structure of (where ● represents a bonding position).

When X is NR ⁶ and Y is OR ¹³ , the 5-7 member saturated heterocycle formed by bonding R ⁶ and R ¹³ to each other is any one of the following (ZH 1 to ZH 3): Represents the structure of (where ● represents a bonding position).

Compounds of the present invention containing one or more asymmetric centers include the respective optical isomers and mixtures containing them in any proportion. In addition, the compound of the present invention containing two or more geometric isomers derived from carbon-carbon double bond, carbon-nitrogen bond, sulfur-oxygen bond, sulfur-nitrogen bond, cyclic structure etc. And mixtures containing them in any proportion.

The compound of the present invention is mixed with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid or benzoic acid to produce an acid addition salt such as hydrochloride, sulfate, nitrate, phosphate, acetate or benzoate. May form.

The following compounds may be mentioned as embodiments of the compound of the present invention.

[Aspect 1] In the compound of the present invention, G is a benzene ring or a pyridine ring (the benzene ring and the pyridine ring may have one or more fluorine atoms), and X is a single bond or NR ⁶ . , Q is an oxygen atom, NH or N-CN, and Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² , R ⁶ is a C1-C6 alkyl group or a hydrogen atom which may have one or more halogen atoms, and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms R ¹¹ and R ¹² each independently represent a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is a halogen atom, a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkyl group; Selected from the group consisting of alkoxy groups C3-C6 alkynyl group optionally having one or more substituents, C3-C6 alkynyl group optionally having one or more halogen atoms, C3-C6 cycloalkyl group optionally having one or more halogen atoms Or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form a 3-6 membered heterocycle (wherein the 3-6 membered heterocycle may have one or more halogen atoms) Compounds that
[Aspect 2] In the compound of the present invention, G is a benzene ring (the benzene ring may have one or more fluorine atoms), X is a single bond or NR ⁶ , and Q is an oxygen atom, NH Or N-CN, Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² , and R ⁶ is one or more halogen atoms A C1 to C6 alkyl group which may have one or more hydrogen atoms, and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms. Or a hydrogen atom, each of R ¹¹ and R ¹² independently being a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is a halogen atom, a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group Even if it has one or more substituents selected Or a C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or a hydrogen atom, or R ¹¹ And R ¹² are bonded to each other to form a 3- to 6-membered heterocyclic ring (the 3- to 6-membered heterocyclic ring may have one or more halogen atoms).
[Aspect 3] In the compound of the present invention, G is a benzene ring (the benzene ring may have one or more fluorine atoms), X is a single bond or NR ⁶ , and Q is an oxygen atom, NH Or N-CN, Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² , and R ⁶ is one or more halogen atoms A C1 to C6 alkyl group which may have one or more hydrogen atoms, and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms, or a C1 to C6 alkyl group which may have one or more halogen atoms; R ¹¹ and R ¹² each independently represent a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a halogen atom, a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group May have one or more substituents. A C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or a hydrogen atom, or R ¹¹ And R ¹² combine with each other to form a 3- to 6-membered heterocyclic ring (wherein the 3- to 6-membered heterocyclic ring may have one or more halogen atoms), and A represents an oxadiazole ring. Compounds that bind to the para or meta position with respect to each other.
[Aspect 4] In the compound of the present invention, G is a benzene ring (the benzene ring may have one or more fluorine atoms), X is a single bond or NR ⁶ , and Q is an oxygen atom, NH Or N-CN, Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² , and R ⁶ is one or more halogen atoms A C1 to C6 alkyl group which may have one or more hydrogen atoms, and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms. Or a hydrogen atom, each of R ¹¹ and R ¹² independently being a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is a halogen atom, a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group Even if it has one or more substituents selected Or a C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or a hydrogen atom, or R ¹¹ And R ¹² combine with each other to form a 3- to 6-membered heterocyclic ring (wherein the 3- to 6-membered heterocyclic ring may have one or more halogen atoms), and A represents an oxadiazole ring. Compounds that bind to or in the para position.
[Aspect 5] In the compound of the present invention, G is a benzene ring, m is 0, X is a single bond or NR ⁶ , Q is an oxygen atom, n is 2 and Y is C 3 -C 6 It is a cycloalkyl group, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² and R ⁶ is a C1-C6 alkyl group optionally having one or more halogen atoms, C3-C6 alkynyl group, C3-C6 cycloalkyl R ⁸ , R ⁹ and R ¹⁰ each independently represent a C 1 -C 6 alkyl group or a hydrogen atom, and R ¹¹ and R ¹² each independently represent a C 1 -C 6 alkyl Compounds wherein A is attached to the benzene ring in a para-position to the oxadiazole ring;
[Aspect 6] In the compound of the present invention, G is a benzene ring, m is 0, X is a single bond or NR ⁶ , Q is an oxygen atom, n is 2 and Y is C3-C6. It is a cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , and R ⁶ is a C 1 to C 6 alkyl group optionally having one or more halogen atoms, a C 3 to C 6 alkynyl group, a C 3 to C 6 cycloalkyl group, or a hydrogen atom Compounds wherein R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded on the benzene ring in the para-position to the oxadiazole ring.

[Aspect 7] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is 1 or more halogen atoms have a C3-C6 cycloalkyl group or a CR ⁸ R ⁹ R ¹⁰ compounds wherein.
[Aspect 8] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is A compound wherein C is a C3 to C6 cycloalkyl group optionally having one or more halogen atoms or CR ⁸ R ⁹ R ¹⁰ , and A is bonded to the para- or meta-position with respect to the oxadiazole ring.
[Aspect 9] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is It is a C3-C6 cycloalkyl group which may have one or more halogen atoms or CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms. A compound wherein the C is a C1 to C6 alkyl group or a hydrogen atom, and A is bonded to the para or meta position with respect to the oxadiazole ring.
[Aspect 10] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is It is a C3-C6 cycloalkyl group which may have one or more halogen atoms or CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ each independently have one or more halogen atoms. A compound wherein the C is a C1 to C6 alkyl group or a hydrogen atom, and A is bonded to a position para to the oxadiazole ring.

[Aspect 11] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is R ⁸ R ⁹ R ¹⁰ , each of R ⁸ , R ⁹ and R ¹⁰ independently being a C 1 -C 6 alkyl group optionally having one or more halogen atoms or a hydrogen atom; A compound bound in the para or meta position to the azole ring.
[Aspect 12] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N—CN, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , Compounds wherein R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded in the para- or meta-position to the oxadiazole ring.
[Aspect 13] In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are Compounds each of which is independently a C1 to C6 alkyl group or a hydrogen atom, and wherein A is bonded to the para- or meta-position to the oxadiazole ring.
Embodiment 14 In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is R ⁸ R ⁹ R ¹⁰ , each of R ⁸ , R ⁹ and R ¹⁰ independently being a C 1 -C 6 alkyl group optionally having one or more halogen atoms or a hydrogen atom; A compound bound in the para-position to the azole ring.

[Aspect 15] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a benzene ring optionally having one or more fluorine atoms, and Y is a CR ⁸ R ⁹ R ^10, independently R ^8, R ⁹ and R ¹⁰ are each a C1-C6 alkyl group or a hydrogen atom, the compound a is attached at the para-position to the oxadiazole ring.
Embodiment 16 In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N—CN, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , Compounds wherein R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded in the para-position to the oxadiazole ring.
[Aspect 17] In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ are Each independently, a compound which is a C1-C6 alkyl group or a hydrogen atom, and in which A is bonded in the para-position to the oxadiazole ring.

Embodiment 18 In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is NR ⁶ , n is 2 and Q is an oxygen atom, and Y is 1 or more halogen atoms have a C3-C6 cycloalkyl group or a CR ⁸ R ⁹ R ¹⁰ compounds wherein.
[Aspect 19] In the compound of the present invention, G may be a benzene ring, X may be NR ⁶ , n may be 2, Q may be an oxygen atom, and Y may have one or more halogen atoms. A compound wherein C is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ and A is bonded to the para- or meta-position to the oxadiazole ring.
[Aspect 20] In the compound of the present invention, G is a benzene ring, X is NR ⁶ , and R ⁶ is a C1-C6 alkyl group optionally having one or more halogen atoms or a hydrogen atom, n Is 2, C is an oxygen atom, and Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ Each independently represents a C1 to C6 alkyl group optionally having one or more halogen atoms, a C3 to C6 alkynyl group, or a hydrogen atom, and A is in the para or meta position with respect to the oxadiazole ring The compound to bind.
[Aspect 21] In the compound of the present invention, G is a benzene ring, X is NR ⁶ , R ⁶ is a C1-C6 alkyl group or a hydrogen atom, n is 2 and Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group, a C 3 -C 6 alkynyl group or a hydrogen atom, The compound which is attached to the para- or meta-position to the oxadiazole ring.

Embodiment 22 In the compound of the present invention, G is a benzene ring, X is NR ⁶ , R ⁶ is a C1-C6 alkyl group or a hydrogen atom, n is 2 and Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group, a C 3 -C 6 alkynyl group or a hydrogen atom, A compound in which p is bonded to the para position relative to the oxadiazole ring.
[Aspect 23] In the compound of the present invention, G is a benzene ring, X is NR ⁶ , R ⁶ is a C1-C6 alkyl group or a hydrogen atom, n is 2 and Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group, a C 3 -C 6 alkynyl group or a hydrogen atom, A compound in which is attached to the meta position relative to the oxadiazole ring.
Embodiment 24 In the compound of the present invention, G is a benzene ring, X is NR ⁶ , R ⁶ is a C1-C6 alkyl group or a hydrogen atom, n is 2 and Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is an oxadiazole ring Compounds that bind to the para position relative to each other.
Embodiment 25 In the compound of the present invention, G is a benzene ring, X is NR ⁶ , R ⁶ is a C1-C6 alkyl group or a hydrogen atom, n is 2 and Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is an oxadiazole ring Compounds that bind to the meta position relative to each other.
Embodiment 26 In the compound of the present invention, C 1 -C 6 alkyl group, C 3 -C 6 alkynyl group, wherein G is a benzene ring, X is NR ⁶ and R ⁶ is optionally substituted by one or more halogen atoms, A C3-C6 cycloalkyl group or a hydrogen atom, n is 2, Q is an oxygen atom, Y is a C3-C6 cycloalkyl group or CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ^10. A compound wherein each of ¹⁰ is independently a C1 to C6 alkyl group or a hydrogen atom, and A is bonded to the benzene ring in a para-position to the oxadiazole ring.
Embodiment 27 In the compound of the present invention, C 1 -C 6 alkyl group, C 3 -C 6 alkynyl group, wherein G is a benzene ring, X is NR ⁶ and R ⁶ is optionally substituted by one or more halogen atoms, A C3-C6 cycloalkyl group or a hydrogen atom, n is 2, Q is an oxygen atom, Y is CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are each independently A compound which is a C1-C6 alkyl group or a hydrogen atom, and in which A is bonded to the benzene ring in a para-position to the oxadiazole ring.

Embodiment 28 In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is The compound which is NR ¹¹ R ¹²
Embodiment 29 In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² each independently represent a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group comprises a halogen atom, a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group C3-C6 alkynyl group optionally having one or more halogen atoms, C3-C6 alkynyl group optionally having one or more halogen atoms, and C3-C3 optionally having one or more halogen atoms A C6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form a 3- to 6-membered heterocyclic ring (the 3- to 6-membered heterocyclic ring may have one or more halogen atoms Good), and A is oxadiazo Compounds that bind to the para or meta position relative to the Le ring.
[Aspect 30] In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group And C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3 to 6 members A compound which forms a hetero ring (wherein the 3- to 6-membered hetero ring may have one or more halogen atoms) and A bonds to the para- or meta-position with respect to the oxadiazole ring.
In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group And C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3 to 6 members A compound which forms a heterocyclic ring (wherein the 3- to 6-membered heterocyclic ring may have one or more halogen atoms), and wherein A is bonded in the para-position to the oxadiazole ring.

Embodiment 32 In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group And C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3 to 6 members A compound which forms a hetero ring (wherein the 3- to 6-membered hetero ring may have one or more halogen atoms), and A bonds to the meta position with respect to the oxadiazole ring.
[Aspect 33] In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² , each of R ¹¹ and R ¹² independently being a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group Or C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form a 3- to 6-membered hetero ring Compounds which form a ring and in which A is bonded to the para- or meta-position to the oxadiazole ring.
[Aspect 34] In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group And C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3 to 6 members A compound which forms a hetero ring and in which A is bonded in the para-position to the oxadiazole ring.
[Aspect 35] In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group And C 3 -C 6 alkynyl group, C 3 -C 6 cycloalkyl group, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3 to 6 members A compound which forms a hetero ring and in which A is bonded to a meta position with respect to the oxadiazole ring.

Embodiment 36 In the compound of the present invention, G is a benzene ring optionally having one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is NR ¹¹ R ¹² wherein R ¹¹ and R ¹² are each independently a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a C 1 -C 6 alkoxy group A compound which is optionally substituted with one or more substituents, a C3 to C6 alkynyl group, a C3 to C6 cycloalkyl group or a hydrogen atom, and wherein A is bonded to the para-position to the oxadiazole ring.
Embodiment 37 In the compound of the present invention, G is a benzene ring, X is a single bond, n is 2, Q is an oxygen atom, Y is NR ¹¹ R ¹² , R ¹¹ and R ^12. Each independently represents a C1-C6 alkyl group (the C1-C6 alkyl group may have one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a C1-C6 alkoxy group And a) a C3 to C6 alkynyl group, a C3 to C6 cycloalkyl group, or a hydrogen atom, wherein A is bonded to a position para to an oxadiazole ring.
[Aspect 38] In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is a NR ¹¹ R ^12, R ¹¹ and R ¹² are each independently one or more C3-C6 cycloalkyl group optionally may C1-C6 alkyl group which may have, or is a hydrogen atom, or R Compounds in which ¹¹ and R ¹² are bonded to each other to form a 3- to 6-membered heterocyclic ring, and A is bonded in the para-position to the oxadiazole ring.
Embodiment 39 In the compound of the present invention, G is a benzene ring, X is a single bond, n is 2, Q is an oxygen atom, Y is NR ¹¹ R ¹² , R ¹¹ and R ^12. Each independently represents a C1-C6 alkyl group optionally having one or more C3-C6 cycloalkyl groups, or a hydrogen atom, or R ¹¹ and R ¹² are bonded to each other to form 3- Compounds which form a 6-membered heterocyclic ring and in which A is bonded to the oxadiazole ring in the para position.

[Aspect 40] In the compound of the present invention, G is a benzene ring which may have one or more fluorine atoms, X is a single bond, n is 2, Q is an oxygen atom, and Y is a NR ¹¹ R ^12, R ¹¹ and R ¹² are each independently, 1 or more C3-C6 cycloalkyl group optionally may be C1-C6 alkyl group or a hydrogen atom has, a is Okisaji A compound bound in the para-position to the azole ring.
Embodiment 41 In the compound of the present invention, G is a benzene ring, X is a single bond, n is 2, Q is an oxygen atom, Y is NR ¹¹ R ¹² , R ¹¹ and R ^12. And each is independently a C1 to C6 alkyl group optionally having one or more C3 to C6 cycloalkyl groups or a hydrogen atom, wherein A is bonded to the para-position to the oxadiazole ring.

Embodiment 42 In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, R ² and R ³ are hydrogen atoms, and Y is CR ⁸ R ⁹ R ¹⁰ Compounds wherein R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded to the para- or meta-position with respect to the oxadiazole ring.
[Aspect 43] In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, R ² and R ³ are hydrogen atoms, and Y is CR ⁸ R ⁹ R ¹⁰ Compounds wherein R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded in the para-position to the oxadiazole ring.
In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, R ² and R ³ are hydrogen atoms, and Y is CR ⁸ R ⁹ R ¹⁰ Compounds wherein R ⁸ , R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is attached to the meta position with respect to the oxadiazole ring.

[Aspect 45] In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring or a pyridine ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and Compounds wherein each R ¹⁰ is independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded in the para-position to the oxadiazole ring;
[Aspect 46] In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a pyridine ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ are Each independently, a compound which is a C1-C6 alkyl group or a hydrogen atom, and in which A is bonded in the para-position to the oxadiazole ring.

Embodiment 47 In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a pyridine ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , Compounds wherein R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded in the para-position to the oxadiazole ring.
[Aspect 48] In the compound of the present invention, X is a single bond, Q is an oxygen atom, NH or N-CN, G is a pyridine ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , Compounds wherein R ⁹ and R ¹⁰ are each independently a C 1 -C 6 alkyl group or a hydrogen atom, and A is bonded to the meta position relative to the oxadiazole ring.
Embodiment 49 In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a pyridine ring, Y is CR ⁸ R ⁹ R ¹⁰ , R ⁸ , R ⁹ and R ¹⁰ are Each independently, a compound which is a C1-C6 alkyl group or a hydrogen atom, and in which A is bonded to a meta position with respect to the oxadiazole ring.
Embodiment 50 In the compound of the present invention, X is a single bond, Q is an oxygen atom, n is 2 and G is a benzene ring, and A is bonded to the para-position to the oxadiazole ring Compound.
In the compound of the present invention, X is a single bond, Q is an oxygen atom, n is 2, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , and A is oxa A compound bound in the para-position to the diazole ring.
Embodiment 52 In the compound of the present invention, X is a single bond, Q is an oxygen atom, G is a benzene ring, Y is CR ⁸ R ⁹ R ¹⁰ , and R ⁸ , R ⁹ and R ¹⁰ are A compound which is a hydrogen atom and in which A is bonded to the oxadiazole ring in the para position.

[Aspect 53] The compound according to any of Aspects 1 to 52, wherein A is a single bond and m is 0.
ASPECT 54 The compound whose A is an oxygen atom in any one of aspects 1-52.
55. A compound according to any one of the preceding embodiments, wherein A is an oxygen atom and m is 1 or 2.
Embodiment 56 A compound according to any of Embodiments 1 to 52, wherein A is an oxygen atom and m is 0.

  Next, the process for producing the compound of the present invention is described.

  The compound of the present invention can be produced by the following production method and the like.

〔式中、記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば、ｎ−ヘキサン、シクロヘキサン、トルエン、キシレン等の炭化水素（以下、炭化水素類と記す。）、ジエチルエーテル、テトラヒドロフラン、１，４−ジオキサン、エチレングリコ−ルジメチルエ−テル、メチルｔｅｒｔ−ブチルエーテル、ジイソプロピルエーテル等のエーテル（以下、エーテル類と記す。）、クロロホルム、ジクロロメタン、クロロベンゼン等のハロゲン化炭化水素（以下、ハロゲン化炭化水素類と記す。）、Ｎ，Ｎ−ジメチルホルムアミド、１，３−ジメチル−２−イミダゾリジノン、Ｎ−メチルピロリドン等のアミド（以下、アミド類と記す。）、酢酸エチル、酢酸メチル等のエステル（以下、エステル類と記す。）、ジメチルスルホキシド等のスルホキシド（以下、スルホキシド類と記す。）、アセトニトリル、プロピオニトリル等のニトリル（以下、ニトリル類と記す。）、水及びこれらの混合物が挙げられる。
反応に用いられる塩基としては例えば、トリエチルアミン、ピリジン、２，２’−ビピリジン、ジアザビシクロウンデセン等の有機塩基（以下、有機塩基類と記す。）、炭酸ナトリウム、炭酸カリウム等の炭酸塩（以下、炭酸塩類と記す。）、炭酸水素ナトリウム、炭酸水素カリウム等の炭酸水素塩（以下、炭酸水素塩類と記す）が挙げられる。
反応には、化合物（Ａ１）１モルに対して、トリフルオロ酢酸無水物が通常１〜１０モルの割合、塩基が通常１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を水と混合した後、有機溶媒で抽出し、有機層を、乾燥、濃縮等の後処理操作に付すことにより本発明化合物を単離することができる。また、反応混合物に水を添加し、析出物をろ取することにより本発明化合物を単離することもできる。 Production method A
The compound of the present invention can be produced by reacting a compound represented by the formula (A1) (hereinafter referred to as compound (A1)) with trifluoroacetic anhydride in the presence of a base.

Wherein the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons such as n-hexane, cyclohexane, toluene and xylene (hereinafter referred to as hydrocarbons), diethyl ether, tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether Ethers such as tellurium, methyl tert-butyl ether and diisopropyl ether (hereinafter referred to as ethers), halogenated hydrocarbons such as chloroform, dichloromethane and chlorobenzene (hereinafter referred to as halogenated hydrocarbons), N, N- Amides such as dimethylformamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone (hereinafter referred to as amides), esters such as ethyl acetate and methyl acetate (hereinafter referred to as esters), Sulfoxide such as dimethyl sulfoxide (hereinafter referred to as sulfo Referred to Sid class.), Acetonitrile, nitriles such as propionitrile (hereinafter, referred to as nitriles.) Water, and mixtures thereof.
Examples of the base used for the reaction include organic bases such as triethylamine, pyridine, 2,2'-bipyridine and diazabicycloundecene (hereinafter referred to as organic bases), carbonates such as sodium carbonate and potassium carbonate Hereinafter, it is described as carbonates), hydrogencarbonates such as sodium hydrogencarbonate and potassium hydrogencarbonate (hereinafter referred to as hydrogencarbonates).
In the reaction, 1 to 10 moles of trifluoroacetic anhydride are generally used, and 1 to 10 moles of a base are usually used, relative to 1 mole of the compound (A1).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the reaction mixture is mixed with water and extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound of the present invention. Alternatively, the compound of the present invention can be isolated by adding water to the reaction mixture and filtering the precipitate.

〔式中、記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、アミド類、エステル類、スルホキシド類、ニトリル類、アルコール、水及びこれらの混合物等が挙げられる。
反応に用いられる酸化剤としては、過酸化水素水、ｍ−クロロ過安息香酸、過ヨウ素酸ナトリウム、過ヨウ素酸カリウム等が挙げられる。
反応には塩基を加えてもよく、塩基としては、炭酸ナトリウム、炭酸カリウム等のアルカリ金属炭酸塩が挙げられる。
反応には添加剤を加えてもよく、例えば、トリフルオロ酢酸、ルテニウム三塩化物・水和物が挙げられる。
化合物（１Ｂ）を製造する際、反応には、化合物（１Ａ）１モルに対して、通常酸化剤が１〜１．９モルの割合、塩基が１〜１０モルの割合、添加剤が０．０１〜１０モルの割合で用いられる。
化合物（１Ｃ）を製造する際、反応には、化合物（１Ａ）１モルに対して、通常酸化剤が２〜１０モルの割合、塩基が１〜１０モルの割合、添加剤が０．０１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を水と混合した後、有機溶媒で抽出し、有機層を、乾燥、濃縮等の後処理操作に付すことにより化合物（１Ｂ）又は化合物（１Ｃ）を単離することができる。また、シリカゲルクロマトグラフィー等により精製することができる。 Manufacturing method B
The compound represented by the formula (1B) (hereinafter referred to as the compound (1B)) or the compound represented by the formula (1C) (hereinafter referred to as the compound (1C)) is a compound represented by the formula (1A) Hereinafter, it can be produced by reacting the compound (1A) with an oxidizing agent.

Wherein the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, sulfoxides, nitriles, alcohols, water, and mixtures thereof.
As an oxidizing agent used for the reaction, hydrogen peroxide water, m-chloroperbenzoic acid, sodium periodate, potassium periodate and the like can be mentioned.
A base may be added to the reaction, and examples of the base include alkali metal carbonates such as sodium carbonate and potassium carbonate.
An additive may be added to the reaction, and examples thereof include trifluoroacetic acid and ruthenium trichloride hydrate.
In the production of compound (1B), the reaction is usually carried out in a proportion of 1 to 1.9 mol of an oxidizing agent, 1 to 10 mol of a base, 0.1 part of an additive or 1 part of a compound (1A). It is used in a proportion of 01 to 10 moles.
In producing the compound (1C), the reaction is usually carried out in a ratio of 2 to 10 moles of an oxidizing agent, 1 to 10 moles of a base, 0.01 to 1 mole of an additive, per 1 mole of the compound (1A) It is used at a rate of 10 moles.
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the reaction mixture is mixed with water and then extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate compound (1B) or compound (1C). Can. It can also be purified by silica gel chromatography or the like.

〔式中、Ｑ¹は、ＣＮ、ＮＯ₂、Ｃ（Ｏ）Ｒ⁷、Ｃ（Ｏ）ＯＲ⁷又はＳ（Ｏ）₂Ｒ⁷を表し、その他の記号は前記と同じ意味を表す。〕 Manufacturing method C
The compound shown by Formula (1E) can be manufactured by making the compound shown by Formula (1D), and an oxidizing agent react. The reaction is carried out according to the method described in Production Method B.

[Wherein, Q ¹ represents CN, NO ₂ , C (O) R ⁷ , C (O) OR ⁷ or S (O) ₂ R ⁷ , and the other symbols have the same meanings as described above. ]

〔式中、記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、アミド類、エステル類、スルホキシド類、ニトリル類、アルコール、水及びこれらの混合物等が挙げられる。
反応に用いられる添加剤としては、ヨードベンゼンジアセテート、ビス（トリフルオロアセトキシ）フェニルヨージド等が挙げられる。
反応には、化合物（１Ａ）１モルに対して、通常シアナミドが１〜１０モルの割合、添加剤が１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を水と混合した後、有機溶媒で抽出し、有機層を、乾燥、濃縮等の後処理操作に付すことにより化合物（１Ｄ１）を単離することができる。 Manufacturing method D
The compound represented by the formula (1D1) (hereinafter referred to as a compound (1D1)) can be produced by reacting the compound (1A) with cyanamide in the presence of an additive.

Wherein the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, sulfoxides, nitriles, alcohols, water, and mixtures thereof.
Examples of the additive used for the reaction include iodobenzene diacetate, bis (trifluoroacetoxy) phenyl iodide and the like.
In the reaction, 1 to 10 moles of cyanamide and 1 to 10 moles of the additive are generally used per 1 mole of the compound (1A).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the reaction mixture is mixed with water and extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate compound (1D1).

〔式中、記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、アミド類、エステル類、ニトリル類、アルコール、水及びこれらの混合物等が挙げられる。
反応に用いられるアミノ化剤としては、アンモニア、ギ酸アンモニウム、カルバミン酸アンモニウム等が挙げられる。
添加剤としては、ヨードベンゼンジアセテート、ビス（トリフルオロアセトキシ）フェニルヨージド等が挙げられる。
反応には、化合物（１Ｂ）１モルに対して、通常アミノ化剤が１〜１０モルの割合、添加剤が１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を濃縮等の後処理操作に付すことにより化合物（１Ｆ）を単離することができる。 Production method E
The compound represented by the formula (1F) (hereinafter referred to as the compound (1F)) can be produced by reacting the compound (1B) with an aminating agent in the presence of an additive.

Wherein the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, alcohols, water and mixtures thereof.
Examples of the aminating agent used for the reaction include ammonia, ammonium formate, ammonium carbamate and the like.
Examples of the additive include iodobenzene diacetate, bis (trifluoroacetoxy) phenyl iodide and the like.
In the reaction, 1 to 10 moles of an aminating agent and 1 to 10 moles of an additive are generally used per 1 mole of a compound (1B).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, compound (1F) can be isolated by subjecting the reaction mixture to post-treatment procedures such as concentration.

〔式中、Ｘ¹は塩素原子、臭素原子、ヨウ素原子、メタンスルホニルオキシ基、トリフルオロメタンスルホニルオキシ基等の脱離基を表し、その他の記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、アミド類、エステル類、ニトリル類、アルコール、水及びこれらの混合物等が挙げられる。
反応に用いられる塩基としては例えば、有機塩基類、炭酸塩類、炭酸水素塩類、及び水素化ナトリウム、水素化カリウム、水素化リチウム等の水素化金属試薬（以下、水素化金属試薬類と記す。）が挙げられる。
反応には通常化合物（１Ｇ１）１モルに対して、化合物（Ｍ１１）が１〜１０モルの割合、塩基が１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を水と混合した後有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（１Ｇ２）を単離することができる。
化合物（Ｍ１１）は、公知であるか、公知の方法に準じて製造することができる。 Manufacturing method F
The compound represented by the formula (1G2) (hereinafter referred to as a compound (1G2)) is a compound represented by the formula (1G1) (hereinafter referred to as a compound (1G1)) and the compound represented by the formula (M11) Hereinafter, it can be produced by reacting the compound (M11)) in the presence of a base.

[Wherein, X ¹ represents a leaving group such as chlorine atom, bromine atom, iodine atom, methanesulfonyloxy group, trifluoromethanesulfonyloxy group and the like, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, alcohols, water and mixtures thereof.
As the base used for the reaction, for example, organic bases, carbonates, hydrogencarbonates and metal hydride reagents such as sodium hydride, potassium hydride and lithium hydride (hereinafter referred to as metal hydride reagents) Can be mentioned.
In the reaction, 1 to 10 moles of Compound (M11) and 1 to 10 moles of Base are usually used per 1 mole of Compound (1G1).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the reaction mixture is mixed with water and then extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (1G2).
Compound (M11) is known or can be produced according to known methods.

〔式中、記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、エステル類及びこれらの混合物等が挙げられる。
反応に用いられるアゾ化合物としては、例えば、アゾジカルボン酸ジエチル、ビス（２−メトキシエチル）ジアゼン−１，２−ジカルボキシレートが挙げられる。
反応には通常化合物（Ａ７）１モルに対して、化合物（Ｍ１２）が１〜１０モルの割合、アゾ化合物が１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を水と混合した後有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（１Ａ１）を単離することができる。
化合物（Ａ７）は、特開昭６３−１６２６８０号公報に記載の方法に準じて製造することができる。 化合物（Ｍ１２）は、公知であるか、公知の方法に準じて製造することができる。 Manufacturing method G
The compound represented by the formula (1A1) (hereinafter referred to as the compound (1A1)) is a compound represented by the formula (A7) (hereinafter referred to as the compound (A7)) and the compound represented by the formula (M12) Hereinafter, it can be produced by reacting the compound (M12)) in the presence of an azo compound.

Wherein the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, esters, and mixtures thereof.
Examples of the azo compound used for the reaction include diethyl azodicarboxylate and bis (2-methoxyethyl) diazene-1,2-dicarboxylate.
In the reaction, 1 to 10 moles of Compound (M12) and 1 to 10 moles of azo compound are usually used per 1 mole of Compound (A7).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the reaction mixture is mixed with water and then extracted with an organic solvent, and the organic layer is subjected to post-treatment procedures such as drying and concentration to isolate the compound (1A1).
Compound (A7) can be produced according to the method described in JP-A-63-162680. Compound (M12) is known or can be produced according to known methods.

〔式中、記号は前記と同じ意味を表す。〕
反応は、例えば国際公開第２００９／０８１８９１号に記載の方法に準じて実施される。 Reference manufacturing method A
The compound (A1) can be produced by reacting a compound represented by the formula (A2) (hereinafter referred to as a compound (A2)) with hydroxylamine.

Wherein the symbols have the same meanings as described above. ]
The reaction is carried out, for example, according to the method described in WO 2009/081891.

〔式中、記号は前記と同じ意味を表す。〕
反応は製造法Ｂに記載の方法に準じて実施される。 Reference manufacturing method B
The compound (A2) can be produced by oxidizing a compound represented by the formula (A3) (hereinafter referred to as a compound (A3)).

Wherein the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method B.

〔式中、Ｙ¹⁰¹はＣ１−Ｃ６アルキル基を表し、Ｍはカリウム、ナトリウム等のアルカリ金属を表し、その他の記号は前記と同じ意味を表す。〕
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、炭化水素類、エーテル類、ハロゲン化炭化水素類、アミド類、エステル類、ニトリル類、アルコール、水及びこれらの混合物等が挙げられる。
反応には、化合物（Ａ４）１モルに対して、化合物（Ｍ１）が通常１〜１０モルの割合で用いられる。
反応温度は通常−２０〜１５０℃の範囲内である。反応時間は通常０．１〜１２０時間の範囲内である。
反応終了後は、反応混合物を抽出及び濃縮、等の後処理操作に付すことにより化合物（Ａ２−１）を単離することができる。
化合物（Ａ４）は、国際公開第２０１２／０５８１３４号に記載の方法に準じて製造することができる。 Reference manufacturing method C
The compound represented by Formula (A2-1) (hereinafter referred to as Compound (A2-1)) is a compound represented by Formula (A4) (hereinafter referred to as Compound (A4)) and Formula (M1). It can be produced by reacting the compound shown (hereinafter referred to as compound (M1)).

[Wherein, Y ¹⁰¹ represents a C 1 -C 6 alkyl group, M represents an alkali metal such as potassium or sodium, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, alcohols, water and mixtures thereof.
In the reaction, the compound (M1) is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (A4).
The reaction temperature is usually in the range of -20 to 150 ° C. The reaction time is usually in the range of 0.1 to 120 hours.
After completion of the reaction, the compound (A2-1) can be isolated by subjecting the reaction mixture to post-treatment procedures such as extraction and concentration.
Compound (A4) can be produced according to the method described in WO 2012/058134.

〔式中、記号は前記と同じ意味を表す。〕
反応は、国際公開第２０１５／００４２８２号に記載の方法に準じて実施される。
化合物（Ａ５）は、国際公開第２０１１／１４２３５６号に記載の方法に準じて製造することができる。
化合物（Ｍ２）は、公知であるか、公知の方法に準じて製造することができる。 Reference manufacturing method D
The compound represented by the formula (A2-2) (hereinafter referred to as the compound (A2-2)) is a compound represented by the formula (A5) (hereinafter referred to as the compound (A5)) and the compound represented by the formula (M2) It can be produced by reacting the compound shown in the presence of a base.

Wherein the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in WO 2015/004282.
Compound (A5) can be produced according to the method described in WO 2011/142356.
Compound (M2) is known or can be produced according to known methods.

〔式中、Ｙ¹¹はＮＲ¹¹Ｒ¹²又はＯＲ¹³を表し、その他の記号は前記と同じ意味を表す。〕
反応は国際公開第２０１３／００８１６２号に記載の方法に準じて実施される。
化合物（Ａ６）は、国際公開第２００７／１４０３１７号に記載の方法に準じて製造することができる。
化合物（Ｍ３）は、公知であるか、公知の方法に準じて製造することができる。 Reference manufacturing method E
The compound represented by the formula (A2-3) (hereinafter referred to as the compound (A2-3)) is a compound represented by the formula (A6) (hereinafter referred to as the compound (A6)) and the formula (M3) It can be produced by reacting the compound shown in the presence of a base.

[Wherein, Y ¹¹ represents NR ¹¹ R ¹² or OR ¹³ and the other symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in WO 2013/008162.
Compound (A6) can be produced according to the method described in WO2007 / 140317.
Compound (M3) is known or can be produced according to known methods.

〔式中、記号は前記と同じ意味を表す。〕
反応はＪｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ， １９４８，ｐ．１５０１−１５０６に記載の方法に準じて製造することができる。
化合物（Ｍ４）は、公知であるか、公知の方法に準じて製造することができる。 Reference manufacturing method F
The compound represented by the formula (A3-1) (hereinafter referred to as the compound (A3-1)) is a compound represented by the formula (A4) (hereinafter referred to as the compound (A4)) and the compound represented by the formula (M4) It can be produced by reacting with a compound shown.

Wherein the symbols have the same meanings as described above. ]
The reaction is described in Journal of the Chemical Society, 1948, p. It can manufacture according to the method as described in 1501-1506.
The compound (M4) is known or can be produced according to known methods.

〔式中、記号は前記と同じ意味を表す。〕
反応は製造法Ｆの方法に準じて実施することができる。
化合物（Ａ８）は、Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ， ２０１６，２６（３）， ｐ７５７−ｐ７６０に記載の方法に準じて製造することができる。 Reference manufacturing method G
The compound represented by the formula (A3-2) (hereinafter referred to as the compound (A3-2)) is a compound represented by the formula (A8) (hereinafter referred to as the compound (A8)) and the compound represented by the formula (M13) It can be produced by reacting the compound shown below (hereinafter referred to as compound (M13)) in the presence of a base.

Wherein the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method of production method F.
Compound (A8) can be produced according to the method described in Bioorganic & Medicinal Chemistry Letters, 2016, 26 (3), p757-p760.

  The control agent of the present invention is usually prepared by mixing the compound of the present invention with a solid carrier, liquid carrier, and / or surfactant, and optionally adding formulation adjuvants such as fixing agents, dispersing agents, stabilizers and the like. Water dispersible granules, water dispersible granules, flowables, granules, dry flowables, emulsions, aqueous solutions, oils, smokes, aerosols, microcapsules, poison baits, resin formulations, shampoos, pastes It is formulated into a preparation, a foam, a carbon dioxide preparation, a tablet, etc. and used. These preparations may be used as processed into mosquito coil, electric mosquito mat, liquid mosquito formula, fuming agent, fumigant, sheet preparation, spot-on agent, oral treatment agent. These preparations contain the compound of the present invention in a weight ratio of usually 0.1 to 99%, preferably 0.2 to 90%.

As a solid carrier, for example, clays (eg, kaolin, diatomaceous earth, fubasami clay, bentonite, acid clay), synthetic hydrous silicon oxide, talcs and other inorganic minerals (eg, sericite, quartz powder, sulfur powder, activated carbon, Fine powders or granules of calcium carbonate, etc. may be mentioned.
Examples of liquid carriers include water, alcohols, ketones (eg, acetone, methyl ethyl ketone, cyclohexanone), aromatic hydrocarbons (eg, benzene, toluene, xylene, ethylbenzene, methyl naphthalene), aliphatic hydrocarbons (eg, For example, n-hexane, kerosene), esters, nitriles, ethers, amides and halogenated hydrocarbons are mentioned.

  As surfactants, for example, alkyl sulfates, alkyl sulfonates, alkyl aryl sulfonates, alkyl aryl ethers and their polyoxyethylene derivatives, polyoxyethylene glycol ethers, polyhydric alcohol esters, sugar alcohol derivatives Can be mentioned.

  Other pharmaceutical auxiliaries include, for example, fixing agents, dispersing agents and stabilizers, and specifically, casein, gelatin, polysaccharides (eg, starch, arabia gum, cellulose derivative, alginic acid), lignin derivative, bentonite, Saccharides, synthetic water-soluble polymers (eg, polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acids), isopropyl acid phosphate, 2,6-di-tert-butyl-4-methylphenol, 2-tert-butyl-4-methoxy Mixtures of phenol and 3-tert-butyl-4-methoxyphenol, vegetable oils, mineral oils, fatty acids or esters thereof, and the like can be mentioned.

In addition, the compound of the present invention may be mixed with an oil such as a mineral oil or a vegetable oil, or with a surfactant or the like to be used for controlling pests. Oils that can be used as a mixture, or surfactants such as Nimbus (registered trademark), Assist (registered trademark), Aureo (registered trademark), Iharol (registered trademark), Silwet L-77 (registered trademark), BreakThru (Breakthrough) Sundance II (registered trademark), Sundance II (registered trademark), Induce (registered trademark), Penetrator (registered trademark), AgriDex (registered trademark), Lutensol A8 (registered trademark), NP-7 (registered trademark), Triton (registered trademark), Nufilm (Registered trademark), Emulgator NP7 (registered trademark), Emulad (registered trademark), TRITON X 45 (registered trademark), AGRAL 90 (registered trademark), AGROTIN (registered trademark), ARPON (registered trademark), EnSpray N (registered trademark) And BANOLE (registered trademark).

As a base material of resin formulation, a vinyl chloride polymer, polyurethane, etc. are mentioned, for example. If necessary, plasticizers such as phthalic acid esters (such as dimethyl phthalate and dioctyl phthalate), adipic acid esters, and stearic acid may be added to these substrates. The resin preparation is obtained by kneading the compound of the present invention in the base using a conventional kneading apparatus and then molding it by injection molding, extrusion molding, press molding or the like, and if necessary, further processes such as molding and cutting Then, it is processed into a resin formulation such as plate, film, tape, net, cord and the like. These resin preparations are processed, for example, as animal collars, animal ear tags, sheet preparations, drawstrings, horticultural posts.
Examples of the base material of poison bait include cereal flour, vegetable oil, sugar, crystalline cellulose, and further, if necessary, antioxidant such as dibutyl hydroxytoluene, nordihydroguaiaretic acid, preservative such as dehydroacetic acid Also, an anti-mistake agent for children and pets such as capsicum powder, a cheese flavor, an onion flavor, a pest-inducing flavor such as peanut oil, etc. are added.

Although the application amount of the control agent of the present invention varies depending on weather conditions, formulation form, application time, application method, application place, application disease, target disease, target pest, target crop, etc., the amount of the compound of the present invention in the control agent of the present invention is The amount is usually 1 to 500 g, preferably ^{2 to} 200 g, per 1000 m ² . Emulsions, wettable powders, suspensions and the like are usually diluted with water and then applied. The concentration of the compound of the present invention after dilution is usually 0.0005 to 2% by weight, preferably 0.005 to It is 2% by weight, and powders and granules are usually applied as they are without dilution.

The method of applying the control agent of the present invention is not particularly limited as long as the compound of the present invention can be applied, but, for example, treatment of plants such as foliage spraying, plant cultivation of soil treatment, etc. Treatment of seeds such as seed disinfection, treatment of harmful arthropods, and the like. In addition, the resin preparation processed into a sheet or string can be treated by a method such as wrapping around a crop, spreading it in the vicinity of a crop, spreading it on stock soil, or the like.
When the control agent of the present invention is treated on the stems and leaves of plants or in the soil where plants are grown, the amount of the compound of the present invention is usually 1 to 500 g per 1000 m ^{2 of} soil. When the seed is treated, the amount of the compound of the present invention in the control agent of the present invention is generally applied in the range of 0.001 to 100 g, preferably 0.01 to 50 g based on 1 kg of the seed.
Emulsions, wettable powders, flowables and the like are usually treated by diluting with water and spraying. In this case, the concentration of the compound of the present invention is usually 0.0005 to 2% by weight. Powders, granules and the like are usually treated as such without dilution.

When the control agent of the present invention is used for controlling harmful arthropods that live in a house, the application amount thereof is usually 0.01 to 10 parts by weight of the present compound per 1 m ² of treated area when treated on a surface. The amount of the compound of the present invention per 1 m ³ of treatment space is usually 0.01 to 500 mg when treated in a space. When the control agent of the present invention is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the compound of the present invention becomes 0.1 to 10000 ppm, and applied. Aerosols, fuming agents, poison bait etc. are applied as they are.

  When the control agent of the present invention is used for ectoparasite control of small animals such as cattle, horses, pigs, sheep, goats, domestic animals for chickens, dogs, cats, rats, mice, etc., known veterinary methods are used. Ru. As a specific method, for the purpose of systemic suppression, for example, a method of administering by tablet, feed mixing, suppository, injection (intramuscular, subcutaneous, intravenous, intraperitoneal, etc.) can be mentioned, and non-systemic For the purpose of suppression, there may be mentioned a method of pour-on treatment or spot-on treatment of spraying oil solution or aqueous solution, a method of washing an animal with a shampoo preparation, or a method of attaching a resin preparation to an animal . The amount of the compound of the present invention when administered to domestic animals or small animals is usually in the range of 0.1 to 1000 mg per 1 kg of animal weight.

  In addition, the control agent of the present invention can be used as a control agent for plant diseases in agricultural land such as fields, paddy fields, lawns, orchards. The compounds of the present invention can control diseases of the agricultural lands in agricultural lands and the like for cultivating the “plants” and the like listed below. In addition, the compound of the present invention can control harmful arthropods of the agricultural land.

Agricultural crops; corn, rice, wheat, barley, rye, oats, sorghum, cotton, soybeans, peanuts, buckwheat, sugar beet, rape, sunflower, sugar cane, tobacco etc. vegetables; solanaceous vegetables (eggplant, tomato, pepper, pepper, potato Etc.), Cucurbitaceae vegetables (cucumber, pumpkin, zucchini, watermelon, melon etc.), Brassicaceae vegetables (Japanese radish, turnip, horseradish, horse mackerel, Chinese cabbage, cabbage, mustard, broccoli, cauliflower etc.) Burdock, sage, artichoke, lettuce, etc., liliaceous vegetables (green onion, onion, garlic, asparagus), pelvic vegetables (carrots, parsley, celery, American buffalo, etc.), lizardaceous vegetables (spinach, swiss etc), perilla Department of vegetables (sesame, mint, basil ), Strawberry, sweet potato, yam, taro, etc., flowers, foliage plants,
Fruits; Fruits (apples, pears, Japanese pears, cullins, quince etc.), Core fruits (momo, plums, nectarines, jujubes, apricots, prunes etc.), citrus fruits (palms, oranges, lemons, limes, grapefruits) Etc), nuts (nuts, walnuts, hazelnuts, almonds, pistachios, cashews, macadamias etc), berries (blueberries, cranberries, blackberries, raspberries etc), grapes, oysters, olives, loquats, bananas, coffee, etc. Date palm, coconut palm, etc.
Trees other than fruit trees; tea, mulberry, flowering trees, street trees (astera, birch, dogwood, eucalyptus, eucalyptus, ginkgo, lilac, maple, oak, poplar, persimmon, perennial, fusarium, plananas, persimmon, perianthus, birch, fir tree, tsuga, nezu, pine Spruce, yew) etc.

  The above plants also include genetically modified crops.

  Examples of pests that can be controlled by the compound of the present invention include, for example, plant pathogens such as filamentous fungi and harmful arthropods. More specifically, the following may be mentioned, but the present invention is not limited thereto.

The plant pathogens include the following.
Rice blast fungus (Magnaporthe grisea), sesame leaf blight (Cochliobolus miyabeanus), sheath blight (Rhizoctonia solani), fool disease (Gibberella fujikuroi), yellow dwarf (Sclerophthora macrospora); wheat powdery mildew (Erysiphe) of wheat graminis), Fusarium head blight (Fusarium graminearum, F. avenaceum, F. culmorum, Microdochium nivale), rust (Puccinia striiformis, P. graminis, P. recondita), scarlet snow rot (Micronectriella nivale, M. majus), Small rot of snowflake (Typhula sp.), Bare broom scrotum (Ustilago tritici), lumber scab (Tilletia caries, T. controversa), eye blight (Pseudocercosporella herpotrichoides), leaf blight (Septoria tritici), blight Disease (Stagonospora nodorum), yellow spot (Pyrenophora tritici-repentis), rhizoctonia spp. Seedling blight (Rhizoctonia solani), blight (Gaeumannomyces graminis); barley powdery mildew (Erysiphe graminis), mildew Fusarium gramine arum, F. avenaceum, F. culmorum, Microdochium nivale), rust (Puccinia striiformis, P. graminis, P. hordei), naked panicle (Ustilago nuda), cloud disease (Rhynchosporium secalis), web spot (Pyrenophora teres) Blight disease (Cochliobolus sativus), leaf blight (Pyrenophora graminea), ramularia disease (Ramularia collo-cygni), seedling blight of rhizoctonia (Rhizoctonia solani); rust of maize (Puccinia sorghi), southern rust Disease (Puccinia polysora), soot disease (Setosphaeria turcica), tropical rust (Physopella zeae), sesame leaf blight (Cochliobolus heterostrophus), anthracnose (Colletotrichum graminicola), gray leaf spot disease (Cercospora zeae-maydis) , Brown spot (Kabatiella zeae), Phaeospha area leaf spot (Phaeosphaeria maydis) diplodia (Stenocarpella maydis, Stenocarpella macrospora), Stochlot's disease (Fusar) ium graminearum, Fusarium verticilioides, Colletotrichum graminicola), black scab (Ustilago maydis); cotton anthracnose (Colletotrichum gossypii), scab (Ramuraria areola), black scab (Alternaria macrospora, A. gossypii), genus Thieliviosis Black root rot disease (Thielaviopsis basicola); coffee rust (Hemileia vastatrix), leaf spot disease (Cercospora coffeicola); rapeseed sclerotia sclerotia (Sclerotinia sclerotiorum), black spot (Alternaria brassicae), root rot (Phoma) lingam); sugar cane rust (Puccinia melanocephala, Puccinia kuehnii), panicle sickness (Ustilago scitaminea); sunflower rust (Puccinia helianthi), downy mildew (Plasmopara halstedii); citrus sweet spot (Diaporthe citri) Disease (Elsinoe fawcetti), fruit rot (Penicillium digitatum, P. italicum), plague (Phytophthora parasitica, Phytophthora citrophthora); apple monilia (Monilinia) mali), rot fungus (Valsa ceratosperma), powdery mildew (Podosphaera leucotricha), spotted leaf rot (Alternaria alternata apple pathotype), scab (Venturia inaequalis), anthracnose (Glomerella cingulata), brown spot (Diplocapon mali) , Botryosmia (Botryosphaeria berengeriana), Plague (Phytophtora cactorum); Scab of the pear (Venturia nashicola, V. pirina), black spot (Alternaria alternata Japanese pear pathotype), red star disease (Gymnosporangium haraeanum); Disease (Monilinia fructicola), scab (Cladosporium carpophilum), Phomopsis rot (Phomopsis sp.); Grape scab (Elsinoe ampelina), late rot (Glomerella cingulata), powdery mildew (Uncinula necator), rust (Phakopsora ampelopsidis), black-lot disease (Guignardia bidwellii), downy mildew (Plasmoparaviticola); anthracnose of oyster (Gloeosporium kaki), leaf disease (Cercospora kaki, Mycosphaerella nawae) Burial anthracnose (Colletotrichum lagenarium), powdery mildew (Sphaerotheca fuliginea), spine blight (Didymella bryoniae), brown spot (Corynespora cassiicola), scab (Fusarium oxysporum), downy mildew (Pseudoperonospora cubensis) , Plague (Phytophthora sp.), Seedling blight (Pythium sp.); Tomato blight (Alternaria solani), leaf blight (Cladosporium fulvum), leaf blight (Pseudocercospora fuligena), plague (Phytophthora infestans), Powdery mildew (Leveillula taurica); eggplant (Phomopsis vexans), powdery mildew (Erysiphe cichoracearum); Brassica cruciferum (Alternaria japonica), white spot (Cercosporella brassicae), clubbing disease (Plasmodiophora) brassicae), downy mildew (Peronospora parasitica); green onion (Puccinia allii); soybean purpura (Cercospora kikuchii), black scab (Elsinoe glycines), black spot disease (Diaporthe phaseolorum var. sojae), Disease (Phakopsora pachyrhizi), brown ring disease (Corynespora cassiicola), anthracnose (Colletotrithum glycines, C. truncatum), leaf blight (Rhizoctonia solani), brown disease (Septoria glycines), spot disease (Cercospora sojina) Nuclear disease (Sclerotinia sclerotiorum), powdery mildew (Microspaera diffusa), stem blight (Phytophthora sojae), downy mildew (Peronospora manshurica), sudden death (Fusarium virguliforme); sclerotiosis of green beans (Sclerotinia sclerotiorum) (Uromyces appendiculatus), Angular mildew (Phaeoisariopsis griseola), Anthracnose (Colletotrichum lindemuthianum); Peanut (Cercospora personata), Brown spot (Cercospora arachidicola), White scab (Sclerotium rolfsii); Blight (Erysiphe pisi); potato blight (Alternaria solani), blight (Phytophthora infestans), green rot (Phytophthora erythropeptica), powdery mildew (Spongospora subterranea f. sp. subterranea), half body wilt (Verticillium albo-atrum, V. dahliae, V. nigrescens); powdery mildew of strawberries (Sphaerotheca humuli); tea scab (Exobasidium reticulatum), scab (Elsinoe leucospila), Rot blotch (Pestalotiopsis sp.), Anthracnose (Colletotrichum theae-sinensis); Tobacco scab (Alternaria longipes), Anthracnose (Colletotrichum tabacum), Downy mildew (Peronospora tabacina), Downy mildew (Phytophthora nicotianae); Sugar beet brown spot (Cercospora beticola), leaf blight (Thanatephorus cucumeris), root rot (Thanatephorus cucumeris), black root disease (Aphanomyces cochlioides); Brown spot of chrysanthemum (Septoria chrysanthemi-indici), white rust (Puccinia horiana); Botrytis of onion (Botrytis cinerea, B. byssoidea, B. squamosa), gray rot (Botrytis alli), small fungus nucleus Sexual rot (Botryt is squamosa); Botrytis cinerea, Sclerotinia sclerotiorum of various crops; Radish radish (Alternaria brassicicola); Dollar spot disease of Shiba (Sclerotinia homoeocarpa), Brown patch disease of Shiva and large Patch disease (Rhizoctonia solani); and Sigatoka disease of bananas (Mycosphaerella fijiensis, Mycosphaerella musicola).
Seed disease or early growth of various crops caused by Aspergillus spp., Penicillium sp., Fusarium sp., Gibberella sp., Tricoderma sp., Thieloviopsis sp., Rhizopus sp., Rhizopus sp., Mucor sp., Corcium sp., Phoma, Rhizoctonia sp., Diplodia sp. Diseases of Virus diseases of various crops that are mediated by Polymyxa or Olpidium etc.
Seedling bacterial blight of rice (Burkholderia plantarii); spotted blight of cucumber (Pseudomonas syringae pv. Lachrymans); blight of eggplant (Ralstonia solanacearum), citrus blight of citrus (Xanthomonas citri); soft rot of Chinese cabbage (Erwinia) carotovora) etc.

The harmful arthropods include the following.
Semi-lepidoptera (Hemiptera): Hemetobiunka (Laodelphax striatellus), Tobiirounka (Nilaparvata lugens), Sejirounka (Sogatella furcifera), Cornflower (Peregrinus maidis), Lobluntia (Javesella pellucida), Black-tailed Ubiclusi Leafhopper family (Delphacidae); green leafhopper (Nephotettix cincticeps), giant leafhopper green leafhopper (Nephotettix virescens), black leafhopper green leafhopper (Nephotettix nigropictus), green leafhopper leafworm (Recilia dorsalis), green leafhopper foliage ), Corn leaf hopper (Dalbulus maidis), white leafhopper (Cofana spectra), etc., leafhopper family (Cicadelidae); Mahanarva posticata, Mahanarva fimbriolata, etc. (Cercopidae); Brash beetle (Aphis fabae), soybean aphid (Aphis glycines), cotton aphid (Aphis gossypii), European apple aphid (Aphis pomi), black-and-white aphid (Aphis spiraecola), green-billed aphid (Myzus persicae), blue-toothed aphid , Radish aphids (brevicoryne brassicae), Rosy apple aphid (Dysaphis plantaginea), imago radish aphids (Lipaphis erysimi), tulip pokeweed aphids (Macrosiphum euphorbiae), potato pokeweed aphids (Macrosiphum euphorbiae), potato pokeweed aphid (Alacorth cichalis). Aphids (Rhopalosiphum padi), corn aphids (Rhopalosiphum maidis), red-handed aphids (Toxoptera citricidus), Peach coptis Aphid (Hyalopterus pruni), bryophytes (Melanaph) Aphididae (Aphididae), such as the black-tailed aphid (Tetranaura nigriabdominalis), the yellow-billed aphid (Ceratovacuna lanigera), and the like (Eriosoma lanigerum); Leaf phylloxera (Phylloxera notabilis), Southern pecan leaf phylloxera (Phylloxera russellae) and other nematode (Phylloxeridae); A rice black bug (Scotinophara lurida), a Malayan rice black bug (Scotinophara coarctata), a green bug (Nezara antennata), a goby bug (Eysarcoris aeneus), a goby bug (Eysarcoris lewisi), a goby beetle (Eysarcoris lewisi), village Blue-headed stink bug (Eysarcoris annamita), Gray-backed bug (Halyomorpha halys), South African stink bug (Nezara viridula), Brown stink bug (Euschistus heros), Red banded stink bug (Piezodorus guildinii), Oebalus pugnax, etc. Brentaridae (Cydnidae), such as Burrower brown bug (Scaptocoris castanea); ;; Helicidae (Coreidae), such as Cletus punctiger, Leptoglossus australis, etc .; Caverelius saccharivorus, Togo hemipterus, Bugs such as Blissus leucopterus) (Lygaeidae); Trichonotidae, such as Trigonotylus caelestialium, Red-handed Tortoise (Stenotus rubrovittatus), Green-winged Tufted Turtle (Stenodema calcarata), Lys-biosis (Lygus linealis) etc. , Bemisia tabaci (Bemisia tabaci), Orange leafworm (Dialeurodes citri), Red-winged leafhopper (Aleurocanthus spiniferus), White-tailed lice (Aleurocanthus camelliae), White-leafed leafworm (Pealius euryae), etc. (Abgrallaspis cyanophylli), Red-backed scale insect (Aonidiella aurantii), Yellow-backed scale insect (Diaspidiotus perniciosus), Red-tailed scale insect (Pseudaulacaspis pentagona), Red-winged scale insect (Unaspis yanonensis), Red-tailed mealybug (Unaspis citri), etc., Marukabidae (Diaspididae); ruby (Ceroplastes rubens), etc., cataclyssidae (Coccidae); Plasmodidae (Margarodidae); Plasmodium (Phenacoccus solani), Plasmodium (Phenacoccus sorenopsis), Plasmodium (Planococcus kraunhiae), Crucifer (Pseudococcus comstocki), Plasmodium (Porococcus) (Pseudococcus calceolariae), mealybug (Pseudococcus longispinus), tutormyri bug (Brevennia rehi), etc. Pseudococcidae (Pseudococcidae); rioza erytreae), Cacopsylla pyrisuga, Cacopsylla prairie (Cacopsylla chinensis), Phytopathidae (Bacterica cockerelli), Pear psylla (Cacopsylla pyricola), etc. Chytichcha marmorata), Stephanitis nashi, Tuftiidae (Stephanitis pyrioides), etc. (Tingidae); .

Lepidoptera insects (Lepidoptera): Nymphs (Chilo suppressalis), Darkheaded stem borer (Chilo polychrysus), White stem borer (Scirpophaga innotata), Itten's tree magnolia (Scirpophaga incertulas), Rupela albina, Kobomeiga (Cinatalitraceitraceitracel Red clover (Marasmia exigua), cotton dwarf (Notarcha derogata), African dwarf (Ostrinia furnacalis), European corn borer (Ostrinia nubilalis), black-legged moth (Hellula undulis), Monquil chronogare (Herpetogramma luctigueta) Rice case worms (Nymphula depunctalis), Sugarcane borer (Diatraea saccharalis), etc. (Cambididae); , Roy Spurge (Spodoptera exigua), Sturgeon (Mythimna separata), Sparrow (Mamestra brassicae), Spurge (Sesamia inferens), Spodoptera mauritia, Phylum oryzae (Naranga aenescens), Spurges exempta), spiny moth (Agrotis ipsilon), spiny eel (Autographa nigrisigna), inykin owava (Plusia festucae), Soybean looper (Chrysodeixis includens), Trichoplusia spp. Helicoverpa armigera), Helicoverpa zea etc. Helicoverpa, Velvetbean caterpillar (Anticarsia gemmatalis), Cotton leafworm (Alabama argillacea), Hop vine borer (Hydraecia immanis) etc. Yagidae (Noctuiipalis); Pae) et al. (Pieridae); Anemonefish (Grapholita molesta), Anemonefish (Grapholita dimorpha), Leguminivora (Leguminivora glycinivorella), Azukisya Mushiga (Matsumuraeses azukivora), Anemone parrotfish (Adoxophycha or Hamaki (Adoxophyes honmai), Chahamaki (Homona magnanima), Midarekamonhamaki (Archips fuscocupreanus), codling moth (Cydia pomonella), Kanshashini Hamami (Tetramoera schistaceana), Bean Shoot Borer (Epinotia aporema) luciferitracit And the like (Coroptilia theivora), and the moth family (Gracillariidae) of the dog moth (Phyllonorycter ringoniella);
(Lyonetia clerkella, Lyonetia prunifoliella, etc .; Lyonetidae); Lymantria dispar, etc. Lymantria, Euproctis pseudoconspersa, etc. ; Pluteliidae such as Plutella xylostella; Pectinidae (Anarsia lineatella); Firefly (Hyphantria cunea) et al. (Arctiidae); Giant Sugarcane borer (Telchin licus) et al. (Castniidae); Family (Geometridae) Black-tailed lizards (Limacodidae) such as Parasa lepida; False-tailed Moths (Stathmopodidae) such as Stathumopoda masinissa, etc .; Sphingidae (Sphingidae) such as Acherontia lachesis; Sevisiidae (Sesiidae); Hesperiidae (Hesperiidae), such as the ladybug Parnara guttata.

  Thysanoptera: Thripsidae (Frankliniella occidentalis), Thrips palmi (Thrips palmi), Chalyss occidentalis (Scirtothrips dorsalis), Locustoids (Thrips tabaci), Philosophis japonicus (Frankliniella intimasite) And Thripidae such as Echinothrips americanus); Thripidae (Phlaeothripidae) such as Haekohrrips aculeatus.

  Diptera: Insect fly (Delia platura), Onion fly (Delia antiqua), etc. Anthomyiidae; Sugar beet rooted magots (Tetanops myopaeformis), etc. A family of freshwater flies such as the tomato leafminer fly (Liriomyza sativae), a bean leafminer fly (Liliomyza trifolii), a leafminer fly (Chromatomyia horticola), and the like; Fruit fly (Bactrocera latifrons), olive fruit fly (Bactrocera oleae), quince fruit fly (Bactrocera tryoni), fruit fly (Ceratitis capitata) and other fruit flies (Tephritidae); Phylogenidae (Ephydridae) such as Hydrellia philippina, Hydrellia sasakii etc .; Drosophila family such as Drosophila melanogaster (Drosophila suzukii); ; Phylogenidae (Psychodidae), such as the great butterfly fly (Clogmia albipunctata); Spermidae (Sciaridae), such as the fly Shrimp (Bradysia divormis), etc .; (Cecidomyiidae); Diopsidae (Diopsidae) such as Diopsis macrophthalma etc .; and Gagobo family (Tipulidae) such as Common cranefly (Tipula oleracea), European cranefly (Tipula paludosa) etc.

  Coleoptera insect pest (Coleoptera): Western corn rootworm (Diabrotica virgifera virgifera), Southern corn rootworm (Diabrotica undecimpunctata howardi), Northern corn rootworm (Diabrotica barberi), Mexican corn rootworm (Diabrotica virgifera zeae), Banded Cucumber Beetle (Diabrotica virgifera zeae) Diabrotica balteata), Cucurbit Beetle (Diabrotica speciosa), Bean Leaf Beetle (Cerotoma trifurcata), Cubial Leaf Beetle (Oulema melanopus), Ground Leaf Beetle (Aulacophora femoralis), Sweet potato leaf beetle (Phyllo tta striola ate leaves) Oulema oryzae), grape coraspis (Colaspis brunnea), corn flare beatle (Chaetocnema pulicaria), sweet potato leaf beetle (Chaetocnema confnis), potato flare beatle (Epitrix cuc) umeris), green leaf beetle (Dicladispa armigera), Grape Colaspis (Colaspis brunnea), southern corn leaf beetle (Myochrous denticollis), pokeweed leaf beetle (Laccoptera quadrimaculata), tobacco leaf beetle (Epitrix hirtipilichidae) Carabidae (Carabidae), such as (Stenolophus lecontei), Slender seedcorn beetle (Clivina impressifrons); Scarabaeidae (Scarabaeidae) such as European Chafer (Rhizotrogus majalis), Black-tailed Beetle (Tomarus gibbosus), Holotrichia sp. coffeae), Arimo Weeping beetle (Cylas formicarius), potato weevil (Euscepes postfasciatus), alfalfa bug (Hypera postica), caterpillar (Sitophilus zeamais), rice weevil (Echinocnemus squameus), rice weevil (Lissoroptrus oryzophilus citivius) Anthonomus grandis), Sphenophorus venatus, Southern Corn Billbug (Sphenophorus callosus), Soyabean stalk weevil (Sternechus subsignatus), Sugarcane weevil (Sphenophorus levis), Sabiphos gossipius ), Brazilian weevil (Zabrotes subfasciatus), Pinus bovis (Tomicus piniperda), Coffee Berry (Hypothenemus hampei) and other weevil families (Curculionidae); Red-tailed beetle (Tribolium confusum) and other beetles (Tenebrionidae); Epilachna vigintioctopunctata such as ladybirds (Coccinellidae); Ptinidae); Longhorn beetles (Anoplophora malasiaca), Migdolus fryanus, etc., Cerambycididae (Cerambycidae); spp., Conoderus spp., Ctenicera spp., Limonius sp., Aeolus sp., and other clickworms (Agriotes sp., Aelous sp., Anchastus sp.) , Melanotus sp., Limonius sp., Conoderus sp., Ctenicera sp.); Staphylinidae (Staphylinidae), such as Paederus fuscipes.

Orthopteran pests (Orthoptera): Toocta grasshopper (Locusta migratoria), Toroca grasshopper (Dociostaurus maroccanus), Australian Tobibatata (Chortoicetes terminifera), Red-footed grasshopper (Nomadacris septemfasciata), Brown Locust (Locustana pallitalucilatio) Italian Locust (Calliptamus italicus), Differential grasshopper (Melanoplus differentialis), Two striped grasshopper (Melanoplus bivittatus), Migratory grasshopper (Melanoplus sanguinipelus), Red-Legged grasshopper (Melh gregaria), Yellow-winged locust (Gastrimargus musicus), Spur-throated locust (Austracris guttulosa), Kobayinago (Oxya yezoensis), Hanekinago (Oxya japonica), Trichoderma japonicus (Patanga succi nectiograms), etc. arientalis) et al. (Gryllotalpidae); European green cricket (Acheta domesticus), Erick's eagle (Teleogrylus emma) et al. (Gryllidae); Mormon cricket (Anabrus simplex) et al.
Hymenoptera pests (Hymenoptera): Aphididae (Athalia rosae), Japanese wasps (Athalia japonica) and other species of the Japanese wasp (Tenthredinidae); Family (Formicidae) etc.

  Cockroach second order (Blattodea): German cockroach (Blattella germanica) and other German cockroaches (Blattellidae); Family (Blattidae); Yamato termites (Reticulitermes speratus), house termites (Coptotermes formosanus), American termites (Incisitermes minor), Dicta termites (Cryptotermes domesticus), Taiwan termites (Odontotermes formosanus), White-spotted termites (Glyptotermes satsumensis), Chinese termite (Glyptotermes nakajimai), Catan termite (Glyptotermes fuscus), Oolongtermite (Hodotermopsis sjostedti), Gl. Loari (Reticulitermes amamianus), Miyatake termite (Reticulitermes miyatakei), Cameroon termite (Reticulitermes kanmonensis), Takasago termite (Nasutitermes takasagoensis), Nitobe termite (Pericapritermes nitobei), Musashi termi (Sinocapritimates) )etc.

  The present invention will be more specifically described below with reference to production examples, reference production examples, formulation examples and test examples, but the present invention is not limited to these examples.

本発明化合物１：¹H-NMR (CDCl₃) δ: 8.09-8.06 (2H, m), 7.48-7.46 (2H, m), 3.73 (2H, s), 2.01 (3H, s). Production Example 1-1
After adding 1.4 mL of trifluoroacetic anhydride to a mixture of 1.7 g of the intermediate (A1a1) described in Reference Production Example 1, 20 mL of N, N-dimethylformamide and 1.4 mL of pyridine at room temperature, 80 ° C. The mixture was heated and stirred for 6 hours. Thereafter, 20 mL of water was added at room temperature, extraction was performed with ethyl acetate, the organic layer was washed with 2N hydrochloric acid, and the organic layer was dried and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 4: 1) to obtain 1.8 g of the present compound 1 shown below.

The present compound 1: ¹ H-NMR (CDCl ₃ ) δ: 8.09-8.06 (2H, m), 7.48-7.46 (2H, m), 3.73 (2H, s), 2.01 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表１］に記載のいずれかの組合せである化合物。
［表１］

本発明化合物１９：¹H-NMR (CDCl₃) δ: 8.08-8.06 (2H, m), 7.49-7.47 (2H, m), 3.78 (2H, s), 2.48-2.43 (2H, m), 1.27-1.22 (3H, m).
本発明化合物３３：¹H-NMR (CDCl₃) δ: 8.07-8.05 (2H, m), 7.50-7.49 (2H, m), 3.80 (2H, s), 2.83-2.78 (1H, m), 1.27 (6H, d, J = 6.5 Hz).
本発明化合物３４：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.53-7.51 (2H, m), 4.18 (2H, s). Production Example 1-2
The compound of the present invention manufactured according to the method described in Production Example 1-1 and the physical properties thereof are shown below.
Formula (1a)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is any combination described in [Table 1].
[Table 1]

The present compound 19: ¹ H-NMR (CDCl ₃ ) δ: 8.08-8.06 (2H, m), 7.49-7.47 (2H, m), 3.78 (2H, s), 2.48-24.43 (2H, m), 1.27 -1.22 (3H, m).
The present compound 33: ¹ H-NMR (CDCl ₃ ) δ: 8.07-8.05 (2H, m), 7.50-7.49 (2H, m), 3.80 (2H, s), 2.83-2 2.78 (1H, m), 1.27 (6H, d, J = 6.5 Hz).
Invention compound 34: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.53-7.51 (2H, m), 4.18 (2H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表２］に記載の組合せである化合物。
［表２］

本発明化合物２：¹H-NMR (CDCl₃) δ: 8.06-8.05 (1H, m), 8.02-8.00 (1H, m), 7.55-7.53 (1H, m), 7.50-7.48 (1H, m), 3.75 (2H, s), 2.02 (3H, s). Formula (1b)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 2].
[Table 2]

The present compound 2: ¹ H-NMR (CDCl ₃ ) δ: 8.06-8.05 (1H, m), 8.02-8.00 (1H, m), 7.55-7.53 (1H, m), 7.50-7.48 (1H, m) , 3.75 (2H, s), 2.02 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹、Ｒ¹⁰、Ｒ²¹及びＲ²²の組合わせが［表３］に記載のいずれかの組合せである化合物。
［表３］

本発明化合物３：¹H-NMR (CDCl₃) δ: 8.20-8.17 (2H, m), 7.61-7.60 (2H, m), 4.34 (2H, s), 2.84 (3H, s).
本発明化合物２１：¹H-NMR (CDCl₃) δ: 8.03-8.01 (1H, m), 7.95-7.93 (1H, m), 7.71-7.68 (1H, m), 4.40 (2H, s), 2.89 (3H, s).
本発明化合物２２：¹H-NMR (CDCl₃) δ: 8.18-8.14 (1H, m), 7.42-7.39 (2H, m), 4.33 (2H, s), 2.88 (3H, s). Formula (1c)

Compounds in which R ⁸ , R ⁹ , R ¹⁰ , R ²¹ and R ²² are in any combination described in [Table 3].
[Table 3]

The present compound 3: ¹ H-NMR (CDCl ₃ ) δ: 8.20-8.17 (2H, m), 7.61-7.60 (2H, m), 4.34 (2H, s), 2.84 (3H, s).
The present compound 21: ¹ H-NMR (CDCl ₃ ) δ: 8.03-8.01 (1H, m), 7.95-7.93 (1H, m), 7.71-7.68 (1H, m), 4.40 (2H, s), 2.89 (3H, s).
Invention compound 22: ¹ H-NMR (CDCl ₃ ) δ: 8.18-8.14 (1H, m), 7.42-7.39 (2H, m), 4.33 (2H, s), 2.88 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表４］に記載の組合せである化合物。
［表４］

本発明化合物４：¹H-NMR (CDCl₃) δ: 8.19 (1H, dt), 8.16-8.16 (1H, m), 7.68 (1H, dt), 7.63-7.60 (1H, m), 4.35 (2H, s), 2.85 (3H, s). Formula (1d)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 4].
[Table 4]

The present compound 4: ¹ H-NMR (CDCl ₃ ) δ: 8.19 (1 H, dt), 8.16-8.16 (1 H, m), 7.68 (1 H, dt), 7.63-7.60 (1 H, m), 4.35 (2 H) , s), 2.85 (3H, s).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表５］に記載のいずれかの組合せである化合物。
［表５］

本発明化合物５：¹H-NMR (CDCl₃) δ: 8.13 (2H, d, J = 8.2 Hz), 7.53 (2H, d, J = 8.2 Hz), 4.72 (1H, s), 4.43 (2H, d, J = 6.1 Hz), 2.94 (3H, s).
本発明化合物２３：¹H-NMR (CDCl₃) δ: 8.14-8.12 (2H, m), 7.54-7.52 (2H, m), 4.64 (1H), 4.40 (2H, d), 3.02 (2H, q), 1.37 (3H, t).
本発明化合物２４：¹H-NMR (CDCl₃) δ: 8.14-8.11 (2H, m), 7.54-7.52 (2H, m), 4.42 (3H, s), 3.14 (1H, t), 1.40 (6H, d).
本発明化合物２５：¹H-NMR (CDCl₃) δ: 8.13-8.11 (2H, m), 7.56-7.53 (2H, m), 4.72 (1H, t), 4.44 (2H, d, J = 6.4 Hz), 2.42-2.35 (1H, m), 1.20-1.16 (2H, m), 0.99-0.94 (2H, m).
本発明化合物３５：¹H-NMR (CDCl₃) δ: 8.14-8.11 (2H, m), 7.53-7.51 (2H, m), 4.46 (1H, br s), 4.40 (2H, d), 2.99-2.95 (2H, m), 1.88-1.82 (2H, m), 1.03 (3H, t).
本発明化合物３６：¹H-NMR (CDCl₃) δ: 8.13-8.11 (2H, m), 7.52 (2H, d), 4.69 (1H, t), 4.40 (2H, d), 3.00-2.96 (2H, m), 1.82-1.74 (2H, m), 1.47-1.37 (2H, m), 0.92 (3H, t).
本発明化合物３７：¹H-NMR (CDCl₃) δ: 8.12 (2H, d), 7.52 (2H, d), 4.72 (1H, t), 4.39 (2H, d), 2.90-2.88 (2H, m), 2.30-2.20 (1H, m), 1.08 (6H, d).
本発明化合物３８：¹H-NMR (DMSO-D₆) δ: 8.06-8.04 (2H, m), 7.80 (1H, s), 7.56-7.54 (2H, m), 7.39-7.37 (5H, m), 4.38 (2H, s), 4.20 (2H, s).
本発明化合物３９：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.58-7.56 (2H, m), 4.51 (2H, s), 2.86 (3H, s), 2.42-2.37 (1H, m), 0.87-0.82 (2H, m), 0.81-0.76 (2H, m).
本発明化合物４０：¹H-NMR (CDCl₃) δ: 8.03-8.01 (2H, m), 7.44 (2H, d, J = 8.2 Hz), 7.36-7.32 (2H, m), 7.30-7.26 (3H, m), 4.93 (2H, s), 2.99 (3H, s).
本発明化合物４１：¹H-NMR (CDCl₃) δ: 8.04-8.01 (2H, m), 7.40-7.37 (2H, m), 7.24-7.15 (4H, m), 4.85 (1H, br s), 4.72 (1H, br s), 3.00 (3H, s), 2.14 (3H, s).
本発明化合物４２：¹H-NMR (CDCl₃) δ: 8.04-8.01 (2H, m), 7.44 (2H, d), 7.23-7.19 (1H, m), 7.10-7.06 (3H, m), 4.91 (2H, s), 2.98 (3H, s), 2.31 (3H, s).
本発明化合物４３：¹H-NMR (CDCl₃) δ: 8.04-8.01 (2H, m), 7.44 (2H, d), 7.16-7.11 (4H, m), 4.90 (2H, s), 2.97 (3H, s), 2.30 (3H, s).
本発明化合物４４：¹H-NMR (CDCl₃) δ: 8.03-8.01 (2H, m), 7.45 (2H, d), 7.32-7.28 (1H, m), 7.20-7.11 (2H, m), 7.07-7.02 (1H, m), 4.88 (2H, s), 3.06 (3H, s).
本発明化合物４５：¹H-NMR (CDCl₃) δ: 8.02-8.00 (2H, m), 7.44 (2H, d), 7.29-7.25 (1H, m), 7.10-7.08 (1H, m), 6.95-6.93 (1H, m), 6.85-6.80 (1H, m), 4.85 (2H, br s), 3.93 (3H, s), 3.02 (3H, s).
本発明化合物４６：¹H-NMR (CDCl₃) δ: 8.09 (2H, d), 7.57 (2H, d), 4.61 (2H, s), 3.02 (3H, s), 1.46 (9H, s)
本発明化合物９０：¹H-NMR (CDCl₃) δ: 8.10 (2H, d), 7.56 (2H, d), 4.44 (2H, s), 4.26-4.35 (1H, m), 2.91 (3H, s), 1.84-1.91 (2H, m), 1.43-1.75 (6H, m)
本発明化合物９１：¹H-NMR (CDCl₃) δ: 8.09 (2H, d), 7.57 (2H, d), 4.46 (2H, s), 3.69-3.77 (1H, m), 2.88 (3H, s), 1.71-1.81 (4H, m), 1.55-1.63 (1H, m), 1.25-1.41 (4H, m), 0.95-1.05 (1H, m)
本発明化合物９２：¹H-NMR (CDCl₃) δ: 8.14-8.11 (2H, m), 7.56-7.54 (2H, m), 4.51 (2H, s), 3.43-3.39 (2H, m), 2.98 (3H, s), 2.60-2.56 (2H, m), 2.06 (3H, s). Formula (1e)

In the compounds shown by, the combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in [Table 5].
[Table 5]

The present compound 5: ¹ H-NMR (CDCl ₃ ) δ: 8.13 (2H, d, J = 8.2 Hz), 7.53 (2H, d, J = 8.2 Hz), 4.72 (1 H, s), 4.43 (2 H, d, J = 6.1 Hz), 2.94 (3 H, s).
The present compound 23: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.12 (2H, m), 7.54-7.52 (2H, m), 4.64 (1H), 4.40 (2H, d), 3.02 (2H, q) ), 1.37 (3H, t).
The present compound 24: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.11 (2H, m), 7.54-7.52 (2H, m), 4.42 (3H, s), 3.14 (1H, t), 1.40 (6H , d).
The present compound 25: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.11 (2H, m), 7.56-7.53 (2H, m), 4.72 (1H, t), 4.44 (2H, d, J = 6.4 Hz ), 2.42-2.35 (1 H, m), 1.20-1. 16 (2 H, m), 0.99-0.94 (2 H, m).
The present compound 35: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.11 (2H, m), 7.53-7.51 (2H, m), 4.46 (1H, br s), 4.40 (2H, d), 2.99- 2.95 (2H, m), 1.88-1.82 (2H, m), 1.03 (3H, t).
The present compound 36: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.11 (2H, m), 7.52 (2H, d), 4.69 (1H, t), 4.40 (2H, d), 3.00-2.96 (2H , m), 1.82-1.74 (2H, m), 1.47-1.37 (2H, m), 0.92 (3H, t).
The present compound 37: ¹ H-NMR (CDCl ₃ ) δ: 8.12 (2H, d), 7.52 (2H, d), 4.72 (1H, t), 4.39 (2H, d), 2.90-2.88 (2H, m) ), 2.30-2.20 (1 H, m), 1.08 (6 H, d).
Invention compound 38: ¹ H-NMR (DMSO-D ₆ ) δ: 8.06-8.04 (2H, m), 7.80 (1H, s), 7.56-7.54 (2H, m), 7.39-7.37 (5H, m) , 4.38 (2H, s), 4.20 (2H, s).
The present compound 39: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.58-7.56 (2H, m), 4.51 (2H, s), 2.86 (3H, s), 2.42-2.37. (1H, m), 0.87-0.82 (2H, m), 0.81-0.76 (2H, m).
Invention compound 40: ¹ H-NMR (CDCl ₃ ) δ: 8.03-8.01 (2H, m), 7.44 (2H, d, J = 8.2 Hz), 7.36-7.32 (2H, m), 7.30-7.26 (3H , m), 4.93 (2H, s), 2.99 (3H, s).
The present compound 41: ¹ H-NMR (CDCl ₃ ) δ: 8.04-8.01 (2H, m), 7.40-7.37 (2H, m), 7.24-7.15 (4H, m), 4.85 (1H, br s), 4.72 (1H, br s), 3.00 (3H, s), 2.14 (3H, s).
Invention compound 42: ¹ H-NMR (CDCl ₃ ) δ: 8.04-8.01 (2H, m), 7.44 (2H, d), 7.23-7.19 (1H, m), 7.10-7.06 (3H, m), 4.91 (2H, s), 2.98 (3H, s), 2.31 (3H, s).
Invention compound 43: ¹ H-NMR (CDCl ₃ ) δ: 8.04-8.01 (2H, m), 7.44 (2H, d), 7.16-7.11 (4H, m), 4.90 (2H, s), 2.97 (3H , s), 2.30 (3H, s).
Invention compound 44: ¹ H-NMR (CDCl ₃ ) δ: 8.03-8.01 (2H, m), 7.45 (2H, d), 7.32-7.28 (1H, m), 7.20-7.11 (2H, m), 7.07 -7.02 (1 H, m), 4.88 (2 H, s), 3.06 (3 H, s).
Invention compound 45: ¹ H-NMR (CDCl ₃ ) δ: 8.02-8.00 (2H, m), 7.44 (2H, d), 7.29-7.25 (1H, m), 7.10-7.08 (1H, m), 6.95 -6.93 (1H, m), 6.85-6.80 (1H, m), 4.85 (2H, br s), 3.93 (3H, s), 3.02 (3H, s).
The present compound 46: ¹ H-NMR (CDCl ₃ ) δ: 8.09 (2H, d), 7.57 (2H, d), 4.61 (2H, s), 3.02 (3H, s), 1.46 (9H, s)
The present compound 90: ¹ H-NMR (CDCl ₃ ) δ: 8.10 (2H, d), 7.56 (2H, d), 4.44 (2H, s), 4.26-4.35 (1H, m), 2.91 (3H, s) ), 1.84-1.91 (2H, m), 1.43-1.75 (6H, m)
The present compound 91: ¹ H-NMR (CDCl ₃ ) δ: 8.09 (2H, d), 7.57 (2H, d), 4.46 (2H, s), 3.69-3.77 (1H, m), 2.88 (3H, s) ), 1.71-1.81 (4H, m), 1.55-1.63 (1 H, m), 1.25-1.41 (4 H, m), 0.95-1. 05 (1 H, m)
The present compound 92: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.11 (2H, m), 7.56-7.54 (2H, m), 4.51 (2H, s), 3.43-3.39 (2H, m), 2.98 (3H, s), 2.60-2.56 (2H, m), 2.06 (3H, s).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表６］に記載のいずれかの組合せである化合物。
［表６］

本発明化合物６：¹H-NMR (CDCl₃) δ: 8.10-8.07 (2H, m), 7.61-7.60 (1H, m), 7.57-7.53 (1H, m), 4.78 (1H, s), 4.43 (2H, d), 2.95 (3H, s).
本発明化合物２６：¹H-NMR (CDCl₃) δ: 8.10-8.06 (2H, m), 7.62-7.60 (1H, m), 7.57-7.53 (1H, m), 4.64 (1H, br s), 4.41 (2H, d), 3.02 (2H, q), 1.37 (3H, t).
本発明化合物２７：¹H-NMR (CDCl₃) δ: 8.09-8.06 (2H, m), 7.62-7.60 (1H, m), 7.56-7.52 (1H, m), 4.50 (1H, br s), 4.42 (2H, d, J = 6.1 Hz), 3.18-3.12 (1H, m), 1.39 (6H, d).
本発明化合物２８：¹H-NMR (CDCl₃) δ: 8.13-8.12 (1H, m), 8.08-8.06 (1H, m), 7.63-7.60 (1H, m), 7.56-7.52 (1H, m), 4.74 (1H, t), 4.45 (2H, d), 2.43-2.37 (1H, m), 1.21-1.16 (2H, m), 1.00-0.95 (2H, m). Formula (1f)

In the compound shown by, a combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in [Table 6].
[Table 6]

The present compound 6: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.07 (2H, m), 7.61-7.60 (1H, m), 7.57-7.53 (1H, m), 4.78 (1H, s), 4.43 (2H, d), 2.95 (3H, s).
The present compound 26: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.06 (2H, m), 7.62-7.60 (1H, m), 7.57-7.53 (1H, m), 4.64 (1H, br s), 4.41 (2H, d), 3.02 (2H, q), 1.37 (3H, t).
The present compound 27: ¹ H-NMR (CDCl ₃ ) δ: 8.09-8.06 (2H, m), 7.62-7.60 (1H, m), 7.56-7.52 (1H, m), 4.50 (1H, br s), 4.42 (2 H, d, J = 6.1 Hz), 3.18-3.12 (1 H, m), 1. 39 (6 H, d).
The present compound 28: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.12 (1H, m), 8.08-8.06 (1H, m), 7.63-7.60 (1H, m), 7.56-7.52 (1H, m) , 4.74 (1H, t), 4.45 (2H, d), 2.43-2.37 (1H, m), 1.21-1.16 (2H, m), 1.00-0.95 (2H, m).

で示される化合物において、Ｒ¹¹及びＲ¹²の組合わせが［表７］に記載のいずれかの組合せである化合物。
［表７］

本発明化合物７：¹H-NMR (CDCl₃) δ: 8.17-8.15 (2H, m), 7.59-7.58 (2H, m), 4.34 (2H, s), 4.08 (1H, d), 2.75 (3H, d).
本発明化合物８：¹H-NMR (CDCl₃) δ: 8.16-8.14 (2H, m), 7.59-7.57 (2H, m), 4.32 (2H, s), 4.06 (1H, t), 3.12-3.05 (2H, m), 1.16 (3H, t).
本発明化合物９：¹H-NMR (CDCl₃) δ: 8.17-8.14 (2H, m), 7.59-7.56 (2H, m), 4.33 (2H, s), 4.11 (1H, t), 3.00 (2H, td), 1.58-1.49 (2H, m), 0.91 (3H, t).
本発明化合物１０：¹H-NMR (CDCl₃) δ: 8.17-8.14 (2H, m), 7.60-7.57 (2H, m), 4.34 (2H, s), 4.25 (1H, t), 2.89 (2H, dd), 1.02-0.94 (1H, m), 0.58-0.52 (2H, m), 0.21-0.17 (2H, m).
本発明化合物１１：¹H-NMR (CDCl₃) δ: 8.17-8.14 (2H, m), 7.60-7.57 (2H, m), 4.29 (2H, s), 2.79 (6H, s).
本発明化合物１２：¹H-NMR (CDCl₃) δ: 8.16-8.13 (2H, m), 7.59-7.57 (2H, m), 4.32 (2H, s), 3.23-3.20 (4H, m), 1.87-1.84 (4H, m). Formula (1g)

In the compounds shown by, the combination of R ¹¹ and R ¹² is any combination described in [Table 7].
[Table 7]

The present compound 7: ¹ H-NMR (CDCl ₃ ) δ: 8.17-8.15 (2H, m), 7.59-7.58 (2H, m), 4.34 (2H, s), 4.08 (1H, d), 2.75 (3H) , d).
The present compound 8: ¹ H-NMR (CDCl ₃ ) δ: 8.16-8.14 (2H, m), 7.59-7.57 (2H, m), 4.32 (2H, s), 4.06 (1H, t), 3.12-3.05 (2H, m), 1.16 (3H, t).
The present compound 9: ¹ H-NMR (CDCl ₃ ) δ: 8.17-8.14 (2H, m), 7.59-7.56 (2H, m), 4.33 (2H, s), 4.11 (1H, t), 3.00 (2H , td), 1.58-1.49 (2H, m), 0.91 (3H, t).
The present compound 10: ¹ H-NMR (CDCl ₃ ) δ: 8.17-8.14 (2H, m), 7.60-7.57 (2H, m), 4.34 (2H, s), 4.25 (1H, t), 2.89 (2H) , dd), 1.02-0.94 (1 H, m), 0.58-0.52 (2 H, m), 0.21-0.17 (2 H, m).
Invention compound 11: ¹ H-NMR (CDCl ₃ ) δ: 8.17-8.14 (2H, m), 7.60-7.57 (2H, m), 4.29 (2H, s), 2.79 (6H, s).
The present compound 12: ¹ H-NMR (CDCl ₃ ) δ: 8.16-8.13 (2H, m), 7.59-7.57 (2H, m), 4.32 (2H, s), 3.23-3.20 (4H, m), 1.87 -1.84 (4H, m).

本発明化合物４７：¹H-NMR (CDCl₃) δ: 8.08-8.06 (2H, m), 7.09-7.06 (2H, m), 5.22 (2H, s), 2.28 (3H, s).

Invention compound 47: ¹ H-NMR (CDCl ₃ ) δ: 8.08-8.06 (2H, m), 7.09-7.06 (2H, m), 5.22 (2H, s), 2.28 (3H, s).

本発明化合物５０：¹H-NMR (CDCl₃) δ: 8.83 (1H, d), 8.27-8.25 (1H, m), 8.08 (1H, dd), 4.37 (2H, s), 2.91 (3H, s).

The present compound 50: ¹ H-NMR (CDCl ₃ ) δ: 8.83 (1 H, d), 8. 27-8. 25 (1 H, m), 8.08 (1 H, dd), 4. 37 (2 H, s), 2. 91 (3 H, s) ).

本発明化合物５１：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.54-7.52 (2H, m), 4.26 (2H, s), 3.26-3.22 (2H, m), 3.16 (2H, t), 2.40-2.33 (2H, m).

Invention compound 51: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.54-7.52 (2H, m), 4.26 (2H, s), 3.26-3.22 (2H, m), 3.16 (2H, t), 2.40-2.33 (2H, m).

本発明化合物５２：¹H-NMR (CDCl₃) δ: 8.12-8.09 (2H, m), 7.53-7.51 (2H, m), 4.39 (2H, s), 3.28-3.25 (2H, m), 3.15-3.12 (2H, m), 2.28-2.22 (2H, m), 1.70-1.64 (2H, m).

Invention compound 52: ¹ H-NMR (CDCl ₃ ) δ: 8.12-8.09 (2H, m), 7.53-7.51 (2H, m), 4.39 (2H, s), 3.28-3.25 (2H, m), 3.15 -3.12 (2H, m), 2.28-2.22 (2H, m), 1.70-1.64 (2H, m).

本発明化合物５３：¹H-NMR (CDCl₃) δ: 8.06-8.03 (2H, m), 7.91-7.87 (2H, m), 7.39-7.37 (2H, m), 7.22-7.17 (2H, m), 4.84 (1H, t), 4.25 (2H, d).

The present compound 53: ¹ H-NMR (CDCl ₃ ) δ: 8.06-8.03 (2H, m), 7.91-7.87 (2H, m), 7.39-7.37 (2H, m), 7.22-7.17 (2H, m) , 4.84 (1H, t), 4.25 (2H, d).

本発明化合物５４：¹H-NMR (CDCl₃) δ: 7.98 (1H, dd), 7.89 (1H, dd), 7.71 (1H, t), 4.36 (2H, s), 2.80 (6H, s).

Invention compound 54: ¹ H-NMR (CDCl ₃ ) δ: 7.98 (1H, dd), 7.89 (1H, dd), 7.71 (1H, t), 4.36 (2H, s), 2.80 (6H, s).

本発明化合物５５：¹H-NMR (DMSO-D₆) δ: 8.07-8.05 (2H, m), 7.84 (1H, t), 7.60-7.58 (2H, m), 4.23 (2H, ｄ), 2.65 (6H, s).

The present compound 55: ¹ H-NMR (DMSO-D ₆ ) δ: 8.07-8.05 (2H, m), 7.84 (1H, t), 7.60-7.58 (2H, m), 4.23 (2H, d), 2.65 (6H, s).

本発明化合物１３：¹H-NMR (CDCl₃) δ: 8.16-8.15 (2H, m), 7.49-7.47 (2H, m), 4.04 (2H, s), 2.51 (3H, s). Production Example 2-1
At 0 ° C., 2.2 g of m-chloroperbenzoic acid was added to a mixture of 2.4 g of the present compound 1 described in Production Example 1-1 and 70 mL of chloroform. The resulting mixture was stirred at room temperature for 4 hours, 70 mL of water was added, extraction was performed with chloroform, and the organic layer was washed with saturated aqueous sodium bisulfite solution. The organic layer was dried and concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 2) to obtain 1.7 g of the present compound 13 shown below.

Invention compound 13: ¹ H-NMR (CDCl ₃ ) δ: 8.16-8.15 (2H, m), 7.49-7.47 (2H, m), 4.04 (2H, s), 2.51 (3H, s).

本発明化合物１４：¹H-NMR (CDCl₃) δ: 8.21-8.20 (2H, m), 7.57-7.55 (2H, m), 4.48 (1H, d), 4.25 (1H, d), 2.82 (3H, s). Production Example 3-1
To a mixture of 1.9 g of the present compound 1 described in Production Example 1-1, 0.4 g of cyanamide and 20 mL of acetonitrile at room temperature, 2.4 g of iodobenzene diacetate was added. The resulting mixture was stirred at room temperature for 7 hours and then concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 2) to obtain 1.5 g of the present compound 14 shown below.

The present compound 14: ¹ H-NMR (CDCl ₃ ) δ: 8.21-8.20 (2H, m), 7.57-7.55 (2H, m), 4.48 (1H, d), 4.25 (1H, d), 2.82 (3H) , s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表９］に記載の組合せである化合物。
［表９］

本発明化合物２９：¹H-NMR (CDCl₃) δ: 8.21-8.19 (2H, m), 7.57-7.55 (2H, m), 4.43 (1H, d), 4.21 (1H, d), 3.22-3.18 (1H, m), 2.97-2.92 (1H, m), 1.49 (3H, t).
本発明化合物５６：¹H-NMR (CDCl₃) δ: 8.20-8.18 (2H, m), 7.60-7.58 (2H, m), 4.33 (1H, d), 4.19 (1H, d), 3.37-3.30 (1H, m), 1.55 (3H, d), 1.50 (3H, d). Production Example 3-2
The compound of the present invention produced according to the method described in Production Example 3-1 and the physical property values thereof are shown below.
Formula (1i)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 9].
[Table 9]

The present compound 29: ¹ H-NMR (CDCl ₃ ) δ: 8.21-8.19 (2H, m), 7.57-7.55 (2H, m), 4.43 (1H, d), 4.21 (1H, d), 3.22-3.18 (1H, m), 2.97-2.92 (1H, m), 1.49 (3H, t).
Invention compound 56: ¹ H-NMR (CDCl ₃ ) δ: 8.20-8.18 (2H, m), 7.60-7.58 (2H, m), 4.33 (1 H, d), 4.19 (1 H, d), 3.37-3.30 (1H, m), 1.55 (3H, d), 1.50 (3H, d).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表１０］に記載の組合せである化合物。
［表１０］

本発明化合物１５：¹H-NMR (CDCl₃) δ: 8.22-8.19 (1H, m), 8.13 (1H, br s), 7.65-7.63 (2H, m), 4.48 (1H, d), 4.29 (1H, d), 2.84 (3H, s). Formula (1 j)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 10].
[Table 10]

The present compound 15: ¹ H-NMR (CDCl ₃ ) δ: 8.22-8.19 (1H, m), 8.13 (1H, br s), 7.65-7.63 (2H, m), 4.48 (1H, d), 4.29 (4H) 1H, d), 2.84 (3H, s).

本発明化合物１６：¹H-NMR (CDCl₃) δ: 8.26-8.23 (2H, m), 7.66-7.63 (2H, m), 4.71 (2H, dd), 3.10 (3H, s). Production Example 4-1
Sodium periodate was added to a mixture of 1.3 g of the compound 14 of the present invention described in Preparation Example 3-1, 0.09 g of ruthenium (III) chloride hydrate, 7 mL of acetonitrile, 7 mL of chloroform and 7 mL of water at room temperature. Added 7g. The resulting mixture was stirred at room temperature for 2 hours and then 20 mL of water was added. The resulting mixture was filtered, the filtrate was extracted with ethyl acetate, the organic layer was washed with saturated aqueous sodium hydrogen sulfite solution and saturated brine, and the organic layer was dried and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 2) to obtain 0.8 g of the present compound 16 shown below.

Present compound 16: ¹ H-NMR (CDCl ₃ ) δ: 8.26-8.23 (2H, m), 7.66-7.63 (2H, m), 4.71 (2H, dd), 3.10 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表１１］に記載の組合せである化合物。
［表１１］

本発明化合物３０：¹H-NMR (CDCl₃) δ: 8.25-8.22 (2H, m), 7.65-7.63 (2H, m), 4.70-4.62 (2H, m), 3.25-3.14 (2H, m), 1.50 (3H, t).
本発明化合物５７：¹H-NMR (CDCl₃) δ: 8.24-8.21 (2H, m), 7.65-7.63 (2H, m), 4.68-4.59 (2H, m), 3.38-3.31 (1H, m), 1.54 (3H, d), 1.52 (3H, d). Production Example 4-2
The compound of the present invention produced according to the method described in Production Example 4-1 and the physical property values thereof are shown below.
Formula (1k)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 11].
[Table 11]

The present compound 30: ¹ H-NMR (CDCl ₃ ) δ: 8.25-8.22 (2H, m), 7.65-7.63 (2H, m), 4.74-4.62 (2H, m), 3.25-3. 14 (2H, m) , 1.5 (3H, t).
The present compound 57: ¹ H-NMR (CDCl ₃ ) δ: 8.24-8.21 (2H, m), 7.65-7.63 (2H, m), 4.68-4.59 (2H, m), 3.38-3.31 (1H, m) , 1.54 (3H, d), 1.52 (3H, d).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが［表１２］に記載の組合せである化合物。
［表１２］

本発明化合物１７：¹H-NMR (CDCl₃) δ: 8.27 (1H, dt), 8.19 (1H, t), 7.73-7.71 (1H, m), 7.72-7.69 (1H, m), 4.70 (2H, dd), 3.12 (3H, s). Formula (1 l)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is a combination described in [Table 12].
[Table 12]

The present compound 17: ¹ H-NMR (CDCl ₃ ) δ: 8.27 (1H, dt), 8.19 (1H, t), 7.73-7.71 (1H, m), 7.72-7.69 (1H, m), 4.70 (2H , dd), 3.12 (3H, s).

本発明化合物１８：¹H-NMR (CDCl₃) δ: 8.20-8.17 (2H, m), 7.61-7.58 (2H, m), 4.46 (1H, d), 4.32 (1H, d), 2.98 (3H, s), 2.67 (1H, br s). Production Example 5-1
To a mixture of 0.5 g of the compound 13 of the present invention described in Production Example 2-1, 0.5 g of ammonium carbamate and 1.7 g of iodobenzene diacetate at room temperature, 4 mL of methanol was added. The resulting mixture is stirred at room temperature for 5 hours, and the resulting mixture is concentrated under reduced pressure, and the resulting residue is subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 2) to give the compound shown below 0.3 g of the inventive compound 18 was obtained.

The present compound 18: ¹ H-NMR (CDCl ₃ ) δ: 8.20-8.17 (2H, m), 7.61-7.58 (2H, m), 4.46 (1H, d), 4.32 (1H, d), 2.98 (3H) , s), 2.67 (1H, br s).

本発明化合物２０：¹H-NMR (CDCl₃) δ: 8.19-8.16 (2H, m), 7.61-7.58 (2H, m), 4.30 (2H, s), 2.93 (2H, q), 1.40 (3H, t). Production Example 6-1
In a mixture of 0.5 g of the compound of the present invention 19 described in Preparation Example 1-2, 0.4 mL of acetonitrile, 0.4 mL of chloroform, and 0.4 mL of water at room temperature, 0.04 g of ruthenium (III) chloride hydrate Was added followed by 1.1 g of sodium periodate. The resulting mixture was stirred at room temperature for 5 hours, filtered, the filtrate was extracted with ethyl acetate, the organic layer was washed with saturated aqueous sodium hydrogen sulfite solution and saturated brine, and the organic layer was dried and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 1) to obtain 0.35 g of the present compound 20 shown below.

The present compound 20: ¹ H-NMR (CDCl ₃ ) δ: 8.19-8.16 (2H, m), 7.61-7.58 (2H, m), 4.30 (2H, s), 2.93 (2H, q), 1.40 (3H) , t).

で示される化合物において、Ｒ⁸、Ｒ⁹、Ｒ¹⁰、Ｒ²¹及びＲ²²の組合せが［表１３］に記載の組合せである化合物。
［表１３］

本発明化合物５８：¹H-NMR (CDCl₃) δ: 8.18-8.15 (2H, m), 7.62-7.59 (2H, m), 4.29 (2H, s), 3.09-3.02 (1H, m), 1.42 (6H, d).
本発明化合物５９：¹H-NMR (CDCl₃) δ: 8.23-8.20 (2H, m), 7.62-7.60 (2H, m), 4.56 (2H, s). Production Example 6-2
The compound of the present invention manufactured according to the method described in Production Example 6-1 and the physical property values thereof are shown below.
Formula (1c)

In the compounds shown by, the combination of R ⁸ , R ⁹ , R ¹⁰ , R ²¹ and R ^{22 is} a combination described in [Table 13].
[Table 13]

The present compound 58: ¹ H-NMR (CDCl ₃ ) δ: 8.18-8.15 (2H, m), 7.62-7.59 (2H, m), 4.29 (2H, s), 3.09-3.02 (1H, m), 1.42 (6H, d).
Invention compound 59: ¹ H-NMR (CDCl ₃ ) δ: 8.23-8.20 (2H, m), 7.62-7.60 (2H, m), 4.56 (2H, s).

で示される化合物において、ｍが［表１４］に記載のいずれかである化合物。
［表１４］

本発明化合物６０：¹H-NMR (CDCl₃) δ: 8.14-8.10 (2H, m), 7.21-7.18 (2H, m), 5.05 (2H, s), 3.06 (3H, s).
本発明化合物６１：¹H-NMR (CDCl₃) δ: 8.10-8.08 (2H, m), 7.05-7.03 (2H, m), 4.53 (2H, t), 3.50 (2H, t), 3.09 (3H, s).
本発明化合物６２：¹H-NMR (CDCl₃) δ: 8.08-8.05 (2H, m), 7.03-7.00 (2H, m), 4.21 (2H, t), 3.28 (2H, t), 2.98 (3H, s), 2.44-2.37 (2H, m). Formula (1 m)

In the compound shown by these, compounds in which m is any of those listed in [Table 14].
[Table 14]

Invention compound 60: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.10 (2H, m), 7.21-7.18 (2H, m), 5.05 (2H, s), 3.06 (3H, s).
The present compound 61: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.08 (2H, m), 7.05-7.03 (2H, m), 4.53 (2H, t), 3.50 (2H, t), 3.09 (3H , s).
The present compound 62: ¹ H-NMR (CDCl ₃ ) δ: 8.08-8.05 (2H, m), 7.03-7.00 (2H, m), 4.21 (2H, t), 3.28 (2H, t), 2.98 (3H) , s), 2.44-2.37 (2H, m).

本発明化合物４８：¹H-NMR (CDCl₃) δ: 8.07-8.04 (2H, m), 7.03-7.01 (2H, m), 4.24 (2H, t), 2.92 (2H, t), 2.24 (3H, s). Production Example 7-1
In a mixture of 1.0 g of 4- [5- (trifluoromethyl) -1,2,4-oxadiazol-3-yl] phenol, 0.8 g of 2- (methylthio) ethanol and 30 mL of tetrahydrofuran at 0 ° C. After 2.0 g of triphenylphosphine and bis (2-methoxyethyl) diazene-1,2-dicarboxylate were sequentially added, the temperature was raised to 45 ° C. and stirring was performed for 3 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure, and then 20 mL of water was added. The mixture was extracted with ethyl acetate, the organic layer was washed with brine, and the organic layer was dried and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 4: 1) to obtain 0.69 g of the present compound 48 shown below.

Invention compound 48: ¹ H-NMR (CDCl ₃ ) δ: 8.07-8.04 (2H, m), 7.03-7.01 (2H, m), 4.24 (2H, t), 2. 92 (2H, t), 2.24 (3H) , s).

本発明化合物４９：¹H-NMR (CDCl₃) δ: 8.06-8.03 (2H, m), 7.03-7.00 (2H, m), 4.15 (2H, t), 2.71 (2H, t), 2.15-2.08 (5H, m). Production Example 7-2
The present compound 49 was produced according to the method described in Production Example 7-1.

The present compound 49: ¹ H-NMR (CDCl ₃ ) δ: 8.06-8.03 (2H, m), 7.03-7.00 (2H, m), 4.15 (2H, t), 2.71 (2H, t), 2.15-2.08 (5H, m).

本発明化合物３１：¹H-NMR (CDCl₃) δ: 8.14-8.12 (2H, m), 7.54-7.52 (2H, m), 4.40 (2H, s), 2.90 (3H, s), 2.82 (3H, s). Production Example 8-1
After adding 0.06 g of sodium hydride (60%, oily) to a mixture of 0.4 g of the compound 5 of the present invention described in Preparation Example 1-2 and 20 mL of N, N-dimethylformamide at 0 ° C. Stir at room temperature for 10 minutes. After 0.3 g of methyl iodide was added to the obtained mixture at 0 ° C., the mixture was stirred at room temperature for 5 hours. To the resulting mixture was added 50 mL of water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 1: 1) to obtain 0.3 g of the present compound 31.

The present compound 31: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.12 (2H, m), 7.54-7.52 (2H, m), 4.40 (2H, s), 2.90 (3H, s), 2.82 (3H) , s).

Production Example 8-2
The compound of the present invention produced according to the method described in Production Example 8-1 and the physical properties thereof are shown below.

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合せが［表１６］に記載のいずれかの組合せである化合物。
［表１６］

本発明化合物６３：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.56-7.53 (2H, m), 4.47 (2H, s), 3.31 (2H, q), 2.91 (3H, s), 1.15 (3H, t).
本発明化合物６４：¹H-NMR (CDCl₃) δ: 8.11-8.08 (2H, m), 7.60-7.57 (2H, m), 4.44 (2H, s), 4.22-4.16 (1H, m), 2.88 (3H, s), 1.19 (6H, d).
本発明化合物６５：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.56-7.54 (2H, m), 4.46 (2H, s), 3.01 (2H, d), 2.86 (3H, s), 1.84-1.74 (1H, m), 0.87 (6H, d).
本発明化合物６６：¹H-NMR (CDCl₃) δ: 8.14-8.12 (2H, m), 7.58-7.56 (2H, m), 4.53 (2H, s), 3.96 (2H, d), 3.05 (3H, s), 2.45 (1H, t).
本発明化合物６７：¹H-NMR (CDCl₃) δ: 8.14 (2H, d), 7.54 (2H, d), 6.06-5.78 (1H, m), 4.62 (2H, s), 3.57 (2H, td), 3.01 (3H, s).
本発明化合物６８：¹H-NMR (CDCl₃) δ: 8.12-8.10 (2H, m), 7.56 (2H, d), 4.58 (2H, s), 3.12 (2H, d), 2.98 (3H, s), 0.94-0.88 (1H, m), 0.54-0.49 (2H, m), 0.20-0.16 (2H, m).
本発明化合物６９：¹H-NMR (CDCl₃) δ: 8.18-8.16 (2H, m), 7.58-7.56 (2H, m), 4.55 (2H, s), 4.09 (2H, s), 3.11 (3H, s).
本発明化合物７０：¹H-NMR (CDCl₃) δ: 8.10-8.08 (2H, m), 7.47-7.45 (2H, m), 7.36-7.32 (3H, m), 7.30-7.28 (2H, m), 4.43 (2H, s), 4.38 (2H, s), 2.85 (3H, s).
本発明化合物７１：¹H-NMR (CDCl₃) δ: 8.13-8.11 (2H, m), 7.55 (2H, d), 4.57 (2H, s), 4.56 (2H, s), 3.47 (2H, q), 3.01 (3H, s), 1.20 (3H, t).
本発明化合物７２：¹H-NMR (CDCl₃) δ: 8.14-8.11 (2H, m), 7.54-7.52 (2H, m), 4.45 (2H, s), 3.09 (2H, q), 2.83 (3H, s), 1.42 (3H, t).
本発明化合物７３：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.55-7.53 (2H, m), 4.51 (2H, s), 3.31 (2H, q), 3.05 (2H, q), 1.40 (3H, t), 1.13 (3H, t).
本発明化合物７４：¹H-NMR (CDCl₃) δ: 8.11-8.07 (2H, m), 7.60-7.57 (2H, m), 4.46 (2H, s), 4.18-4.11 (1H, m), 2.93 (2H, q), 1.35 (3H, t), 1.19 (6H, d).
本発明化合物７５：¹H-NMR (CDCl₃) δ: 8.14-8.10 (2H, m), 7.53 (2H, d), 4.48 (2H, s), 3.36-3.29 (1H, m), 2.84 (3H, s), 1.42 (6H, d).
本発明化合物７６：¹H-NMR (CDCl₃) δ: 8.12-8.09 (2H, m), 7.55 (2H, d), 4.53 (2H, s), 3.30 (2H, q), 3.24-3.17 (1H, m), 1.40 (6H, d), 1.12 (3H, t).
本発明化合物７７：¹H-NMR (CDCl₃) δ: 8.10-8.07 (2H, m), 7.59 (2H, d), 4.47 (2H, s), 4.15-4.08 (1H, m), 3.03-2.96 (1H, m), 1.34 (6H, d), 1.17 (6H, d). Formula (1e)

In the compounds shown by, the combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in [Table 16].
[Table 16]

The present compound 63: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.56-7.53 (2H, m), 4.47 (2H, s), 3.31 (2H, q), 2.91 (3H) , s), 1.15 (3H, t).
Invention compound 64: ¹ H-NMR (CDCl ₃ ) δ: 8.11-8.08 (2H, m), 7.60-7.57 (2H, m), 4.44 (2H, s), 4.22-4.16 (1H, m), 2.88 (3H, s), 1.19 (6H, d).
The present compound 65: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.56-7.54 (2H, m), 4.46 (2H, s), 3.01 (2H, d), 2.86 (3H) , s), 1.84-1.74 (1 H, m), 0.87 (6 H, d).
The present compound 66: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.12 (2H, m), 7.58-7.56 (2H, m), 4.53 (2H, s), 3.96 (2H, d), 3.05 (3H , s), 2.45 (1 H, t).
The present compound 67: ¹ H-NMR (CDCl ₃ ) δ: 8.14 (2H, d), 7.54 (2H, d), 6.06-5.78 (1H, m), 4.62 (2H, s), 3.57 (2H, td ), 3.01 (3H, s).
Invention compound 68: ¹ H-NMR (CDCl ₃ ) δ: 8.12-8.10 (2H, m), 7.56 (2H, d), 4.58 (2H, s), 3.12 (2H, d), 2.98 (3H, s) ), 0.94-0.88 (1 H, m), 0.54-0.49 (2 H, m), 0.20-0.16 (2 H, m).
The present compound 69: ¹ H-NMR (CDCl ₃ ) δ: 8.18-8.16 (2H, m), 7.58-7.56 (2H, m), 4.55 (2H, s), 4.09 (2H, s), 3.11 (3H , s).
The present compound 70: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.08 (2H, m), 7.47-7.45 (2H, m), 7.36-7.32 (3H, m), 7.30-7. 28 (2H, m) , 4.43 (2H, s), 4.38 (2H, s), 2.85 (3H, s).
The present compound 71: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.11 (2H, m), 7.55 (2H, d), 4.57 (2H, s), 4.56 (2H, s), 3.47 (2H, q) ), 3.01 (3H, s), 1.20 (3H, t).
The present compound 72: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.11 (2H, m), 7.54-7.52 (2H, m), 4.45 (2H, s), 3.09 (2H, q), 2.83 (3H , s), 1.42 (3H, t).
Invention compound 73: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.55 to 7.53 (2H, m), 4.51 (2H, s), 3.31 (2H, q), 3.05 (2H , q), 1.40 (3H, t), 1.13 (3H, t).
The present compound 74: ¹ H-NMR (CDCl ₃ ) δ: 8.11 to 8.07 (2H, m), 7.60 to 7.57 (2H, m), 4.46 (2H, s), 4.18 to 4.11 (1H, m), 2.93 (2H, q), 1.35 (3H, t), 1.19 (6H, d).
The present compound 75: ¹ H-NMR (CDCl ₃ ) δ: 8.14-8.10 (2H, m), 7.53 (2H, d), 4.48 (2H, s), 3.36-3.29 (1H, m), 2.84 (3H) , s), 1.42 (6H, d).
The present compound 76: ¹ H-NMR (CDCl ₃ ) δ: 8.12-8.09 (2H, m), 7.55 (2H, d), 4.53 (2H, s), 3.30 (2H, q), 3.24-3.17 (1H , m), 1.40 (6H, d), 1.12 (3H, t).
Invention compound 77: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.07 (2H, m), 7.59 (2H, d), 4.47 (2H, s), 4.15-4.08 (1H, m), 3.03-2.96 (1H, m), 1.34 (6H, d), 1.17 (6H, d).

［表１７］

本発明化合物３２：¹H-NMR (CDCl₃) δ: 8.10-8.07 (2H, m), 7.65-7.63 (1H, m), 7.58-7.54 (1H, m), 4.40 (2H, s), 2.90 (3H, s), 2.81 (3H, s).
本発明化合物７８：¹H-NMR (CDCl₃) δ: 8.09-8.06 (2H, m), 7.68-7.65 (1H, m), 7.57-7.53 (1H, m), 4.48 (2H, s), 3.30 (2H, q), 2.92 (3H, s), 1.16 (3H, t). In the compound represented by the formula (1o), compounds wherein the combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any one of the combinations described in [Table 17].

[Table 17]

Invention compound 32: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.07 (2H, m), 7.65-7.63 (1H, m), 7.58-7.54 (1H, m), 4.40 (2H, s), 2.90 (3H, s), 2.81 (3H, s).
Invention compound 78: ¹ H-NMR (CDCl ₃ ) δ: 8.09-8.06 (2H, m), 7.68-7.65 (1H, m), 7.57-7.53 (1H, m), 4.48 (2H, s), 3.30 (2H, q), 2.92 (3H, s), 1.16 (3H, t).

で示される化合物において、Ｒ⁶、Ｒ¹¹及びＲ¹²の組合せが［表１８］に記載のいずれかの組合せである化合物。
［表１８］

本発明化合物７９：¹H-NMR (CDCl₃) δ: 8.13-8.10 (2H, m), 7.51 (2H, d), 4.41 (2H, s), 2.87 (6H, s), 2.75 (3H, s).
本発明化合物８０：¹H-NMR (CDCl₃) δ: 8.12-8.10 (2H, m), 7.53 (2H, d), 4.47 (2H, s), 3.24 (2H, q), 2.82 (6H, s), 1.13 (3H, t).
本発明化合物８１：¹H-NMR (CDCl₃) δ: 8.10-8.07 (2H, m), 7.57-7.55 (2H, m), 4.42 (2H, s), 4.07-4.01 (1H, m), 2.72 (6H, s), 1.19 (6H, d).
本発明化合物８２：¹H-NMR (CDCl₃) δ: 8.15-8.13 (2H, m), 7.54-7.52 (2H, m), 6.11-5.81 (1H, m), 4.56 (2H, s), 3.49-3.41 (2H, m), 2.85 (6H, s).
本発明化合物８３：¹H-NMR (CDCl₃) δ: 8.13-8.11 (2H, m), 7.56-7.54 (2H, m), 4.60 (2H, s), 3.89 (2H, d), 2.91 (6H, s), 2.40 (1H, t).
本発明化合物８４：¹H-NMR (CDCl₃) δ: 8.11 (2H, d), 7.54 (2H, d), 4.58 (2H, s), 3.85-3.84 (2H, m), 2.89 (6H, s), 1.88 (3H, t).
本発明化合物８５：¹H-NMR (CDCl₃) δ: 8.17-8.15 (2H, m), 7.55 (2H, d), 4.60 (2H, s), 4.00 (2H, s), 2.96 (6H, s). Formula (1p)

In the compounds shown by, the combination of R ⁶ , R ¹¹ and R ¹² is any combination described in [Table 18].
[Table 18]

Invention compound 79: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.10 (2H, m), 7.51 (2H, d), 4.41 (2H, s), 2.87 (6H, s), 2.75 (3H, s) ).
The present compound 80: ¹ H-NMR (CDCl ₃ ) δ: 8.12-8.10 (2H, m), 7.53 (2H, d), 4.47 (2H, s), 3.24 (2H, q), 2.82 (6H, s) ), 1.13 (3H, t).
Invention compound 81: ¹ H-NMR (CDCl ₃ ) δ: 8.10-8.07 (2H, m), 7.57-7.55 (2H, m), 4.42 (2H, s), 4.07-4.01 (1H, m), 2.72 (6H, s), 1.19 (6H, d).
Invention compound 82: ¹ H-NMR (CDCl ₃ ) δ: 8.15-8.13 (2H, m), 7.54-7.52 (2H, m), 6.11-5.81 (1H, m), 4.56 (2H, s), 3.49 -3.41 (2H, m), 2.85 (6H, s).
The present compound 83: ¹ H-NMR (CDCl ₃ ) δ: 8.13-8.11 (2H, m), 7.56-7.54 (2H, m), 4.60 (2H, s), 3.89 (2H, d), 2.91 (6H , s), 2.40 (1 H, t).
Invention compound 84: ¹ H-NMR (CDCl ₃ ) δ: 8.11 (2H, d), 7.54 (2H, d), 4.58 (2H, s), 3.85-3.84 (2H, m), 2.89 (6H, s) ), 1.88 (3H, t).
Invention compound 85: ¹ H-NMR (CDCl ₃ ) δ: 8.17-8.15 (2H, m), 7.55 (2H, d), 4.60 (2H, s), 4.00 (2H, s), 2.96 (6H, s) ).

本発明化合物８６：¹H-NMR (CDCl₃) δ: 8.19-8.17 (2H, m), 7.59-7.57 (2H, m), 4.83-4.75 (2H, m), 3.08 (3H, s), 2.39 (2H, q), 1.13 (3H, t). Production Example 9-1
After 0.3 mL of triethylamine was added to a mixture of 0.4 g of the present compound 18 described in Preparation Example 5-1 and 10 mL of chloroform at room temperature, 0.12 g of propionyl chloride was added, and the mixture was stirred at room temperature for 20 hours. . The reaction mixture was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (ethyl acetate) to give 0.4 g of the present compound 86.

Invention compound 86: ¹ H-NMR (CDCl ₃ ) δ: 8.19-8.17 (2H, m), 7.59-7.57 (2H, m), 4.83-4.75 (2H, m), 3.08 (3H, s), 2.39 (2H, q), 1.13 (3H, t).

Production Example 9-2
The compound of the present invention produced according to the method described in Production Example 9-1 and the physical properties thereof are shown below.

で示される化合物において、Ｒ⁷が［表１９］に記載のいずれかである化合物。
［表１９］

本発明化合物８７：¹H-NMR (CDCl₃) δ: 8.19-8.16 (2H, m), 7.60-7.57 (2H, m), 4.83-4.74 (2H, m), 3.09 (3H, s), 2.59-2.52 (1H, m), 1.15 (6H, dd).
本発明化合物８８：¹H-NMR (CDCl₃) δ: 8.24-8.21 (2H, m), 7.62-7.59 (2H, m), 4.88-4.80 (2H, m), 3.22 (3H, s). Formula (1 q)

In the compounds shown by these, compounds in which R ⁷ is any of those described in [Table 19].
[Table 19]

Invention compound 87: ¹ H-NMR (CDCl ₃ ) δ: 8.19-8.16 (2H, m), 7.60-7.57 (2H, m), 4.83-4.74 (2H, m), 3.09 (3H, s), 2.59 -2.52 (1 H, m), 1.15 (6 H, dd).
Invention compound 88: ¹ H-NMR (CDCl ₃ ) δ: 8.24-8.21 (2H, m), 7.62-7.59 (2H, m), 4.88-4.80 (2H, m), 3.22 (3H, s).

本発明化合物８９：¹H-NMR (CDCl₃) δ: 8.22-8.19 (2H, m), 7.63-7.60 (2H, m), 4.84-4.74 (2H, m), 3.76 (3H, s), 3.05 (3H, s).

Invention compound 89: ¹ H-NMR (CDCl ₃ ) δ: 8.22-8.19 (2H, m), 7.63-7.60 (2H, m), 4.84-4.74 (2H, m), 3.76 (3H, s), 3.05 (3H, s).

Next, production examples of the intermediate compounds in producing the above-mentioned compound of the present invention will be shown.

中間体（Ａ１ａ１）：¹H-NMR (DMSO-D₆) δ: 9.60 (1H, s), 7.63-7.60 (2H, m), 7.30-7.28 (2H, m), 5.78 (2H, s), 3.69 (2H, s), 1.95 (3H, s). Reference Production Example 1-1
A mixture of 1.7 g of the intermediate (A2a1) described in Reference Production Example 3-1, 60 mL of ethanol, and 2.2 mL of a 50% -hydroxylamine aqueous solution was stirred under heating reflux for 5 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, 20 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure to obtain 1.7 g of an intermediate (A1a1).

Intermediate (A1a1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.60 (1H, s), 7.63-7.60 (2H, m), 7.30-7.28 (2H, m), 5.78 (2H, s), 3.69 (2H, s), 1.95 (3H, s).

Reference Production Example 1-2
Intermediate compounds produced according to the method described in Reference Production Example 1-1 and physical properties thereof are shown below.

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ１ａ２）：¹H-NMR (CDCl₃) δ: 7.59-7.56 (2H, m), 7.37-7.33 (2H, m), 4.86 (2H, s), 3.73 (2H, s), 2.43 (2H, q), 1.23 (3H, t).
中間体（Ａ１ａ３）：¹H-NMR (CDCl₃) δ: 7.58-7.56 (2H, m), 7.38-7.36 (2H, m), 4.87 (2H, s), 3.75 (2H, s), 2.81-2.75 (1H, m), 1.25 (6H, d, J = 6.9 Hz).
中間体（Ａ１ａ４）：¹H-NMR (DMSO-D₆) δ: 9.65 (1H, s), 7.65 (2H, d), 7.39 (2H, d), 5.81 (2H, s), 4.32 (2H, s). Formula (A1a)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A1a2): ¹ H-NMR (CDCl ₃ ) δ: 7.59 to 7.56 (2H, m), 7.37 to 7.33 (2H, m), 4.86 (2H, s), 3.73 (2H, s), 2.43 ( 2H, q), 1.23 (3H, t).
Intermediate (A1a3): ¹ H-NMR (CDCl ₃ ) δ: 7.58 to 7.56 (2H, m), 7.38 to 7.36 (2H, m), 4.87 (2H, s), 3.75 (2H, s), 2.81- 2.75 (1 H, m), 1.25 (6 H, d, J = 6.9 Hz).
Intermediate (A1a4): ¹ H-NMR (DMSO-D ₆ ) δ: 9.65 (1H, s), 7.65 (2H, d), 7.39 (2H, d), 5.81 (2H, s), 4.32 (2H, 2) s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載の組合せである化合物。

中間体（Ａ１ｂ１）：¹H-NMR (CDCl₃) δ: 8.25 (1H, s), 7.58-7.57 (1H, m), 7.52-7.51 (1H, m), 7.37-7.36 (2H, m), 4.90 (2H, s), 3.69 (2H, s), 1.99 (3H, s). Formula (A1 b)

Compounds in which R ⁸ , R ⁹ and R ¹⁰ have the combinations given in the following table.

Intermediate (A1b1): ¹ H-NMR (CDCl ₃ ) δ: 8.25 (1H, s), 7.58-7.57 (1H, m), 7.52-7.51 (1H, m), 7.37-7.36 (2H, m), 4.90 (2H, s), 3.69 (2H, s), 1.99 (3H, s).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ１ｅ１）：¹H-NMR (DMSO-D₆) δ: 9.61 (1H, s), 7.66-7.64 (2H, m), 7.58 (1H, s), 7.33 (2H, d, J = 8.5 Hz), 5.80 (2H, s), 4.16 (2H, d, J = 3.9 Hz), 2.86 (3H, s).
中間体（Ａ１ｅ２）：¹H-NMR (DMSO-D₆) δ: 9.61 (1H, s), 7.66-7.64 (2H, m), 7.34-7.32 (2H, m), 5.81 (2H, s), 4.14 (2H, d), 2.94 (2H, q), 1.16 (3H, t).
中間体（Ａ１ｅ３）：¹H-NMR (DMSO-D₆) δ: 9.64 (1H, s), 7.65-7.58 (3H, m), 7.34-7.32 (2H, m), 5.86 (2H, s), 4.17 (2H, d), 3.08 (1H, t), 1.21 (6H, d).
中間体（Ａ１ｅ４）：¹H-NMR (DMSO-D₆) δ: 9.43-9.19 (1H, m), 7.74-7.64 (3H, m), 7.36 (2H, t), 6.07 (2H, s), 4.20 (2H, d), 2.50-2.44 (1H, m), 1.02-0.97 (2H, m), 0.88-0.87 (2H, m).
中間体（Ａ１ｅ５）：¹H-NMR (DMSO-D₆) δ: 9.61 (1H, s), 7.66-7.63 (2H, m), 7.33 (2H, d), 5.79 (2H, s), 4.19-4.15 (2H, m), 2.93-2.88 (2H, m), 1.68-1.59 (2H, m), 0.93-0.89 (3H, m).
中間体（Ａ１ｅ６）：¹H-NMR (DMSO-D₆) δ: 9.64 (1H, s), 7.66-7.60 (3H, m), 7.35-7.32 (2H, m), 5.85 (2H, s), 4.15 (2H, d), 2.93-2.89 (2H, m), 1.62-1.54 (2H, m), 1.36-1.26 (2H, m), 0.84 (3H, t).
中間体（Ａ１ｅ７）：¹H-NMR (DMSO-D₆) δ: 9.60 (1H, s), 7.66-7.59 (3H, m), 7.34-7.32 (2H, m), 5.79 (2H, s), 4.15 (2H, d), 2.83 (2H, d), 2.10-2.00 (1H, m), 0.97 (6H, d).
中間体（Ａ１ｅ８）：¹H-NMR (DMSO-D₆) δ: 9.60 (1H, s), 7.68 (1H, s), 7.65-7.62 (2H, m), 7.40-7.34 (5H, m), 7.30 (2H, d), 5.79 (2H, s), 4.33 (2H, s), 4.10 (2H, s).
中間体（Ａ１ｅ９）：¹H-NMR (DMSO-D₆) δ: 9.63 (1H, s), 7.66 (2H, d), 7.34 (2H, d), 5.80 (2H, s), 4.35 (2H, s), 2.95 (3H, s), 2.48-2.43 (1H, m), 0.64 (4H, d).
中間体（Ａ１ｅ１０）：¹H-NMR (DMSO-D₆) δ: 9.59 (1H, s), 7.56 (2H, d), 7.39-7.31 (4H, m), 7.26-7.23 (3H, m), 5.74 (2H, s), 4.87 (2H, s), 3.09 (3H, s).
中間体（Ａ１ｅ１１）：¹H-NMR (DMSO-D₆) δ: 9.61 (1H, s), 7.56-7.54 (2H, m), 7.48-7.46 (1H, m), 7.26-7.20 (1H, m), 7.19-7.14 (4H, m), 5.76 (2H, s), 4.88-4.85 (1H, m), 4.59-4.56 (1H, m), 3.13 (3H, s), 2.02 (3H, s).
中間体（Ａ１ｅ１２）：¹H-NMR (DMSO-D₆) δ: 9.59 (1H, s), 7.57-7.55 (2H, m), 7.26-7.23 (2H, m), 7.21-7.15 (3H, m), 7.07-7.05 (1H, m), 5.75 (2H, s), 4.85 (2H, s), 3.08 (3H, s), 2.26 (3H, s).
中間体（Ａ１ｅ１３）：¹H-NMR (DMSO-D₆) δ: 9.59 (1H, s), 7.56-7.54 (2H, m), 7.26-7.22 (4H, m), 7.13-7.11 (2H, m), 5.75 (2H, s), 4.83 (2H, s), 3.06 (3H, s), 2.24 (3H, s).
中間体（Ａ１ｅ１４）：¹H-NMR (DMSO-D₆) δ: 9.61 (1H, s), 7.57 (2H, d), 7.46-7.42 (1H, m), 7.36-7.30 (1H, m), 7.27-7.21 (3H, m), 7.18-7.14 (1H, m), 5.76 (2H, s), 4.80 (2H, s), 3.17 (3H, s).
中間体（Ａ１ｅ１５）：¹H-NMR (DMSO-D₆) δ: 9.60 (1H, s), 7.56 (2H, d), 7.29-7.23 (3H, m), 7.09-7.07 (1H, m), 7.04-7.02 (1H, m), 6.83-6.79 (1H, m), 5.76 (2H, s), 4.73 (2H, s), 3.87 (3H, s), 3.07 (3H, s).
中間体（Ａ１ｅ１６）：¹H-NMR (DMSO-D₆) δ: 9.58 (1H, s), 7.64-7.62 (2H, m), 7.38-7.36 (2H, m), 5.77 (2H, s), 4.48 (2H, s), 3.04 (3H, s), 1.34 (9H, s).
中間体（Ａ１ｅ１７）：¹H-NMR (DMSO-D₆) δ: 9.63 (1H, s), 7.68-7.66 (2H, m), 7.39-7.36 (2H, m), 5.81 (2H, s), 4.38 (2H, s), 3.29-3.25 (2H, m), 3.03 (3H, s), 2.49-2.46 (2H, m), 1.97 (3H, s). Formula (A1e)

In the compounds shown by, a combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A1e1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.61 (1H, s), 7.66-7.64 (2H, m), 7.58 (1H, s), 7.33 (2H, d, J = 8.5) Hz), 5.80 (2H, s), 4.16 (2H, d, J = 3.9 Hz), 2.86 (3H, s).
Intermediate (A1e2): ¹ H-NMR (DMSO-D ₆ ) δ: 9.61 (1H, s), 7.66-7.64 (2H, m), 7.34-7.32 (2H, m), 5.81 (2H, s), 4.14 (2H, d), 2.94 (2H, q), 1.16 (3H, t).
Intermediate (A1e3): ¹ H-NMR (DMSO-D ₆ ) δ: 9.64 (1H, s), 7.65-7.58 (3H, m), 7.34-7.32 (2H, m), 5.86 (2H, s), 4.17 (2H, d), 3.08 (1 H, t), 1.21 (6 H, d).
Intermediate (A1e4): ¹ H-NMR (DMSO-D ₆ ) δ: 9.43-9.19 (1H, m), 7.74-7.64 (3H, m), 7.36 (2H, t), 6.07 (2H, s), 4.20 (2H, d), 2.50-2.44 (1H, m), 1.02-0.97 (2H, m), 0.88-0.87 (2H, m).
Intermediate (A1e5): ¹ H-NMR (DMSO-D ₆ ) δ: 9.61 (1H, s), 7.66-7.63 (2H, m), 7.33 (2H, d), 5.79 (2H, s), 4.19- 4.15 (2H, m), 2.93-2.88 (2H, m), 1.68-1.59 (2H, m), 0.93-0.89 (3H, m).
Intermediate (A1e6): ¹ H-NMR (DMSO-D ₆ ) δ: 9.64 (1H, s), 7.66-7.60 (3H, m), 7.35-7. 32 (2H, m), 5.85 (2H, s), 4.15 (2H, d), 2.93-2.89 (2H, m), 1.62-1.54 (2H, m), 1.36-1.26 (2H, m), 0.84 (3H, t).
Intermediate (A1e7): ¹ H-NMR (DMSO-D ₆ ) δ: 9.60 (1H, s), 7.66-7.59 (3H, m), 7.34-7.32 (2H, m), 5.79 (2H, s), 4.15 (2H, d), 2.83 (2H, d), 2.10-2.00 (1 H, m), 0.97 (6 H, d).
Intermediate (A1e8): ¹ H-NMR (DMSO-D ₆ ) δ: 9.60 (1H, s), 7.68 (1H, s), 7.65-7.62 (2H, m), 7.40-7.34 (5H, m), 7.30 (2H, d), 5.79 (2H, s), 4.33 (2H, s), 4.10 (2H, s).
Intermediate (A1e9): ¹ H-NMR (DMSO-D ₆ ) δ: 9.63 (1H, s), 7.66 (2H, d), 7.34 (2H, d), 5.80 (2H, s), 4.35 (2H, s) s), 2.95 (3 H, s), 2.48-2.43 (1 H, m), 0.64 (4 H, d).
Intermediate (A1e10): ¹ H-NMR (DMSO-D ₆ ) δ: 9.59 (1H, s), 7.56 (2H, d), 7.39-7.31 (4H, m), 7.26-7.23 (3H, m), 5.74 (2H, s), 4.87 (2H, s), 3.09 (3H, s).
Intermediate (A1e11): ¹ H-NMR (DMSO-D ₆ ) δ: 9.61 (1H, s), 7.56-7.54 (2H, m), 7.48-7.46 (1H, m), 7.26-7.20 (1H, m) ), 7.19-7.14 (4H, m), 5.76 (2H, s), 4.88-4.85 (1H, m), 4.59-4.56 (1H, m), 3.13 (3H, s), 2.02 (3H, s).
Intermediate (A1e12): ¹ H-NMR (DMSO-D ₆ ) δ: 9.59 (1H, s), 7.57-7.55 (2H, m), 7.26-7.23 (2H, m), 7.21-7.15 (3H, m) , 7.07-7.05 (1H, m), 5.75 (2H, s), 4.85 (2H, s), 3.08 (3H, s), 2.26 (3H, s).
Intermediate (A1e13): ¹ H-NMR (DMSO-D ₆ ) δ: 9.59 (1H, s), 7.56-7.54 (2H, m), 7.26-7.22 (4H, m), 7.13-7.11 (2H, m) ), 5.75 (2H, s), 4.83 (2H, s), 3.06 (3H, s), 2.24 (3H, s).
Intermediate (A1e14): ¹ H-NMR (DMSO-D ₆ ) δ: 9.61 (1H, s), 7.57 (2H, d), 7.46-7.42 (1H, m), 7.36-7.30 (1H, m), 7.27-7.21 (3H, m), 7.18-7.14 (1H, m), 5.76 (2H, s), 4.80 (2H, s), 3.17 (3H, s).
Intermediate (A1e15): ¹ H-NMR (DMSO-D ₆ ) δ: 9.60 (1H, s), 7.56 (2H, d), 7.29-7.23 (3H, m), 7.09-7.07 (1H, m), 7.04-7.02 (1H, m), 6.83-6.79 (1H, m), 5.76 (2H, s), 4.73 (2H, s), 3.87 (3H, s), 3.07 (3H, s).
Intermediate (A1e16): ¹ H-NMR (DMSO-D ₆ ) δ: 9.58 (1H, s), 7.64-7.62 (2H, m), 7.38-7.36 (2H, m), 5.77 (2H, s), 4.48 (2H, s), 3.04 (3H, s), 1.34 (9H, s).
Intermediate (A1e17): ¹ H-NMR (DMSO-D ₆ ) δ: 9.63 (1H, s), 7.68-7.66 (2H, m), 7.39-7.36 (2H, m), 5.81 (2H, s), 4.38 (2H, s), 3.29-3.25 (2H, m), 3.03 (3H, s), 2.49-2.46 (2H, m), 1.97 (3H, s).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ１ｆ１）：¹H-NMR (DMSO-D₆) δ: 9.64 (1H, s), 7.67 (1H, s), 7.58-7.55 (2H, m), 7.36-7.34 (2H, m), 5.79 (2H, s), 4.16 (2H, s), 2.86 (3H, s).
中間体（Ａ１ｆ２）：¹H-NMR (DMSO-D₆) δ: 9.65 (1H, s), 7.68 (1H, s), 7.62-7.58 (1H, m), 7.57-7.55 (1H, m), 7.36-7.34 (2H, m), 5.79 (2H, s), 4.14 (2H, d), 2.94 (2H, q), 1.16 (3H, t).
中間体（Ａ１ｆ３）：¹H-NMR (DMSO-D₆) δ: 9.64 (1H, s), 7.67 (1H, br s), 7.60-7.54 (2H, m), 7.36-7.34 (2H, m), 5.78 (2H, s), 4.17 (2H, d), 3.10-3.06 (1H, m), 1.21 (6H, d).
中間体（Ａ１ｆ４）：¹H-NMR (DMSO-D₆) δ: 9.78 (1H, s), 7.69-7.65 (2H, m), 7.58-7.55 (1H, m), 7.41-7.35 (2H, m), 6.08 (2H, s), 4.20 (2H, d, J = 6.2 Hz), 2.49-2.47 (1H, m), 0.90-0.85 (4H, m). Formula (A1 f)

In the compounds shown by, a combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A1f1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.64 (1H, s), 7.67 (1H, s), 7.58-7.55 (2H, m), 7.36-7.34 (2H, m), 5.79 (2H, s), 4.16 (2H, s), 2.86 (3H, s).
Intermediate (A1 f2): ¹ H-NMR (DMSO-D ₆ ) δ: 9.65 (1 H, s), 7.68 (1 H, s), 7.62-7.58 (1 H, m), 7.57-7.55 (1 H, m), 7.36-7.34 (2H, m), 5.79 (2H, s), 4.14 (2H, d), 2.94 (2H, q), 1.16 (3H, t).
Intermediate (A1f3): ¹ H-NMR (DMSO-D ₆ ) δ: 9.64 (1H, s), 7.67 (1H, br s), 7.60-7.54 (2H, m), 7.36-7.34 (2H, m) , 5.78 (2H, s), 4.17 (2H, d), 3.10-3.06 (1 H, m), 1.21 (6 H, d).
Intermediate (A1f4): ¹ H-NMR (DMSO-D ₆ ) δ: 9.78 (1H, s), 7.69-7.65 (2H, m), 7.58-7.55 (1H, m), 7.41-7.35 (2H, m) ), 6.08 (2H, s), 4.20 (2H, d, J = 6.2 Hz), 2.49-2.47 (1 H, m), 0.90-0.85 (4 H, m).

で示される化合物において、Ｒ¹¹及びＲ¹²の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ１ｇ１）：¹H-NMR (DMSO-D₆) δ: 9.69 (1H, s), 7.67 (2H, d), 7.36 (2H, d), 6.95 (1H, q), 5.87 (2H, s), 4.34 (2H, s), 2.57 (3H, d).
中間体（Ａ１ｇ２）：¹H-NMR (DMSO-D₆) δ: 9.67 (1H, s), 7.68-7.66 (2H, m), 7.36-7.34 (2H, m), 7.07 (1H, t), 5.83 (2H, s), 4.32 (2H, s), 2.97-2.90 (2H, m), 1.04 (3H, t).
中間体（Ａ１ｇ３）：¹H-NMR (DMSO-D₆) δ: 9.68 (1H, s), 7.68-7.65 (2H, m), 7.36 (2H, d), 7.09 (1H, t), 5.86 (2H, s), 4.32 (2H, s), 2.88-2.82 (2H, m), 1.47-1.38 (2H, m), 0.84 (3H, t).
中間体（Ａ１ｇ４）：¹H-NMR (DMSO-D₆) δ: 9.67 (1H, s), 7.66 (2H, d), 7.36 (2H, d), 7.21 (1H, t), 5.83 (2H, s), 4.32 (2H, s), 2.80-2.76 (2H, m), 0.91 (1H, d), 0.45-0.41 (2H, m), 0.18-0.15 (2H, m).
中間体（Ａ１ｇ５）：¹H-NMR (DMSO-D₆) δ: 9.68 (1H, s), 7.69-7.66 (2H, m), 7.41-7.39 (2H, m), 5.84 (2H, s), 4.42 (2H, s), 2.72 (6H, s).
中間体（Ａ１ｇ６）：¹H-NMR (DMSO-D₆) δ: 9.67 (1H, s), 7.68-7.65 (2H, m), 7.42-7.39 (2H, m), 5.83 (2H, s), 4.44 (2H, s), 3.17-3.14 (4H, m), 1.81-1.77 (4H, m). Formula (A1g)

In the compounds shown by, the combination of R ¹¹ and R ¹² is any combination described in the following table.

Intermediate (A1g1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.69 (1H, s), 7.67 (2H, d), 7.36 (2H, d), 6.95 (1H, q), 5.87 (2H, d) s), 4.34 (2H, s), 2.57 (3H, d).
Intermediate (A1g2): ¹ H-NMR (DMSO-D ₆ ) δ: 9.67 (1H, s), 7.68-7.66 (2H, m), 7.36-7.34 (2H, m), 7.07 (1H, t), 5.83 (2H, s), 4.32 (2H, s), 2.97-2.90 (2H, m), 1.04 (3H, t).
Intermediate (A1g3): ¹ H-NMR (DMSO-D ₆ ) δ: 9.68 (1H, s), 7.68-7.65 (2H, m), 7.36 (2H, d), 7.09 (1H, t), 5.86 ( 2H, s), 4.32 (2H, s), 2.88-2.82 (2H, m), 1.47-1.38 (2H, m), 0.84 (3H, t).
Intermediate (A1g4): ¹ H-NMR (DMSO-D ₆ ) δ: 9.67 (1H, s), 7.66 (2H, d), 7.36 (2H, d), 7.21 (1H, t), 5.83 (2H, 5) s), 4.32 (2H, s), 2.80-2.76 (2H, m), 0.91 (1H, d), 0.45-0.41 (2H, m), 0.18-0.15 (2H, m).
Intermediate (A1g5): ¹ H-NMR (DMSO-D ₆ ) δ: 9.68 (1H, s), 7.69-7.66 (2H, m), 7.41-7.39 (2H, m), 5.84 (2H, s), 4.42 (2H, s), 2.72 (6H, s).
Intermediate (A1g6): ¹ H-NMR (DMSO-D ₆ ) δ: 9.67 (1H, s), 7.68-7.65 (2H, m), 7.42-7.39 (2H, m), 5.83 (2H, s), 4.44 (2H, s), 3.17-3.14 (4H, m), 1.81-1.77 (4H, m).

中間体（Ａ１ｇ７）：¹H-NMR (CDCl₃) δ: 7.60-7.56 (2H, m), 6.99-6.95 (2H, m), 5.17 (2H, s), 4.83 (2H, s), 2.26 (3H, s).

Intermediate (A1g7): ¹ H-NMR (CDCl ₃ ) δ: 7.60-7.56 (2H, m), 6.99-6.95 (2H, m), 5.17 (2H, s), 4.83 (2H, s), 2.26 (2. 3H, s).

中間体（Ａ１ｇ８）：¹H-NMR (DMSO-D₆) δ: 9.99 (1H, s), 8.56 (1H, s), 7.89 (1H, d), 7.84-7.81 (1H, m), 5.87 (2H, s), 4.60 (2H, s), 2.97 (3H, s).

Intermediate (A1g8): ¹ H-NMR (DMSO-D ₆ ) δ: 9.99 (1H, s), 8.56 (1H, s), 7.89 (1H, d), 7.84-7.81 (1H, m), 5.87 (1H, s) 2H, s), 4.60 (2H, s), 2.97 (3H, s).

中間体（Ａ１ｇ９）：¹H-NMR (DMSO-D₆) δ: 9.63 (1H, s), 7.66 (2H, d), 7.33 (2H, d), 5.81 (2H, s), 4.09 (2H, s), 3.25 (2H, t), 3.08 (2H, t), 2.25-2.18 (2H, m).

Intermediate (A1g9): ¹ H-NMR (DMSO-D ₆ ) δ: 9.63 (1 H, s), 7.66 (2 H, d), 7.33 (2 H, d), 5.81 (2 H, s), 4.09 (2 H, s), 3.25 (2H, t), 3.08 (2H, t), 2.25-2.18 (2H, m).

中間体（Ａ１ｇ１０）：¹H-NMR (DMSO-D₆) δ: 9.63 (1H, s), 7.66 (2H, d), 7.33 (2H, d), 5.80 (2H, s), 4.26 (2H, s), 3.17 (4H, t), 2.07-2.01 (2H, m), 1.60-1.54 (2H, m).

Intermediate (A1g10): ¹ H-NMR (DMSO-D ₆ ) δ: 9.63 (1H, s), 7.66 (2H, d), 7.33 (2H, d), 5.80 (2H, s), 4.26 (2H, 2) s), 3.17 (4H, t), 2.07-2.01 (2H, m), 1.60-1.54 (2H, m).

中間体（Ａ１ｇ１１）：¹H-NMR (DMSO-D₆) δ: 9.60 (1H, s), 8.22 (1H, s), 7.88-7.83 (2H, m), 7.59-7.57 (2H, m), 7.44-7.38 (2H, m), 7.21 (2H, d), 5.77 (2H, s), 4.00 (2H, s).

Intermediate (A1g11): ¹ H-NMR (DMSO-D ₆ ) δ: 9.60 (1H, s), 8.22 (1H, s), 7.88-7.83 (2H, m), 7.59-7.57 (2H, m), 7.44-7.38 (2H, m), 7.21 (2H, d), 5.77 (2H, s), 4.00 (2H, s).

中間体（Ａ１ｇ１２）：¹H-NMR (DMSO-D₆) δ: 9.84 (1H, s), 7.57-7.45 (3H, m), 5.93 (2H, s), 4.44 (2H, s), 2.76 (6H, s).

Intermediate (A1g12): ¹ H-NMR (DMSO-D ₆ ) δ: 9.84 (1H, s), 7.57-7.45 (3H, m), 5.93 (2H, s), 4.44 (2H, s), 2.76 (2. 6H, s).

中間体（Ａ１ｇ１３）：¹H-NMR (DMSO-D₆) δ: 9.57 (1H, s), 7.68 (1H, s), 7.62-7.60 (2H, m), 7.30 (2H, d), 5.77 (2H, s), 4.09 (2H, s), 2.61 (6H, s).

Intermediate (A1g13): ¹ H-NMR (DMSO-D ₆ ) δ: 9.57 (1H, s), 7.68 (1H, s), 7.62-7.60 (2H, m), 7.30 (2H, d), 5.77 (5 2H, s), 4.09 (2H, s), 2.61 (6H, s).

中間体（Ａ１ｃ１）：¹H-NMR (DMSO-D₆) δ: 9.70 (1H, s), 7.70-7.68 (2H, m), 7.41-7.39 (2H, m), 5.84 (2H, s), 4.50 (2H, s), 2.91 (3H, s). Reference Production Example 2-1
A mixture of 1.7 g of the intermediate (A2c1) described in Reference Production Example 4-1, 20 mL of ethanol, and 1.9 mL of 50% aqueous hydroxylamine solution was stirred for 5 hours under heating to reflux. After cooling to room temperature, the precipitate was collected by filtration, and the obtained precipitate was washed with 50 mL of ethanol and dried under reduced pressure to obtain 1.2 g of an intermediate (A1c1).

Intermediate (A1c1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.70 (1H, s), 7.70-7.68 (2H, m), 7.41-7.39 (2H, m), 5.84 (2H, s), 4.50 (2H, s), 2.91 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹、Ｒ¹⁰、Ｒ²¹及びＲ²²の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ１ｃ２）：¹H-NMR (DMSO-D₆) δ: 9.86 (1H, s), 7.58-7.56 (1H, m), 7.54-7.51 (1H, m), 7.48-7.44 (1H, m), 5.94 (2H, s), 4.56 (2H, s), 3.01 (3H, s).
中間体（Ａ１ｃ３）：¹H-NMR (DMSO-D₆) δ: 9.70 (1H, s), 7.55-7.51 (1H, m), 7.29-7.24 (2H, m), 5.85 (2H, s), 4.55 (2H, s), 2.94 (3H, s). Reference Production Example 2-2
The intermediate compounds produced according to the method described in Reference Production Example 2-1 and the physical properties thereof are shown below.
Formula (A1c)

And R ⁸ , R ⁹ , R ¹⁰ , R ²¹ and R ²² in any of the combinations shown in the following table.

Intermediate (A1c2): ¹ H-NMR (DMSO-D ₆ ) δ: 9.86 (1H, s), 7.58 to 7.56 (1H, m), 7.54 to 7.51 (1H, m), 7.48 to 7.44 (1H, m) ), 5.94 (2H, s), 4.56 (2H, s), 3.01 (3H, s).
Intermediate (A1c3): ¹ H-NMR (DMSO-D ₆ ) δ: 9.70 (1H, s), 7.55 to 7.51 (1H, m), 7.29 to 7.24 (2H, m), 5.85 (2H, s), 4.55 (2H, s), 2.94 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載の組合せである化合物。

中間体（Ａ１ｄ１）：¹H-NMR (DMSO-D₆) δ: 9.68 (1H, s), 7.74-7.72 (1H, m), 7.67-7.64 (1H, m), 7.42-7.40 (2H, m), 5.82 (2H, s), 4.49 (2H, s), 2.91 (3H, s). Formula (A1d)

Compounds in which R ⁸ , R ⁹ and R ¹⁰ have the combinations given in the following table.

Intermediate (A1d1): ¹ H-NMR (DMSO-D ₆ ) δ: 9.68 (1H, s), 7.74-7.72 (1H, m), 7.67-7.64 (1H, m), 7.42-7.40 (2H, m) ), 5.82 (2H, s), 4.49 (2H, s), 2.91 (3H, s).

中間体（Ａ２ａ１）：¹H-NMR (CDCl₃) δ: 7.63-7.61 (2H, m), 7.43-7.41 (2H, m), 3.70 (2H, s), 1.99 (3H, s). Reference Production Example 3-1
A mixture of 2.0 g of 4- (bromomethyl) benzonitrile, 50 mL of ethanol, and 0.72 g of sodium methanethiolate was stirred for 5 hours while heating to reflux. After cooling to room temperature, 20 mL of water was added to the reaction mixture and then extracted with diethyl ether. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure to give 1.7 g of an intermediate (A2a1).

Intermediate (A2a1): ¹ H-NMR (CDCl ₃ ) δ: 7.63-7.61 (2H, m), 7.43-7.41 (2H, m), 3.70 (2H, s), 1.99 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ２ａ２）：¹H-NMR (CDCl₃) δ: 7.62-7.60 (2H, m), 7.44-7.42 (2H, m), 3.74 (2H, s), 2.42 (2H, q), 1.23 (3H, t).
中間体（Ａ２ａ３）：¹H-NMR (CDCl₃) δ: 7.61-7.59 (2H, m), 7.45-7.44 (2H, m), 3.76 (2H, s), 2.80-2.73 (1H, m), 1.25 (6H, d, J = 6.6 Hz). Reference Production Example 3-2
Intermediate compounds produced according to the method described in Reference Production Example 3-1 and physical property values thereof are shown below.
Formula (A2a)

In the compounds shown by, the combination of R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A2a2): ¹ H-NMR (CDCl ₃ ) δ: 7.62 to 7.60 (2H, m), 7.44 to 7.42 (2H, m), 3.74 (2H, s), 2.42 (2H, q), 1.23 (1.23) 3H, t).
Intermediate (A2a3): ¹ H-NMR (CDCl ₃ ) δ: 7.61-7.59 (2H, m), 7.45-7.44 (2H, m), 3.76 (2H, s), 2.80-2.73 (1H, m), 1.25 (6H, d, J = 6.6 Hz).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載の組合せである化合物。

中間体（Ａ２ｂ１）：¹H-NMR (CDCl₃) δ: 7.62-7.61 (1H, m), 7.57-7.56 (1H, m), 7.55-7.54 (1H, m), 7.45-7.41 (1H, m), 3.68 (2H, s), 2.00 (3H, s). Formula (A2b)

Compounds in which R ⁸ , R ⁹ and R ¹⁰ have the combinations given in the following table.

Intermediate (A2b1): ¹ H-NMR (CDCl ₃ ) δ: 7.62 to 7.61 (1H, m), 7.57 to 7.56 (1H, m), 7.55 to 7.54 (1H, m), 7.45 to 7.41 (1H, m) ), 3.68 (2H, s), 2.00 (3H, s).

中間体（Ａ２ｃ１）：¹H-NMR (CDCl₃) δ: 7.73 (2H, d), 7.56 (2H, d), 4.31 (2H, s), 2.85 (3H, s). Reference Production Example 4-1
A mixture of 1.5 g of 4- (bromomethyl) benzonitrile, 50 mL of 1-methyl-2-pyrrolidone, and 0.78 g of sodium methanesulfinate was stirred at 100 ° C. for 10 hours. After cooling to room temperature, 100 mL of water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure to give 1.8 g of an intermediate (A2c1).

Intermediate (A2c1): ¹ H-NMR (CDCl ₃ ) δ: 7.73 (2H, d), 7.56 (2H, d), 4.31 (2H, s), 2.85 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹、Ｒ¹⁰、Ｒ²¹及びＲ²²の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ２ｃ２）：¹H-NMR (DMSO-D₆) δ: 7.97-7.95 (1H, m), 7.79-7.77 (1H, m), 7.70-7.66 (1H, m), 4.69 (2H, s), 3.06 (3H, s).
中間体（Ａ２ｃ３）：¹H-NMR (DMSO-D₆) δ: 8.02-7.98 (1H, m), 7.58-7.56 (1H, m), 7.48-7.45 (1H, m), 4.68 (2H, s), 2.97 (3H, s). Reference Production Example 4-2
The intermediate compounds produced according to the method described in Reference Production Example 4-1 and the physical properties thereof are shown below.
Formula (A2c)

And R ⁸ , R ⁹ , R ¹⁰ , R ²¹ and R ²² in any of the combinations shown in the following table.

Intermediate (A2c2): ¹ H-NMR (DMSO-D ₆ ) δ: 7.97-7.95 (1H, m), 7.79-7.77 (1H, m), 7.70-7.66 (1H, m), 4.69 (2H, s) ), 3.06 (3H, s).
Intermediate (A2c3): ¹ H-NMR (DMSO-D ₆ ) δ: 8.02 to 7.98 (1H, m), 7.58 to 7.56 (1H, m), 7.48 to 7.45 (1H, m), 4.68 (2H, s) ), 2.97 (3H, s).

で示される化合物において、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載の組合せである化合物。

中間体（Ａ２ｄ１）：¹H-NMR (CDCl₃) δ: 7.74-7.69 (3H, m), 7.57 (1H, t), 4.29 (2H, s), 2.86 (3H, s). Formula (A2d)

Compounds in which R ⁸ , R ⁹ and R ¹⁰ have the combinations given in the following table.

Intermediate (A2d1): ¹ H-NMR (CDCl ₃ ) δ: 7.74-7.69 (3H, m), 7.57 (1H, t), 4.29 (2H, s), 2.86 (3H, s).

中間体（Ａ２ｄ２）：¹H-NMR (DMSO-D₆) δ: 8.76-8.75 (1H, m), 8.12-8.07 (2H, m), 4.73 (2H, s), 3.01 (3H, s).

Intermediate (A2d2): ¹ H-NMR (DMSO-D ₆ ) δ: 8.76-8.75 (1H, m), 8.12-8.07 (2H, m), 4.73 (2H, s), 3.01 (3H, s).

中間体（Ａ２ｅ１）：¹H-NMR (DMSO-D₆) δ: 7.85-7.82 (2H, m), 7.76 (1H, br s), 7.56-7.54 (2H, m), 4.26 (2H, s), 2.92 (3H, s). Reference Production Example 5-1
After sequentially adding 1.0 mL of methanesulfonyl chloride and 1.6 mL of triethylamine to a mixture of 1.0 g of 4- (aminomethyl) benzonitrile and 20 mL of tetrahydrofuran at room temperature, the mixture was stirred for 10 hours. To the reaction mixture was added 20 mL of water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure to give 1.1 g of an intermediate (A2e1).

Intermediate (A2e1): ¹ H-NMR (DMSO-D ₆ ) δ: 7.85-7.82 (2H, m), 7.76 (1H, br s), 7.56-7.54 (2H, m), 4.26 (2H, s) , 2.92 (3H, s).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ２ｅ２）：¹H-NMR (CDCl₃) δ: 7.68-7.66 (2H, m), 7.50-7.48 (2H, m), 4.66 (1H, br s), 4.38 (2H, d), 3.02 (2H, q), 1.37 (3H, t).
中間体（Ａ２ｅ３）：¹H-NMR (CDCl₃) δ: 7.68-7.66 (2H, m), 7.50-7.48 (2H, m), 4.41 (3H, br s), 3.16-3.13 (1H, m), 1.39 (6H, d).
中間体（Ａ２ｅ４）：¹H-NMR (CDCl₃) δ: 7.67-7.63 (2H, m), 7.52-7.49 (2H, m), 5.15 (1H, s), 4.42-4.39 (2H, m), 2.40-2.33 (1H, m), 1.16-1.11 (2H, m), 1.00-0.93 (2H, m).
中間体（Ａ２ｅ５）：¹H-NMR (CDCl₃) δ: 7.68-7.66 (2H, m), 7.50-7.48 (2H, m), 4.65-4.64 (1H, m), 4.38 (2H, d), 2.99-2.95 (2H, m), 1.89-1.80 (2H, m), 1.04 (3H, t).
中間体（Ａ２ｅ６）：¹H-NMR (CDCl₃) δ: 7.68-7.65 (2H, m), 7.50-7.48 (2H, m), 4.74 (1H, t), 4.38 (2H, d), 3.00-2.96 (2H, m), 1.81-1.73 (2H, m), 1.47-1.38 (2H, m), 0.93 (3H, t).
中間体（Ａ２ｅ７）：¹H-NMR (CDCl₃) δ: 7.67 (2H, d), 7.49 (2H, d), 4.70-4.67 (1H, m), 4.37 (2H, d), 2.89 (2H, d), 2.30-2.20 (1H, m), 1.09 (6H, d). Reference Production Example 5-2
Intermediate compounds produced according to the method described in Reference Production Example 5-1 and physical property values thereof are shown below.
Formula (A2e)

In the compounds shown by, a combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A2e2): ¹ H-NMR (CDCl ₃ ) δ: 7.68-7.66 (2H, m), 7.50-1.48 (2H, m), 4.66 (1H, br s), 4.38 (2H, d), 3.02 (2H, q), 1.37 (3H, t).
Intermediate (A2e3): ¹ H-NMR (CDCl ₃ ) δ: 7.68-7.66 (2H, m), 7.50-1.48 (2H, m), 4.41 (3H, br s), 3.16-3. 13 (1H, m) , 1.39 (6H, d).
Intermediate (A2e4): ¹ H-NMR (CDCl ₃ ) δ: 7.67-7.63 (2H, m), 7.52-7.49 (2H, m), 5.15 (1H, s), 4.42-4.39 (2H, m), 2.40-2.33 (1 H, m), 1.16-1.11 (2 H, m), 1.00-0.93 (2 H, m).
Intermediate (A2e5): ¹ H-NMR (CDCl ₃ ) δ: 7.68-7.66 (2H, m), 7.50-7.48 (2H, m), 4.65-4.64 (1H, m), 4.38 (2H, d), 2.99-2.95 (2H, m), 1.89-1.80 (2H, m), 1.04 (3H, t).
Intermediate (A2e6): ¹ H-NMR (CDCl ₃ ) δ: 7.68-7.65 (2H, m), 7.50-1.48 (2H, m), 4.74 (1H, t), 4.38 (2H, d), 3.00- 2.96 (2H, m), 1.81-1.73 (2H, m), 1.47-1.38 (2H, m), 0.93 (3H, t).
Intermediate (A2e7): ¹ H-NMR (CDCl ₃ ) δ: 7.67 (2H, d), 7.49 (2H, d), 4.704 to 4.67 (1H, m), 4.37 (2H, d), 2.89 (2H, d) d), 2.30-2.20 (1 H, m), 1.09 (6 H, d).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合わせが下表に記載のいずれかの組合せである化合物。

中間体（Ａ２ｆ１）：¹H-NMR (CDCl₃) δ: 7.67-7.62 (3H, m), 7.53-7.48 (1H, m), 4.76 (1H, br s), 4.38 (2H, d, J = 6.6 Hz), 2.96 (3H, s).
中間体（Ａ２ｆ２）：¹H-NMR (CDCl₃) δ: 7.66-7.60 (3H, m), 7.52-7.47 (1H, m), 5.04 (1H, s), 4.36-4.34 (2H, m), 3.04-2.98 (2H, m), 1.38-1.33 (3H, m).
中間体（Ａ２ｆ３）：¹H-NMR (CDCl₃) δ: 7.66-7.59 (3H, m), 7.51-7.47 (1H, m), 4.84 (1H, s), 4.36 (2H, s), 3.17-3.10 (1H, m), 1.38 (6H, d).
中間体（Ａ２ｆ４）：¹H-NMR (CDCl₃) δ: 7.69-7.67 (1H, m), 7.65-7.58 (2H, m), 7.51-7.45 (1H, m), 5.01 (1H, s), 4.39-4.38 (2H, m), 2.42-2.34 (1H, m), 1.18-1.10 (2H, m), 1.04-0.93 (2H, m). Formula (A2f)

In the compounds shown by, a combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in the following table.

Intermediate (A2f1): ¹ H-NMR (CDCl ₃ ) δ: 7.67-7.62 (3H, m), 7.53-7.48 (1H, m), 4.76 (1H, br s), 4.38 (2H, d, J = 6.6 Hz), 2.96 (3H, s).
Intermediate (A2f2): ¹ H-NMR (CDCl ₃ ) δ: 7.66-7.60 (3H, m), 7.52-7.47 (1H, m), 5.04 (1H, s), 4.36-4.34 (2H, m), 3.04-2.98 (2H, m), 1.38-1.33 (3H, m).
Intermediate (A2f3): ¹ H-NMR (CDCl ₃ ) δ: 7.66-7.59 (3H, m), 7.51-7.47 (1H, m), 4.84 (1H, s), 4.36 (2H, s), 3.17- 3.10 (1 H, m), 1. 38 (6 H, d).
Intermediate (A2f4): ¹ H-NMR (CDCl ₃ ) δ: 7.69-7.67 (1H, m), 7.65-7.58 (2H, m), 7.51-7.45 (1H, m), 5.01 (1H, s), 4.39-4.38 (2H, m), 2.42-2.34 (1H, m), 1.18-1.10 (2H, m), 1.04-0.93 (2H, m).

中間体（Ａ２ｆ５）：¹H-NMR (CDCl₃) δ: 7.68-7.64 (2H, m), 7.49-7.47 (2H, m), 4.61 (1H, s), 4.30 (2H, d), 2.78 (6H, s).

Intermediate (A2f5): ¹ H-NMR (CDCl ₃ ) δ: 7.68-7.64 (2H, m), 7.49-7.47 (2H, m), 4.61 (1H, s), 4.30 (2H, d), 2.78 (2. 6H, s).

中間体（Ａ２ｇ３）：¹H-NMR (CDCl₃) δ: 7.71-7.68 (2H, m), 7.54-7.52 (2H, m), 4.29 (2H, s), 4.21 (1H, t), 3.02-2.97 (2H, m), 1.59-1.49 (2H, m), 0.92 (3H, t). Reference Production Example 6-1
After 0.27 g of propylamine was added to a mixture of 0.5 g of (4-cyanophenyl) methanesulfonyl chloride and 5 mL of tetrahydrofuran at 0 ° C., the mixture was stirred at room temperature for 5 hours. 10 mL of water was added to the reaction mixture, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography to obtain 0.4 g of an intermediate (A2g3).

Intermediate (A2g3): ¹ H-NMR (CDCl ₃ ) δ: 7.71-7.68 (2H, m), 7.54-7.52 (2H, m), 4.29 (2H, s), 4.21 (1H, t), 3.02- 2.97 (2H, m), 1.59-1.49 (2H, m), 0.92 (3H, t).

で示される化合物において、Ｒ¹¹及びＲ¹²の組合わせが下表に記載の組合せである化合物。

中間体（Ａ２ｇ１）：¹H-NMR (CDCl₃) δ: 7.70 (2H, d), 7.53 (2H, d), 4.30 (2H, s), 4.20 (1H, br s), 2.75-2.73 (3H, m).
中間体（Ａ２ｇ２）：¹H-NMR (CDCl₃) δ: 7.70-7.68 (2H, m), 7.54-7.52 (2H, m), 4.29 (2H, s), 3.11-3.04 (2H, m), 1.17 (3H, t).
中間体（Ａ２ｇ４）：¹H-NMR (CDCl₃) δ: 7.71-7.68 (2H, m), 7.55-7.52 (2H, m), 4.31 (2H, s), 2.89 (2H, dd), 1.01-0.94 (1H, m), 0.59-0.54 (2H, m), 0.22-0.18 (2H, m).
中間体（Ａ２ｇ５）：¹H-NMR (CDCl₃) δ: 7.70 (2H, d, J = 8.2 Hz), 7.54 (2H, d, J = 8.2 Hz), 4.24 (2H, s), 2.80 (6H, s).
中間体（Ａ２ｇ６）：¹H-NMR (CDCl₃) δ: 7.70-7.67 (2H, m), 7.55-7.52 (2H, m), 4.27 (2H, s), 3.24-3.21 (4H, m), 1.89-1.86 (4H, m). Reference Production Example 6-2
Intermediate compounds produced according to the method described in Reference Production Example 6-1 and physical properties thereof are shown below.
Formula (A2g)

In the compounds shown by, the combination of R ¹¹ and R ¹² is a combination described in the following table.

Intermediate (A2g1): ¹ H-NMR (CDCl ₃ ) δ: 7.70 (2H, d), 7.53 (2H, d), 4.30 (2H, s), 4.20 (1H, br s), 2.75-2.73 (3H , m).
Intermediate (A2g2): ¹ H-NMR (CDCl ₃ ) δ: 7.70-7.68 (2H, m), 7.54-7.52 (2H, m), 4.29 (2H, s), 3.11-3.04 (2H, m), 1.17 (3H, t).
Intermediate (A2g4): ¹ H-NMR (CDCl ₃ ) δ: 7.71-7.68 (2H, m), 7.55-7.52 (2H, m), 4.31 (2H, s), 2.89 (2H, dd), 1.01- 0.94 (1 H, m), 0.59-0.54 (2 H, m), 0.22-0.18 (2 H, m).
Intermediate (A2g5): ¹ H-NMR (CDCl ₃ ) δ: 7.70 (2H, d, J = 8.2 Hz), 7.54 (2H, d, J = 8.2 Hz), 4.24 (2H, s), 2.80 (6H , s).
Intermediate (A2g6): ¹ H-NMR (CDCl ₃ ) δ: 7.70-7.67 (2H, m), 7.55-7.52 (2H, m), 4.27 (2H, s), 3.24-3.21 (4H, m), 1.89-1.86 (4H, m).

中間体（Ａ２ｇ７）：¹H-NMR (CDCl₃) δ: 7.67 (1H, t), 7.53-7.50 (1H, m), 7.45-7.42 (1H, m), 4.32-4.31 (2H, m), 2.81 (6H, s).

Intermediate (A2g7): ¹ H-NMR (CDCl ₃ ) δ: 7.67 (1H, t), 7.53-7.50 (1H, m), 7. 45-7. 42 (1H, m), 4.32-4. 31 (2H, m), 2.81 (6H, s).

中間体（Ａ２ｅ８）：¹H-NMR (CDCl₃) δ: 7.67-7.65 (2H, m), 7.53-7.51 (2H, m), 4.47 (2H, s), 2.89 (3H, s), 2.42-2.37 (1H, m), 0.81-0.76 (4H, m). Reference Production Example 7-1
At 0 ° C., 0.1 g of sodium hydride (60%, oily) was added to a mixture of 0.3 g of N-cyclopropylmethanesulfonamide and 20 mL of N, N-dimethylformamide, and the mixture was stirred for 0.5 hours. 0.5 g of 4-cyanobenzyl bromide was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. 10 mL of water was added to the reaction mixture, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography to obtain 0.4 g of an intermediate (A2e8).

Intermediate (A2e8): ¹ H-NMR (CDCl ₃ ) δ: 7.67-7.65 (2H, m), 7.53 to 7.51 (2H, m), 4.47 (2H, s), 2.89 (3H, s), 2.42- 2.37 (1 H, m), 0.81-0.76 (4 H, m).

で示される化合物において、Ｒ⁶、Ｒ⁸、Ｒ⁹及びＲ¹⁰の組合せが下表に記載のいずれかの組合せである化合物。

中間体（Ａ２ｅ９）：¹H-NMR (CDCl₃) δ: 7.58-7.56 (2H, m), 7.41-7.39 (2H, m), 7.37-7.30 (3H, m), 7.28-7.25 (2H, m), 4.91 (2H, s), 2.98 (3H, s).
中間体（Ａ２ｅ１０）：¹H-NMR (CDCl₃) δ: 7.58-7.55 (2H, m), 7.36-7.34 (2H, m), 7.25-7.19 (3H, m), 7.16-7.14 (1H, m), 4.83-4.69 (2H, m), 2.99 (3H, s), 2.12 (3H, s).
中間体（Ａ２ｅ１１）：¹H-NMR (CDCl₃) δ: 7.59-7.56 (2H, m), 7.42-7.40 (2H, m), 7.24-7.21 (1H, m), 7.11-7.04 (3H, m), 4.89 (2H, s), 2.97 (3H, s), 2.32 (3H, s).
中間体（Ａ２ｅ１２）：¹H-NMR (CDCl₃) δ: 7.58-7.55 (2H, m), 7.41-7.39 (2H, m), 7.13 (4H, s), 4.87 (2H, s), 2.96 (3H, s), 2.31 (3H, s).
中間体（Ａ２ｅ１３）：¹H-NMR (CDCl₃) δ: 7.59-7.57 (2H, m), 7.51-7.48 (1H, m), 7.42 (2H, d), 7.33-7.31 (1H, m), 7.18-7.14 (1H, m), 7.09-7.06 (1H, m), 4.85 (2H, s), 3.04 (3H, d).
中間体（Ａ２ｅ１４）：¹H-NMR (CDCl₃) δ: 7.57-7.54 (2H, m), 7.40 (2H, d), 7.31-7.27 (1H, m), 7.09-7.07 (1H, m), 6.96-6.93 (1H, m), 6.87-6.83 (1H, m), 4.82 (2H, s), 3.93 (3H, s), 2.99 (3H, s).
中間体（Ａ２ｅ１５）：¹H-NMR (CDCl₃) δ: 7.65-7.63 (2H, m), 7.54-7.51 (2H, m), 4.57 (2H, s), 3.01 (3H, s), 1.43 (9H, s).
中間体（Ａ２ｅ１６）：¹H-NMR (CDCl₃) δ: 7.64 (2H, d), 7.50 (2H, d), 4.39 (2H, s), 4.24-4.33 (1H, m), 2.90 (3H, s), 1.36-1.90 (8H, m)
中間体（Ａ２ｅ１７）：¹H-NMR (CDCl₃) δ: 7.63 (2H, d), 7.53 (2H, d), 4.42 (2H, s), 3.69-3.76 (1H, m), 2.88 (3H, s), 1.77 (4H, d), 1.58-1.64 (1H, m), 1.28-1.33 (5H, m).
中間体（Ａ２ｅ１８）：¹H-NMR (CDCl₃) δ: 7.69-7.66 (2H, m), 7.52-7.50 (2H, m), 4.48 (2H, s), 3.40 (2H, t), 2.99 (3H, s), 2.56 (2H, t), 2.07 (3H, s). Reference Production Example 7-2
Intermediate compounds produced according to the method described in Reference Production Example 7-1 and physical property values thereof are shown below.
Formula (A2e)

In the compounds shown by, the combination of R ⁶ , R ⁸ , R ⁹ and R ¹⁰ is any combination described in the table below.

Intermediate (A2e9): ¹ H-NMR (CDCl ₃ ) δ: 7.58 to 7.56 (2H, m), 7.41 to 7.39 (2H, m), 7.37 to 7.30 (3H, m), 7.28 to 7.25 (2H, m) ), 4.91 (2H, s), 2.98 (3H, s).
Intermediate (A2e10): ¹ H-NMR (CDCl ₃ ) δ: 7.58 to 7.55 (2H, m), 7.36 to 7.34 (2H, m), 7.25 to 7.19 (3H, m), 7.16 to 7.14 (1H, m) ), 4.83-4.69 (2H, m), 2.99 (3H, s), 2.12 (3H, s).
Intermediate (A2e11): ¹ H-NMR (CDCl ₃ ) δ: 7.59-7.56 (2H, m), 7.42-7.40 (2H, m), 7.24-7.21 (1H, m), 711-7.04 (3H, m) ), 4.89 (2H, s), 2.97 (3H, s), 2.32 (3H, s).
Intermediate (A2e12): ¹ H-NMR (CDCl ₃ ) δ: 7.58 to 7.55 (2H, m), 7.41-7.39 (2H, m), 7.13 (4H, s), 4.87 (2H, s), 2.96 (2. 3H, s), 2.31 (3H, s).
Intermediate (A2e13): ¹ H-NMR (CDCl ₃ ) δ: 7.59 to 7.57 (2H, m), 7.51 to 7.48 (1H, m), 7.42 (2H, d), 7.33 to 7.31 (1H, m), 7.18-7.14 (1 H, m), 7.09-7.06 (1 H, m), 4. 85 (2 H, s), 3.04 (3 H, d).
Intermediate (A2e14): ¹ H-NMR (CDCl ₃ ) δ: 7.57-7.54 (2H, m), 7.40 (2H, d), 7.31-7.27 (1H, m), 7.09-7.07 (1H, m), 6.96-6.93 (1H, m), 6.87-6.83 (1H, m), 4.82 (2H, s), 3.93 (3H, s), 2.99 (3H, s).
Intermediate (A2e15): ¹ H-NMR (CDCl ₃ ) δ: 7.65-7.63 (2H, m), 7.54-7.51 (2H, m), 4.57 (2H, s), 3.01 (3H, s), 1.43 (1.42) 9H, s).
Intermediate (A2e16): ¹ H-NMR (CDCl ₃ ) δ: 7.64 (2H, d), 7.50 (2H, d), 4.39 (2H, s), 4.24-4.33 (1H, m), 2.90 (3H, 3) s), 1.36 to 1.90 (8H, m)
Intermediate (A2e17): ¹ H-NMR (CDCl ₃ ) δ: 7.63 (2H, d), 7.53 (2H, d), 4.42 (2H, s), 3.69-3.76 (1H, m), 2.88 (3H, 3) s), 1.77 (4H, d), 1.58-1.64 (1H, m), 1.28-1.33 (5H, m).
Intermediate (A2e18): ¹ H-NMR (CDCl ₃ ) δ: 7.69-7.66 (2H, m), 7.52-7.50 (2H, m), 4.48 (2H, s), 3.40 (2H, t), 2.99 (2.99) 3H, s), 2.56 (2H, t), 2.07 (3H, s).

中間体（Ａ２ｅ１９）：¹H-NMR (CDCl₃) δ: 7.67-7.65 (2H, m), 7.49-7.47 (2H, m), 4.36 (2H, s), 3.23 (2H, t), 3.12 (2H, t), 2.28-2.22 (2H, m), 1.70-1.64 (2H, m).

Intermediate (A2e19): ¹ H-NMR (CDCl ₃ ) δ: 7.67-7.65 (2H, m), 7.49-7.47 (2H, m), 4.36 (2H, s), 3.23 (2H, t), 3.12 (3) 2H, t), 2.28-2.22 (2H, m), 1. 70-1. 64 (2H, m).

中間体（Ａ２ｈ１）：¹H-NMR (CDCl₃) δ: 7.62-7.60 (2H, m), 7.02-7.00 (2H, m), 5.19 (2H, s), 2.26 (3H, s). Reference Production Example 8-1
At 0 ° C., 0.8 g of sodium hydride (60%, oily) was added to a mixture of 2.0 g of 4-cyanophenol and 40 mL of N, N-dimethylformamide and stirred for 0.5 hours. To the reaction mixture, 2.4 g of chloromethyl methyl sulfide was added and stirred at room temperature for 12 hours. To the reaction mixture was added 20 mL of water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography to obtain 3.0 g of an intermediate (A2h1).

Intermediate (A2h1): ¹ H-NMR (CDCl ₃ ) δ: 7.62-7.60 (2H, m), 7.02-7.00 (2H, m), 5.19 (2H, s), 2.26 (3H, s).

  In the present specification, Me represents a methyl group, Et represents an ethyl group, Pr represents a propyl group, i-Pr represents an isopropyl group, c-Pr represents a cyclopropyl group, and Bu represents a butyl group. I-Bu represents an isobutyl group, t-Bu represents a tert-butyl group, c-Pentyl represents a cyclopentyl group, c-Hexyl represents a cyclohexyl group, Ph represents a phenyl group, and Bn represents benzyl The group, Py represents a pyridyl group.

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³及びＲ²⁴は、水素原子又は群Ｉで表される置換基を表し、Ｒ²⁵は群Ａ及び群Ｆからなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基又は１以上のハロゲン原子を有していてもよいフェニル基を表す。〕
で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが、下記に示される置換基番号ＲＡ１〜ＲＡ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＡ１〜ＲＡ１１２の化合物を本発明化合物ＲＡ１〜ＲＡ１１２と表し、本発明化合物ＲＡ１〜ＲＡ１１２をまとめて本発明化合物ＲＡと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＡ１〜ＲＡ１１２とは、式（ＩＩ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＡ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (II)

[Wherein, R ²¹ , R ²² , R ²³ and R ^{24 each} represent a hydrogen atom or a substituent represented by group I, and R ²⁵ represents one or more substituents selected from the group consisting of group A and group F] And an optionally substituted C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group optionally having one or more halogen atoms, or a phenyl group optionally having one or more halogen atoms. ]
In the compound represented by this, the compound in which the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ is a combination described in any of the substituent numbers RA1 to RA112 shown below (hereinafter referred to as Compounds of Substituent Nos. RA1 to RA112 are referred to as Inventive Compounds RA1 to RA112, and Inventive Compounds RA1 to RA112 are collectively referred to as Inventive Compound RA) can be obtained according to the method described in the above-mentioned production method it can.
Substituent numbers RA1 to RA112 represent a combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 in} the compound represented by the formula (II), and Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RA4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RA4 of the present invention means a compound having a substituent number of RA4 in the compound represented by the formula (II), and R ²¹ , R ²² and R ²³ in the compound represented by the formula (II) And R ²⁴ is a hydrogen atom, and R ²⁵ is an isopropyl group.

[Substituent group ^{number; R 21, R 22, R} 23, R 24, R 25]: [RA1; H, H, H, H, Me], [RA2; H, H, H, H, Et], [ RA3; H, H, H, H, Pr, [RA 4; H, H, H, H, i-Pr], [RA 5; H, H, H, H, c-Pr], [RA 6; H, H, H, H, Bu], [RA7; H, H, H, H, i, Bu], [RA 8; H, H, H, H, t, Bu], [RA 9; H, H, H, H _{H, c-PrCH 2],} [RA10; H, H, H, H, Ph], [RA11; H, H, H, H, Bn], [RA12; H, H, H, H, CF 3] , [RA 13; H, H, H, H, CF ₃ CH ₂ ], [RA 14; H, H, H, H, CF ₃ CF ₂ ], [RA 15; H, H, H, H, CF ₂ H] , [RA 16; H, H, H, H, CF ₂ HCH ₂ ], [RA 17; F, H, H, H, Me], [RA 18; F, H, H, H, Et], [RA 19; , H, H, H, Pr], [RA 20; F, H, H, H, i-Pr], [RA 21; F, H, H, H, c, Pr], [RA 22; F, H, H , H, Bu], [RA23; F, H, H, H, i-Bu], [RA 24; F, H, H, H, t, Bu], [RA 25; F, H, H, H, c _{-PrCH 2], [RA26; F} , H, H, H, Ph], [RA27; F, H, H, H, Bn], [RA28; F, H, H, H, CF 3], [RA29 F, H, H, H, H, CF ₃ CH ₂ ], [RA 30; F, H, H, H, CF ₃ CF ₂ ], [RA 31; F, H, H, H, CF ₂ H], [RA 32 F, H, H, H, H, CF ₂ HCH ₂ ], [RA 33; H, F, H, H, Me], [RA 34; H, F, H, H, Et], [RA 35; H, F, H, H, Pr], [RA 36; H, F, H, H, i-Pr], [RA 37; H, F, H, H, c-Pr], [RA 38; H, F, H, H, H Bu], [RA 39; H, F, H, H, i-Bu], [RA 40; H, F, H, H, t-Bu], [RA 41; H, F, H, H, c-PrCH ₂ ], [RA42; H, F, H, H, Ph], [RA 43; H, F, H, H, Bn], [RA 44; H, F, H, H, CF ₃ ], [RA 45; H, F, H, H, CF ₃ CH ₂ ], [RA 46; H, F, H, H, CF ₃ CF ₂ ], [RA 47 H, F, H, H, CF ₂ H], [RA 48; H, F, H, H, CF ₂ HCH ₂ ], [RA 49; F, F, H, H, Me], [RA 50; F, F, H, H, Et], [RA 51; F, F, H, H, Pr], [RA 52; F, F, H, H, i-Pr], [RA 53; F, F, H, H, c-Pr], [RA 54; F, F, H, H, Bu], [RA 55; F, F, H, H, i-Bu], [RA 56; F, F, H, H, t-Bu] , [RA 57; F, F, H, H, c-PrCH ₂ ], [RA 58; F, F, H, H, Ph], [RA 59; F, F, H, H, Bn], [RA 60; , F, H, H, CF ₃ ], [RA 61; F, F, H, H, CF ₃ CH ₂ ], [RA 62; F, F, H, H, CF ₃ CF ₂ ], [RA 63; F, F, H, H, CF ₂ H], [RA 64; F, F, H, H, CF ₂ HCH ₂ ], [RA 65; F, H, F, H, Me], [RA 66; F, H, F , H, Et], [RA 67; F, H, F, H, Pr], [RA 68; F, H, F, H, i-Pr], [RA 69; F, H, F, H, c-Pr ], [RA 70; F, H, F, H, Bu], [RA 71; F, H, F, H, i-Bu], [RA 72; F, H, F, H, t-Bu], [RA 73] F, H, F, H, c-PrCH ₂ ], [RA 74; F, H, F, H, Ph], [RA 75; F, H, F, H, Bn], [RA 76; F, H, F, H, CF ₃ ], [RA 77; F, H, F, H, CF ₃ CH ₂ ], [RA 78; F, H, F, H, CF ₃ CF ₂ ], [RA 79; F, H, F _{, H, CF 2 H],} [RA80; F, H, F, H, CF 2 HCH 2], [RA81; F, H, H, F, Me], [RA82; F, H, H, F, Et], [RA 83; F, H, H, F, Pr], [RA 84; F, H, H, F, i-Pr], [RA 85; F, H, H, F, c-Pr], [RA RA 86; F, H, H, F, Bu], [RA 87; F, H, H, F, i-Bu], [RA 88; F, H, H, F, t-Bu], [RA 89; H, H, F, c- PrCH 2], [RA90; F, H, H, F, Ph], [RA91; F, H, H, F, Bn], [RA92; F, H, H, F , CF ₃ ], [RA 93; F, H, H, F, CF ₃ CH ₂ ], [RA 94; F, H, H, F, CF ₃ CF ₂ ], [RA 95; F, H, H, F, CF ₂ H], [RA 96; F, H, H, F, CF ₂ HCH ₂ ], [RA 97; H, F, H, F, Me], [RA 98; H, F, H, F, Et], [RA 99; H, F, H, F, Pr], [RA 100; H, F, H, F, i-Pr], [RA 101; H, F, H, F, c-Pr], [RA 102; H, F, H, F, Bu], [RA 103; H, F, H, F, i-Bu], [RA 104; H, F, H, F, t- Bu], [RA 105; H, F, H, F, c-PrCH ₂ ], [RA 106; H, F, H, F, Ph], [RA 107; H, F, H, F, Bn], [RA 108 H, F, H, F, CF ₃ ], [RA 109; H, F, H, F, CF ₃ CH ₂ ], [RA 110; H, F, H, F, CF ₃ CF ₂ ], [RA 111; H, F, H, F, CF ₂ H], [RA 112; H, F, H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³、Ｒ²⁴及びＲ²⁵は上記と同じ意味を表す。〕で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが下記に示される置換基番号ＲＢ１〜ＲＢ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＢ１〜ＲＢ１１２の化合物を本発明化合物ＲＢ１〜ＲＢ１１２と表し、本発明化合物ＲＢ１〜ＲＢ１１２をまとめて本発明化合物ＲＢと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＢ１〜ＲＢ１１２とは、式（ＩＩＩ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＢ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (III)

[Wherein, R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ represent the same meaning as described above. In the compound represented by the above, a compound in which the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ is a combination described in any of the substituent numbers RB1 to RB112 shown below (hereinafter referred to as Compounds of Substituent Nos. RB1 to RB112 are referred to as Compounds of the Invention RB1 to RB112, and Compounds RB1 to RB112 of the Invention are collectively referred to as Compound of the Invention RB) can be obtained according to the method described in the above-mentioned production method it can.
Note that the substituent number RB1～RB112, in the compound represented by the formula (III), and represents the combination of ^{R 21, R 22, R 23} , R 24 and R ^25, or less, [substituent group Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RB4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RB4 of the present invention means a compound having a substituent number of RB4 in the compound represented by the formula (III), and R ²¹ , R ²² and R ²³ in the compound represented by the formula (III) And R ²⁴ is a hydrogen atom, and R ²⁵ is an isopropyl group.

[Substituent number; R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ]: [RB 1; H, H, H, H, Me], [RB 2; H, H, H, H, Et], [[ RB3, H, H, H, H, Pr, [RB4; H, H, H, H, i-Pr], [RB5; H, H, H, H, c-Pr], [RB6; H, H, H, H, Bu], [RB7; H, H, H, H, i, Bu], [RB 8; H, H, H, H, t, Bu], [RB 9; H, H, H, H _{H, c-PrCH 2],} [RB10; H, H, H, H, Ph], [RB11; H, H, H, H, Bn], [RB12; H, H, H, H, CF 3] , [RB13; H, H, H, H, CF ₃ CH ₂ ], [RB 14; H, H, H, H, CF ₃ CF ₂ ], [RB 15; H, H, H, H, CF ₂ H] , [RB16; H, H, H, H, CF ₂ HCH ₂ ], [RB 17; F, H, H, H, Me], [RB 18; F, H, H, H, Et], [RB 19; F , H, H, H, Pr], [RB 20; F, H, H, H, i-Pr], [RB 21; F, H, H, H, c, Pr], [RB 22; F, H, H] , H, Bu], [RB23; F, H, H, H, i, Bu], [RB 24; F, H, H, H, t, Bu], [RB 25; F, H, H, H, c _{-PrCH 2], [RB26; F} , H, H, H, Ph], [RB27; F, H, H, H, Bn], [RB28; F, H, H, H, CF 3], [RB29 ; F, H, H, H , CF 3 CH 2], [RB30; F, H, H, H, CF 3 CF 2], [RB31; F, H, H, H, CF 2 H], [RB32 F, H, H, H, H, CF ₂ HCH ₂ ], [RB 33; H, F, H, H, Me], [RB 34; H, F, H, H, Et], [RB 35; H, F, H, H, Pr], [RB 36; H, F, H, H, i-Pr], [RB 37; H, F, H, H, c-Pr], [RB 38; H, F, H, H, H Bu], [RB 39; H, F, H, H, i-Bu], [RB 40; H, F, H, H, t-Bu], [RB 41; H, F, H, H, c-PrCH ₂ ], [RB42; H, F, H, H, Ph], [RB 43; H, F, H, H, Bn], [RB 44; H, F, H, H, CF ₃ ], [RB 45; H, F, H, H, CF ₃ CH ₂ ], [RB 46; H, F, H, H, CF ₃ CF ₂ ], [RB 47 H, F, H, H, CF ₂ H], [RB 48; H, F, H, H, CF ₂ HCH ₂ ], [RB 49; F, F, H, H, Me], [RB 50; F, F, H, H, Et], [RB 51; F, F, H, H, Pr], [RB 52; F, F, H, H, i-Pr], [RB 53; F, F, H, H, c-Pr], [RB 54; F, F, H, H, Bu], [RB 55; F, F, H, H, i-Bu], [RB 56; F, F, H, H, t-Bu] , [RB 57; F, F, H, H, c, -PrCH ₂ ], [RB 58; F, F, H, H, Ph], [RB 59; F, F, H, H, Bn], [RB 60; , F, H, H, CF ₃ ], [RB 61; F, F, H, H, CF ₃ CH ₂ ], [RB 62; F, F, H, H, CF ₃ CF ₂ ], [RB 63; F, F, H, H, CF ₂ H], [RB 64; F, F, H, H, CF ₂ HCH ₂ ], [RB 65; F, H, F, H, Me], [RB 66; F, H, F , H, Et], [RB67; F, H, F, H, Pr], [RB 68; F, H, F, H, i-Pr], [RB69; F, H, F, H, c-Pr ], [RB70; F, H, F, H, Bu], [RB 71; F, H, F, H, i-Bu], [RB 72; F, H, F, H, t-Bu], [RB 73] F, H, F, H, c-PrCH ₂ ], [RB 74; F, H, F, H, Ph], [RB 75; F, H, F, H, Bn], [RB 76; F, H, F, H, CF ₃ ], [RB 77; F, H, F, H, CF ₃ CH ₂ ], [RB 78; F, H, F, H, CF ₃ CF ₂ ], [RB 79; F, H, F _{, H, CF 2 H],} [RB80; F, H, F, H, CF 2 HCH 2], [RB81; F, H, H, F, Me], [RB82; F, H, H, F, Et], [RB 83; F, H, H, F, Pr], [RB 84; F, H, H, F, i-Pr], [RB 85; F, H, H, F, c-Pr], [RB RB 86; F, H, H, F, Bu], [RB 87; F, H, H, F, i-Bu], [RB 88; F, H, H, F, t-Bu], [RB 89; F, H, H, F, c- PrCH 2], [RB90; F, H, H, F, Ph], [RB91; F, H, H, F, Bn], [RB92; F, H, H, F , CF ₃ ], [RB 93; F, H, H, F, CF ₃ CH ₂ ], [RB 94; F, H, H, F, CF ₃ CF ₂ ], [RB95; F, H, H , F, CF 2 H], [RB96; F, H, H, F, CF 2 HCH 2], [RB97; H, F, H, F, Me], [RB98; H, F, H, F, Et], [RB99; H, F, H, F, Pr], [RB 100; H, F, H, F, i-Pr], [RB 101; H, F, H, F, c-Pr], [RB 102; H, F, H, F, Bu], [RB 103; H, F, H, F, i-Bu], [RB 104; H, F, H, F, t- Bu], [RB 105; H, F, H, F, c-PrCH ₂ ], [RB 106; H, F, H, F, Ph], [RB 107; H, F, H, F, Bn], [RB 108 H, F, H, F, CF ₃ ], [RB 109; H, F, H, F, CF ₃ CH ₂ ], [RB 110; H, F, H, F, CF ₃ CF ₂ ], [RB 111; H, F, H, F, CF 2 H], [RB112; H, F, H, F, CF 2 HCH 2]

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³、Ｒ²⁴及びＲ²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが下記に示される置換基番号ＲＣ１〜ＲＣ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＣ１〜ＲＣ１１２の化合物を本発明化合物ＲＣ１〜ＲＣ１１２と表し、本発明化合物ＲＣ１〜ＲＣ１１２をまとめて本発明化合物ＲＣと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＣ１〜ＲＣ１１２とは、式（ＩＶ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＣ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (IV)

[Wherein, R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ represent the same meaning as described above. ]
Wherein the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 is} a combination as described in any of the substituent numbers RC1 to RC112 shown below (hereinafter referred to as substitution Compounds of group numbers RC1 to RC112 are referred to as compounds of the present invention RC1 to RC112, and compounds of the present invention RC1 to RC112 are collectively referred to as the compound of the present invention RC) can be obtained according to the method described in the above-mentioned production method .
In addition, the substituent numbers RC1 to RC112 represent a combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 in} the compound represented by the formula (IV), and hereinafter, [Substituent Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RC4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RC4 of the present invention means a compound having a substituent number of RC4 in the compound represented by the formula (IV), and R ²¹ , R ²² and R ²³ in the compound represented by the formula (IV) And R ²⁴ is a hydrogen atom, and R ²⁵ is an isopropyl group.

[Substituent number; R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ]: [RC1; H, H, H, H, Me], [RC 2; H, H, H, H, Et], [[ RC3, H, H, H, H, Pr, [RC 4; H, H, H, H, i-Pr], [RC 5; H, H, H, H, c-Pr], [RC 6; H, H, H, H, Bu], [RC7; H, H, H, H, i, Bu], [RC 8; H, H, H, H, t, Bu], [RC 9; H, H, H, _{H, c-PrCH 2],} [RC10; H, H, H, H, Ph], [RC11; H, H, H, H, Bn], [RC12; H, H, H, H, CF 3] , [RC13; H, H, H, H, CF ₃ CH ₂ ], [RC 14; H, H, H, H, CF ₃ CF ₂ ], [RC 15; H, H, H, H, CF ₂ H] , [RC16; H, H, H, H, CF ₂ HCH ₂ ], [RC 17; F, H, H, H, Me], [RC 18; F, H, H, H, Et], [RC 19; , H, H, H, Pr], [RC 20; F, H, H, H, i-Pr], [RC 21; F, H, H, H, c, Pr], [RC 22; F, H, H , H, Bu], [RC23; F, H, H, H, i-Bu], [RC 24; F, H, H, H, t-Bu], [RC 25; F, H, H, H, c _{-PrCH 2], [RC26; F} , H, H, H, Ph], [RC27; F, H, H, H, Bn], [RC28; F, H, H, H, CF 3], [RC29 F, H, H, H, H, CF ₃ CH ₂ ], [RC 30; F, H, H, H, CF ₃ CF ₂ ], [RC 31; F, H, H, H, CF ₂ H], [RC 32 F, H, H, H, H, CF ₂ HCH ₂ ], [RC 33; H, F, H, H, Me], [RC 34; H, F, H, H, Et], [RC 35; H, F, H, H, Pr], [RC 36; H, F, H, H, i-Pr], [RC 37; H, F, H, H, c-Pr], [RC 38; H, F, H, H, H Bu], [RC 39; H, F, H, H, i-Bu], [RC 40; H, F, H, H, t-Bu], [RC 41; H, F, H, H, c-PrCH ₂ H, F, H, H, Ph], [RC 43; H, F, H, H, Bn], [RC 44; H, F, H, H, CF ₃ ], [RC 45; H, F, H, H, CF ₃ CH ₂ ], [RC 46; H, F, H, H, CF ₃ CF ₂ ], [RC 47 H, F, H, H, CF ₂ H], [RC 48; H, F, H, H, CF ₂ HCH ₂ ], [RC 49; F, F, H, H, Me], [RC 50; F, F, H, H, Et], [RC 51; F, F, H, H, Pr], [RC 52; F, F, H, H, i-Pr], [RC 53; F, F, H, H, c-Pr], [RC 54; F, F, H, H, Bu], [RC 55; F, F, H, H, i-Bu], [RC 56; F, F, H, H, t-Bu] , [RC 57; F, F, H, H, c-PrCH ₂ ], [RC 58; F, F, H, H, Ph], [RC 59; F, F, H, H, Bn], [RC 60; , F, H, H, CF ₃ ], [RC 61; F, F, H, H, CF ₃ CH ₂ ], [RC 62; F, F, H, H, CF ₃ CF ₂ ], [RC 63; F, F, H, H, CF ₂ H], [RC 64; F, F, H, H, CF ₂ HCH ₂ ], [RC 65; F, H, F, H, Me], [RC 66; F, H, F , H, Et], [RC 67; F, H, F, H, Pr], [RC 68; F, H, F, H, i-Pr], [RC 69; F, H, F, H, c-Pr ], [RC 70; F, H, F, H, Bu], [RC 71; F, H, F, H, i-Bu], [RC 72; F, H, F, H, t-Bu], [RC 73] F, H, F, H, c-PrCH ₂ ], [RC 74; F, H, F, H, Ph], [RC 75; F, H, F, H, Bn], [RC 76; F, H, F, H, CF ₃ ], [RC 77; F, H, F, H, CF ₃ CH ₂ ], [RC 78; F, H, F, H, CF ₃ CF ₂ ], [RC 79; F, H, F _{, H, CF 2 H],} [RC80; F, H, F, H, CF 2 HCH 2], [RC81; F, H, H, F, Me], [RC82; F, H, H, F, Et], [RC 83; F, H, H, F, Pr], [RC 84; F, H, H, F, i-Pr], [RC 85; F, H, H, F, c-Pr], [RC RC86; F, H, H, F, Bu], [RC 87; F, H, H, F, i-Bu], [RC 88; F, H, H, F, t-Bu], [RC 89; F, H, H, F, c- PrCH 2], [RC90; F, H, H, F, Ph], [RC91; F, H, H, F, Bn], [RC92; F, H, H, F , CF ₃ ], [RC 93; F, H, H, F, CF ₃ CH ₂ ], [RC 94; F, H, H, F, CF ₃ CF ₂ ], [RC 95; F, H, H, F, CF ₂ H], [RC 96; F, H, H, F, CF ₂ HCH ₂ ], [RC 97; H, F, H, F, Me], [RC 98; H, F, H, F, Et], [RC 99; H, F, H, F, Pr], [RC 100; H, F, H, F, i-Pr], [RC 101; H, F, H, F, c-Pr], [RC 102; H, F, H, F, Bu], [RC 103; H, F, H, F, i-Bu], [RC 104; H, F, H, F, t- Bu], [RC 105; H, F, H, F, c-PrCH ₂ ], [RC 106; H, F, H, F, Ph], [RC 107; H, F, H, F, Bn], [RC 108 H, F, H, F, CF ₃ ], [RC 109; H, F, H, F, CF ₃ CH ₂ ], [RC 110; H, F, H, F, CF ₃ CF ₂ ], [RC 111; H, F, H, F, CF ₂ H], [RC 112; H, F, H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³、Ｒ²⁴及びＲ²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが下記に示される置換基番号ＲＤ１〜ＲＤ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＤ１〜ＲＤ１１２の化合物を本発明化合物ＲＤ１〜ＲＤ１１２と表し、本発明化合物ＲＤ１〜ＲＤ１１２をまとめて本発明化合物ＲＤと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＤ１〜ＲＤ１１２とは、式（Ｖ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＤ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (V)

[Wherein, R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ represent the same meaning as described above. ]
Wherein the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 is} a combination as set forth in any of Substituent Nos. RD1 to RD112 shown below (hereinafter referred to as substitution Compounds of group numbers RD1 to RD112 are represented as compounds of the present invention RD1 to RD112, and compounds of the present invention RD1 to RD112 are collectively represented as the compound of the present invention RD) can be obtained according to the method described in the above-mentioned production method .
Note that the substituent number RD1～RD112, in the compound represented by formula (V), and represents the combination of ^{R 21, R 22, R 23} , R 24 and R ^25, or less, [substituent group Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RD4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RD4 of the present invention means a compound in which the substituent number is RD4, and in the compound represented by the formula (V), R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom, R ²⁵ represents the following compound in which an isopropyl group is present.

[Substituent number; R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ]: [RD 1; H, H, H, H, Me], [RD 2; H, H, H, H, Et], [[ RD3, H, H, H, H, H, Pr], [RD4; H, H, H, H, i, Pr], [RD5; H, H, H, H, c, Pr], [RD 6; H, H, H, H, Bu], [RD7; H, H, H, H, i, Bu], [RD 8; H, H, H, H, t, Bu], [RD 9; H, H, H, H _{H, c-PrCH 2],} [RD10; H, H, H, H, Ph], [RD11; H, H, H, H, Bn], [RD12; H, H, H, H, CF 3] , [RD13; H, H, H, H, CF ₃ CH ₂ ], [RD 14; H, H, H, H, CF ₃ CF ₂ ], [RD 15; H, H, H, H, CF ₂ H] , [RD16; H, H, H, H, CF ₂ HCH ₂ ], [RD 17; F, H, H, H, Me], [RD 18; F, H, H, H, Et], [RD 19; F , H, H, H, Pr], [RD 20; F, H, H, H, i-Pr], [RD 21; F, H, H, H, c, Pr], [RD 22; F, H, H , H, Bu], [RD23; F, H, H, H, i, Bu], [RD 24; F, H, H, H, t, Bu], [RD 25; F, H, H, H, c _{-PrCH 2], [RD26; F} , H, H, H, Ph], [RD27; F, H, H, H, Bn], [RD28; F, H, H, H, CF 3], [RD29 ; F, H, H, H , CF 3 CH 2], [RD30; F, H, H, H, CF 3 CF 2], [RD31; F, H, H, H, CF 2 H], [RD32 F, H, H, H, H, CF ₂ HCH ₂ ], [RD 33; H, F, H, H, Me], [RD 34; H, F, H, H, Et], [RD 35; H, F, H, H, Pr], [RD 36; H, F, H, H, i-Pr], [RD 37; H, F, H, H, c-Pr], [RD 38; H, F, H, H, H Bu], [RD 39; H, F, H, H, i-Bu], [RD 40; H, F, H, H, t-Bu], [RD 41; H, F, H, H, c-PrCH ₂ ], [RD 42; H, F, H, H, Ph], [RD 43; H, F, H, H, Bn], [RD 44; H, F, H, H, CF ₃ ], [RD 45; H, F, H, H, CF ₃ CH ₂ ], [RD 46; H, F, H, H, CF ₃ CF ₂ ], [RD 47 H, F, H, H, CF ₂ H], [RD 48; H, F, H, H, CF ₂ HCH ₂ ], [RD 49; F, F, H, H, Me], [RD 50; F, F, H, H, Et], [RD 51; F, F, H, H, Pr], [RD 52; F, F, H, H, i-Pr], [RD 53; F, F, H, H, c-Pr], [RD 54; F, F, H, H, Bu], [RD 55; F, F, H, H, i-Bu], [RD 56; F, F, H, H, t-Bu] , [RD57; F, F, H, H, c-PrCH 2], [RD58; F, F, H, H, Ph], [RD59; F, F, H, H, Bn], [RD60; F , F, H, H, CF ₃ ], [RD 61; F, F, H, H, CF ₃ CH ₂ ], [RD 62; F, F, H, H, CF ₃ CF ₂ ], [RD 63; F, F, H, H, CF ₂ H], [RD 64; F, F, H, H, CF ₂ HCH ₂ ], [RD 65; F, H, F, H, Me], [RD 66; F, H, F , H, Et], [RD 67; F, H, F, H, Pr], [RD 68; F, H, F, H, i-Pr], [RD 69; F, H, F, H, c-Pr ], [RD 70; F, H, F, H, Bu], [RD 71; F, H, F, H, i-Bu], [RD 72; F, H, F, H, t-Bu], [RD 73] F, H, F, H, c-PrCH ₂ ], [RD 74; F, H, F, H, Ph], [RD 75; F, H, F, H, Bn], [RD 76; F, H, F, H, CF ₃ ], [RD 77; F, H, F, H, CF ₃ CH ₂ ], [RD 78; F, H, F, H, CF ₃ CF ₂ ], [RD 79; F, H, F _{, H, CF 2 H],} [RD80; F, H, F, H, CF 2 HCH 2], [RD81; F, H, H, F, Me], [RD82; F, H, H, F, Et], [RD 83; F, H, H, F, Pr], [RD 84; F, H, H, F, i-Pr], [RD 85; F, H, H, F, c-Pr], [[ RD 86; F, H, H, F, Bu], [RD 87; F, H, H, F, i-Bu], [RD 88; F, H, H, F, t-Bu], [RD 89; F, H, H, F, c- PrCH 2], [RD90; F, H, H, F, Ph], [RD91; F, H, H, F, Bn], [RD92; F, H, H, F , CF ₃ ], [RD 93; F, H, H, F, CF ₃ CH ₂ ], [RD 94; F, H, H, F, CF ₃ CF ₂ ], [RD 95; F, H, H, F, CF ₂ H], [RD 96; F, H, H, F, CF ₂ HCH ₂ ], [RD 97; H, F, H, F, Me], [RD 98; H, F, H, F, Et, [RD 99; H, F, H, F, Pr], [RD 100; H, F, H, F, i-Pr], [RD 101; H, F, H, F, c-Pr], [RD 102; H, F, H, F, Bu], [RD 103; H, F, H, F, i-Bu], [RD 104; H, F, H, F, t- Bu], [RD 105; H, F, H, F, c-PrCH ₂ ], [RD 106; H, F, H, F, Ph], [RD 107; H, F, H, F, Bn], [RD 108 H, F, H, F, CF ₃ ], [RD 109; H, F, H, F, CF ₃ CH ₂ ], [RD 110; H, F, H, F, CF ₃ CF ₂ ], [RD 111; H, F, H, F, CF ₂ H], [RD 112; H, F, H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³、Ｒ²⁴及びＲ²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが下記に示される置換基番号ＲＥ１〜ＲＥ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＥ１〜ＲＥ１１２の化合物を本発明化合物ＲＥ１〜ＲＥ１１２と表し、本発明化合物ＲＥ１〜ＲＥ１１２をまとめて本発明化合物ＲＥと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＥ１〜ＲＥ１１２とは、式（ＶＩ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＥ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (VI)

[Wherein, R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ represent the same meaning as described above. ]
In the compound represented by the above, a compound in which the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 is} a combination as described in any of the substituent numbers RE1 to RE112 shown below (hereinafter referred to as substitution The compounds of group numbers RE1 to RE112 are referred to as present compounds RE1 to RE112, and the present compounds RE1 to RE112 are collectively referred to as the present compound RE)) can be obtained according to the method described in the above-mentioned production method .
In addition, Substituent Nos. RE1 to RE112 represent a combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 in} the compound represented by Formula (VI), and the [Substituent Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RE4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RE4 of the present invention means a compound having a substituent number of RE4 in the compound represented by the formula (VI), and R ²¹ , R ²² and R ²³ in the compound represented by the formula (VI) And R ²⁴ is a hydrogen atom, and R ²⁵ is an isopropyl group.

[Substituent number; R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ]: [RE 1; H, H, H, H, Me], [RE 2; H, H, H, H, Et], [[ RE3, H, H, H, H, Pr, [RE 4; H, H, H, H, i-Pr], [RE 5; H, H, H, H, c-Pr], [RE 6; H, H, H, H, Bu], [RE7; H, H, H, H, i, Bu], [RE 8; H, H, H, H, t, Bu], [RE 9; H, H, H, H, c-PrCH ₂ ], [RE 10; H, H, H, H, Ph, [RE 11; H, H, H, H, Bn], [RE 12; H, H, H, H, CF ₃ ] , [RE13; H, H, H, H, CF ₃ CH ₂ ], [RE 14; H, H, H, H, CF ₃ CF ₂ ], [RE 15; H, H, H, H, CF ₂ H] , [RE16; H, H, H, H, CF ₂ HCH ₂ ], [RE 17; F, H, H, H, Me], [RE 18; F, H, H, H, Et], [RE 19; F , H, H, H, Pr], [RE 20; F, H, H, H, i-Pr], [RE 21; F, H, H, H, c, Pr], [RE 22; F, H, H , H, Bu], [RE23; F, H, H, H, i-Bu], [RE 24; F, H, H, H, t-Bu], [RE 25; F, H, H, H, c -PrCH ₂ ], [RE26; F, H, H, H, Ph, [RE 27; F, H, H, H, Bn], [RE 28; F, H, H, H, CF ₃ ], [RE 29 ; F, H, H, H , CF 3 CH 2], [RE30; F, H, H, H, CF 3 CF 2], [RE31; F, H, H, H, CF 2 H], [RE32 F, H, H, H, H, CF ₂ HCH ₂ ], [RE 33; H, F, H, H, Me], [RE 34; H, F, H, H, Et], [RE 35; H, F, H, H, Pr], [RE36; H, F, H, H, i-Pr], [RE 37; H, F, H, H, c-Pr], [RE 38; H, F, H, H, H, Bu], [RE 39; H, F, H, H, i-Bu], [RE 40; H, F, H, H, t-Bu], [RE 41; H, F, H, H, c-PrCH ₂ ], [RE 42; H, F, H, H, Ph], [RE 43; H, F, H, H, Bn], [RE 44; H, F, H, H, CF ₃ ], [RE 45; H, F, H, H, CF ₃ CH ₂ ], [RE 46; H, F, H, H, CF ₃ CF ₂ ], [RE 47 H, F, H, H, CF ₂ H], [RE 48; H, F, H, H, CF ₂ HCH ₂ ], [RE 49; F, F, H, H, Me], [RE 50; F, F, H, H, Et], [RE 51; F, F, H, H, Pr], [RE 52; F, F, H, H, i-Pr], [RE 53; F, F, H, H, c-Pr], [RE 54; F, F, H, H, Bu], [RE 55; F, F, H, H, i-Bu], [RE 56; F, F, H, H, t-Bu] , [RE 57; F, F, H, H, c-PrCH ₂ ], [RE 58; F, F, H, H, Ph], [RE 59; F, F, H, H, Bn], [RE 60; F , F, H, H, CF ₃ ], [RE 61; F, F, H, H, CF ₃ CH ₂ ], [RE 62; F, F, H, H, CF ₃ CF ₂ ], [RE 63; F, F, H, H, CF ₂ H], [RE 64; F, F, H, H, CF ₂ HCH ₂ ], [RE 65; F, H, F, H, Me], [RE 66; F, H, F , H, Et], [RE 67; F, H, F, H, Pr], [RE 68; F, H, F, H, i-Pr], [RE 69; F, H, F, H, c-Pr ], [RE 70; F, H, F, H, Bu], [RE 71; F, H, F, H, i-Bu], [RE 72; F, H, F, H, t-Bu], [RE 73 F, H, F, H, c-PrCH ₂ ], [RE 74; F, H, F, H, Ph], [RE 75; F, H, F, H, Bn], [RE 76; F, H, F, H, CF ₃ ], [RE 77; F, H, F, H, CF ₃ CH ₂ ], [RE 78; F, H, F, H, CF ₃ CF ₂ ], [RE 79; F, H, F _{, H, CF 2 H],} [RE80; F, H, F, H, CF 2 HCH 2], [RE81; F, H, H, F, Me], [RE82; F, H, H, F, Et], [RE 83; F, H, H, F, Pr], [RE 84; F, H, H, F, i-Pr], [RE 85; F, H, H, F, c-Pr], [RE RE 86; F, H, H, F, Bu], [RE 87; F, H, H, F, i-Bu], [RE 88; F, H, H, F, t-Bu], [RE 89; F, H, H, F, c- PrCH 2], [RE90; F, H, H, F, Ph], [RE91; F, H, H, F, Bn], [RE92; F, H, H, F , CF ₃ ], [RE 93; F, H, H, F, CF ₃ CH ₂ ], [RE 94; F, H, H, F, CF ₃ CF ₂ ], [RE 95; F, H, H, F, CF ₂ H], [RE 96; F, H, H, F, CF ₂ HCH ₂ ], [RE 97; H, F, H, F, Me], [RE 98; H, F, H, F, Et, [RE99; H, F, H, F, Pr], [RE 100; H, F, H, F, i-Pr], [RE 101; H, F, H, F, c-Pr], [RE 102; H, F, H, F, Bu], [RE 103; H, F, H, F, i-Bu], [RE 104; H, F, H, F, t- Bu], [RE 105; H, F, H, F, c-PrCH ₂ ], [RE 106; H, F, H, F, Ph], [RE 107; H, F, H, F, Bn], [RE 108 H, F, H, F, CF ₃ ], [RE 109; H, F, H, F, CF ₃ CH ₂ ], [RE 110; H, F, H, F, CF ₃ CF ₂ ], [RE 111; H, F, H, F, CF ₂ H], [RE 112; H, F, H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²²、Ｒ²³、Ｒ²⁴及びＲ²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせが下記に示される置換基番号ＲＦ１〜ＲＦ１１２のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＦ１〜ＲＦ１１２の化合物を本発明化合物ＲＦ１〜ＲＦ１１２と表し、本発明化合物ＲＦ１〜ＲＦ１１２をまとめて本発明化合物ＲＦと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＦ１〜ＲＦ１１２とは、式（ＶＩＩ）で表される化合物における、R²¹、R²²、R²³、R²⁴及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²³,R²⁴,R²⁵]と記す。
例えば、置換基番号ＲＦ４とは、R²¹、R²²、R²³、及びR²⁴が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (VII)

[Wherein, R ²¹ , R ²² , R ²³ , R ²⁴ and R ²⁵ represent the same meaning as described above. ]
In the compound represented by the above, a compound in which the combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 is} a combination as described in any of the substituent numbers RF1 to RF112 shown below (hereinafter referred to as substitution The compounds of group numbers RF1 to RF112 are referred to as compounds of the present invention RF1 to RF112, and the compounds of the present invention RF1 to RF112 are collectively referred to as the compound of the present invention RF) can be obtained according to the method described in the above-mentioned production method .
In addition, the substituent numbers RF1 to RF112 represent a combination of R ²¹ , R ²² , R ²³ , R ²⁴ and R ^{25 in} the compound represented by the formula (VII), and hereinafter, [Substituent Number: R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ].
For example, the substituent number RF4 represents a combination in which R ²¹ , R ²² , R ²³ and R ²⁴ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RF4 means a compound represented by the formula (VII) in which the substituent number is RF4, and in the compound represented by the formula (VII), R ²¹ , R ²² and R ²³ And R ²⁴ is a hydrogen atom, and R ²⁵ is an isopropyl group.

[Substituent number; R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁵ ]: [RF 1; H, H, H, H, Me], [RF 2; H, H, H, H, Et], [[ RF3, H, H, H, H, Pr, [RF4; H, H, H, H, i-Pr], [RF5; H, H, H, H, c-Pr], [RF6; H, H, H, H, Bu], [RF7; H, H, H, H, i, Bu], [RF 8; H, H, H, H, t, Bu], [RF 9; H, H, H, H _{H, c-PrCH 2],} [RF10; H, H, H, H, Ph], [RF11; H, H, H, H, Bn], [RF12; H, H, H, H, CF 3] , [RF 13; H, H, H, H, CF ₃ CH ₂ ], [RF 14; H, H, H, H, CF ₃ CF ₂ ], [RF 15; H, H, H, H, CF ₂ H] , [RF16; H, H, H, H, CF ₂ HCH ₂ ], [RF 17; F, H, H, H, Me], [RF 18; F, H, H, H, Et], [RF 19; F , H, H, H, Pr], [RF 20; F, H, H, H, i-Pr], [RF 21; F, H, H, H, c, Pr], [RF 22; F, H, H , H, Bu], [RF23; F, H, H, H, i-Bu], [RF 24; F, H, H, H, t-Bu], [RF 25; F, H, H, H, c _{-PrCH 2], [RF26; F} , H, H, H, Ph], [RF27; F, H, H, H, Bn], [RF28; F, H, H, H, CF 3], [RF29 ; F, H, H, H , CF 3 CH 2], [RF30; F, H, H, H, CF 3 CF 2], [RF31; F, H, H, H, CF 2 H], [RF32 F, H, H, H, H, CF ₂ HCH ₂ ], [RF 33; H, F, H, H, Me], [RF 34; H, F, H, H, Et], [RF 35; H, F, H, H, Pr], [RF 36; H, F, H, H, i-Pr], [RF 37; H, F, H, H, c-Pr], [RF 38; H, F, H, H, H Bu], [RF 39; H, F, H, H, i-Bu], [RF 40; H, F, H, H, t-Bu], [RF 41; H, F, H, H, c-PrCH ₂ ], [RF 42; H, F, H, H, Ph], [RF 43; H, F, H, H, Bn], [RF 44; H, F, H, H, CF ₃ ], [RF 45; H, F, H, H, CF ₃ CH ₂ ], [RF 46; H, F, H, H, CF ₃ CF ₂ ], [RF 47 H, F, H, H, CF ₂ H], [RF 48; H, F, H, H, CF ₂ HCH ₂ ], [RF 49; F, F, H, H, Me], [RF 50; F, F, H, H, Et], [RF 51; F, F, H, H, Pr], [RF 52; F, F, H, H, i-Pr], [RF 53; F, F, H, H, c-Pr], [RF 54; F, F, H, H, Bu], [RF 55; F, F, H, H, i-Bu], [RF 56; F, F, H, H, t-Bu] , [RF57; F, F, H, H, c-PrCH 2], [RF58; F, F, H, H, Ph], [RF59; F, F, H, H, Bn], [RF60; F , F, H, H, CF ₃ ], [RF 61; F, F, H, H, CF ₃ CH ₂ ], [RF 62; F, F, H, H, CF ₃ CF ₂ ], [RF 63; F, F, H, H, CF ₂ H], [RF 64; F, F, H, H, CF ₂ HCH ₂ ], [RF 65; F, H, F, H, Me], [RF 66; F, H, F , H, Et], [RF67; F, H, F, H, Pr], [RF 68; F, H, F, H, i-Pr], [RF 69; F, H, F, H, c-Pr ], [RF 70; F, H, F, H, Bu], [RF 71; F, H, F, H, i-Bu], [RF 72; F, H, F, H, t-Bu], [RF 73] F, H, F, H, c-PrCH ₂ ], [RF 74; F, H, F, H, Ph], [RF 75; F, H, F, H, Bn], [RF 76; F, H, F, H, CF ₃ ], [RF 77; F, H, F, H, CF ₃ CH ₂ ], [RF 78; F, H, F, H, CF ₃ CF ₂ ], [RF 79; F, H, F _{, H, CF 2 H],} [RF80; F, H, F, H, CF 2 HCH 2], [RF81; F, H, H, F, Me], [RF82; F, H, H, F, Et], [RF 83; F, H, H, F, Pr], [RF 84; F, H, H, F, i-Pr], [RF 85; F, H, H, F, c-Pr], [[ RF86; F, H, H, F, Bu], [RF 87; F, H, H, F, i-Bu], [RF 88; F, H, H, F, t-Bu], [RF 89; F, H, H, F, c- PrCH 2], [RF90; F, H, H, F, Ph], [RF91; F, H, H, F, Bn], [RF92; F, H, H, F , CF ₃ ], [RF 93; F, H, H, F, CF ₃ CH ₂ ], [RF 94; F, H, H, F, CF ₃ CF ₂ ], [RF 95; F, H, H, F, CF ₂ H], [RF 96; F, H, H, F, CF ₂ HCH ₂ ], [RF 97; H, F, H, F, Me], [RF 98; H, F, H, F, Et], [RF 99; H, F, H, F, Pr], [RF 100; H, F, H, F, i-Pr], [RF 101; H, F, H, F, c-Pr], [RF 102; H, F, H, F, Bu], [RF 103; H, F, H, F, i-Bu], [RF 104; H, F, H, F, t- Bu], [RF 105; H, F, H, F, c-PrCH ₂ ], [RF 106; H, F, H, F, Ph], [RF 107; H, F, H, F, Bn], [RF 108 H, F, H, F, CF ₃ ], [RF 109; H, F, H, F, CF ₃ CH ₂ ], [RF 110; H, F, H, F, CF ₃ CF ₂ ], [RF 111; H, F, H, F, CF 2 H], [RF112; H, F, H, F, CF 2 HCH 2]

〔式中、Ｒ²⁵は上記と同じ意味を表し、Ｑ²¹は酸素原子又はＮＲ⁷を表す。〕
で表される化合物において、Q²¹及びＲ²⁵の組合わせが下記に示される置換基番号ＲＧ１〜ＲＧ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＧ１〜ＲＧ３０の化合物を本発明化合物ＲＧ１〜ＲＧ３０と表し、本発明化合物ＲＧ１〜ＲＧ３０をまとめて本発明化合物ＲＧと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＧ１〜ＲＧ３０とは、式（ＶＩＩＩ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＧ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (VIII)

[Wherein, R ²⁵ represents the same meaning as described above, and Q ²¹ represents an oxygen atom or NR ⁷ . ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any one of Substituent Nos. RG 1 to RG 30 (hereinafter referred to as “compound of Substituent No. RG 1 to RG 30”) Inventive compounds RG1 to RG30, and the compounds of the present invention RG1 to RG30 are collectively referred to as the compound of the present invention RG) can be obtained according to the method described in the above-mentioned production method.
Substituent numbers RG1 to RG30 each represent a combination of Q ²¹ and R ²⁵ in the compound represented by formula (VIII), and hereinafter referred to as [substituent number: Q ²¹ , R ²⁵ ]. .
For example, substituent number RG4 represents a combination wherein Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound RG4 of the present invention means a compound represented by the formula (VIII) in which the substituent number is RG4, and in the compound represented by the formula (VIII), Q ²¹ is an oxygen atom, Represents the following compound wherein R ²⁵ is an isopropyl group.

[Substituent No. Q ²¹ , R ²⁵ ]: [RG1; O, Me], [RG2; O, Et], [RG3; O, Pr], [RG4; O, i-Pr], [RG5; , c-Pr], [RG6 ; O, Bu], [RG7; O, t-Bu], [RG8; O, c-PrCH 2], [RG9; O, Ph], [RG10; O, Bn] _{, [RG11; O, CF 3} ], [RG12; O, CF 3 CH 2], [RG13; O, CF 3 CF 2], [RG14; O, CF 2 H], [RG15; O, CF 2 HCH ₂ ], [RG16; NH, Me], [RG17; NH, Et], [RG18; NH, Pr], [RG19; NH, i-Pr], [RG20; NH, c-Pr], [RG21; NH, Bu], [RG22; NH, t-Bu], [RG23; NH, c-PrCH 2], [RG24; NH, Ph], [RG25; NH, Bn], [RG26; NH, CF 3] _{, [RG27; NH, CF 3} CH 2], [RG28; NH, CF 3 CF 2], [RG29; NH, CF 2 H], [RG30; NH, CF 2 HCH 2]

〔式中、Ｒ²⁵は上記と同じ意味を表し、Ｒ²⁶はＮＯ₂、Ｃ（Ｏ）Ｒ⁷、Ｃ（Ｏ）ＯＲ⁷又はＳ（Ｏ）₂Ｒ⁷を表す。〕で表される化合物において、R²⁵及びR²⁶の組合わせが下記に示される置換基番号ＲＨ１〜ＲＨ５４のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＨ１〜ＲＨ５４の化合物を本発明化合物ＲＨ１〜ＲＨ５４と表し、本発明化合物ＲＨ１〜ＲＨ５４をまとめて本発明化合物ＲＨと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＨ１〜ＲＨ５４とは、式（ＩＸ）で表される化合物における、R²⁵及びR²⁶の組合せを表すものであり、以下、［置換基番号;R²⁵,R²⁶]と記す。
例えば、置換基番号ＲＨ４とは、R²⁵がシクロプロピル基であり、R²⁶がC(O)Meである組合せを表す。 Formula (IX)

[Wherein, R ²⁵ represents the same meaning as described above, and R ²⁶ represents NO ₂ , C (O) R ⁷ , C (O) OR ⁷ or S (O) ₂ R ⁷ . In which R ²⁵ and R ²⁶ are a combination of any of Substituent Nos. RH 1 to RH 54 shown below (hereinafter referred to as compounds of Substituent Nos. RH 1 to RH 54) The compounds of the present invention RH1 to RH54, and the compounds of the present invention RH1 to RH54 are collectively referred to as the compound of the present invention RH) can be obtained according to the method described in the above production method.
The substituent numbers RH1 to RH54 represent the combination of R ²⁵ and R ²⁶ in the compound represented by the formula (IX), and hereinafter referred to as [substituent number; R ²⁵ , R ²⁶ ] .
For example, the substituent number RH4 represents a combination wherein R ²⁵ is a cyclopropyl group and R ²⁶ is C (O) Me.

For example, the compound RH4 of the present invention means a compound represented by the formula (IX) wherein the substituent number is RH4, and in the compound represented by the formula (IX), R ²⁵ is a cyclopropyl group , R ²⁶ is C (O) Me.

[Substituent number; R ²⁵ , R ²⁶ ]: [RH 1; Me, C (O) Me], [RH 2; Et, C (O) Me], [RH 3; i-Pr, C (O) Me], [RH4; c-Pr, C (O) Me], [RH5; CF 2 H, C (O) Me], [RH6; CF 3, C (O) Me], [RH7; Me, C (O) Et], [RH 8; Et, C (O) Et], [RH 9; i-Pr, C (O) Et], [RH 10; c-Pr, C (O) Et], [RH 11; CF ₂ H, C (O) Et], [ RH12; CF 3, C (O) Et], [RH13; Me, C (O) CF 3], [RH14; Et, C (O) CF 3], [RH15; i _{-Pr, C (O) CF 3} ], [RH16; c-Pr, C (O) CF 3], [RH17; CF 2 H, C (O) CF 3], [RH18; CF 3, C (O ) CF ₃ ], [RH 19; Me, C (O) OMe], [RH 20; Et, C (O) OMe], [RH 21; i-Pr, C (O) OMe], [RH 22; c-Pr, C (O) OMe], [ RH23; CF 2 H, C (O) OMe], [RH24; CF 3, C (O) OMe], [RH25; Me, C (O) OEt], [RH26; Et , C (O) OEt], [RH27; i-Pr, C (O) OEt], [RH28; c-Pr, C (O) OEt], [RH29; CF 2 H, C (O) OEt], _{[RH30; CF 3, C (} O) OEt], [RH31; Me, S (O) 2 Me], [RH32; Et, S (O) 2 Me], [RH33; i-Pr, S (O) ₂ Me !, [RH 34; c-Pr, S (O) ₂ Me], [RH 35; CF ₂ H, S (O) ₂ Me], [RH 36; CF ₃ , S (O) ₂ Me], [RH 37 Me, S (O) ₂ Et], [RH 38; Et, S (O) ₂ Et], [RH 39; i-Pr, S (O) ₂ Et], [RH 40; c-Pr, S (O) ₂ Et], [RH 41; CF ₂ H, S (O) ₂ Et], [RH 42; CF ₃ , S (O) ₂ Et], [RH 43; Me, S (O) ₂ CF ₃ ], [RH 44; Et, S (O) ₂ CF ₃ ], [RH 45; i-Pr, S (O) ₂ CF ₃ ], [RH 46; c-Pr, S (O) ₂ CF ₃ ], [RH 47; CF ₂ H, S (O) ₂ CF ₃ ], [RH 48; CF ₃ , S (O) ₂ CF ₃ ], [RH 49; Me, C (O) CF ₂ H], [RH 50; Et, C (O) CF ₂ H], [RH 51; _{Pr, C (O) CF 2} H], [RH52; c-Pr, C (O) CF 2 H], [RH53; CF 2 H, C (O) CF 2 H], [RH54; CF 3, C (O) CF ₂ H]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＩ１〜ＲＩ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＩ１〜ＲＩ３０の化合物を本発明化合物ＲＩ１〜ＲＩ３０と表し、本発明化合物ＲＩ１〜ＲＩ３０をまとめて本発明化合物ＲＩと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＩ１〜ＲＩ３０とは、式（Ｘ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＩ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (X)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any one of Substituent Nos. RI 1 to RI 30 (hereinafter referred to as “compound of Substituent Nos. RI 1 to RI 30” Invention compounds RI1 to RI30, and the compounds of the present invention RI1 to RI30 are collectively referred to as the compounds of the invention RI) can be obtained according to the method described in the above-mentioned production method.
Note that the substituent number RI1～RI30, in the compound of formula (X), and represents the combination of Q ²¹ and R ^25, or less; referred to as Substituent number Q ^21, R ^25] .
For example, the substituent number RI4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RI4 means a compound represented by the formula (X) in which the substituent number is RI4, and in the compound represented by the formula (X), Q ²¹ is an oxygen atom, Represents the following compound wherein R ²⁵ is an isopropyl group.

[Substituent No. Q ²¹ , R ²⁵ ]: [RI 1; O, Me], [RI 2; O, Et], [RI 3; O, Pr], [RI 4; O, i-Pr], [RI 5; , c-Pr], [RI 6; O, Bu], [RI 7; O, t-Bu], [RI 8; O, c-PrCH ₂ ], [RI 9; O, Ph], [RI 10; O, Bn] , [RI 11; O, CF ₃ ], [RI 12; O, CF ₃ CH ₂ ], [RI 13; O, CF ₃ CF ₂ ], [RI 14; O, CF ₂ H], [RI 15; O, CF ₂ HCH ₂ ], [RI 16; NH, Me], [RI 17; NH, Et, [RI 18; NH, Pr], [RI 19; NH, i-Pr], [RI 20; NH, c-Pr], [RI 21; NH, Bu], [RI 22; NH, t-Bu], [RI 23; NH, c-PrCH ₂ ], [RI 24; NH, Ph], [RI 25; NH, Bn], [RI 26; NH, CF ₃ ] , [RI 27; NH, CF ₃ CH ₂ ], [RI 28; NH, CF ₃ CF ₂ ], [RI 29; NH, CF ₂ H], [RI 30; NH, CF ₂ HCH ₂ ]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＪ１〜ＲＪ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＪ１〜ＲＪ３０の化合物を本発明化合物ＲＪ１〜ＲＪ３０と表し、本発明化合物ＲＪ１〜ＲＪ３０をまとめて本発明化合物ＲＪと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＪ１〜ＲＪ３０とは、式（ＸＩ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＪ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XI)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any of Substituent Nos. RJ 1 to RJ 30 (hereinafter referred to as the compound of Substituent No. RJ 1 to RJ 30) Inventive compounds RJ1 to RJ30, and the compounds of the present invention RJ1 to RJ30 are collectively referred to as the compound of the invention RJ) can be obtained according to the method described in the above-mentioned production method.
Substituent numbers RJ1 to RJ30 represent the combination of Q ²¹ and R ²⁵ in the compound represented by formula (XI), and hereinafter referred to as [substituent number: Q ²¹ , R ²⁵ ] .
For example, the substituent number RJ4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound RJ4 of the present invention means a compound having a substituent number of RJ4 in the compound represented by (XI), and in the compound represented by the formula (XI), Q ²¹ is an oxygen atom, R ²⁵ represents the following compound in which an isopropyl group is present.

[Substituent number: Q ²¹ , R ²⁵ ]: [RJ 1; O, Me], [RJ 2; O, Et], [RJ 3; O, Pr], [RJ 4; O, i-Pr], [RJ 5; , c-Pr], [RJ6; O, Bu], [RJ 7; O, t-Bu], [RJ 8; O, c-PrCH ₂ ], [RJ 9; O, Ph], [RJ 10; O, Bn] _{, [RJ11; O, CF 3} ], [RJ12; O, CF 3 CH 2], [RJ13; O, CF 3 CF 2], [RJ14; O, CF 2 H], [RJ15; O, CF 2 HCH ₂ ], [RJ 16; NH, Me], [RJ 17; NH, Et], [RJ 18; NH, Pr], [RJ 19; NH, i-Pr], [RJ 20; NH, c-Pr], [RJ 21; NH, Bu], [RJ 22; NH, t-Bu], [RJ 23; NH, c-PrCH ₂ ], [RJ 24; NH, Ph], [RJ 25; NH, Bn], [RJ 26; NH, CF ₃ ] _{, [RJ27; NH, CF 3} CH 2], [RJ28; NH, CF 3 CF 2], [RJ29; NH, CF 2 H], [RJ30; NH, CF 2 HCH 2]

〔式中、Ｒ²⁵は上記と同じ意味を表し、Ｒ³¹は水素原子、群Ａより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基もしくは群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基を表すか、又は、Ｒ²⁵とＲ³¹とは、互いに結合して５−７員ヘテロ環（該５−７員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）を形成していてもよい。〕
で表される化合物において、R³¹及びR²⁵の組合わせが下記に示される置換基番号ＲＫ１〜ＲＫ４０７のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＫ１〜ＲＫ４０７の化合物を本発明化合物ＲＫ１〜ＲＫ４０７と表し、本発明化合物ＲＫ１〜ＲＫ４０７をまとめて本発明化合物ＲＫと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＫ１〜ＲＫ４０７とは、式（ＸＩＩ）で表される化合物における、R³¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;R³¹,R²⁵]と記す。ただし、置換基番号ＲＫ１６６及びＲＫ１６７においては、Ｒ³¹とＲ²⁵とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＫ４とは、Ｒ³¹が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XII)

[Wherein, R ²⁵ represents the same meaning as above, and R ³¹ has a hydrogen atom, a C1-C6 alkyl group optionally having one or more substituents selected from group A, and one or more halogen atoms] C3-C6 alkynyl group which may be substituted, C1-C6 alkoxy group which may have one or more halogen atoms, C3-C6 cyclo group which may have one or more substituents selected from group D R ²⁵ represents an alkyl group or a phenyl group which may have one or more substituents selected from group D, or R ²⁵ and R ³¹ are bonded to each other to form a 5- to 7-membered heterocyclic ring The 7-membered heterocycle may form one or more substituents selected from Group D). ]
Wherein the combination of R ³¹ and R ^{25 is} a combination as set forth in any of Substituent Nos. RK 1 to R K 407 as shown below (hereinafter referred to as “compound of Substituent Nos. RK 1 to RK 407” Inventive compounds RK1 to RK407, and the compounds of the present invention RK1 to RK407 are collectively referred to as the compounds of the present invention RK) can be obtained according to the method described in the above-mentioned production method.
Note that the substituent number RK1～RK407, in the compound of formula (XII), and represents the combination of R ³¹ and R ^25, or less; referred to as Substituent Number R ^31, R ^25] . However, in the substituent numbers RK166 and RK167, it represents that R ³¹ and R ²⁵ bond with each other to form a heterocycle.
For example, the substituent number RK4 represents a combination in which R ³¹ is a hydrogen atom and R ²⁵ is an isopropyl group.

The 5-7 membered heterocyclic ring formed by bonding R ²⁵ and R ³¹ to each other represents any of the structures shown in the following (ZF 11 to ZF 13) (● represents a bonding position).

For example, the compound RK4 of the present invention means a compound represented by the formula (XII) in which the substituent number is RK4, and in the compound represented by the formula (XII), R ³¹ is a hydrogen atom, Represents the following compound wherein R ²⁵ is an isopropyl group.

[Substituent number; R ³¹ , R ²⁵ ]: [RK1; H, Me], [RK2; H, Et], [RK3; H, Pr], [RK4; H, i-Pr], [RK5; H , c-Pr], [RK6 ; H, Bu], [RK7; H, t-Bu], [RK8; H, c-PrCH 2], [RK9; H, Ph], [RK10; H, Bn] , [RK11; H, CF ₃ ], [RK 12; H, CF ₃ CH ₂ ], [RK 13; H, CF ₃ CF ₂ ], [RK 14; H, CF ₂ H], [RK 15; H, CF ₂ HCH ₂ ], [RK16; Me, Me], [RK17; Me, Et], [RK18; Me, Pr], [RK19; Me, i-Pr], [RK20; Me, c-Pr], [RK21 Me, Bu], [RK22; Me, t-Bu], [RK23; Me, c-PrCH 2], [RK24; Me, Ph], [RK25; Me, Bn], [RK26; Me, CF 3], [ _{RK27; Me, CF 3 CH 2} ], [RK28; Me, CF 3 CF 2], [RK29; Me, CF 2 H], [RK30; Me, CF 2 HCH 2], [RK31; Et, Me], [RK 32; Et, Et], [RK 33; Et, Pr], [RK 34; Et, i-Pr], [RK 35; Et, c-Pr], [RK 36; Et, Bu], [RK 37; Et, t -Bu], [rK38; Et, c-PrCH 2], [RK39; Et, Ph], [RK40; Et, Bn], [RK41; Et, CF 3], [RK42; Et, CF 3 CH 2] , [RK 43; Et, CF ₃ CF ₂ ], [RK 44; Et, CF ₂ H], [RK 45; Et, CF ₂ HCH ₂ ], [RK 46; Pr, Me], [RK 47; Pr, Et], [RK RK 48; Pr, Pr], [RK 49; Pr, i-Pr], [RK 50; Pr, c-Pr], [RK 51; Pr, Bu], [RK 52; Pr, t-Bu], [RK 53; Pr, c-PrCH ₂ ], [RK 54; Pr, Ph], [RK 55; Pr, Bn], [RK 56; Pr, CF ₃ ], [RK 57; Pr, CF ₃ CH ₂ ], [RK 58; Pr, CF ₃ CF _{2], [RK59; Pr,} CF 2 H], [RK60; Pr, CF 2 HCH 2], [RK61; i-Pr, Me], [RK62; i-Pr, Et], [RK63 i-Pr, Pr], [RK64; i-Pr, i-Pr], [RK65; i-Pr, c-Pr], [RK66; i-Pr, Bu], [RK67; i-Pr, t -Bu], [RK68; i- Pr, c-PrCH 2], [RK69; i-Pr, Ph], [RK70; i-Pr, Bn], [RK71; i-Pr, CF 3], [RK72 _{; i-Pr, CF 3 CH} 2], [RK73; i-Pr, CF 3 CF 2], [RK74; i-Pr, CF 2 H], [RK75; i-Pr, CF 2 HCH 2], [ RK 76; c-Pr, Me], [RK 77; c-Pr, Et], [RK 78; c-Pr, Pr], [RK 79; c-Pr, i-Pr], [RK 80; c-Pr, c- Pr], [RK 81; c-Pr, Bu], [RK 82; c-Pr, t-Bu], [RK 83; c-Pr, c-PrCH ₂ ], [RK 84; c-Pr, Ph], [RK 85 c-Pr, Bn], [RK 86; c-Pr, CF ₃ ], [RK 87; c-Pr, CF ₃ CH ₂ ], [RK 88; c-Pr, CF ₃ CF ₂ ], [RK 89; c- _{Pr, CF 2 H], [} RK90; c-Pr, CF 2 HCH 2], [RK91; c-PrCH 2, Me], [RK92; c-PrCH 2, Et], [RK93; c-PrCH 2, Pr], [RK94; c- PrCH 2, i-Pr], [RK95; c-PrCH 2, c-Pr], [RK96; c-PrCH 2, Bu], [RK97; c-PrCH 2, t- Bu], [RK98; c- PrCH 2, c-PrCH 2], [RK99; c-PrCH 2, Ph], [RK100; c-PrCH 2, Bn], [RK101; c-PrCH 2, CF 3] _{, [RK102; c-PrCH 2} , CF 3 CH 2], [RK103; c-PrCH 2, CF 3 CF 2], [RK104; c-PrCH 2, CF 2 H], [RK105; c-PrCH 2, _{CF 2 HCH 2], [RK106} ; CF 3 CH 2, Me], [RK107; CF 3 CH 2, Et], [RK108; CF 3 CH 2, Pr], [RK109; CF 3 CH 2, i-Pr _{], [RK110; CF 3 CH} 2, c-Pr], [RK111; CF 3 CH 2, Bu], [RK112; C _{F 3 CH 2, t-Bu} ], [RK113; CF 3 CH 2, c-PrCH 2], [RK114; CF 3 CH 2, Ph], [RK115; CF 3 CH 2, Bn], [RK116; CF ₃ CH ₂ , CF ₃ ], [RK 117; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RK 118; CF ₃ CH ₂ , CF ₃ CF ₂ ], [RK 119; CF ₃ CH ₂ , CF ₂ H], [RK _{RK120; CF 3 CH 2, CF} 2 HCH 2], [RK121; CF 2 HCH 2, Me], [RK122; CF 2 HCH 2, Et], [RK123; CF 2 HCH 2, Pr], [RK124; CF ₂ HCH ₂ , i-Pr], [RK 125; CF ₂ HCH ₂ , c-Pr], [RK 126; CF ₂ HCH ₂ , Bu], [RK 127; CF ₂ HCH ₂ , t-Bu], [RK 128; CF _{2 HCH 2, c-PrCH 2} ], [RK129; CF 2 HCH 2, Ph], [RK130; CF 2 HCH 2, Bn], [RK131; CF 2 HCH 2, CF 3], [RK132; CF 2 HCH _{2, CF 3 CH 2],} [RK133; CF 2 HCH 2, CF 3 CF 2], [RK134; CF 2 HCH 2, CF 2 H], [RK135; CF 2 HCH 2, CF 2 HCH 2], [ _{RK136; MeOCH 2, Me],} [RK137; MeOCH 2, Et], [RK138; MeOCH 2, Pr], [RK139; MeOCH 2, i-Pr], [RK140; MeOCH 2, c-Pr], [RK141 _{; MeOCH 2, Bu], [} RK142; MeOCH 2, t-Bu], [RK143; MeOCH 2, c-PrCH 2], [RK144; MeOCH 2, Ph], [RK145; MeOCH 2, Bn], [RK146 _{; MeOCH 2, CF 3],} [RK147; MeOCH 2, CF 3 CH 2], [RK148; MeOCH 2, CF 3 CF 2], [RK149; MeOCH 2, CF 2 H], [RK150; MeOCH 2, CF ₂ HCH ₂ ], [RK 151; EtOCH ₂ , Me], [RK 152; EtOCH ₂ , Et], [RK153; EtOCH 2, Pr], [RK154; EtOCH 2, i-Pr], [RK155; EtOCH 2, c-Pr], [RK156; EtOCH 2, Bu], [RK157; EtOCH 2, t-Bu], [RK158; EtOCH 2, c-PrCH 2], [RK159; EtOCH 2, Ph], [RK160; EtOCH 2, Bn], [RK161; EtOCH 2, CF 3], [RK162; EtOCH 2 , CF ₃ CH ₂ ], [RK 163; EtOCH ₂ , CF ₃ CF ₂ ], [RK 164; EtOCH ₂ , CF ₂ H], [RK 165; EtOCH ₂ , CF ₂ HCH ₂ ], [RK 166; CH ₂ CH ₂ CH _{2], [RK167; CH 2} CH 2 CH 2 CH 2], [RK168; t-Bu, Me], [RK169; t-Bu, Et], [RK170; t-Bu, Pr], [RK171; t -Bu, i-Pr], [RK172; t-Bu, c-Pr], [RK173; t-Bu, t-Bu], [RK174; t-Bu, Bu], [RK175; t-Bu, t -Bu], [RK176; t- Bu, c-PrCH 2], [RK177; t-Bu, Ph], [RK178; t-Bu, Bn], [RK179; t-Bu, CF 3], [RK180 t-Bu, CF ₃ CH ₂ ], [RK 181; t-Bu, CF ₃ CF ₂ ], [RK 182; t-Bu, CF ₂ H], [RK 183; t-Bu, CF ₂ HCH ₂ ], [RK RK 184; i-Bu, Me], [RK 185; i-Bu, Et], [RK 186; i-Bu, Pr], [RK 187; i-Bu, i-Pr], [RK 188; i-Bu, c- Pr], [RK189; i-Bu, t-Bu], [RK190; i-Bu, Bu], [RK191; i-Bu, t-Bu], [RK192; i-Bu, c-PrCH ₂ ], [RK193; i-Bu, Ph ], [RK194; i-Bu, Bn], [RK195; i-Bu, CF 3], [RK196; i-Bu, CF 3 CH 2], [RK197; i-Bu , CF ₃ CF ₂ ], [RK 198; i-Bu, CF ₂ H], [RK 199: i-Bu, CF ₂ HCH ₂ ], [RK 200; HCCCH ₂ , Me], [RK 201; HCC _{CH 2, Et], [RK202} ; HCCCH 2, Pr], [RK203; HCCCH 2, i-Pr], [RK204; HCCCH 2, c-Pr], [RK205; HCCCH 2, t-Bu], [RK206 _{; HCCCH 2, Bu], [} RK207; HCCCH 2, t-Bu], [RK208; HCCCH 2, c-PrCH 2], [RK209; HCCCH 2, Ph], [RK210; HCCCH 2, Bn], [RK211 _{; HCCCH 2, CF 3],} [RK212; HCCCH 2, CF 3 CH 2], [RK213; HCCCH 2, CF 3 CF 2], [RK214; HCCCH 2, CF 2 H], [RK215; HCCCH 2, CF _{2 HCH 2], [RK216;} MeCCCH 2, Me], [RK217; MeCCCH 2, Et], [RK218; MeCCCH 2, Pr], [RK219; MeCCCH 2, i-Pr], [RK220; MeCCCH 2, c _{-Pr], [RK221; MeCCCH 2} , t-Bu], [RK222; MeCCCH 2, Bu], [RK223; MeCCCH 2, t-Bu], [RK224; MeCCCH 2, c-PrCH 2], [RK225; _{MeCCCH 2, Ph], [RK226} ; MeCCCH 2, Bn], [RK227; MeCCCH 2, CF 3], [RK228; MeCCCH 2, CF 3 CH 2], [RK229; MeCCCH 2, CF 3 CF 2], [ _{RK230; MeCCCH 2, CF 2 H} ], [RK231; MeCCCH 2, CF 2 HCH 2], [RK232; MeSCH 2, Me], [RK233; MeSCH 2, Et], [RK234; MeSCH 2, Pr], [ _{RK235; MeSCH 2, i-Pr} ], [RK236; MeSCH 2, c-Pr], [RK237; MeSCH 2, t-Bu], [RK238; MeSCH 2, Bu], [RK239; MeSCH 2, t-Bu _{], [RK240; MeSCH 2,} c-PrCH 2], [RK241; MeSCH 2, Ph], [RK242; MeSCH 2, Bn], [RK243; MeSCH 2, CF 3], [RK244; MeSCH 2, CF 3 C _{H 2], [RK245; MeSCH} 2, CF 3 CF 2], [RK246; MeSCH 2, CF 2 H], [RK247; MeSCH 2, CF 2 HCH 2], [RK248; EtSCH 2, Me], [RK249 EtSCH ₂ , Et], [RK 250; EtSCH ₂ , Pr],

[RK251; EtSCH ₂ , i-Pr], [RK 252; EtSCH ₂ , c-Pr], [RK 253; EtSCH ₂ , t-Bu], [RK 254; EtSCH ₂ , Bu], [RK 255; EtSCH ₂ , t- _{Bu], [RK256; EtSCH 2} , c-PrCH 2], [RK257; EtSCH 2, Ph], [RK258; EtSCH 2, Bn], [RK259; EtSCH 2, CF 3], [RK260; EtSCH 2, CF _{3 CH 2], [RK261;} EtSCH 2, CF 3 CF 2], [RK262; EtSCH 2, CF 2 H], [RK263; EtSCH 2, CF 2 HCH 2], [RK264; 2-Me-Ph, Me ], [RK265; 2-Me-Ph, Et], [RK266; 2-Me-Ph, Pr], [RK267; 2-Me-Ph, i-Pr], [RK268; 2-Me-Ph, c] -Pr], [RK 269; 2-Me-Ph, t-Bu], [RK 270; 2-Me-Ph, Bu], [RK 271; 2-Me-Ph, t-Bu], [RK 272; _{-Ph, c-PrCH 2],} [RK273; 2-Me-Ph, Ph], [RK274; 2-Me-Ph, Bn], [RK275; 2-Me-Ph, CF 3], [RK276; 2 _{-Me-Ph, CF 3 CH 2} ], [RK277; 2-Me-Ph, CF 3 CF 2], [RK278; 2-Me-Ph, CF 2 H], [RK279; 2-Me-Ph, CF ₂ HCH ₂ ], [RK 280; 3-Me-Ph, Me], [RK 281; 3-Me-Ph, Et], [RK 282, 3-Me-Ph, Pr], [RK 283; 3-Me-Ph, i-Pr], [RK284; 3-Me-Ph, c-Pr], [RK 285; 3-Me-Ph, t-Bu], [RK 286; 3-Me-Ph, Bu], [RK 287; Me-Ph, t-Bu] , [RK288; 3-Me-Ph, c-PrCH 2], [RK289; 3-Me-Ph, Ph], [RK290; 3-Me-Ph, Bn], [RK291 ; 3-Me-Ph, CF 3], [RK292; 3-Me-Ph, CF 3 CH 2], [RK293; 3-Me-Ph, CF 3 CF 2], [RK294; 3-Me-Ph, CF ₂ H], [RK 295; 3-Me-Ph, CF _{2 HCH 2], [RK296; 4} -Me-Ph, Me], [RK297; 4-Me-Ph, Et], [RK298; 4-Me-Ph, Pr], [RK299; 4-Me-Ph, i -Pr], [RK300; 4-Me-Ph, c-Pr], [RK301; 4-Me-Ph, t-Bu], [RK302; 4-Me-Ph, Bu], [RK303; -Ph, t-Bu], [ RK304; 4-Me-Ph, c-PrCH 2], [RK305; 4-Me-Ph, Ph], [RK306; 4-Me-Ph, Bn], [RK307; _{4-Me-Ph, CF 3} ], [RK308; 4-Me-Ph, CF 3 CH 2], [RK309; 4-Me-Ph, CF 3 CF 2], [RK310; 4-Me-Ph, CF ₂ H], [RK 311; 4-Me-Ph, CF ₂ HCH ₂ ], [RK 312; 2-F-Ph, Me], [RK 313; 2-F-Ph, Et], [RK 314; 2-F- Ph, Pr], [RK315; 2-F-Ph, i-Pr], [RK316; 2-F-Ph, c-Pr], [RK317; 2-F-Ph, t-Bu], [RK318; 2-F-Ph, Bu], [RK 319; 2-F-Ph, t-Bu], [RK 320; 2-F-Ph, c-PrCH ₂ ], [RK 321; 2-F-Ph, Ph], [RK322; 2-F-Ph , Bn], [RK323; 2-F-Ph, CF 3], [RK324; 2-F-Ph, CF 3 CH 2], [RK325; 2-F-Ph, CF _{3 CF 2], [RK326;} 2-F-Ph, CF 2 H], [RK327; 2-F-Ph, CF 2 HCH 2], [RK328; 3-F-Ph, Me], [RK329; 3 -F-Ph, Et], [RK330; 3-F-Ph, Pr], [RK331; 3-F-Ph, i-Pr], [RK332; 3-F-Ph, c-Pr], [RK333] 3-F-Ph, t-Bu], [RK334; 3-F-Ph, Bu], [RK335; 3-F-Ph, t-Bu], [RK336; 3-F-Ph, c-PrCH] ₂ ], [RK 337; 3-F-Ph, Ph], [RK 338; 3-F-Ph, Bn], [RK 339; 3-F-Ph, CF ₃ ], [RK 340; 3-F-Ph, CF] ₃ CH ₂ ], [RK 341; 3-F-Ph, CF ₃ CF ₂ ], [RK 342; 3-F-Ph, CF ₂ H], [RK343; 3- F-Ph, CF 2 HCH 2], [RK344; 4-F-Ph, Me], [RK345; 4-F-Ph, Et], [RK346; 4-F-Ph , Pr], [RK 347; 4-F-Ph, i-Pr], [RK 348; 4-F-Ph, c-Pr], [RK 349; 4-F-Ph, t-Bu], [RK 350; -F-Ph, Bu], [RK 351; 4-F-Ph, t-Bu], [RK 352; 4-F-Ph, c-PrCH ₂ ], [RK 353; 4-F-Ph, Ph], [RK] RK 354; 4-F-Ph, Bn], [RK 355; 4-F-Ph, CF ₃ ], [RK 356; 4-F-Ph, CF ₃ CH ₂ ], [RK 357; 4-F-Ph, CF _{3 CF 2], [RK358; 4} -F-Ph, CF 2 H], [RK359; 4-F-Ph, CF 2 HCH 2], [RK360; 2-MeO-Ph, Me], [RK361; 2- MeO-Ph, Et], [RK362; 2-MeO-Ph, Pr], [RK363; 2-MeO-Ph, i-Pr], [RK364; 2-MeO-Ph, c-Pr], [RK365; 2-MeO-Ph, t-Bu], [RK 366; 2-MeO-Ph, Bu], [RK 367; 2-MeO-Ph, t-Bu], [RK 368; 2-MeO-Ph, c-PrCH ₂ ], [RK369; 2-MeO -Ph, Ph], [RK370; 2-MeO-Ph, Bn], [RK371; 2-MeO-Ph, CF 3], [RK372; 2-MeO-Ph, CF 3 _{CH 2], [RK373; 2} -MeO-Ph, CF 3 CF 2], [RK374; 2-MeO-Ph, CF 2 H], [RK375; 2-MeO-Ph, CF 2 HCH 2], [RK376 3-MeO-Ph, Me], [RK377; 3-MeO-Ph, Et], [RK378; 3-MeO-Ph, Pr], [RK379; 3-MeO-Ph, i-Pr], [RK380] 3-MeO-Ph, c-Pr], [RK 381; 3-MeO-Ph, t-Bu], [RK 382; 3-MeO-Ph, Bu], [RK 383; 3-MeO-Ph, t-Bu ], [RK 384; 3-MeO-Ph, c-PrCH ₂ ], [RK 385; 3-MeO-Ph, Ph], [RK 386; 3-MeO-Ph, Bn], [RK 387; 3-MeO-Ph, CF ₃ ], [RK 388; 3-M _{eO-Ph, CF 3 CH 2} ], [RK389; 3-MeO-Ph, CF 3 CF 2], [RK390; 3-MeO-Ph, CF 2 H], [RK391; 3-MeO-Ph, CF 2 _{HCH 2], [RK392; 4} -MeO-Ph, Me], [RK393; 4-MeO-Ph, Et], [RK394; 4-MeO-Ph, Pr], [RK395; 4-MeO-Ph, i -Pr], [RK396; 4-MeO-Ph, c-Pr], [RK 397; 4-MeO-Ph, t-Bu], [RK 398; 4-MeO-Ph, Bu], [RK 399; 4-MeO -Ph, t-Bu], [ RK400; 4-MeO-Ph, c-PrCH 2], [RK401; 4-MeO-Ph, Ph], [RK402; 4-MeO-Ph, Bn], [RK403; _{4-MeO-Ph, CF 3} ], [RK404; 4-MeO-Ph, CF 3 CH 2], [RK405; 4-MeO-Ph, CF 3 CF 2], [RK406; 4-MeO-Ph, CF ₂ H], [RK 407; 4-MeO-Ph, CF ₂ HCH ₂ ]

〔式中、Ｒ²⁵及びＲ³¹は上記と同じ意味を表す。〕
で表される化合物において、R³¹及びR²⁵の組合わせが下記に示される置換基番号ＲＬ１〜ＲＬ４０７のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＬ１〜ＲＬ４０７の化合物を本発明化合物ＲＬ１〜ＲＬ４０７と表し、本発明化合物ＲＬ１〜ＲＬ４０７をまとめて本発明化合物ＲＬと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＬ１〜ＲＬ４０７とは、式（ＸＩＩＩ）で表される化合物における、R³¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;R³¹,R²⁵]と記す。ただし、置換基番号ＲＬ１６６及びＲＬ１６７においては、Ｒ³¹とＲ²⁵とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＬ４とは、R³¹が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XIII)

[Wherein, R ²⁵ and R ³¹ represent the same meaning as described above. ]
Wherein the combination of R ³¹ and R ^{25 is} a combination as set forth in any of Substituent Nos. RL 1 to RL 407 shown below (hereinafter referred to as “compound of Substituent Nos. RL 1 to RL 407” Invention compounds RL1 to RL407, and the invention compounds RL1 to RL407 are collectively referred to as the invention compound RL) can be obtained according to the method described in the above-mentioned production method.
The substituent numbers RL1 to RL407 represent a combination of R ³¹ and R ²⁵ in the compound represented by the formula (XIII), and hereinafter referred to as [substituent number: R ³¹ , R ²⁵ ]. . However, in Substituent Nos. RL166 and RL167, R ³¹ and R ²⁵ represent that they combine with each other to form a heterocycle.
For example, the substituent number RL4 represents a combination in which R ³¹ is a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RL4 means a compound represented by the formula (XIII) in which the substituent number is RL4, and in the compound represented by the formula (XIII), R ³¹ is a hydrogen atom, Represents the following compound wherein R ²⁵ is an isopropyl group.

[Substituent number; R ³¹ , R ²⁵ ]: [RL 1; H, Me], [RL 2; H, Et], [RL 3; H, Pr], [RL 4; H, i-Pr], [RL 5; , c-Pr], [RL 6; H, Bu], [RL 7; H, t-Bu], [RL 8; H, c-PrCH ₂ ], [RL 9; H, Ph], [RL 10; H, Bn] , [RL 11; H, CF ₃ ], [RL 12; H, CF ₃ CH ₂ ], [RL 13; H, CF ₃ CF ₂ ], [RL 14; H, CF ₂ H], [RL 15; H, CF ₂ HCH ₂ ], [RL 16; Me, Me], [RL 17; Me, Et], [RL 18; Me, Pr], [RL 19; Me, i-Pr], [RL 20; Me, c-Pr], [RL 21 Me, [RL 21 Me, Bu], [RL 22; Me, t-Bu], [RL 23; Me, c-PrCH ₂ ], [RL 24; Me, Ph], [RL 25; Me, Bn], [RL 26; Me, CF ₃ ], [[ _{RL27; Me, CF 3 CH 2} ], [RL28; Me, CF 3 CF 2], [RL29; Me, CF 2 H], [RL30; Me, CF 2 HCH 2], [RL31; Et, Me], [RL 32; Et, Et], [RL 33; Et, Pr], [RL 34; Et, i-Pr], [RL 35; Et, c-Pr], [RL 36; Et, Bu], [RL 37; Et, t -Bu], [RL 38; Et, c-PrCH ₂ ], [RL 39; Et, Ph], [RL 40; Et, Bn], [RL 41; Et, CF ₃ ], [RL 42; Et, CF ₃ CH ₂ ] , [RL 43; Et, CF ₃ CF ₂ ], [RL 44; Et, CF ₂ H], [RL 45; Et, CF ₂ HCH ₂ ], [RL 46; Pr, Me], [RL 47; Pr, Et], [RL RL 48; Pr, Pr], [RL 49; Pr, i-Pr], [RL 50; Pr, c-Pr], [RL 51; Pr, Bu], [RL 52; Pr, t-Bu], [RL 53; Pr, c-PrCH ₂ ], [RL 54; Pr, Ph], [RL 55; Pr, Bn], [RL 56; Pr, CF ₃ ], [RL 57; Pr, CF ₃ CH ₂ ], [RL 58; Pr, CF ₃ CF ₂ ], [RL 59; Pr, CF ₂ H], [RL 60; Pr, CF ₂ HCH ₂ ], [RL 61; i-Pr, Me], [RL 62; i-Pr, Et], [RL 63] i-Pr, Pr], [RL 64; i-Pr, i-Pr], [RL 65; i-Pr, c-Pr], [RL 66; i-Pr, Bu], [RL 67; i-Pr, t -Bu], [RL 68; i-Pr, c-PrCH ₂ ], [RL 69; i-Pr, Ph], [RL 70; i-Pr, Bn], [RL 71; i-Pr, CF ₃ ], [RL 72 i-Pr, CF ₃ CH ₂ ], [RL 73; i-Pr, CF ₃ CF ₂ ], [RL 74; i-Pr, CF ₂ H], [RL 75; i-Pr, CF ₂ HCH ₂ ], [RL 75; RL 76; c-Pr, Me], [RL 77; c-Pr, Et], [RL 78; c-Pr, Pr], [RL 79; c-Pr, i-Pr], [RL 80; c-Pr, c- Pr], [RL 81; c-Pr, Bu], [RL 82; c-Pr, t-Bu], [RL 83; c-Pr, c-PrCH ₂ ], [RL 84; c-Pr, Ph], [RL 85 c-Pr, Bn], [RL 86; c-Pr, CF ₃ ], [RL 87; c-Pr, CF ₃ CH ₂ ], [RL 88; c-Pr, CF ₃ CF ₂ ], [RL 89; c- _{Pr, CF 2 H], [} RL90; c-Pr, CF 2 HCH 2], [RL91; c-PrCH 2, Me], [RL92; c-PrCH 2, Et], [RL93; c-PrCH 2, Pr], [RL94; c- PrCH 2, i-Pr], [RL95; c-PrCH 2, c-Pr], [RL96; c-PrCH 2, Bu], [RL97; c-PrCH 2, t- Bu], [RL 98; c-PrCH ₂ , c-PrCH ₂ ], [RL 99; c-PrCH ₂ , Ph], [RL 100; c-PrCH ₂ , Bn], [RL 101; c-PrCH ₂ , CF ₃ ] _{, [RL102; c-PrCH 2} , CF 3 CH 2], [RL103; c-PrCH 2, CF 3 CF 2], [RL104; c-PrCH 2, CF 2 H], [RL105; c-PrCH 2, CF ₂ HCH ₂ ], [RL 106; CF ₃ CH ₂ , Me], [RL 107; CF ₃ CH ₂ , Et], [RL 108; CF ₃ CH ₂ , Pr], [RL 109; CF ₃ CH ₂ , i-Pr ], [RL 110; CF ₃ CH ₂ , c-Pr], [RL 111; CF ₃ CH ₂ , Bu], [RL 112; C] _{F 3 CH 2, t-Bu} ], [RL113; CF 3 CH 2, c-PrCH 2], [RL114; CF 3 CH 2, Ph], [RL115; CF 3 CH 2, Bn], [RL116; CF ₃ CH ₂ , CF ₃ ], [RL 117; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RL 118; CF ₃ CH ₂ , CF ₃ CF ₂ ], [RL 119; CF ₃ CH ₂ , CF ₂ H], [RL _{RL120; CF 3 CH 2, CF} 2 HCH 2], [RL121; CF 2 HCH 2, Me], [RL122; CF 2 HCH 2, Et], [RL123; CF 2 HCH 2, Pr], [RL124; CF ₂ HCH ₂ , i-Pr], [RL 125; CF ₂ HCH ₂ , c-Pr], [RL 126; CF ₂ HCH ₂ , Bu], [RL 127; CF ₂ HCH ₂ , t-Bu], [RL 128; CF ₂ HCH ₂ , c-PrCH ₂ ], [RL 129; CF ₂ HCH ₂ , Ph], [RL 130; CF ₂ HCH ₂ , Bn], [RL 131; CF ₂ HCH ₂ , CF ₃ ], [RL 132; CF ₂ HCH _{2, CF 3 CH 2],} [RL133; CF 2 HCH 2, CF 3 CF 2], [RL134; CF 2 HCH 2, CF 2 H], [RL135; CF 2 HCH 2, CF 2 HCH 2], [ _{RL136; MeOCH 2, Me],} [RL137; MeOCH 2, Et], [RL138; MeOCH 2, Pr], [RL139; MeOCH 2, i-Pr], [RL140; MeOCH 2, c-Pr], [RL141 _{; MeOCH 2, Bu], [} RL142; MeOCH 2, t-Bu], [RL143; MeOCH 2, c-PrCH 2], [RL144; MeOCH 2, Ph], [RL145; MeOCH 2, Bn], [RL146 MeOCH ₂ , CF ₃ ], [RL 147; MeOCH ₂ , CF ₃ CH ₂ ], [RL 148; MeOCH ₂ , CF ₃ CF ₂ ], [RL 149; MeOCH ₂ , CF ₂ H], [RL 150; MeOCH ₂ , CF ₂ HCH ₂ ], [RL 151; EtOCH ₂ , Me], [RL 152; EtOCH ₂ , Et], [RL153; EtOCH 2, Pr], [RL154; EtOCH 2, i-Pr], [RL155; EtOCH 2, c-Pr], [RL156; EtOCH 2, Bu], [RL157; EtOCH 2, t-Bu], [RL 158; EtOCH ₂ , c-PrCH ₂ ], [RL 159; EtOCH ₂ , Ph], [RL 160; EtOCH ₂ , Bn], [RL 161; EtOCH ₂ , CF ₃ ], [RL 162; EtOCH ₂ , CF ₃ CH ₂ ], [RL 163; EtOCH ₂ , CF ₃ CF ₂ ], [RL 164; EtOCH ₂ , CF ₂ H], [RL 165; EtOCH ₂ , CF ₂ HCH ₂ ], [RL 166; CH ₂ CH ₂ CH ₂ ], [RL 167; CH ₂ CH ₂ CH ₂ CH ₂ ], [RL 168; t-Bu, Me], [RL 169; t-Bu, Et], [RL 170; t-Bu, Pr], [RL 171; t -Bu, i-Pr], [RL 172; t-Bu, c-Pr], [RL 173; t-Bu, t-Bu], [RL 174; t-Bu, Bu], [RL 175; t-Bu, t -Bu], [RL 176; t-Bu, c-PrCH ₂ ], [RL 177; t-Bu, Ph], [RL 178; t-Bu, Bn], [RL 179; t-Bu, CF ₃ ], [RL 180] t-Bu, CF ₃ CH ₂ ], [RL 181; t-Bu, CF ₃ CF ₂ ], [RL 182; t-Bu, CF ₂ H], [RL 183; t-Bu, CF ₂ HCH ₂ ], [RL 182; RL 184; i-Bu, Me], [RL 185; i-Bu, Et], [RL 186; i-Bu, Pr], [RL 187; i-Bu, i-Pr], [RL 188; i-Bu, c- Pr], [RL 189; i-Bu, t-Bu], [RL 190; i-Bu, Bu], [RL 191; i-Bu, t-Bu], [RL 192; i-Bu, c-PrCH ₂ ], [RL 193; i-Bu, Ph], [RL 194; i-Bu, Bn], [RL 195; i-Bu, CF ₃ ], [RL 196; i-Bu, CF ₃ CH ₂ ], [RL 197; i-Bu , CF ₃ CF ₂ ], [RL 198; i-Bu, CF ₂ H], [RL 199; i-Bu, CF ₂ HCH ₂ ], [RL 200; HCCCH ₂ , Me], [RL 201; HCC _{CH 2, Et], [RL202} ; HCCCH 2, Pr], [RL203; HCCCH 2, i-Pr], [RL204; HCCCH 2, c-Pr], [RL205; HCCCH 2, t-Bu], [RL206 _{; HCCCH 2, Bu], [} RL207; HCCCH 2, t-Bu], [RL208; HCCCH 2, c-PrCH 2], [RL209; HCCCH 2, Ph], [RL210; HCCCH 2, Bn], [RL211 HCCCH ₂ , CF ₃ ], [RL 212; HCCCH ₂ , CF ₃ CH ₂ ], [RL 213; HCCCH ₂ , CF ₃ CF ₂ ], [RL 214; HCCCH ₂ , CF ₂ H], [RL 215; HCCCH ₂ , CF _{2 HCH 2], [RL216;} MeCCCH 2, Me], [RL217; MeCCCH 2, Et], [RL218; MeCCCH 2, Pr], [RL219; MeCCCH 2, i-Pr], [RL220; MeCCCH 2, c _{-Pr], [RL221; MeCCCH 2} , t-Bu], [RL222; MeCCCH 2, Bu], [RL223; MeCCCH 2, t-Bu], [RL224; MeCCCH 2, c-PrCH 2], [RL225; _{MeCCCH 2, Ph], [RL226} ; MeCCCH 2, Bn], [RL227; MeCCCH 2, CF 3], [RL228; MeCCCH 2, CF 3 CH 2], [RL229; MeCCCH 2, CF 3 CF 2], [ _{RL230; MeCCCH 2, CF 2 H} ], [RL231; MeCCCH 2, CF 2 HCH 2], [RL232; MeSCH 2, Me], [RL233; MeSCH 2, Et], [RL234; MeSCH 2, Pr], [ _{RL235; MeSCH 2, i-Pr} ], [RL236; MeSCH 2, c-Pr], [RL237; MeSCH 2, t-Bu], [RL238; MeSCH 2, Bu], [RL239; MeSCH 2, t-Bu _{], [RL240; MeSCH 2,} c-PrCH 2], [RL241; MeSCH 2, Ph], [RL242; MeSCH 2, Bn], [RL243; MeSCH 2, CF 3], [RL244; MeSCH 2, CF 3 C H ₂ ], [RL245; MeSCH ₂ , CF ₃ CF ₂ ], [RL 246; MeSCH ₂ , CF ₂ H], [RL 247; MeSCH ₂ , CF ₂ HCH ₂ ], [RL 248; EtSCH ₂ , Me], [RL 249 EtSCH ₂ , Et], [RL 250; EtSCH ₂ , Pr],

[RL 251; EtSCH ₂ , i-Pr], [RL 252; EtSCH ₂ , c-Pr], [RL 253; EtSCH ₂ , t-Bu], [RL 254; EtSCH ₂ , Bu], [RL 255; EtSCH ₂ , t- _{Bu], [RL256; EtSCH 2} , c-PrCH 2], [RL257; EtSCH 2, Ph], [RL258; EtSCH 2, Bn], [RL259; EtSCH 2, CF 3], [RL260; EtSCH 2, CF ₃ CH ₂ ], [RL 261; EtSCH ₂ , CF ₃ CF ₂ ], [RL 262; EtSCH ₂ , CF ₂ H], [RL 263; EtSCH ₂ , CF ₂ HCH ₂ ], [RL 264; 2-Me-Ph, Me ], [RL 265; 2-Me-Ph, Et], [RL 266; 2-Me-Ph, Pr], [RL 267; 2-Me-Ph, i-Pr], [RL 268; 2-Me-Ph, c] -Pr], [RL 269; 2-Me-Ph, t-Bu], [RL 270; 2-Me-Ph, Bu], [RL 271; 2-Me-Ph, t-Bu], [RL 272; _{-Ph, c-PrCH 2],} [RL273; 2-Me-Ph, Ph], [RL274; 2-Me-Ph, Bn], [RL275; 2-Me-Ph, CF 3], [RL276; 2 _{-Me-Ph, CF 3 CH 2} ], [RL277; 2-Me-Ph, CF 3 CF 2], [RL278; 2-Me-Ph, CF 2 H], [RL279; 2-Me-Ph, CF ₂ HCH ₂ ], [RL 280; 3-Me-Ph, Me], [RL 281; 3-Me-Ph, Et], [RL 282, 3-Me-Ph, Pr], [RL 283; 3-Me-Ph, i-Pr], [RL 284; 3-Me-Ph, c-Pr], [RL 285; 3-Me-Ph, t-Bu], [RL 286; 3-Me-Ph, Bu], [RL 287; Me-Ph, t-Bu], [RL 288; 3-Me-Ph, c-PrCH ₂ ], [RL 289; 3-Me-Ph, Ph], [RL 290; 3-Me-Ph, Bn], [RL 291 ; 3-Me-Ph, CF 3], [RL292; 3-Me-Ph, CF 3 CH 2], [RL293; 3-Me-Ph, CF 3 CF 2], [RL294; 3-Me-Ph, CF ₂ H], [RL 295; 3-Me-Ph, CF _{2 HCH 2], [RL296; 4} -Me-Ph, Me], [RL297; 4-Me-Ph, Et], [RL298; 4-Me-Ph, Pr], [RL299; 4-Me-Ph, i -Pr], [RL 300; 4-Me-Ph, c-Pr], [RL 301; 4-Me-Ph, t-Bu], [RL 302; 4-Me-Ph, Bu], [RL 303; -Ph, t-Bu], [RL 304; 4-Me-Ph, c-PrCH ₂ ], [RL 305; 4-Me-Ph, Ph], [RL 306; 4-Me-Ph, Bn], [RL 307; _{4-Me-Ph, CF 3} ], [RL308; 4-Me-Ph, CF 3 CH 2], [RL309; 4-Me-Ph, CF 3 CF 2], [RL310; 4-Me-Ph, CF ₂ H], [RL 311; 4-Me-Ph, CF ₂ HCH ₂ ], [RL 312; 2-F-Ph, Me], [RL 313; 2-F-Ph, Et], [RL 314; 2-F- Ph, Pr], [RL 315; 2-F-Ph, i-Pr], [RL 316; 2-F-Ph, c-Pr], [RL 317; 2-F-Ph, t-Bu], [RL 318; 2-F-Ph, Bu], [RL 319; 2-F-Ph, t-Bu], [RL 320; 2-F-Ph, c-PrCH ₂ ], [RL 321; 2-F-Ph, Ph], [RL 322; 2-F-Ph, Bn], [RL 323; 2-F-Ph, CF ₃ ], [RL 324; 2-F-Ph, CF ₃ CH ₂ ], [RL 325; 2-F-Ph, CF] ₃ CF ₂ ], [RL 326; 2-F-Ph, CF ₂ H], [RL 327; 2-F-Ph, CF ₂ HCH ₂ ], [RL 328; 3-F-Ph, Me], [RL 329] -F-Ph, Et], [RL 330; 3-F-Ph, Pr], [RL 331; 3-F-Ph, i-Pr], [RL 332; 3-F-Ph, c-Pr], [RL 333 3-F-Ph, t-Bu], [RL 334; 3-F-Ph, Bu], [RL 335; 3-F-Ph, t-Bu], [RL 336; 3-F-Ph, c-PrCH ₂ ], [RL 337; 3-F-Ph, Ph], [RL 338; 3-F-Ph, Bn], [RL 339; 3-F-Ph, CF ₃ ], [RL 340; 3-F-Ph, CF] ₃ CH ₂ ], [RL 341; 3-F-Ph, CF ₃ CF ₂ ], [RL 342; 3-F-Ph, CF ₂ H], [RL343; 3- F-Ph, CF 2 HCH 2], [RL344; 4-F-Ph, Me], [RL345; 4-F-Ph, Et], [RL346; 4-F-Ph , Pr], [RL 347; 4-F-Ph, i-Pr], [RL 348; 4-F-Ph, c-Pr], [RL 349; 4-F-Ph, t-Bu], [RL 350; -F-Ph, Bu], [RL 351; 4-F-Ph, t-Bu], [RL 352; 4-F-Ph, c-PrCH ₂ ], [RL 353; 4-F-Ph, Ph], [[R 353; RL354; 4-F-Ph, Bn], [RL355; 4-F-Ph, CF 3], [RL356; 4-F-Ph, CF 3 CH 2], [RL357; 4-F-Ph, CF 3 CF ₂ ], [RL 358; 4-F-Ph, CF ₂ H], [RL 359; 4-F-Ph, CF ₂ HCH ₂ ], [RL 360; 2-MeO-Ph, Me], [RL 361; MeO-Ph, Et], [RL 362; 2-MeO-Ph, Pr], [RL 363; 2-MeO-Ph, i-Pr], [RL 364; 2-MeO-Ph, c-Pr], [RL 365; 2-MeO-Ph, t-Bu], [RL 366; 2-MeO-Ph, Bu], [RL 367; 2-MeO-Ph, t-Bu], [RL 368; 2-MeO-Ph, c-PrCH ₂ ], [RL 369; 2-MeO-Ph, Ph], [RL 370; 2-MeO-Ph, Bn], [RL 371; 2-MeO-Ph, CF ₃ ], [RL 372; 2-MeO-Ph, CF _{3] CH 2], [RL373; 2} -MeO-Ph, CF 3 CF 2], [RL374; 2-MeO-Ph, CF 2 H], [RL375; 2-MeO-Ph, CF 2 HCH 2], [RL376 3-MeO-Ph, Me], [RL 377; 3-MeO-Ph, Et], [RL 378; 3-MeO-Ph, Pr], [RL 379; 3-MeO-Ph, i-Pr], [RL 380; 3-MeO-Ph, c-Pr], [RL 381; 3-MeO-Ph, t-Bu], [RL 382; 3-MeO-Ph, Bu], [RL 383; 3-MeO-Ph, t-Bu ], [RL 384; 3-MeO-Ph, c-PrCH ₂ ], [RL 385; 3-MeO-Ph, Ph], [RL 386; 3-MeO-Ph, Bn], [RL 387; 3-MeO-Ph, CF ₃ ], [RL 388; 3-M _{eO-Ph, CF 3 CH 2} ], [RL389; 3-MeO-Ph, CF 3 CF 2], [RL390; 3-MeO-Ph, CF 2 H], [RL391; 3-MeO-Ph, CF 2 HCH ₂ ], [RL 392; 4-MeO-Ph, Me], [RL 393; 4-MeO-Ph, Et], [RL 394; 4-MeO-Ph, Pr], [RL 395; 4-MeO-Ph, i -Pr], [RL 396; 4-MeO-Ph, c-Pr], [RL 397; 4-MeO-Ph, t-Bu], [RL 398; 4-MeO-Ph, Bu], [RL 399; 4-MeO -Ph, t-Bu], [RL 400; 4-MeO-Ph, c-PrCH ₂ ], [RL 401; 4-MeO-Ph, Ph], [RL 402; 4-MeO-Ph, Bn], [RL 403; _{4-MeO-Ph, CF 3} ], [RL404; 4-MeO-Ph, CF 3 CH 2], [RL405; 4-MeO-Ph, CF 3 CF 2], [RL406; 4-MeO-Ph, CF ₂ H], [RL 407; 4-MeO-Ph, CF ₂ HCH ₂ ]

〔式中、Ｒ³²及びＲ³³は各々独立して、水素原子、群Ｅ及び群Ｆからなる群より選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、群Ｄより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基もしくは群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基を表すか、又はＲ³²とＲ³³とは、互いに結合して３−６員ヘテロ環（該３−６員ヘテロ環は群Ｄより選ばれる１以上の置換基を有していてもよい）を形成していてもよい。〕
で表される化合物において、R³²及びR³³の組合わせが下記に示される置換基番号ＲＭ１〜ＲＭ１３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＭ１〜ＲＭ１３０の化合物を本発明化合物ＲＭ１〜ＲＭ１３０と表し、本発明化合物ＲＭ１〜ＲＭ１３０をまとめて本発明化合物ＲＭと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＭ１〜ＲＭ１３０とは、式（ＸＩＶ）で表される化合物における、R³²及びR³³の組合せを表すものであり、以下、[置換基番号;R³²,R³³]と記す。ただし、置換基番号ＲＭ１２７〜ＲＭ１２９においては、Ｒ³²とＲ³³とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＭ４とは、R³²が水素原子であり、R¹²がイソプロピル基である組合せを表す。 Formula (XIV)

[Wherein, R ³² and R ³³ each independently represent a hydrogen atom, a C 1 -C 6 alkyl group optionally having one or more substituents selected from the group consisting of Group E and Group F, one or more A C3-C6 alkynyl group which may have a halogen atom, a C1-C6 alkoxy group which may have one or more halogen atoms, and one or more substituents selected from Group D A C3-C6 cycloalkyl group or a phenyl group which may have one or more substituents selected from group D, or R ³² and R ³³ are bonded to each other to form a 3- to 6-membered heterocyclic ring ( The 3- to 6-membered heterocyclic ring may form one or more substituents selected from Group D). ]
Wherein the combination of R ³² and R ^{33 is} a combination according to any one of the substituent numbers RM 1 to RM 130 shown below (hereinafter referred to as a compound of the substituent numbers RM 1 to RM 130 Invention compounds RM1 to RM130, and the compounds of the present invention RM1 to RM130 are collectively referred to as the compound of the invention RM) can be obtained according to the method described in the above-mentioned production method.
Substituent numbers RM1 to RM130 each represent a combination of R ³² and R ³³ in the compound represented by formula (XIV), and hereinafter referred to as [substituent number; R ³² , R ³³ ] . However, in Substituent Nos. RM127 to RM129, R ³² and R ³³ represent that they combine with each other to form a heterocycle.
For example, the substituent number RM4 represents a combination in which R ³² is a hydrogen atom and R ¹² is an isopropyl group.

Here, the 3- to 6-membered heterocyclic ring formed by bonding R ³² and R ³³ to each other represents any structure shown in the following (ZB1 to ZB4 and ZB7 to ZB21) (● represents a bonding position) ).

For example, the compound RM4 of the present invention means a compound represented by the formula (XIV) in which the substituent number is RM4, and in the compound represented by the formula (XIV), R ³² is a hydrogen atom, It represents the following compound wherein R ³³ is an isopropyl group.

[Substituent number; R ³² , R ³³ ]: [RM 1; H, Me], [RM 2; H, Et], [RM 3; H, Pr], [RM 4; H, i-Pr], [RM 5; , c-Pr], [RM 6; H, Bu], [RM 7; H, t-Bu], [RM 8; H, c-PrCH ₂ ], [RM 9; H, Ph], [RM 10; H, Bn] _{, [RM11; H, CF 3} CH 2], [RM12; H, CF 2 HCH 2], [RM13; H, CHCCH 2], [RM14; H, MeCCCH 2], [RM15; Me, Me], [ RM16; Me, Et], [RM17; Me, Pr], [RM18; Me, i-Pr], [RM19; Me, c-Pr], [RM20; Me, Bu], [RM21; Me, t- Bu], [RM22; Me, c-PrCH 2], [RM23; Me, Ph], [RM24; Me, Bn], [RM25; Me, CF 3 CH 2], [RM26; Me, CF 2 HCH 2 ], [RM 27; Me, CHCCH ₂ ], [RM 28; Me, MeCCCH ₂ ], [RM 29; Et, Et], [RM 30; Et, Pr], [RM 31; Et, i-Pr], [RM 32; , c-Pr], [RM 33; Et, Bu], [RM 34; Et, t-Bu], [RM 35; Et, c-PrCH ₂ ], [RM 36; Et, Ph], [RM 37; Et, Bn] , [RM 38; Et, CF ₃ CH ₂ ], [RM 39; Et, CF ₂ HCH ₂ ], [RM 40; Et, CHCCH ₂ ], [RM 41; Et, MeCCCH ₂ ], [RM 42; Pr, Pr], [RM 38; RM 43; Pr, i-Pr], [RM 44; Prc-Pr], [RM 45; Pr, Bu], [RM 46; Pr, t-Bu], [RM 47; Pr, c-PrCH ₂ ], [RM 48; , Ph], [RM 49; Pr, Bn], [RM 50; Pr, CF ₃ CH ₂ ], [RM 51; Pr, CF ₂ HCH ₂ ], [RM 52; Pr, CHCCH ₂ ], [RM 53; Pr, MeCCCH ₂ ], [RM 54; i-Pr, i-Pr], [RM 55; i-Pr, c-Pr], [RM 56; i-Pr, Bu], [RM 57; i-Pr, t-Bu], [RM 58 i-Pr, c-PrCH ₂ ], [RM 59; i-Pr, Ph], [RM 60; i-Pr, Bn], [RM 61; i-Pr, CF _{3 CH 2], [RM62; i} -Pr, CF 2 HCH 2], [RM63; i-Pr, CHCCH 2], [RM64; i-Pr, MeCCCH 2], [RM65; c-Pr, c-Pr] , [RM 66; c-Pr, Bu], [RM 67; c-Pr, t-Bu], [RM 68; c-Pr, c-PrCH ₂ ], [RM 69; c-Pr, Ph], [RM 70; -Pr, Bn], [RM 71; c-Pr, CF ₃ CH ₂ ], [RM 72; c-Pr, CF ₂ HCH ₂ ], [RM 73; c-Pr, CHCCH ₂ ], [RM 74; c-Pr, _{MeCCCH 2], [RM75; c} -PrCH 2, Bu], [RM76; c-PrCH 2, t-Bu], [RM77; c-PrCH 2, c-PrCH 2], [RM78; c-PrCH 2, Ph], [RM79; c- PrCH 2, Bn], [RM80; c-PrCH 2, CF 3 CH 2], [RM81; c-PrCH 2, CF 2 HCH 2], [RM82; c-PrCH 2, _{CHCCH 2], [RM83; c} -PrCH 2, MeCCCH 2], [RM84; CF 3 CH 2, Bu], [RM85; CF 3 CH 2, t-Bu], [RM86; CF 3 CH 2, Ph] , [RM 87; CF ₃ CH ₂ , Bn], [RM 88; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RM 89; CF ₃ CH ₂ , CF ₂ HCH ₂ ], [RM 90; CF ₃ CH ₂ , CHCCH _{2 ], [RM91; CF 3 CH} 2, MeCCCH 2], [RM92; CF 2 HCH 2, Bu], [RM93; CF 2 HCH 2, t-Bu], [RM94; CF 2 HCH 2, Ph], [ RM 95; CF ₂ HCH ₂ , Bn], [RM 96; CF ₂ HCH ₂ , CF ₂ HCH ₂ ], [RM 97; CF ₂ HCH ₂ , CHCCH ₂ ], [RM 98; CF ₂ HCH ₂ , MeCCCH ₂ ], [RM 99 _{; MeOCH 2, Me], [} RM100; MeOCH 2, Et], [RM101; MeOCH 2, Pr], [RM102; MeOCH 2, i-Pr], [RM103; MeOCH 2, c-Pr], [RM104; MeOCH ₂ , Bu], [RM 105; MeOCH ₂ , t-Bu], [RM106 ; MeOCH 2, c-PrCH 2], [RM107; MeOCH 2, Ph], [RM108; MeOCH 2, Bn], [RM109; MeOCH 2, CF 3 CH 2], [RM110 _{; MeOCH 2, CF 2 HCH 2} ], [RM111; MeOCH 2, CHCCH 2], [RM112; MeOCH 2, MeCCCH 2], [RM113; EtOCH 2, Me], [RM114; EtOCH 2, Et], [RM115 EtOCH ₂ , Pr], [RM 116; EtOCH ₂ , i-Pr], [RM 117; EtOCH ₂ , c-Pr], [RM 118; EtOCH ₂ , Bu], [RM 119; EtOCH ₂ , t-Bu], [RM _{RM120; EtOCH 2, c-PrCH} 2], [RM121; EtOCH 2, Ph], [RM122; EtOCH 2, Bn], [RM123; EtOCH 2, CF 3 CH 2], [RM124; EtOCH 2, CF 2 HCH _{2], [RM125; EtOCH 2} , CHCCH 2], [RM126; EtOCH 2, MeCCCH 2], [RM127; CH 2 (CH 2) 2 CH 2], [RM128; CH 2 (CH 2) 3 CH 2] , [RM129; CH ₂ CH ₂ OCH ₂ CH ₂ ], [RM 130; H, H]

〔式中、Ｒ³²及びＲ³³は上記と同じ意味を表す。〕
で表される化合物において、R³²及びR³³の組合わせが下記に示される置換基番号ＲＮ１〜ＲＮ１３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＮ１〜ＲＮ１３０の化合物を本発明化合物ＲＮ１〜ＲＮ１３０と表し、本発明化合物ＲＮ１〜ＲＮ１３０をまとめて本発明化合物ＲＮと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＮ１〜ＲＮ１３０とは、式（ＸＶ）で表される化合物における、R³²及びR³³の組合せを表すものであり、以下、[置換基番号;R³²,R³³]と記す。ただし、置換基番号ＲＮ１２７〜ＲＮ１２９においては、Ｒ³²とＲ³³とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＮ４とは、R³²が水素原子であり、R³³がイソプロピル基である組合せを表す。 Formula (XV)

[Wherein, R ³² and R ³³ represent the same meaning as described above. ]
Wherein the combination of R ³² and R ^{33 is} a combination as set forth in any of Substituent Nos. RN 1 to RN 130 shown below (hereinafter referred to as “compound of Substituent Nos. RN 1 to RN 130” Inventive compounds RN1 to RN130, and the compounds of the present invention RN1 to RN130 are collectively referred to as the compound of the present invention RN) can be obtained according to the method described in the above-mentioned production method.
The substituent numbers RN1 to RN130 represent a combination of R ³² and R ³³ in the compound represented by the formula (XV), and hereinafter, referred to as [substituent number: R ³² , R ³³ ] . However, in Substituent Nos. RN127 to RN129, R ³² and R ³³ represent that they combine with each other to form a heterocycle.
For example, the substituent number RN4 represents a combination in which R ³² is a hydrogen atom and R ³³ is an isopropyl group.

For example, the compound RN4 of the present invention means a compound represented by the formula (XV) in which the substituent number is RN4, and in the compound represented by the formula (XV), R ³² is a hydrogen atom, It represents the following compound wherein R ³³ is an isopropyl group.

[Substituent number; R ³² , R ³³ ]: [RN1; H, Me], [RN2; H, Et], [RN3; H, Pr], [RN4; H, i-Pr], [RN5; H , c-Pr], [RN6 ; H, Bu], [RN7; H, t-Bu], [RN8; H, c-PrCH 2], [RN9; H, Ph], [RN10; H, Bn] _{, [RN11; H, CF 3} CH 2], [RN12; H, CF 2 HCH 2], [RN13; H, CHCCH 2], [RN14; H, MeCCCH 2], [RN15; Me, Me], [ RN16; Me, Et], [RN17; Me, Pr], [RN18; Me, i-Pr], [RN19; Me, c-Pr], [RN20; Me, Bu], [RN21; Me, t- Bu], [RN22; Me, c-PrCH 2], [RN23; Me, Ph], [RN24; Me, Bn], [RN25; Me, CF 3 CH 2], [RN26; Me, CF 2 HCH 2 ], [RN27; Me, CHCCH 2], [RN28; Me, MeCCCH 2], [RN29; Et, Et], [RN30; Et, Pr], [RN31; Et, i-Pr], [RN32; Et , c-Pr], [RN 33; Et, Bu], [RN 34; Et, t-Bu], [RN 35; Et, c-PrCH ₂ ], [RN 36; Et, Ph], [RN 37; Et, Bn] _{, [RN38; Et, CF 3} CH 2], [RN39; Et, CF 2 HCH 2], [RN40; Et, CHCCH 2], [RN41; Et, MeCCCH 2], [RN42; Pr, Pr], [ RN43; Pr, i-Pr] , [RN44; Prc-Pr], [RN45; Pr, Bu], [RN46; Pr, t-Bu], [RN47; Pr, c-PrCH 2], [RN48; Pr , Ph], [RN 49; Pr, Bn], [RN 50; Pr, CF ₃ CH ₂ ], [RN 51; Pr, CF ₂ HCH ₂ ], [RN 52; Pr, CHCCH ₂ ], [RN 53; Pr, MeCCCH ₂ ], [RN54; i-Pr, i-Pr], [RN55; i-Pr, c-Pr], [RN56; i-Pr, Bu], [RN57; i-Pr, t-Bu], [RN58] i-Pr, c-PrCH ₂ ], [RN 59; i-Pr, Ph], [RN 60; i-Pr, Bn], [RN 61; i-Pr, CF _{3 CH 2], [RN62; i} -Pr, CF 2 HCH 2], [RN63; i-Pr, CHCCH 2], [RN64; i-Pr, MeCCCH 2], [RN65; c-Pr, c-Pr] , [RN66; c-Pr, Bu], [RN67; c-Pr, t-Bu], [RN68; c-Pr, c-PrCH 2], [RN69; c-Pr, Ph], [RN70; c -Pr, Bn], [RN71; c-Pr, CF 3 CH 2], [RN72; c-Pr, CF 2 HCH 2], [RN73; c-Pr, CHCCH 2], [RN74; c-Pr, _{MeCCCH 2], [RN75; c} -PrCH 2, Bu], [RN76; c-PrCH 2, t-Bu], [RN77; c-PrCH 2, c-PrCH 2], [RN78; c-PrCH 2, Ph], [RN 79; c-PrCH ₂ , Bn], [RN 80; c-PrCH ₂ , CF ₃ CH ₂ ], [RN 81; c-PrCH ₂ , CF ₂ HCH ₂ ], [RN 82; c-PrCH ₂ , _{CHCCH 2], [RN83; c} -PrCH 2, MeCCCH 2], [RN84; CF 3 CH 2, Bu], [RN85; CF 3 CH 2, t-Bu], [RN86; CF 3 CH 2, Ph] , [RN 87; CF ₃ CH ₂ , Bn], [RN 88; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RN 89; CF ₃ CH ₂ , CF ₂ HCH ₂ ], [RN 90; CF ₃ CH ₂ , CHCCH _{2 ], [RN91; CF 3 CH} 2, MeCCCH 2], [RN92; CF 2 HCH 2, Bu], [RN93; CF 2 HCH 2, t-Bu], [RN94; CF 2 HCH 2, Ph], [ _{RN95; CF 2 HCH 2, Bn} ], [RN96; CF 2 HCH 2, CF 2 HCH 2], [RN97; CF 2 HCH 2, CHCCH 2], [RN98; CF 2 HCH 2, MeCCCH 2], [RN99 _{; MeOCH 2, Me], [} RN100; MeOCH 2, Et], [RN101; MeOCH 2, Pr], [RN102; MeOCH 2, i-Pr], [RN103; MeOCH 2, c-Pr], [RN104; MeOCH ₂ , Bu], [RN 105; MeOCH ₂ , t-Bu], [RN106 ; MeOCH 2, c-PrCH 2], [RN107; MeOCH 2, Ph], [RN108; MeOCH 2, Bn], [RN109; MeOCH 2, CF 3 CH 2], [RN110 _{; MeOCH 2, CF 2 HCH 2} ], [RN111; MeOCH 2, CHCCH 2], [RN112; MeOCH 2, MeCCCH 2], [RN113; EtOCH 2, Me], [RN114; EtOCH 2, Et], [RN115 _{; EtOCH 2, Pr], [} RN116; EtOCH 2, i-Pr], [RN117; EtOCH 2, c-Pr], [RN118; EtOCH 2, Bu], [RN119; EtOCH 2, t-Bu], [ _{RN120; EtOCH 2, c-PrCH} 2], [RN121; EtOCH 2, Ph], [RN122; EtOCH 2, Bn], [RN123; EtOCH 2, CF 3 CH 2], [RN124; EtOCH 2, CF 2 HCH ₂ ], [RN 125; EtOCH ₂ , CHCCH ₂ ], [RN 126; EtOCH ₂ , MeCCCH ₂ ], [RN 127; CH ₂ (CH ₂ ) ₂ CH ₂ ], [RN 128; CH ₂ (CH ₂ ) ₃ CH ₂ ] , [RN 129; CH ₂ CH ₂ OCH ₂ CH ₂ ], [RN 130; H, H]

〔式中、Ｒ³²及びＲ³³は上記と同じ意味を表す。〕
で表される化合物において、R³²及びR³³の組合わせが下記に示される置換基番号ＲＯ１〜ＲＯ１３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＯ１〜ＲＯ１３０の化合物を本発明化合物ＲＯ１〜ＲＯ１３０と表し、本発明化合物ＲＯ１〜ＲＯ１３０をまとめて本発明化合物ＲＯと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＯ１〜ＲＯ１３０とは、式（ＸＶＩ）で表される化合物における、R³²及びR³³の組合せを表すものであり、以下、[置換基番号;R³²,R³³]と記す。ただし、置換基番号ＲＯ１２７〜ＲＯ１２９においては、Ｒ³²とＲ³³とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＯ４とは、R³²が水素原子であり、R³³がイソプロピル基である組合せを表す。 Formula (XVI)

[Wherein, R ³² and R ³³ represent the same meaning as described above. ]
Wherein the combination of R ³² and R ^{33 is} a combination as set forth in any of Substituent Nos. RO 1 to RO 130 shown below (hereinafter referred to as “compound of Substituent No. RO 1 to RO 130” Invention compounds RO1 to RO130, and the compounds of the present invention RO1 to RO130 are collectively referred to as the compound of the invention RO) can be obtained according to the method described in the above-mentioned production method.
The substituent numbers RO1 to RO130 represent a combination of R ³² and R ³³ in the compound represented by the formula (XVI), and hereinafter referred to as [substituent number; R ³² , R ³³ ] . However, in Substituent Nos. RO127 to RO129, R ³² and R ³³ represent that they combine with each other to form a heterocycle.
For example, the substituent number RO4 represents a combination in which R ³² is a hydrogen atom and R ³³ is an isopropyl group.

For example, the compound RO4 of the present invention means a compound represented by the formula (XVI) in which the substituent number is RO4, and in the compound represented by the formula (XVI), R ³² is a hydrogen atom, It represents the following compound wherein R ³³ is an isopropyl group.

[Substituent number; R ³² , R ³³ ]: [RO 1; H, Me], [RO 2; H, Et], [RO 3; H, Pr], [RO 4; H, i-Pr], [RO 5; , c-Pr], [RO 6; H, Bu], [RO 7; H, t-Bu], [RO 8; H, c-PrCH ₂ ], [RO 9; H, Ph], [RO 10; H, Bn] , [RO 11; H, CF ₃ CH ₂ ], [RO 12; H, CF ₂ HCH ₂ ], [RO 13; H, CHCCH ₂ ], [RO 14; H, MeCCCH ₂ ], [RO 15; Me, Me], [RO RO16; Me, Et], [RO17; Me, Pr], [RO18; Me, i-Pr], [RO19; Me, c-Pr], [RO20; Me, Bu], [RO21; Me, t- Bu], [RO22; Me, c-PrCH 2], [RO23; Me, Ph], [RO24; Me, Bn], [RO25; Me, CF 3 CH 2], [RO26; Me, CF 2 HCH 2 ], [RO27; Me, CHCCH 2], [RO28; Me, MeCCCH 2], [RO29; Et, Et], [RO30; Et, Pr], [RO31; Et, i-Pr], [RO32; Et , c-Pr], [RO 33; Et, Bu], [RO 34; Et, t-Bu], [RO 35; Et, c-PrCH ₂ ], [RO 36; Et, Ph], [RO 37; Et, Bn] _{, [RO38; Et, CF 3} CH 2], [RO39; Et, CF 2 HCH 2], [RO40; Et, CHCCH 2], [RO41; Et, MeCCCH 2], [RO42; Pr, Pr], [ RO 43; Pr, i-Pr], [RO 44; Prc-Pr], [RO 45; Pr, Bu], [RO 46; Pr, t-Bu], [RO 47; Pr, c-PrCH ₂ ], [RO 48; , Ph], [RO 49; Pr, Bn], [RO 50; Pr, CF ₃ CH ₂ ], [RO 51; Pr, CF ₂ HCH ₂ ], [RO 52; Pr, CHCCH ₂ ], [RO 53; Pr, MeCCCH ₂ ], [RO 54; i-Pr, i-Pr], [RO 55; i-Pr, c-Pr], [RO 56; i-Pr, Bu], [RO 57; i-Pr, t-Bu], [RO 58 i-Pr, c-PrCH ₂ ], [RO 59; i-Pr, Ph], [RO 60; i-Pr, Bn], [RO 61; i-Pr, CF ₃ CH ₂ ], [RO 62; i-Pr, CF ₂ HCH ₂ ], [RO 63; i-Pr, CHCCH ₂ ], [RO 64; i-Pr, MeCCCH ₂ ], [RO 65; c-Pr, c-Pr] , [RO 66; c-Pr, Bu], [RO 67; c-Pr, t-Bu], [RO 68; c-Pr, c-PrCH ₂ ], [RO 69; c-Pr, Ph], [RO 70; -Pr, Bn], [RO71; c-Pr, CF 3 CH 2], [RO72; c-Pr, CF 2 HCH 2], [RO73; c-Pr, CHCCH 2], [RO74; c-Pr, _{MeCCCH 2], [RO75; c} -PrCH 2, Bu], [RO76; c-PrCH 2, t-Bu], [RO77; c-PrCH 2, c-PrCH 2], [RO78; c-PrCH 2, Ph], [RO79; c- PrCH 2, Bn], [RO80; c-PrCH 2, CF 3 CH 2], [RO81; c-PrCH 2, CF 2 HCH 2], [RO82; c-PrCH 2, _{CHCCH 2], [RO83; c} -PrCH 2, MeCCCH 2], [RO84; CF 3 CH 2, Bu], [RO85; CF 3 CH 2, t-Bu], [RO86; CF 3 CH 2, Ph] , [RO 87; CF ₃ CH ₂ , Bn], [RO 88; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RO 89; CF ₃ CH ₂ , CF ₂ HCH ₂ ], [RO 90; CF ₃ CH ₂ , CHCCH _{2 ], [RO91; CF 3 CH} 2, MeCCCH 2], [RO92; CF 2 HCH 2, Bu], [RO93; CF 2 HCH 2, t-Bu], [RO94; CF 2 HCH 2, Ph], [ _{RO95; CF 2 HCH 2, Bn} ], [RO96; CF 2 HCH 2, CF 2 HCH 2], [RO97; CF 2 HCH 2, CHCCH 2], [RO98; CF 2 HCH 2, MeCCCH 2], [RO99 _{; MeOCH 2, Me], [} RO100; MeOCH 2, Et], [RO101; MeOCH 2, Pr], [RO102; MeOCH 2, i-Pr], [RO103; MeOCH 2, c-Pr], [RO104; MeOCH ₂ , Bu], [RO 105; MeOCH ₂ , t-Bu], [RO106 ; MeOCH 2, c-PrCH 2], [RO107; MeOCH 2, Ph], [RO108; MeOCH 2, Bn], [RO109; MeOCH 2, CF 3 CH 2], [RO110 _{; MeOCH 2, CF 2 HCH 2} ], [RO111; MeOCH 2, CHCCH 2], [RO112; MeOCH 2, MeCCCH 2], [RO113; EtOCH 2, Me], [RO114; EtOCH 2, Et], [RO115 _{; EtOCH 2, Pr], [} RO116; EtOCH 2, i-Pr], [RO117; EtOCH 2, c-Pr], [RO118; EtOCH 2, Bu], [RO119; EtOCH 2, t-Bu], [ _{RO120; EtOCH 2, c-PrCH} 2], [RO121; EtOCH 2, Ph], [RO122; EtOCH 2, Bn], [RO123; EtOCH 2, CF 3 CH 2], [RO124; EtOCH 2, CF 2 HCH _{2], [RO125; EtOCH 2} , CHCCH 2], [RO126; EtOCH 2, MeCCCH 2], [RO127; CH 2 (CH 2) 2 CH 2], [RO128; CH 2 (CH 2) 3 CH 2] _{, [rO129; CH 2 CH 2} OCH 2 CH 2], [RO130; H, H]

〔式中、Ｒ³²及びＲ³³は上記と同じ意味を表す。〕
で表される化合物において、R³²及びR³³の組合わせが下記に示される置換基番号ＲＰ１〜ＲＰ１３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＰ１〜ＲＰ１３０の化合物を本発明化合物ＲＰ１〜ＲＰ１３０と表し、本発明化合物ＲＰ１〜ＲＰ１３０をまとめて本発明化合物ＲＰと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＰ１〜ＲＰ１３０とは、式（ＸＶＩＩ）で表される化合物における、R³²及びR³³の組合せを表すものであり、以下、[置換基番号;R³²,R³³]と記す。ただし、置換基番号ＲＰ１２７〜ＲＰ１２９においては、Ｒ³²とＲ³³とが、互いに結合してヘテロ環を形成することを表す。
例えば、置換基番号ＲＰ４とは、R³²が水素原子であり、R³³がイソプロピル基である組合せを表す。 Formula (XVII)

[Wherein, R ³² and R ³³ represent the same meaning as described above. ]
Wherein the combination of R ³² and R ^{33 is} a combination as set forth in any one of Substituent Nos. RP 1 to RP 130 shown below (hereinafter referred to as “compound of Substituent No. RP 1 to RP 130” Invention compounds RP1 to RP130, and the compounds of the present invention RP1 to RP130 are collectively referred to as the compound of the invention RP) can be obtained according to the method described in the above-mentioned production method.
In addition, the substituent numbers RP1 to RP130 represent a combination of R ³² and R ³³ in the compound represented by the formula (XVII), and hereinafter referred to as [substituent number: R ³² , R ³³ ] . However, in Substituent Nos. RP127 to RP129, R ³² and R ³³ represent that they combine with each other to form a heterocycle.
For example, the substituent number RP4 represents a combination in which R ³² is a hydrogen atom and R ³³ is an isopropyl group.

For example, the compound RP4 of the present invention means a compound represented by the formula (XVII) in which the substituent number is RP4, and in the compound represented by the formula (XVII), R ³² is a hydrogen atom, Represents the following compound wherein R ³³ is an isopropyl group.

[Substituent number; R ³² , R ³³ ]: [RP1; H, Me], [RP2; H, Et], [RP3; H, Pr], [RP4; H, i-Pr], [RP5; H , c-Pr], [RP6 ; H, Bu], [RP7; H, t-Bu], [RP8; H, c-PrCH 2], [RP9; H, Ph], [RP10; H, Bn] _{, [RP11; H, CF 3} CH 2], [RP12; H, CF 2 HCH 2], [RP13; H, CHCCH 2], [RP14; H, MeCCCH 2], [RP15; Me, Me], [ RP16; Me, Et], [RP17; Me, Pr], [RP18; Me, i-Pr], [RP19; Me, c-Pr], [RP20; Me, Bu], [RP21; Me, t- Bu], [RP22; Me, c-PrCH 2], [RP23; Me, Ph], [RP24; Me, Bn], [RP25; Me, CF 3 CH 2], [RP26; Me, CF 2 HCH 2 ], [RP27; Me, CHCCH 2], [RP28; Me, MeCCCH 2], [RP29; Et, Et], [RP30; Et, Pr], [RP31; Et, i-Pr], [RP32; Et , c-Pr], [RP33 ; Et, Bu], [RP34; Et, t-Bu], [rP35; Et, c-PrCH 2], [RP36; Et, Ph], [RP37; Et, Bn] , [RP 38; Et, CF ₃ CH ₂ ], [RP 39; Et, CF ₂ HCH ₂ ], [RP 40; Et, CHCCH ₂ ], [RP 41; Et, MeCCCH ₂ ], [RP 42; Pr, Pr], [RP 38; RP43; Pr, i-Pr] , [RP44; Prc-Pr], [RP45; Pr, Bu], [RP46; Pr, t-Bu], [RP47; Pr, c-PrCH 2], [RP48; Pr , Ph], [RP 49; Pr, Bn], [RP 50; Pr, CF ₃ CH ₂ ], [RP 51; Pr, CF ₂ HCH ₂ ], [RP 52; Pr, CHCCH ₂ ], [RP 53; Pr, MeCCCH ₂ ], [RP54; i-Pr, i-Pr], [RP55; i-Pr, c-Pr], [RP56; i-Pr, Bu], [RP57; i-Pr, t-Bu], [RP58] ; i-Pr, c-PrCH 2], [RP59; i-Pr, Ph], [RP60; i-Pr, Bn], [RP61; i-Pr, CF 3 _{CH 2], [RP62; i} -Pr, CF 2 HCH 2], [RP63; i-Pr, CHCCH 2], [RP64; i-Pr, MeCCCH 2], [RP65; c-Pr, c-Pr] , [RP 66; c-Pr, Bu], [RP 67; c-Pr, t-Bu], [RP 68; c-Pr, c-PrCH ₂ ], [RP 69; c-Pr, Ph], [RP 70; -Pr, Bn], [RP71; c-Pr, CF 3 CH 2], [RP72; c-Pr, CF 2 HCH 2], [RP73; c-Pr, CHCCH 2], [RP74; c-Pr, _{MeCCCH 2], [RP75; c} -PrCH 2, Bu], [RP76; c-PrCH 2, t-Bu], [RP77; c-PrCH 2, c-PrCH 2], [RP78; c-PrCH 2, Ph], [RP79; c- PrCH 2, Bn], [RP80; c-PrCH 2, CF 3 CH 2], [RP81; c-PrCH 2, CF 2 HCH 2], [RP82; c-PrCH 2, _{CHCCH 2], [RP83; c} -PrCH 2, MeCCCH 2], [RP84; CF 3 CH 2, Bu], [RP85; CF 3 CH 2, t-Bu], [RP86; CF 3 CH 2, Ph] , [RP 87; CF ₃ CH ₂ , Bn], [RP 88; CF ₃ CH ₂ , CF ₃ CH ₂ ], [RP 89; CF ₃ CH ₂ , CF ₂ HCH ₂ ], [RP 90; CF ₃ CH ₂ , CHCCH _{2 ], [RP91; CF 3 CH} 2, MeCCCH 2], [RP92; CF 2 HCH 2, Bu], [RP93; CF 2 HCH 2, t-Bu], [RP94; CF 2 HCH 2, Ph], [ _{RP95; CF 2 HCH 2, Bn} ], [RP96; CF 2 HCH 2, CF 2 HCH 2], [RP97; CF 2 HCH 2, CHCCH 2], [RP98; CF 2 HCH 2, MeCCCH 2], [RP99 _{; MeOCH 2, Me], [} RP100; MeOCH 2, Et], [RP101; MeOCH 2, Pr], [RP102; MeOCH 2, i-Pr], [RP103; MeOCH 2, c-Pr], [RP104; MeOCH ₂ , Bu], [RP 105; MeOCH ₂ , t-Bu], [RP106 ; MeOCH 2, c-PrCH 2], [RP107; MeOCH 2, Ph], [RP108; MeOCH 2, Bn], [RP109; MeOCH 2, CF 3 CH 2], [RP110 _{; MeOCH 2, CF 2 HCH 2} ], [RP111; MeOCH 2, CHCCH 2], [RP112; MeOCH 2, MeCCCH 2], [RP113; EtOCH 2, Me], [RP114; EtOCH 2, Et], [RP115 _{; EtOCH 2, Pr], [} RP116; EtOCH 2, i-Pr], [RP117; EtOCH 2, c-Pr], [RP118; EtOCH 2, Bu], [RP119; EtOCH 2, t-Bu], [ _{RP120; EtOCH 2, c-PrCH} 2], [RP121; EtOCH 2, Ph], [RP122; EtOCH 2, Bn], [RP123; EtOCH 2, CF 3 CH 2], [RP124; EtOCH 2, CF 2 HCH ₂ ], [RP 125; EtOCH ₂ , CHCCH ₂ ], [RP 126; EtOCH ₂ , MeCCCH ₂ ], [RP 127; CH ₂ (CH ₂ ) ₂ CH ₂ ], [RP 128; CH ₂ (CH ₂ ) ₃ CH ₂ ] , [RP129; CH ₂ CH ₂ OCH ₂ CH ₂ ], [RP 130; H, H]

〔式中、Ｒ²¹、Ｒ²²及びＲ²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²及びR²⁵の組合わせが下記に示される置換基番号ＲＱ１〜ＲＱ４５のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＱ１〜ＲＱ４５の化合物を本発明化合物ＲＱ１〜ＲＱ４５と表し、本発明化合物ＲＱ１〜ＲＱ４５をまとめて本発明化合物ＲＱと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＱ１〜ＲＱ４５とは、式（ＸＶＩＩＩ）で表される化合物における、R²¹、R²²及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²⁵]と記す。
例えば、置換基番号ＲＱ４とは、R²¹及びR²²が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XVIII)

[Wherein, R ²¹ , R ²² and R ²⁵ represent the same meaning as described above. ]
Wherein the combination of R ²¹ , R ²² and R ^{25 is} a combination as set forth in any of the substituent numbers RQ 1 to R 45 shown below (hereinafter referred to as “substituent numbers RQ 1 to RQ 45 The compounds are represented as the compounds of the present invention RQ1 to RQ45, and the compounds of the present invention RQ1 to RQ45 are collectively referred to as the compounds of the present invention RQ) can be obtained according to the method described in the above-mentioned production method.
In addition, the substituent numbers RQ1 to R45 represent a combination of R ²¹ , R ²² and R ²⁵ in the compound represented by the formula (XVIII), and hereinafter, [Substituent number: R ²¹ , R ²² , R ²⁵ ].
For example, the substituent number RQ4 represents a combination in which R ²¹ and R ²² are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RQ4 means a compound represented by the formula (XVIII) in which the substituent number is RQ4, and in the compound represented by the formula (XVIII), R ²¹ and R ²² are a hydrogen atom And the following compounds in which R ²⁵ is an isopropyl group.

[Substituent number; R ²¹ , R ²² , R ²⁵ ]: [RQ1; H, H, Me], [RQ 2; H, H, Et], [RQ 3; H, H, Pr], [RQ 4; H, H, i-Pr], [RQ 5; H, H, c-Pr], [RQ 6; H, H, Bu], [RQ 7; H, H, t-Bu], [RQ 8; H, H, c- _{PrCH 2], [RQ9; H} , H, Ph], [RQ10; H, H, Bn], [RQ11; H, H, CF 3], [RQ12; H, H, CF 3 CH 2], [RQ13 _{; H, H, CF 3 CF} 2], [RQ14; H, H, CF 2 H], [RQ15; H, H, CF 2 HCH 2], [RQ16; F, H, Me], [RQ17; F , H, Et], [RQ 18; F, H, Pr], [RQ 19; F, H, i-Pr], [RQ 20; F, H, c-Pr], [RQ 21; F, H, Bu], [RQ 22; F, H, t-Bu], [RQ 23; F, H, c-PrCH ₂ ], [RQ 24; F, H, Ph], [RQ 25; F, H, Bn], [RQ 26; F, H, CF ₃ ], [RQ 27; F, H, CF ₃ CH ₂ ], [RQ 28; F, H, CF ₃ CF ₂ ], [RQ 29; F, H, CF ₂ H], [RQ 30; F, H , CF ₂ HCH ₂ ], [RQ 31; H, F, Me], [RQ 32; H, F, Et], [RQ 33; H, F, Pr], [RQ 34; H, F, i-Pr], [RQ H, F, c-Pr], [RQ 36; H, F, Bu], [RQ 37; H, F, t-Bu], [RQ 38; H, F, c-PrCH ₂ ], [RQ 39; H , F, Ph], [RQ 40; H, F, Bn], [RQ 41; H, F, CF ₃ ], [RQ 42; H, F, CF ₃ CH ₂ ], [RQ 43; H, F, CF ₃ CF ₂ ], [RQ 44; H, F, CF ₂ H], [RQ 45; H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²²及び²⁵は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²²及びR²⁵の組合わせが下記に示される置換基番号ＲＲ１〜ＲＲ４５のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＲ１〜ＲＲ４５の化合物を本発明化合物ＲＲ１〜ＲＲ４５と表し、本発明化合物ＲＲ１〜ＲＲ４５をまとめて本発明化合物ＲＲと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＲ１〜ＲＲ４５とは、式（ＸＩＸ）で表される化合物における、R²¹、R²²及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²²,R²⁵]と記す。
例えば、置換基番号ＲＲ４とは、R²¹及びR²²が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XIX)

[Wherein, R ²¹ , R ²² and ²⁵ represent the same meaning as described above. ]
Wherein the combination of R ²¹ , R ²² and R ^{25 is} a combination as set forth in any one of Substituent Nos. RR 1 to RR 45 shown below (hereinafter referred to as Substituent Nos. RR 1 to RR 45 The compounds are represented by the compounds of the present invention RR1 to RR45, and the compounds of the present invention RR1 to RR45 are collectively referred to as the compound of the present invention RR) can be obtained according to the method described in the above-mentioned production method.
In addition, the substituent numbers RR1 to RR45 represent a combination of R ²¹ , R ²² and R ²⁵ in the compound represented by the formula (XIX), and the [substituent number; R ²¹ , R] ²² , R ²⁵ ].
For example, the substituent number RR4 represents a combination in which R ²¹ and R ²² are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the present compound RR4, means a compound substituent number is RR4 in the compound represented by the formula (XIX), in the compounds represented by the formula (XIX), R ²¹ and R ²² is a hydrogen atom And the following compounds in which R ²⁵ is an isopropyl group.

[Substituent group ^{number; R 21, R 22, R} 25]: [RR1; H, H, Me], [RR2; H, H, Et], [RR3; H, H, Pr], [RR4; H, H, i-Pr], [RR 5; H, H, c-Pr], [RR 6; H, H, Bu], [RR 7; H, H, t-Bu], [RR 8; H, H, c- PrCH ₂ ], [RR 9; H, H, Ph], [RR 10; H, H, Bn], [RR 11; H, H, CF ₃ ], [RR 12; H, H, CF ₃ CH ₂ ], [RR 13 _{; H, H, CF 3 CF} 2], [RR14; H, H, CF 2 H], [RR15; H, H, CF 2 HCH 2], [RR16; F, H, Me], [RR17; F , H, Et], [RR 18; F, H, Pr], [RR 19; F, H, i-Pr], [RR 20; F, H, c-Pr], [RR 21; F, H, Bu], [RR22; F, H, t -Bu], [RR23; F, H, c-PrCH 2], [RR24; F, H, Ph], [RR25; F, H, Bn], [RR26; F, _{H, CF 3], [RR27} ; F, H, CF 3 CH 2], [RR28; F, H, CF 3 CF 2], [RR29; F, H, CF 2 H], [RR30; F, H , CF ₂ HCH ₂ ], [RR 31; H, F, Me], [RR 32; H, F, Et], [RR 33; H, F, Pr], [RR 34; H, F, i-Pr], [[ H, F, c-Pr], [RR 36; H, F, Bu], [RR 37; H, F, t-Bu], [RR 38; H, F, c-PrCH ₂ ], [RR 39; H , F, Ph], [RR 40; H, F, Bn], [RR 41; H, F, CF ₃ ], [RR 42; H, F, CF ₃ CH ₂ ], [RR 43; H, F, CF ₃ CF ₂ ], [RR 44; H, F, CF ₂ H], [RR 45; H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹及びＲ²⁵は上記と同じ意味を表し、Ｒ²⁷は水素原子又はフッ素原子を表す。〕
で表される化合物において、R²¹、R²⁷及びR²⁵の組合わせが下記に示される置換基番号ＲＳ１〜ＲＳ４５のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＳ１〜ＲＳ４５の化合物を本発明化合物ＲＳ１〜ＲＳ４５と表し、本発明化合物ＲＳ１〜ＲＳ４５をまとめて本発明化合物ＲＳと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＳ１〜ＲＳ４５とは、式（ＸＸ）で表される化合物における、R²¹、R²⁷及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²⁷,R²⁵]と記す。
例えば、置換基番号ＲＳ４とは、R²¹及びR²⁷が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XX)

[Wherein, R ²¹ and R ²⁵ have the same meaning as described above, and R ²⁷ represents a hydrogen atom or a fluorine atom. ]
Wherein the combination of R ²¹ , R ²⁷ and R ^{25 is} a combination as described in any one of the substituent numbers RS 1 to RS 45 shown below (hereinafter, referred to as substituent numbers RS 1 to RS 45 The compounds are referred to as the present compounds RS1 to RS45, and the present compounds RS1 to RS45 are collectively referred to as the present compound RS)) can be obtained according to the method described in the above-mentioned production method.
Note that the substituent number RS1～RS45, in the compound of formula (XX), and represents the combination of R ^21, R ²⁷ and R ^25, below, Substituent group number; R ^21, R ²⁷ , R ²⁵ ].
For example, the substituent number RS4 represents a combination in which R ²¹ and R ²⁷ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RS4 of the present invention means a compound represented by the formula (XX) in which the substituent number is RS4, and in the compound represented by the formula (XX), R ²¹ and R ²⁷ are a hydrogen atom And the following compounds in which R ²⁵ is an isopropyl group.

[Substituent group ^{number; R 21, R 27, R} 25]: [RS1; H, H, Me], [RS2; H, H, Et], [RS3; H, H, Pr], [RS4; H, H, i-Pr], [RS 5; H, H, c-Pr], [RS 6; H, H, Bu], [RS 7; H, H, t-Bu], [RS 8; H, H, c- PrCH ₂ ], [RS 9; H, H, Ph], [RS 10; H, H, Bn], [RS 11; H, H, CF ₃ ], [RS 12; H, H, CF ₃ CH ₂ ], [RS 13 _{; H, H, CF 3 CF} 2], [RS14; H, H, CF 2 H], [RS15; H, H, CF 2 HCH 2], [RS16; F, H, Me], [RS17; F , H, Et], [RS 18; F, H, Pr], [RS 19; F, H, i-Pr], [RS 20; F, H, c-Pr], [RS 21; F, H, Bu], [RS22; F, H, t-Bu], [RS 23; F, H, c-PrCH ₂ ], [RS 24; F, H, Ph], [RS 25; F, H, Bn], [RS 26; F, H, CF ₃ ], [RS 27; F, H, CF ₃ CH ₂ ], [RS 28; F, H, CF ₃ CF ₂ ], [RS 29; F, H, CF ₂ H], [RS 30; F, H , CF ₂ HCH ₂ ], [RS 31; H, F, Me], [RS 32; H, F, Et], [RS 33; H, F, Pr], [RS 34; H, F, i-Pr], [[ RS 35; H, F, c-Pr], [RS 36; H, F, Bu], [RS 37; H, F, t-Bu], [RS 38; H, F, c-PrCH ₂ ], [RS 39; H , F, Ph], [RS 40; H, F, Bn], [RS 41; H, F, CF ₃ ], [RS 42; H, F, CF ₃ CH ₂ ], [RS 43; H, F, CF ₃ CF ₂ ], [RS 44; H, F, CF ₂ H], [RS 45; H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²¹、Ｒ²⁵及びＲ²⁷は上記と同じ意味を表す。〕
で表される化合物において、R²¹、R²⁷及びR²⁵の組合わせが下記に示される置換基番号ＲＴ１〜ＲＴ４５のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＴ１〜ＲＴ４５の化合物を本発明化合物ＲＴ１〜ＲＴ４５と表し、本発明化合物ＲＴ１〜ＲＴ４５をまとめて本発明化合物ＲＴと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＴ１〜ＲＴ４５とは、式（ＸＸＩ）で表される化合物における、R²¹、R²⁷及びR²⁵の組合わせを表すものであり、以下、[置換基番号;R²¹,R²⁷,R²⁵]と記す。
例えば、置換基番号ＲＴ４とは、R²¹及びR²⁷が水素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XXI)

[Wherein, R ²¹ , R ²⁵ and R ²⁷ represent the same meaning as described above. ]
Wherein the combination of R ²¹ , R ²⁷ and R ^{25 is} a combination as set forth in any one of Substituent Nos. RT 1 to RT 45 shown below (hereinafter referred to as Substituent Nos. RT 1 to RT 45 The compounds are referred to as present compounds RT1 to RT45, and the present compounds RT1 to RT45 are collectively referred to as present compound RT)) can be obtained according to the method described in the above-mentioned production method.
Note that the substituent number RT1～RT45, in the compound of formula (XXI), and represents the combination of R ^21, R ²⁷ and R ^25, below, Substituent group number; R ^21, R ²⁷ , R ²⁵ ].
For example, the substituent number RT4 represents a combination in which R ²¹ and R ²⁷ are a hydrogen atom and R ²⁵ is an isopropyl group.

For example, the compound RT4 of the present invention means a compound having a substituent number of RT4 in the compound represented by the formula (XXI), and in the compound represented by the formula (XXI), R ²¹ and R ²⁷ are a hydrogen atom And the following compounds in which R ²⁵ is an isopropyl group.

[Substituent group ^{number; R 21, R 27, R} 25]: [RT1; H, H, Me], [RT2; H, H, Et], [RT3; H, H, Pr], [RT4; H, H, i-Pr], [RT5; H, H, c-Pr], [RT 6; H, H, Bu], [RT 7; H, H, t-Bu], [RT 8; H, H, c- _{PrCH 2], [RT9; H} , H, Ph], [RT10; H, H, Bn], [RT11; H, H, CF 3], [RT12; H, H, CF 3 CH 2], [RT13 _{; H, H, CF 3 CF} 2], [RT14; H, H, CF 2 H], [RT15; H, H, CF 2 HCH 2], [RT16; F, H, Me], [RT17; F , H, Et], [RT 18; F, H, Pr], [RT 19; F, H, i-Pr], [RT 20; F, H, c-Pr], [RT 21; F, H, Bu], [RT 22; F, H, t-Bu], [RT 23; F, H, c-PrCH ₂ ], [RT 24; F, H, Ph], [RT 25; F, H, Bn], [RT 26; H, CF ₃ ], [RT 27; F, H, CF ₃ CH ₂ ], [RT 28; F, H, CF ₃ CF ₂ ], [RT 29; F, H, CF ₂ H], [RT 30; F, H , CF ₂ HCH ₂ ], [RT 31; H, F, Me], [RT 32; H, F, Et], [RT 33; H, F, Pr], [RT 34; H, F, i-Pr], [RT RT 35; H, F, c-Pr], [RT 36; H, F, Bu], [RT 37; H, F, t-Bu], [RT 38; H, F, c-PrCH ₂ ], [RT 39; H , F, Ph], [RT 40; H, F, Bn], [RT 41; H, F, CF ₃ ], [RT 42; H, F, CF ₃ CH ₂ ], [RT 43; H, F, CF ₃ CF ₂ ], [RT 44; H, F, CF ₂ H], [RT 45; H, F, CF ₂ HCH ₂ ]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＵ１〜ＲＵ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＵ１〜ＲＵ３０の化合物を本発明化合物ＲＵ１〜ＲＵ３０と表し、本発明化合物ＲＵ１〜ＲＵ３０をまとめて本発明化合物ＲＵと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＵ１〜ＲＵ３０とは、式（ＸＸＩＩ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＵ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XXII)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any of Substituent Nos. RU 1 to RU 30 shown below (hereinafter referred to as “compound of Substituent No. RU 1 to RU 30” Inventive compounds RU1 to RU30, and the compounds RU1 to RU30 of the present invention are collectively referred to as the compound RU of the present invention) can be obtained according to the method described in the above production method.
In addition, the substituent numbers RU1 to RU30 represent a combination of Q ²¹ and R ²⁵ in the compound represented by the formula (XXII), and hereinafter referred to as [substituent number: Q ²¹ , R ²⁵ ] .
For example, the substituent number RU4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound RU4 of the present invention means a compound represented by the formula (XXII) in which the substituent number is RU4, and in the compound represented by the formula (XXII), Q ²¹ is an oxygen atom, The following compounds in which R ²⁵ is an isopropyl group are represented.

[Substituent No. Q ²¹ , R ²⁵ ]: [RU 1; O, Me], [RU 2; O, Et], [RU 3; O, Pr], [RU 4; O, i-Pr], [RU 5; , c-Pr], [RU6; O, Bu], [RU 7; O, t-Bu], [RU 8; O, c-PrCH ₂ ], [RU 9; O, Ph], [RU 10; O, Bn] , [RU 11; O, CF ₃ ], [RU 12; O, CF ₃ CH ₂ ], [RU 13; O, CF ₃ CF ₂ ], [RU 14; O, CF ₂ H], [RU 15; O, CF ₂ HCH ₂ ], [RU16; NH, Me], [RU17; NH, Et], [RU18; NH, Pr], [RU19; NH, i-Pr], [RU20; NH, c-Pr], [RU21; NH, Bu], [RU 22; NH, t-Bu], [RU 23; NH, c-PrCH ₂ ], [RU 24; NH, Ph], [RU 25; NH, Bn], [RU 26; NH, CF ₃ ] , [RU 27; NH, CF ₃ CH ₂ ], [RU 28; NH, CF ₃ CF ₂ ], [RU 29; NH, CF ₂ H], [RU 30; NH, CF ₂ HCH ₂ ]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＶ１〜ＲＶ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＶ１〜ＲＶ３０の化合物を本発明化合物ＲＶ１〜ＲＶ３０と表し、本発明化合物ＲＶ１〜ＲＶ３０をまとめて本発明化合物ＲＶと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＶ１〜ＲＶ３０とは、式（ＸＸＩＩＩ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＶ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XXIII)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any one of Substituent Nos. RV 1 to RV 30 (hereinafter referred to as “compound of Substituent No. RV 1 to RV 30”) Invention compounds RV1 to RV30, and compounds of the invention RV1 to RV30 are collectively referred to as compound of the invention RV) can be obtained according to the method described in the above-mentioned production method.
Substituent numbers RV1 to RV30 each denote a combination of Q ²¹ and R ²⁵ in the compound represented by formula (XXIII), and hereinafter, referred to as [substituent number: Q ²¹ , R ²⁵ ] .
For example, the substituent number RV4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RV4 means a compound represented by the formula (XXIII) in which the substituent number is RV4, and in the compound represented by the formula (XXIII), Q ²¹ is an oxygen atom, The following compounds in which R ²⁵ is an isopropyl group are represented.

[Substituent No. Q ²¹ , R ²⁵ ]: [RV 1; O, Me], [RV 2; O, Et], [RV 3; O, Pr], [RV 4; O, i-Pr], [RV 5; , c-Pr], [RV 6; O, Bu], [RV 7; O, t-Bu], [RV 8; O, c-PrCH ₂ ], [RV 9; O, Ph], [RV 10; O, Bn] _{, [RV11; O, CF 3} ], [RV12; O, CF 3 CH 2], [RV13; O, CF 3 CF 2], [RV14; O, CF 2 H], [RV15; O, CF 2 HCH ₂ ], [RV16; NH, Me], [RV17; NH, Et], [RV18; NH, Pr], [RV19; NH, i-Pr], [RV20; NH, c-Pr], [RV21; NH, Bu], [RV 22; NH, t-Bu], [RV 23; NH, c-PrCH ₂ ], [RV 24; NH, Ph], [RV 25; NH, Bn], [RV 26; NH, CF ₃ ] _{, [RV27; NH, CF 3} CH 2], [RV28; NH, CF 3 CF 2], [RV29; NH, CF 2 H], [RV30; NH, CF 2 HCH 2]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＷ１〜ＲＷ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＷ１〜ＲＷ３０の化合物を本発明化合物ＲＷ１〜ＲＷ３０と表し、本発明化合物ＲＷ１〜ＲＷ３０をまとめて本発明化合物ＲＷと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＷ１〜ＲＷ３０とは、式（ＸＸＩＶ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＷ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XXIV)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination according to any one of the substituent numbers RW 1 to RW 30 shown below (hereinafter referred to as a compound of substituent numbers RW 1 to RW 30 Invention compounds RW1 to RW30, and the compounds of the invention RW1 to RW30 are collectively referred to as the compound of the invention RW) can be obtained according to the method described in the above production method.
Substituent numbers RW1 to RW30 each represent a combination of Q ²¹ and R ²⁵ in the compound represented by formula (XXIV), and hereinafter, referred to as [substituent number: Q ²¹ , R ²⁵ ] .
For example, the substituent number RW4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound RW4 of the present invention means a compound represented by the formula (XXIV) in which the substituent number is RW4, and in the compound represented by the formula (XXIV), Q ²¹ is an oxygen atom, The following compounds in which R ²⁵ is an isopropyl group are represented.

[Substituent No. Q ²¹ , R ²⁵ ]: [RW 1; O, Me], [RW 2; O, Et], [RW 3; O, Pr], [RW 4; O, i-Pr], [RW 5; , c-Pr], [RW 6; O, Bu], [RW 7; O, t-Bu], [RW 8; O, c-PrCH ₂ ], [RW 9; O, Ph], [RW 10; O, Bn] [RW 11; O, CF ₃ ], [RW 12; O, CF ₃ CH ₂ ], [RW 13; O, CF ₃ CF ₂ ], [RW 14; O, CF ₂ H], [RW 15; O, CF ₂ HCH ₂ ], [RW 16; NH, Me], [RW 17; NH, Et], [RW 18; NH, Pr], [RW 19; NH, i-Pr], [RW 20; NH, c-Pr], [RW 21; NH, Bu], [RW 22; NH, t-Bu], [RW 23; NH, c-PrCH ₂ ], [RW 24; NH, Ph], [RW 25; NH, Bn], [RW 26; NH, CF ₃ ] , [RW 27; NH, CF ₃ CH ₂ ], [RW 28; NH, CF ₃ CF ₂ ], [RW 29; NH, CF ₂ H], [RW 30; NH, CF ₂ HCH ₂ ]

〔式中、Ｒ²⁵及びＱ²¹は上記と同じ意味を表す。〕
で表される化合物において、Q²¹及びR²⁵の組合わせが下記に示される置換基番号ＲＸ１〜ＲＸ３０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＸ１〜ＲＸ３０の化合物を本発明化合物ＲＸ１〜ＲＸ３０と表し、本発明化合物ＲX１〜ＲＸ３０をまとめて本発明化合物ＲＸと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＸ１〜ＲＸ３０とは、式（ＸＸＶ）で表される化合物における、Q²¹及びR²⁵の組合せを表すものであり、以下、［置換基番号;Q²¹,R²⁵]と記す。
例えば、置換基番号ＲＸ４とは、Q²¹が酸素原子であり、R²⁵がイソプロピル基である組合せを表す。 Formula (XXV)

[Wherein, R ²⁵ and Q ²¹ represent the same meaning as described above. ]
Wherein the combination of Q ²¹ and R ^{25 is} a combination as set forth in any one of Substituent Nos. RX 1 to RX 30 shown below (hereinafter referred to as “compound of Substituent No. RX 1 to RX 30” Inventive compounds RX1 to RX30, and the compounds of the present invention RX1 to RX30 are collectively referred to as the compound of the present invention RX) can be obtained according to the method described in the above-mentioned production method.
Substituent numbers RX1 to RX30 each represent a combination of Q ²¹ and R ²⁵ in the compound represented by formula (XXV), and hereinafter referred to as [substituent number; Q ²¹ , R ²⁵ ] .
For example, the substituent number RX4 represents a combination in which Q ²¹ is an oxygen atom and R ²⁵ is an isopropyl group.

For example, the compound of the present invention RX4 means a compound represented by the formula (XXV) in which the substituent number is RX4, and in the compound represented by the formula (XXV), Q ²¹ is an oxygen atom, It represents the following compound wherein R ²³ is an isopropyl group.

[Substituent No. Q ²¹ , R ²⁵ ]: [RX1; O, Me], [RX2; O, Et], [RX3; O, Pr], [RX4; O, i-Pr], [RX5; , c-Pr], [RX6 ; O, Bu], [RX7; O, t-Bu], [RX8; O, c-PrCH 2], [RX9; O, Ph], [RX10; O, Bn] _{, [RX11; O, CF 3} ], [RX12; O, CF 3 CH 2], [RX13; O, CF 3 CF 2], [RX14; O, CF 2 H], [RX15; O, CF 2 HCH ₂ ], [RX16; NH, Me], [RX17; NH, Et], [RX18; NH, Pr], [RX19; NH, i-Pr], [RX20; NH, c-Pr], [RX21; NH, Bu], [RX22; NH, t-Bu], [RX23; NH, c-PrCH 2], [RX24; NH, Ph], [RX25; NH, Bn], [RX26; NH, CF 3] _{, [RX27; NH, CF 3} CH 2], [RX28; NH, CF 3 CF 2], [RX29; NH, CF 2 H], [RX30; NH, CF 2 HCH 2]

〔式中、Ｒ³¹、Ｒ³²及びＲ³³は上記と同じ意味を表す。〕
で表される化合物において、Ｒ³¹、R³²及びR³³の組合わせが下記に示される置換基番号ＲＹ１〜ＲＹ１５５０のいずれかに記載の組合わせである化合物（以下、置換基番号ＲＹ１〜ＲＹ１５５０の化合物を本発明化合物ＲＹ１〜ＲＹ１５５０と表し、本発明化合物ＲＹ１〜ＲＹ１５５０をまとめて本発明化合物ＲＹと表す）は、上記の製造法に記載の方法に準じて得ることができる。
なお、置換基番号ＲＹ１〜ＲＹ１５５０とは、式（ＸＸＶＩ）で表される化合物における、Ｒ³¹、R³²及びR³³の組合せを表すものであり、以下、[置換基番号;R³¹,R³²,R³³]と記す。
例えば、置換基番号ＲＹ４とは、R³¹が水素原子であり、R³²が水素原子であり、R³³がイソプロピル基である組合せを表す。 Formula (XXVI)

[Wherein, R ³¹ , R ³² and R ³³ represent the same meaning as described above. ]
Wherein the combination of R ³¹ , R ³² and R ^{33 is} a combination as set forth in any one of Substituent Nos. RY 1 to RY 15 50 shown below (hereinafter referred to as Substituent Nos. RY 1 to RY 1550) The compounds are represented by the compounds RY1 to RY1550 of the present invention, and the compounds RY1 to RY1550 of the present invention are collectively referred to as the compound RY of the present invention) can be obtained according to the method described in the above-mentioned production method.
Note that the substituent number RY1～RY1550, in the compound of formula (XXVI), and represents the combination of R ^31, R ³² and R ^33, below, Substituent group number; R ^31, R ³² , R ³³ ].
For example, the substituent number RY4 represents a combination in which R ³¹ is a hydrogen atom, R ³² is a hydrogen atom, and R ³³ is an isopropyl group.

For example, the compound of the present invention RY4 means a compound represented by the formula (XXVI) in which the substituent number is RX4, and in the compound represented by the formula (XXVI), R ³¹ is a hydrogen atom, R ³² represents a hydrogen atom, and R ³³ represents an isopropyl group.

[Substituent number; R ³¹ , R ³² , R ³³ ]: [RY 1; H, H, Me], [RY 2; H, H, Et], [RY 3; H, H, Pr], [RY 4; H, H, i-Pr], [RY5; H, H, c-Pr], [RY 6; H, H, t-Bu], [RY 7; H, H, Bu], [RY 8; H, H, t- Bu], [RY9; H, H, c-PrCH 2], [RY10; H, H, Ph], [RY11; H, H, Bn], [RY12; H, H, CF 3], [RY13; H, H, CF ₃ CH ₂ ], [RY 14; H, H, CF ₃ CF ₂ ], [RY 15; H, H, CF ₂ H], [RY 16; H, H, CF ₂ HCH ₂ ], [RY 17 Me, H, Me], [RY 18; Me, H, Et], [RY 19; Me, H, Pr], [RY 20; Me, H, i-Pr], [RY 21; Me, H, c-Pr ], [RY 22; Me, H, t-Bu], [RY 23; Me, H, Bu], [RY 24; Me, H, t-Bu], [RY 25; Me, H, c-PrCH ₂ ], [ RY26; Me, H, Ph] , [RY27; Me, H, Bn], [RY28; Me, H, CF 3], [RY29; Me, H, CF 3 CH 2], [RY30; Me, H, CF ₃ CF ₂ ], [RY 31; Me, H, CF ₂ H], [RY 32; Me, H, CF ₂ HCH ₂ ], [RY 33; Et, H, Me], [RY 34; Et, H, Et] , [RY 35; Et, H, Pr], [RY 36; Et, H, i-Pr], [RY 37; Et, H, c-Pr], [RY 38; Et, H, t-Bu], [RY 39; Et, H, Bu], [ RY40; Et, H, t-Bu], [RY41; Et, H, c-PrCH 2], [RY42; Et, H, Ph], [RY43; Et, H, Bn ], [RY 44; Et, H, CF ₃ ], [RY 45; Et, H, CF ₃ CH ₂ ], [RY 46; Et, H, CF ₃ CF ₂ ], [RY 47; Et, H, CF ₂ H] , [RY 48; Et, H, CF ₂ HCH ₂ ], [RY 49; Pr, H, Me], [RY 50; Pr, H, Et], [RY 51; Pr, H, Pr], [RY 52; Pr, H , i-Pr], [RY 53; Pr, H, c-Pr], [RY 54; Pr, H, t-Bu], [RY 55; Pr, H, Bu], [RY 56; Pr, H, t-Bu ], [RY 57; Pr, H, c-PrCH ₂ ], [RY 58; Pr, H, Ph], [RY 59; Pr, H, Bn], [RY 60; Pr, H, CF ₃ ], [RY 61; Pr, H , CF ₃ CH ₂ ], [RY 62; Pr, H, CF ₃ CF ₂ ], [RY 63; Pr, H, CF ₂ H], [RY 64; Pr, H, CF ₂ HCH ₂ ], [RY 65; Pr, H, Me], [RY 66; i-Pr, H, Et], [RY 67; i-Pr, H, Pr], [RY 68; i-Pr, H, i-Pr], [RY 69; Pr, H, c-Pr], [RY 70; i-Pr, H, t-Bu], [RY 71; i-Pr, H, Bu], [RY 72; i-Pr, H, t-Bu], [RY 72; RY 73; i-Pr, H, c-PrCH ₂ ], [RY 74; i-Pr, H, Ph], [RY 75; i-Pr, H, Bn], [RY 76; i-Pr, H, CF ₃ ] , [RY 77; i-Pr, H, CF ₃ CH ₂ ], [RY 78; i-Pr, H, CF ₃ CF ₂ ], [RY 79; i-Pr, H, CF ₂ H], [RY 80; _{Pr, H, CF 2 HCH 2} ], [RY81; c-Pr, H, Me], [RY82; c-Pr, H, Et], [RY83; c-Pr, H, Pr], [RY84; c -Pr, H, i-Pr], [RY 85; c-Pr, H, c-Pr], [RY 86; c-Pr, H, t-Bu], [RY 87; c-Pr, H, Bu], [RY88; c-Pr, H , t-Bu], [RY89; c-Pr, H, c-PrCH 2], [RY90; c-Pr, H, Ph], [RY91; c-Pr, H, Bn], [RY 92; c-Pr, H, CF ₃ ], [RY 93; c-Pr, H, CF ₃ CH ₂ ], [RY 94; c-Pr, H, CF ₃ CF ₂ ], [RY 95; c _{-Pr, H, CF 2 H]} , [RY96; c-Pr, H, CF 2 HCH 2], [RY97; c-PrCH 2, H, Me], [RY98; c-PrCH 2, H, Et] _{, [RY99; c-PrCH 2} , H, Pr], [RY100; c-PrCH 2, H, i-Pr], [RY101; c-PrCH 2, H, c-Pr], [RY102; c-PrCH _{2, H, t-Bu]} , [RY103; c-PrCH 2, H, Bu], [RY104; c-PrCH 2, H, t-Bu], [RY105; c-PrCH _{2, H, c-PrCH 2} ], [RY106; c-PrCH 2, H, Ph], [RY107; c-PrCH 2, H, Bn], [RY108; c-PrCH 2, H, CF 3], _{[RY109; c-PrCH 2,} H, CF 3 CH 2], [RY110; c-PrCH 2, H, CF 3 CF 2], [RY111; c-PrCH 2, H, CF 2 H], [RY112; _{c-PrCH 2, H, CF} 2 HCH 2], [RY113; i-Bu, H, Me], [RY114; i-Bu, H, Et], [RY115; i-Bu, H, Pr], [ RY116; i-Bu, H, i-Pr], [RY117; i-Bu, H, c-Pr], [RY 118; i-Bu, H, t-Bu], [RY119; i-Bu, H, Bu], [RY 120; i-Bu, H, t-Bu], [RY 121; i-Bu, H, c-PrCH ₂ ], [RY 122; i-Bu, H, Ph], [RY 123; i-Bu , H, Bn], [RY 124; i-Bu, H, CF ₃ ], [RY 125; i-Bu, H, CF ₃ CH ₂ ], [RY 126; i-Bu, H, CF ₃ CF ₂ ], [[ RY 127; i-Bu, H, CF ₂ H], [RY 128; i-Bu, H, CF ₂ HCH ₂ ], [RY 129; CF ₃ CH ₂ , H, Me], [RY 130; CF ₃ CH ₂ , H , Et], [RY131; CF ₃ CH ₂ , H, Pr], [RY 132; CF ₃ CH ₂ , H, i-Pr], [RY 133; CF ₃ CH ₂ , H, c-Pr], [RY 134; CF ₃ CH ₂ , H, t-Bu], [RY 135; CF ₃ CH ₂ , H, Bu], [RY 136; CF ₃ CH ₂ , H, t-Bu], [RY 137; CF ₃ CH ₂ , H, _{c-PrCH 2], [RY138} ; CF 3 CH 2, H, Ph], [RY139; CF 3 CH 2, H, Bn], [RY140; CF 3 CH 2, H, CF 3], [RY141; CF ₃ CH ₂ , H, CF ₃ CH ₂ ], [RY 142; CF ₃ CH ₂ , H, CF ₃ CF ₂ ], [RY 143; CF ₃ CH ₂ , H, CF ₂ H], [RY 144; CF ₃ CH ₂ , H, CF ₂ HCH ₂ ], [RY 145; CF ₂ HCH ₂ , Me, Me] _{, [RY146; CF 2 HCH 2} , H, Et], [RY147; CF 2 HCH 2, H, Pr], [RY148; CF 2 HCH 2, H, i-Pr], [RY149; CF 2 HCH 2, H, c-Pr], [ RY150; CF 2 HCH 2, H, t-Bu], [RY151; CF 2 HCH 2, H, Bu], [RY152; CF 2 HCH 2, H, t-Bu], _{[RY153; CF 2 HCH 2,} H, c-PrCH 2], [RY154; CF 2 HCH 2, H, Ph], [RY155; CF 2 HCH 2, H, Bn], [RY156; CF 2 HCH 2, _{H, CF 3], [RY157} ; CF 2 HCH 2, H, CF 3 CH 2], [RY158; CF 2 HCH 2, H, CF 3 CF 2], [RY159; CF 2 HCH 2, H, CF 2 _{H], [RY160; CF 2} HCH 2, H, CF 2 HCH 2], [RY161; MeOCH 2, H, Me], [RY162; MeOCH 2, H, Et], [RY163; MeOCH 2, H, Pr _{], [RY164; MeOCH 2,} H, i-Pr], [RY165; MeOCH 2, H, c-Pr], [RY166; MeOCH 2, H, t-Bu], [RY167; MeOCH 2, H, Bu _{], [RY168; MeOCH 2,} H, t-Bu], [RY169; MeOCH 2, H, c-PrCH 2], [RY170; MeOCH 2, H, Ph], [RY171; MeOCH 2, H, Bn] , [RY172; MeOCH ₂ , H, CF ₃ ], [RY 173; MeOCH ₂ , H, CF ₃ CH ₂ ], [RY 174; MeOCH ₂ , H, CF ₃ CF ₂ ], [RY 175; MeOCH ₂ , H, CF ₂ H], [RY 176; MeOCH ₂ , H, CF ₂ HCH ₂ ], [RY 177; EtOCH ₂ , H, Me], [RY 178; EtOCH ₂ , H, Et], [RY 179; EtOCH ₂ , H, Pr] , [RY180; EtOCH ₂ , H, i-Pr], [RY 181; EtOCH ₂ , H, c-Pr], [RY 182; EtOCH ₂ , H, t-Bu], [RY 183; EtOCH ₂ , H, Bu] , [RY 184; EtOCH ₂ , H, t-Bu], [RY 185; EtOCH ₂ , H, c-PrCH ₂ ], [RY 186; EtOCH ₂ , H, Ph], [RY 187; EtOCH ₂ , H, Bn], [RY 188; EtOCH ₂ , H, CF ₃ ], [RY 189; EtOCH ₂ , H, CF ₃ CH ₂ ], [RY 190; EtOCH ₂ , H, CF ₃ CF ₂ ], [RY 191; EtOCH ₂ , H, CF ₂ H], [RY 192; EtOCH ₂ , _{H, CF 2 HCH 2],} [RY193; MeSCH 2, H, Me], [RY194; MeSCH 2, H, Et], [RY195; MeSCH 2, H, Pr], [RY196; MeSCH 2, H, i -Pr], [RY 197; MeSCH ₂ , H, c-Pr], [RY 198; MeSCH ₂ , H, t-Bu], [RY 199; MeSCH ₂ , H, Bu], [RY ₂₀₀ ; MeSCH ₂ , H, t -Bu],

_{[RY201; MeSCH 2, H,} c-PrCH 2], [RY202; MeSCH 2, H, Ph], [RY203; MeSCH 2, H, Bn], [RY204; MeSCH 2, H, CF 3], [RY205 _{; MeSCH 2, H, CF 3} CH 2], [RY206; MeSCH 2, H, CF 3 CF 2], [RY207; MeSCH 2, H, CF 2 H], [RY208; MeSCH 2, H, CF 2 HCH ₂ ], [RY 209; EtSCH ₂ , H, Me], [RY 210; EtSCH ₂ , H, Et], [RY 211; EtSCH ₂ , H, Pr], [RY 212; EtSCH ₂ , H, i-Pr], [ RY 213; EtSCH ₂ , H, c-Pr], [RY 214; EtSCH ₂ , H, t-Bu], [RY 215; EtSCH ₂ , H, Bu], [RY 216; EtSCH ₂ , H, t-Bu], [RY 216; _{RY217; EtSCH 2, H, c} -PrCH 2], [RY218; EtSCH 2, H, Ph], [RY219; EtSCH 2, H, Bn], [RY220; EtSCH 2, H, CF 3], [RY221; EtSCH ₂ , H, CF ₃ CH ₂ ], [RY222; EtSCH ₂ , H, CF ₃ CF ₂ ], [RY 223; EtSCH ₂ , H, CF ₂ H], [RY 224; EtSCH ₂ , H, CF ₂ HCH ₂ ], [RY 225; Ph, H, Me], [RY 226; Ph, H, Et], [RY 227; Ph, H, Pr], [RY 228; Ph, H, i-Pr], [RY 229; Ph, H , c-Pr], [RY 230; Ph, H, t-Bu], [RY 231; Ph, H, Bu], [RY 232; Ph, H, t-Bu], [RY 233; Ph, H, c-PrCH ₂ ], [RY 234; Ph, H, Ph], [RY 235; Ph, H, Bn], [RY 236; Ph, H, CF ₃ ], [RY 237; Ph, H, CF ₃ CH ₂ ], [RY 238; _{Ph, H, CF 3 CF 2} ], [RY239; Ph, H, CF 2 H], [RY240; Ph, H, CF 2 HCH 2], [RY241; Bn, H, Me], [RY242; Bn, H, Et], [RY 243; Bn, H, Pr], [RY 244; Bn, H, i-Pr], [RY 245; Bn, H, c-Pr] , [RY 246; Bn, H, t-Bu], [RY 247; Bn, H, Bu], [RY 248; Bn, H, t-Bu], [RY 249; Bn, H, c-PrCH ₂ ], [RY 250] Bn, H, Ph], [RY 251; Bn, H, Bn], [RY 252; Bn, H, CF ₃ ], [RY 253; Bn, H, CF ₃ CH ₂ ], [RY 254; Bn, H, CF _{3 CF 2], [RY255;} Bn, H, CF 2 H], [RY256; Bn, H, CF 2 HCH 2], [RY257; HCCCH 2, H, Me], [RY258; HCCCH 2, H, Et _{], [RY259; HCCCH 2,} H, Pr], [RY260; HCCCH 2, H, i-Pr], [RY261; HCCCH 2, H, c-Pr], [RY262; HCCCH 2, H, t-Bu _{], [RY263; HCCCH 2,} H, Bu], [RY264; HCCCH 2, H, t-Bu], [RY265; HCCCH 2, H, c-PrCH 2], [RY266; HCCCH 2, H, Ph] _{, [RY267; HCCCH 2, H} , Bn], [RY268; HCCCH 2, H, CF 3], [RY269; HCCCH 2, H, CF 3 CH 2], [RY270; HCCCH 2, H, CF 3 CF 2 , [RY 271; HCCCH ₂ , H, CF ₂ H], [RY 272; HCCCH ₂ , H, CF ₂ HCH ₂ ], [RY 273; CH ₃ CCCH ₂ , H, Me], [RY 274; CH ₃ CCCH ₂ , H, Et], [RY275; CH 3 CCCH 2, H, Pr], [RY276; CH 3 CCCH 2, H, i-Pr], [RY277; CH 3 CCCH 2, H, c-Pr], [RY278 _{; CH 3 CCCH 2, H,} t-Bu], [RY279; CH 3 CCCH 2, H, Bu], [RY280; CH 3 CCCH 2, H, t-Bu], [RY281; CH 3 CCCH 2, H _{, c-PrCH 2], [} RY282; CH 3 CCCH 2, H, Ph], [RY283; CH 3 CCCH 2, H, Bn], [RY284; CH 3 CCCH 2, H, CF 3], [RY285; CH ₃ CCCH ₂ , H, CF ₃ CH ₂ ], [RY 286; CH ₃ CCCH _{2, H, CF 3 CF 2} ], [RY287; CH 3 CCCH 2, H, CF 2 H], [RY288; CH 3 CCCH 2, H, CF 2 HCH 2], [RY289; H, Me, Me] , [RY 290; H, Me, Et], [RY 291; H, Me, Pr], [RY 292; H, Me, i-Pr], [RY 293; H, Me, c-Pr], [RY 294; H, Me, t-Bu], [RY 295; H, Me, Bu], [RY 296; H, Me, t-Bu], [RY 297; H, Me, c-PrCH ₂ ], [RY 298; H, Me, Ph ], [RY 299; H, Me, Bn], [RY 300; H, Me, CF ₃ ], [RY 301; H, Me, CF ₃ CH ₂ ], [RY 302; H, Me, CF ₃ CF ₂ ], [RY _{RY303; H, Me, CF 2} H], [RY304; H, Me, CF 2 HCH 2], [RY305; Me, Me, Me], [RY306; Me, Me, Et], [RY307; Me, Me , Pr], [RY 308; Me, Me, i-Pr], [RY 309; Me, Me, c-Pr], [RY 310; Me, Me, t-Bu], [RY 311; Me, Me, Bu], [RY312; Me, Me, t -Bu], [RY313; Me, Me, c-PrCH 2], [RY314; Me, Me, Ph], [RY315; Me, Me, Bn], [RY316; Me, _{Me, CF 3], [RY317} ; Me, Me, CF 3 CH 2], [RY318; Me, Me, CF 3 CF 2], [RY319; Me, Me, CF 2 H], [RY320; Me, Me , CF ₂ HCH ₂ ], [RY 321; Et, Me, Me], [RY 322; Et, Me, Et], [RY 323; Et, Me, Pr], [RY 324; Et, Me, i-Pr], [, RY 325; Et, Me, c-Pr], [RY 326; Et, Me, t-Bu], [RY 327; Et, Me, Bu], [RY 328; Et, Me, t-Bu], [RY 329; Et, _{Me, c-PrCH 2],} [RY330; Et, Me, Ph], [RY331; Et, Me, Bn], [RY332; Et, Me, CF 3], [RY333; Et, Me, CF 3 CH 2 ], [RY 334; Et, Me, CF ₃ CF ₂ ], [RY 335; Et, Me, CF ₂ H], [RY 336; Et, Me, CF ₂ HCH ₂ ], [RY 337; Pr, Me, Me], [RY 338; Pr, Me, Et], [RY 339; Pr, Me, Pr], [RY 340; Pr, Me, i -Pr], [RY 341; Pr, Me, c-Pr], [RY 342; Pr, Me, t-Bu], [RY 343; Pr, Me, Bu], [RY 344; Pr, Me, t-Bu], [RY345; Pr, Me, c -PrCH 2], [RY346; Pr, Me, Ph], [RY347; Pr, Me, Bn], [RY348; Pr, Me, CF 3], [RY349; Pr, Me , CF ₃ CH ₂ ], [RY 350; Pr, Me, CF ₃ CF ₂ ], [RY 351; Pr, Me, CF ₂ H], [RY 352; Pr, Me, CF ₂ HCH ₂ ], [RY 353; Pr, Me, Me], [RY 354; i-Pr, Me, Et], [RY 355; i-Pr, Me, Pr], [RY 356; i-Pr, Me, i-Pr], [RY 357; Pr, Me, c-Pr], [RY 358; i-Pr, Me, t-Bu], [RY 359; i-Pr, Me, Bu], [RY 360; i-Pr, Me, t-Bu], [ RY361; i-Pr, Me, c-PrCH 2], [RY362; i-Pr, Me, Ph], [RY363; i-Pr, Me, Bn], [RY364; i-Pr, Me, CF 3] , [RY365; i-Pr, Me, CF 3 CH 2], [RY366; i-Pr, Me, CF 3 CF 2], [RY367; i-Pr, Me, CF 2 H], [RY368; i- _{Pr, Me, CF 2 HCH 2} ], [RY369; c-Pr, Me, Me], [RY370; c-Pr, Me, Et], [RY371; c-Pr, Me, Pr], [RY372; c -Pr, Me, i-Pr], [RY 373; c-Pr, Me, c-Pr], [RY 374; c-Pr, Me, t-Bu], [RY 375; c-Pr, Me, Bu], [RY376; c-Pr, Me , t-Bu], [RY377; c-Pr, Me, c-PrCH 2], [RY378; c-Pr, Me, Ph], [RY379; c-Pr, Me, Bn], [RY 380; c-Pr, Me, CF ₃ ], [RY 381; c-Pr, Me, CF ₃ CH ₂ ], [RY 382; c-Pr, Me, CF ₃ CF ₂ ], [RY 383; _{c-Pr, Me, CF 2} H], [RY384; c-Pr, Me, CF 2 HCH 2], [RY385; c-PrCH 2, Me, Me], [RY386; c-PrCH 2, Me, Et ], [RY387; c-PrCH 2, Me, Pr], [RY388; c-PrCH 2, Me, i-Pr], [RY389; c-PrCH 2, Me, c-Pr], [RY390; c- _{PrCH 2, Me, t-Bu} ], [RY391; c-PrCH 2, Me, Bu], [RY392; c-PrCH 2, Me, t-Bu], [RY393; c-PrCH 2, Me, c- _{PrCH 2], [RY394; c} -PrCH 2, Me, Ph], [RY395; c-PrCH 2, Me, Bn], [RY396; c-PrCH 2, Me, CF 3], [RY397; c-PrCH _{2, Me, CF 3 CH 2} ], [RY398; c-PrCH 2, Me, CF 3 CF 2], [RY399; c-PrCH 2, Me, CF 2 H], [RY400; c-PrCH 2, Me , CF ₂ HCH ₂ ],

[RY 401; i-Bu, Me, Me], [RY 402; i-Bu, Me, Et], [RY 403; i-Bu, Me, Pr], [RY 404; i-Bu, Me, i-Pr], [RY 405; i-Bu, Me, c-Pr], [RY 406; i-Bu, Me, t-Bu], [RY 407; i-Bu, Me, Bu], [RY 408; i-Bu, Me, t -Bu], [RY 409; i-Bu, Me, c-PrCH ₂ ], [RY 410; i-Bu, Me, Ph], [RY 411; i-Bu, Me, Bn], [RY 412; i-Bu, Me, CF ₃ ], [RY 413; i-Bu, Me, CF ₃ CH ₂ ], [RY 414; i-Bu, Me, CF ₃ CF ₂ ], [RY 415; i-Bu, Me, CF ₂ H], [RY 416; i-Bu, Me, CF ₂ HCH ₂ ], [RY 417; CF ₃ CH ₂ , Me, Me], [RY 418; CF ₃ CH ₂ , Me, Et], [RY 419; CF ₃ CH ₂ , Me , Pr], [RY 420; CF ₃ CH ₂ , Me, i-Pr], [RY 421; CF ₃ CH ₂ , Me, c-Pr], [RY 422; CF ₃ CH ₂ , Me, t-Bu], [RY _{RY423; CF 3 CH 2, Me} , Bu], [RY424; CF 3 CH 2, Me, t-Bu], [RY425; CF 3 CH 2, Me, c-PrCH 2], [RY426; CF 3 CH 2 , Me, Ph], [RY 427; CF ₃ CH ₂ , Me, Bn], [RY 428; CF ₃ CH ₂ , Me, CF ₃ ], [RY 429; CF ₃ CH ₂ , Me, CF ₃ CH ₂ ], [ _{RY430; CF 3 CH 2, Me} , CF 3 CF 2], [RY431; CF 3 CH 2, Me, CF 2 H], [RY432; CF 3 CH 2, Me, CF 2 HCH 2], [RY433; CF ₂ HCH ₂ , Me, Me], [RY 434; CF ₂ HCH ₂ , Me, Et], [RY 435; CF ₂ HCH ₂ , Me, Pr], [RY 436; CF ₂ HCH ₂ , Me, i-Pr], _{[RY437; CF 2 HCH 2,} Me, c-Pr], [RY438; CF 2 HCH 2, Me, t-Bu], [RY439; CF 2 HCH 2, Me, Bu], [RY440; CF 2 HC _{H 2, Me, t-Bu} ], [RY441; CF 2 HCH 2, Me, c-PrCH 2], [RY442; CF 2 HCH 2, Me, Ph], [RY443; CF 2 HCH 2, Me, Bn _{], [RY444; CF 2 HCH} 2, Me, CF 3], [RY445; CF 2 HCH 2, Me, CF 3 CH 2], [RY446; CF 2 HCH 2, Me, CF 3 CF 2], [RY447 _{; CF 2 HCH 2, Me,} CF 2 H], [RY448; CF 2 HCH 2, Me, CF 2 HCH 2], [RY449; MeOCH 2, Me, Me], [RY450; MeOCH 2, Me, Et] , [RY 451; MeOCH ₂ , Me, Pr], [RY 452; MeOCH ₂ , Me, i-Pr], [RY 453; MeOCH ₂ , Me, c-Pr], [RY 454; MeOCH ₂ , Me, t-Bu] _{, [RY455; MeOCH 2, Me} , Bu], [RY456; MeOCH 2, Me, t-Bu], [RY457; MeOCH 2, Me, c-PrCH 2], [RY458; MeOCH 2, Me, Ph], _{[RY459; MeOCH 2, Me,} Bn], [RY460; MeOCH 2, Me, CF 3], [RY461; MeOCH 2, Me, CF 3 CH 2], [RY462; MeOCH 2, Me, CF 3 CF 2] _{, [RY463; MeOCH 2, Me} , CF 2 H], [RY464; MeOCH 2, Me, CF 2 HCH 2], [RY465; EtOCH 2, Me, Me], [RY466; EtOCH 2, Me, Et], [RY 467; EtOCH ₂ , Me, Pr], [RY 468; EtOCH ₂ , Me, i-Pr], [RY 469; EtOCH ₂ , Me, c-Pr], [RY 470; EtOCH ₂ , Me, t-Bu], [RY 471; EtOCH ₂ , Me, Bu], [RY 472; EtOCH ₂ , Me, t-Bu], [RY 473; EtOCH ₂ , Me, c-PrCH ₂ ], [RY 474; EtOCH ₂ , Me, Ph], [RY RY 475; EtOCH ₂ , Me, Bn], [RY 476; EtOCH ₂ , Me, CF ₃ ], [RY 477; EtOCH ₂ , Me, CF ₃ CH ₂ ] , [RY 478; EtOCH ₂ , Me, CF ₃ CF ₂ ], [RY 479; EtOCH ₂ , Me, CF ₂ H], [RY 480; EtOCH ₂ , Me, CF ₂ HCH ₂ ], [RY 481; MeSCH ₂ , Me, Me], [RY 482; MeSCH ₂ , Me, Et], [RY 483; MeSCH ₂ , Me, Pr], [RY 484; MeSCH ₂ , Me, i-Pr], [RY 485; MeSCH ₂ , Me, c-Pr] , [RY486; MeSCH ₂ , Me, t-Bu], [RY 487; MeSCH ₂ , Me, Bu], [RY 488; MeSCH ₂ , Me, t-Bu], [RY 489; MeSCH ₂ , Me, c-PrCH ₂ ], [RY 490; MeSCH ₂ , Me, Ph], [RY 491; MeSCH ₂ , Me, Bn], [RY 492; MeSCH ₂ , Me, CF ₃ ], [RY 493; MeSCH ₂ , Me, CF ₃ CH ₂ ], _{[RY494; MeSCH 2, Me,} CF 3 CF 2], [RY495; MeSCH 2, Me, CF 2 H], [RY496; MeSCH 2, Me, CF 2 HCH 2], [RY497; EtSCH 2, Me, Me ], [RY 498; EtSCH ₂ , Me, Et], [RY 499; EtSCH ₂ , Me, Pr], [RY 500; EtSCH ₂ , Me, i-Pr], [RY 501; EtSCH ₂ , Me, c-Pr], _{[RY502; EtSCH 2, Me,} t-Bu], [RY503; EtSCH 2, Me, Bu], [RY504; EtSCH 2, Me, t-Bu], [RY505; EtSCH 2, Me, c-PrCH 2] _{, [RY506; EtSCH 2, Me} , Ph], [RY507; EtSCH 2, Me, Bn], [RY508; EtSCH 2, Me, CF 3], [RY509; EtSCH 2, Me, CF 3 CH 2], [ _{RY510; EtSCH 2, Me, CF} 3 CF 2], [RY511; EtSCH 2, Me, CF 2 H], [RY512; EtSCH 2, Me, CF 2 HCH 2], [RY513; Ph, Me, Me], [RY514; Ph, Me, Et], [RY 515; Ph, Me, Pr], [RY 516; Ph, Me, i-Pr], [RY 517; Ph , Me, c-Pr], [RY518; Ph, Me, t-Bu], [RY519; Ph, Me, Bu], [RY520; Ph, Me, t-Bu], [RY 521; Ph, Me, c _{-PrCH 2], [RY522; Ph} , Me, Ph], [RY523; Ph, Me, Bn], [RY524; Ph, Me, CF 3], [RY525; Ph, Me, CF 3 CH 2], [ _{RY526; Ph, Me, CF 3} CF 2], [RY527; Ph, Me, CF 2 H], [RY528; Ph, Me, CF 2 HCH 2], [RY529; Bn, Me, Me], [RY530; Bn, Me, Et], [RY 531; Bn, Me, Pr], [RY 532: Bn, Me, i-Pr], [RY 533; Bn, Me, c-Pr], [RY 534; Bn, Me, t- Bu], [RY535; Bn, Me, Bu], [RY536; Bn, Me, t-Bu], [RY537; Bn, Me, c-PrCH 2], [RY538; Bn, Me, Ph], [RY539 ; Bn, Me, Bn], [RY540; Bn, Me, CF 3], [RY541; Bn, Me, CF 3 CH 2], [RY542; Bn, Me, CF 3 CF 2], [RY543; Bn, _{Me, CF 2 H], [} RY544; Bn, Me, CF 2 HCH 2], [RY545; HCCCH 2, Me, Me], [RY546; HCCCH 2, Me, Et], [RY547; HCCCH 2, Me, _{Pr], [RY548; HCCCH 2} , Me, i-Pr], [RY549; HCCCH 2, Me, c-Pr], [RY550; HCCCH 2, Me, t-Bu], [RY551; HCCCH 2, Me, _{Bu], [RY552; HCCCH 2} , Me, t-Bu], [RY553; HCCCH 2, Me, c-PrCH 2], [RY554; HCCCH 2, Me, Ph], [RY555; HCCCH 2, Me, Bn ], [RY 556; HCCCH ₂ , Me, CF ₃ ], [RY 557; HCCCH ₂ , Me, CF ₃ CH ₂ ], [RY 558; HCCCH ₂ , Me, CF ₃ CF ₂ ], [RY 559: HCCCH ₂ , Me, CF ₂ H], [RY 560; HCCCH ₂ , Me, CF ₂ HCH ₂ ], [RY 561; CH ₃ CCCH ₂ , Me, Me] _{, [RY562; CH 3 CCCH 2} , Me, Et], [RY563; CH 3 CCCH 2, Me, Pr], [RY564; CH 3 CCCH 2, Me, i-Pr], [RY565; CH 3 CCCH 2, Me, c-Pr], [ RY566; CH 3 CCCH 2, Me, t-Bu], [RY567; CH 3 CCCH 2, Me, Bu], [RY568; CH 3 CCCH 2, Me, t-Bu], _{[RY569; CH 3 CCCH 2,} Me, c-PrCH 2], [RY570; CH 3 CCCH 2, Me, Ph], [RY571; CH 3 CCCH 2, Me, Bn], [RY572; CH 3 CCCH 2, _{Me, CF 3], [RY573} ; CH 3 CCCH 2, Me, CF 3 CH 2], [RY574; CH 3 CCCH 2, Me, CF 3 CF 2], [RY575; CH 3 CCCH 2, Me, CF 2 _{H], [RY576; CH 3} CCCH 2, Me, CF 2 HCH 2], [RY577; H, Et, Et], [RY578; H, Et, Pr], [RY579; H, Et, i-Pr] , [RY 580; H, Et, c-Pr], [RY 581; H, Et, t-Bu], [RY 582; H, Et, Bu], [RY 583; H, Et, t-Bu], [RY 584; _{H, Et, c-PrCH 2} ], [RY585; H, Et, Ph], [RY586; H, Et, Bn], [RY587; H, Et, CF 3], [RY588; H, Et, CF 3 _{CH 2], [RY589; H} , Et, CF 3 CF 2], [RY590; H, Et, CF 2 H], [RY591; H, Et, CF 2 HCH 2], [RY592; Me, Et, Et ], [RY593; Me, Et, Pr], [RY594; Me, Et, i-Pr], [RY595; Me, Et, c-Pr], [RY596; Me, Et, t-Bu], [RY 597] Me, Et, Bu], [RY 598; Me, Et, t-Bu], [RY 599; Me, Et, c-PrCH ₂ ], [RY 600; Me, Et, Ph],

[RY601; Me, Et, Bn ], [RY602; Me, Et, CF 3], [RY603; Me, Et, CF 3 CH 2], [RY604; Me, Et, CF 3 CF 2], [RY605; Me, Et, CF ₂ H], [RY 606; Me, Et, CF ₂ HCH ₂ ], [RY 607; Et, Et, Et], [RY 608; Et, Et, Pr], [RY 609; Et, Et, i -Pr], [RY610; Et, Et, c-Pr], [RY611; Et, Et, t-Bu], [RY612; Et, Et, Bu], [RY613; Et, Et, t-Bu], [RY614; Et, Et, c -PrCH 2], [RY615; Et, Et, Ph], [RY616; Et, Et, Bn], [RY617; Et, Et, CF 3], [RY618; Et, Et , CF ₃ CH ₂ ], [RY 619; Et, Et, CF ₃ CF ₂ ], [RY 620; Et, Et, CF ₂ H], [RY 621; Et, Et, CF ₂ HCH ₂ ], [RY 622; Pr, Et, Et], [RY 623; Pr, Et, Pr], [RY 624; Pr, Et, i-Pr], [RY 625; Pr, Et, c-Pr], [RY 626; Pr, Et, t-Bu] , [RY 627; Pr, Et, Bu], [RY 628; Pr, Et, t-Bu], [RY 629; Pr, Et, c-PrCH ₂ ], [RY 630; Pr, Et, Ph], [RY 631; Pr , Et, Bn], [RY 632; Pr, Et, CF ₃ ], [RY 633; Pr, Et, CF ₃ CH ₂ ], [RY 634; Pr, Et, CF ₃ CF ₂ ], [RY 635; Pr, Et, CF ₂ H], [RY 636; Pr, Et, CF ₂ HCH ₂ ], [RY 637; i-Pr, Et, Et], [RY 638; i-Pr, Et, Pr], [RY 639; i-Pr, Et , i-Pr], [RY 640; i-Pr, Et, c-Pr], [RY 641; i-Pr, Et, t-Bu], [RY 642; i-Pr, Et, Bu], [RY 643; -Pr, Et, t-Bu], [RY 644; i-Pr, Et, c-PrCH ₂ ], [RY 645; i-Pr, Et, Ph], [RY 646; i-Pr, Et, Bn], [ RY 647; i-Pr, Et, CF ₃ ], [RY 648; i-Pr, Et, CF ₃ CH ₂ ], [RY 649; _{-Pr, Et, CF 3 CF 2} ], [RY650; i-Pr, Et, CF 2 H], [RY651; i-Pr, Et, CF 2 HCH 2], [RY652; c-Pr, Et, Et ], [RY 653; c-Pr, Et, Pr], [RY 654; c-Pr, Et, i-Pr], [RY 655; c-Pr, Et, c-Pr], [RY 656; c-Pr, Et , t-Bu], [RY657; c-Pr, Et, Bu], [RY658; c-Pr, Et, t-Bu], [RY 659; c-Pr, Et, c-PrCH ₂ ], [RY 660; c-Pr, Et, Ph], [RY 661; c-Pr, Et, Bn], [RY 662; c-Pr, Et, CF ₃ ], [RY 66; c-Pr, Et, CF ₃ CH ₂ ], [ RY664; c-Pr, Et, CF 3 CF 2], [RY665; c-Pr, Et, CF 2 H], [RY666; c-Pr, Et, CF 2 HCH 2], [RY667; c-PrCH 2 , Et, Et], [RY668 ; c-PrCH 2, Et, Pr], [RY669; c-PrCH 2, Et, i-Pr], [RY670; c-PrCH 2, Et, c-Pr], [ _{RY671; c-PrCH 2, Et} , t-Bu], [RY672; c-PrCH 2, Et, Bu], [RY673; c-PrCH 2, Et, t-Bu], [RY674; c-PrCH 2, _{Et, c-PrCH 2],} [RY675; c-PrCH 2, Et, Ph], [RY676; c-PrCH 2, Et, Bn], [RY677; c-PrCH 2, Et, CF 3], [RY678 _{; c-PrCH 2, Et,} CF 3 CH 2], [RY679; c-PrCH 2, Et, CF 3 CF 2], [RY680; c-PrCH 2, Et, CF 2 H], [RY681; c- _{PrCH 2, Et, CF 2 HCH} 2], [RY682; i-Bu, Et, Et], [RY683; i-Bu, Et, Pr], [RY684; i-Bu, Et, i-Pr], [ RY 685; i-Bu, Et, c-Pr], [RY 686; i-Bu, Et, t-Bu], [RY 687; i-Bu, Et, Bu], [RY 688; i-Bu, Et, t- Bu], [RY 689; i-Bu, Et, c-PrCH ₂ ], [RY 690; i-Bu, Et, Ph], [RY 69 1; i-Bu, Et, Bn], [RY 692; i-Bu, Et, CF ₃ ], [RY 693; i-Bu, Et, CF ₃ CH ₂ ], [RY 694; i-Bu, Et, CF ₃ CF ₂ ], [RY 695; i-Bu, Et, CF ₂ H], [RY 696; i-Bu, Et, CF ₂ HCH ₂ ], [RY 697; CF ₃ CH ₂ , Et, Et], [RY 698; CF ₃ CH ₂ , Et, Pr], [RY 699; CF ₃ CH ₂ , Et, i-Pr], [RY 700; CF ₃ CH ₂ , Et, c-Pr], [RY 701; CF ₃ CH ₂ , Et, t _{-Bu], [RY702; CF 3} CH 2, Et, Bu], [RY703; CF 3 CH 2, Et, t-Bu], [RY704; CF 3 CH 2, Et, c-PrCH 2], [RY705 _{; CF 3 CH 2, Et,} Ph], [RY706; CF 3 CH 2, Et, Bn], [RY707; CF 3 CH 2, Et, CF 3], [RY708; CF 3 CH 2, Et, CF 3 _{CH 2], [RY709; CF} 3 CH 2, Et, CF 3 CF 2], [RY710; CF 3 CH 2, Et, CF 2 H], [RY711; CF 3 CH 2, Et, CF 2 HCH 2] _{, [RY712; CF 2 HCH 2} , Et, Et], [RY713; CF 2 HCH 2, Et, Pr], [RY714; CF 2 HCH 2, Et, i-Pr], [RY715; CF 2 HCH 2, Et, c-Pr], [ RY716; CF 2 HCH 2, Et, t-Bu], [RY717; CF 2 HCH 2, Et, Bu], [RY718; CF 2 HCH 2, Et, t-Bu], _{[RY719; CF 2 HCH 2,} Et, c-PrCH 2], [RY720; CF 2 HCH 2, Et, Ph], [RY721; CF 2 HCH 2, Et, Bn], [RY722; CF 2 HCH 2, _{Et, CF 3], [RY723} ; CF 2 HCH 2, Et, CF 3 CH 2], [RY724; CF 2 HCH 2, Et, CF 3 CF 2], [RY725; CF 2 HCH 2, Et, CF 2 _{H], [RY726; CF 2} HCH 2, Et, CF 2 HCH 2], _{[RY727; MeOCH 2, Et,} Et], [RY728; MeOCH 2, Et, Pr], [RY729; MeOCH 2, Et, i-Pr], [RY730; MeOCH 2, Et, c-Pr], [RY731 _{; MeOCH 2, Et, t-} Bu], [RY732; MeOCH 2, Et, Bu], [RY733; MeOCH 2, Et, t-Bu], [RY734; MeOCH 2, Et, c-PrCH 2], [ _{RY735; MeOCH 2, Et, Ph} ], [RY736; MeOCH 2, Et, Bn], [RY737; MeOCH 2, Et, CF 3], [RY738; MeOCH 2, Et, CF 3 CH 2], [RY739; _{MeOCH 2, Et, CF 3 CF} 2], [RY740; MeOCH 2, Et, CF 2 H], [RY741; MeOCH 2, Et, CF 2 HCH 2], [RY742; EtOCH 2, Et, Et], [ _{RY743; EtOCH 2, Et, Pr} ], [RY744; EtOCH 2, Et, i-Pr], [RY745; EtOCH 2, Et, c-Pr], [RY746; EtOCH 2, Et, t-Bu], [ _{RY747; EtOCH 2, Et, Bu} ], [RY748; EtOCH 2, Et, t-Bu], [RY749; EtOCH 2, Et, c-PrCH 2], [RY750; EtOCH 2, Et, Ph], [RY751 EtOCH ₂ , Et, Bn], [RY 752; EtOCH ₂ , Et, CF ₃ ], [RY 753; EtOCH ₂ , Et, CF ₃ CH ₂ ], [RY 754; EtOCH ₂ , Et, CF ₃ CF ₂ ], [, _{RY755; EtOCH 2, Et, CF} 2 H], [RY756; EtOCH 2, Et, CF 2 HCH 2], [RY757; MeSCH 2, Et, Et], [RY758; MeSCH 2, Et, Pr], [RY759 MeSCH ₂ , Et, i-Pr], [RY 760; MeSCH ₂ , Et, c-Pr], [RY 761; MeSCH ₂ , Et, t-Bu], [RY 762; MeSCH ₂ , Et, Bu], [RY 763 _{; MeSCH 2, Et, t-} Bu], [RY764; MeSCH 2, Et, c-PrCH 2], [RY765; MeSCH 2, E t, Ph], [RY766; MeSCH 2, Et, Bn], [RY767; MeSCH 2, Et, CF 3], [RY768; MeSCH 2, Et, CF 3 CH 2], [RY769; MeSCH 2, Et, _{CF 3 CF 2], [RY770} ; MeSCH 2, Et, CF 2 H], [RY771; MeSCH 2, Et, CF 2 HCH 2], [RY772; EtSCH 2, Et, Et], [RY773; EtSCH 2, Et, Pr], [RY774; EtSCH 2, Et, i-Pr], [RY775; EtSCH 2, Et, c-Pr], [RY776; EtSCH 2, Et, t-Bu], [RY777; EtSCH 2, Et, Bu], [RY 778; EtSCH ₂ , Et, t-Bu], [RY 779; EtSCH ₂ , Et, c-PrCH ₂ ], [RY 780; EtSCH ₂ , Et, Ph], [RY 781; EtSCH ₂ , Et Et ₂ , Bn], [RY782; EtSCH 2, Et, CF 3], [RY783; EtSCH 2, Et, CF 3 CH 2], [RY784; EtSCH 2, Et, CF 3 CF 2], [RY785; EtSCH 2, _{Et, CF 2 H], [} RY786; EtSCH 2, Et, CF 2 HCH 2], [RY787; Ph, Et, Et], [RY788; Ph, Et, Pr], [RY789; Ph, Et, i- Pr], [RY 790; Ph, Et, c-Pr], [RY 791; Ph, Et, t-Bu], [RY 792; Ph, Et, Bu], [RY 793; Ph, Et, t-Bu], [ RY794; Ph, Et, c- PrCH 2], [RY795; Ph, Et, Ph], [RY796; Ph, Et, Bn], [RY797; Ph, Et, CF 3], [RY798; Ph, Et, _{CF 3 CH 2], [RY799} ; Ph, Et, CF 3 CF 2], [RY800; Ph, Et, CF 2 H],

[RY801; Ph, Et, CF 2 HCH 2], [RY802; Bn, Et, Et], [RY803; Bn, Et, Pr], [RY804; Bn, Et, i-Pr], [RY805; Bn, Et, c-Pr], [RY 806; Bn, Et, t-Bu], [RY 807; Bn, Et, Bu], [RY 808; Bn, Et, t-Bu], [RY 809; Bn, Et, c- _{PrCH 2], [RY810; Bn} , Et, Ph], [RY811; Bn, Et, Bn], [RY812; Bn, Et, CF 3], [RY813; Bn, Et, CF 3 CH 2], [RY814 _{; Bn, Et, CF 3 CF} 2], [RY815; Bn, Et, CF 2 H], [RY816; Bn, Et, CF 2 HCH 2], [RY817; HCCCH 2, Et, Et], [RY818; _{HCCCH 2, Et, Pr],} [RY819; HCCCH 2, Et, i-Pr], [RY820; HCCCH 2, Et, c-Pr], [RY821; HCCCH 2, Et, t-Bu], [RY822; _{HCCCH 2, Et, Bu],} [RY823; HCCCH 2, Et, t-Bu], [RY824; HCCCH 2, Et, c-PrCH 2], [RY825; HCCCH 2, Et, Ph], [RY826; HCCCH _{2, Et, Bn], [} RY827; HCCCH 2, Et, CF 3], [RY828; HCCCH 2, Et, CF 3 CH 2], [RY829; HCCCH 2, Et, CF 3 CF 2], [RY830; _{HCCCH 2, Et, CF 2 H} ], [RY831; HCCCH 2, Et, CF 2 HCH 2], [RY832; CH 3 CCCH 2, Et, Et], [RY833; CH 3 CCCH 2, Et, Pr], _{[RY834; CH 3 CCCH 2,} Et, i-Pr], [RY835; CH 3 CCCH 2, Et, c-Pr], [RY836; CH 3 CCCH 2, Et, t-Bu], [RY837; CH 3 _{CCCH 2, Et, Bu],} [RY838; CH 3 CCCH 2, Et, t-Bu], [RY839; CH 3 CCCH 2, Et, c-PrCH 2], [RY840; CH 3 CCCH 2, Et, Ph ], [RY 841; CH ₃ CCCH ₂ , Et , Bn], [RY842; CH 3 CCCH 2, Et, CF 3], [RY843; CH 3 CCCH 2, Et, CF 3 CH 2], [RY844; CH 3 CCCH 2, Et, CF 3 CF 2], _{[RY845; CH 3 CCCH 2,} Et, CF 2 H], [RY846; CH 3 CCCH 2, Et, CF 2 HCH 2], [RY847; H, Pr, Pr], [RY848; H, Pr, i- H, Pr, c-Pr], [RY 850; H, Pr, t-Bu], [RY 851; H, Pr, Bu], [RY 852; H, Pr, t-Bu], [Pr 8] RY853; H, Pr, c- PrCH 2], [RY854; H, Pr, Ph], [RY855; H, Pr, Bn], [RY856; H, Pr, CF 3], [RY857; H, Pr, CF ₃ CH ₂ ], [RY 858; H, Pr, CF ₃ CF ₂ ], [RY 859; H, Pr, CF ₂ H], [RY 860; H, Pr, CF ₂ HCH ₂ ], [RY 861; Me, Pr , Me], [RY 862; Me, Pr, Et], [RY 863; Me, Pr, Pr], [RY 864; Me, Pr, i-Pr], [RY 865; Me, Pr, c-Pr], [RY 866 Me, Pr, t-Bu], [RY867; Me, Pr, Bu], [RY 868; Me, Pr, t-Bu], [RY 869; Me, Pr, c-PrCH ₂ ], [RY 870; Me, Pr, Ph], [RY 871; Me, Pr, Bn], [RY 872; Me, Pr, CF ₃ ], [RY 873; Me, Pr, CF ₃ CH ₂ ], [RY 874; Me, Pr, CF ₃ CF ₂ ], [RY 875; Me, Pr, CF ₂ H], [RY 876; Me, Pr, CF ₂ HCH ₂ ], [RY 877; Et, Pr, Pr], [RY 878; Et, Pr, i-Pr], [ RY 879; Et, Pr, c-Pr], [RY 880; Et, Pr, t-Bu], [RY 881; Et, Pr, Bu], [RY 882; Et, Pr, t-Bu], [RY 883; Et, _{Pr, c-PrCH 2],} [RY884; Et, Pr, Ph], [RY885; Et, Pr, Bn], [RY886; Et, Pr, CF 3], [RY887; Et, Pr, CF 3 CH 2 ], [RY 888; Et, Pr, CF ₃ CF ₂ ], [RY889; Et, Pr, CF 2 H], [RY890; Et, Pr, CF 2 HCH 2], [RY891; Pr, Pr, Pr], [RY892; Pr, Pr, i-Pr], [RY893; Pr, Pr, c-Pr], [RY 894; Pr, Pr, t-Bu], [RY 895; Pr, Pr, Bu], [RY 896; Pr, Pr, t-Bu], [RY 897; Pr, Pr, _{c-PrCH 2], [RY898} ; Pr, Pr, Ph], [RY899; Pr, Pr, Bn], [RY900; Pr, Pr, CF 3], [RY901; Pr, Pr, CF 3 CH 2], [RY902; Pr, Pr, CF 3 CF 2], [RY903; Pr, Pr, CF 2 H], [RY904; Pr, Pr, CF 2 HCH 2], [RY905; i-Pr, Pr, Pr], [RY906; i-Pr, Pr, i-Pr], [RY 907; i-Pr, Pr, c-Pr], [RY 908; i-Pr, Pr, t-Bu], [RY 909; i-Pr, Pr , Bu], [RY 910; i-Pr, Pr, t-Bu], [RY 911; i-Pr, Pr, c-PrCH ₂ ], [RY 912; i-Pr, Pr, Ph], [RY 913; Pr, Pr, Bn], [RY 914; i-Pr, Pr, CF ₃ ], [RY 915; i-Pr, Pr, CF ₃ CH ₂ ], [RY 916; i-Pr, Pr, CF ₃ CF ₂ ], [RY917; i-Pr, Pr , CF 2 H], [RY918; i-Pr, Pr, CF 2 HCH 2], [RY919; c-Pr, Pr, Pr], [RY920; c-Pr, Pr, i-Pr], [RY 921; c-Pr, Pr, c-Pr], [RY 922; c-Pr, Pr, t-Bu], [RY 923; c-Pr, Pr, Bu], [RY 924; c- Pr, Pr, t-Bu], [RY 925; c-Pr, Pr, c-PrCH ₂ ], [RY 926; c-Pr, Pr, Ph], [RY 927; c-Pr, Pr, Bn], [RY 928 c-Pr, Pr, CF ₃ ], [RY 929; c-Pr, Pr, CF ₃ CH ₂ ], [RY 930; c-Pr, Pr, CF ₃ CF ₂ ], [RY 931; c-Pr, Pr, _{CF 2 H], [RY932;} c-Pr, Pr, CF 2 HCH 2], [RY933; c-PrCH 2, Pr, Pr], [RY934; c-PrCH 2, P r, i-Pr], [ RY935; c-PrCH 2, Pr, c-Pr], [RY936; c-PrCH 2, Pr, t-Bu], [RY937; c-PrCH 2, Pr, Bu], _{[RY938; c-PrCH 2,} Pr, t-Bu], [RY939; c-PrCH 2, Pr, c-PrCH 2], [RY940; c-PrCH 2, Pr, Ph], [RY941; c-PrCH _{2, Pr, Bn], [} RY942; c-PrCH 2, Pr, CF 3], [RY943; c-PrCH 2, Pr, CF 3 CH 2], [RY944; c-PrCH 2, Pr, CF 3 CF _{2], [RY945; c-} PrCH 2, Pr, CF 2 H], [RY946; c-PrCH 2, Pr, CF 2 HCH 2], [RY947; i-Bu, Pr, Pr], [RY948; i -Bu, Pr, i-Pr], [RY949; i-Bu, Pr, c-Pr], [RY950; i-Bu, Pr, t-Bu], [RY951; i-Bu, Pr, Bu], [RY952; i-Bu, Pr , t-Bu], [RY953; i-Bu, Pr, c-PrCH 2], [RY954; i-Bu, Pr, Ph], [RY955; i-Bu, Pr, bn], [RY956; i- Bu, Pr, CF 3], [RY957; i-Bu, Pr, CF 3 CH 2], [RY958; i-Bu, Pr, CF 3 CF 2], [RY959; i _{-Bu, Pr, CF 2 H]} , [RY960; i-Bu, Pr, CF 2 HCH 2], [RY961; CF 3 CH 2, Pr, Pr], [RY962; CF 3 CH 2, Pr, i- _{Pr], [RY963; CF 3} CH 2, Pr, c-Pr], [RY964; CF 3 CH 2, Pr, t-Bu], [RY965; CF 3 CH 2, Pr, Bu], [RY966; CF ₃ CH ₂ , Pr, t-Bu], [RY 967; CF ₃ CH ₂ , Pr, c-Pr CH ₂ ], [RY 968; CF ₃ CH ₂ , Pr, Ph], [RY 969; CF ₃ CH ₂ , Pr, _{bn], [RY970; CF 3} CH 2, Pr, CF 3], [RY971; CF 3 CH 2, Pr, CF 3 CH 2], [RY972; CF 3 CH 2, Pr, CF 3 CF 2], [ RY 973; CF _{3 CH 2, Pr, CF 2 H} ], [RY974; CF 3 CH 2, Pr, CF 2 HCH 2], [RY975; CF 2 HCH 2, Pr, Pr], [RY976; CF 2 HCH 2, Pr, i _{-Pr], [RY977; CF 2} HCH 2, Pr, c-Pr], [RY978; CF 2 HCH 2, Pr, t-Bu], [RY979; CF 2 HCH 2, Pr, Bu], [RY980; _{CF 2 HCH 2, Pr, t} -Bu], [RY981; CF 2 HCH 2, Pr, c-PrCH 2], [RY982; CF 2 HCH 2, Pr, Ph], [RY983; CF 2 HCH 2, Pr , Bn], [RY984; CF 2 HCH 2, Pr, CF 3], [RY985; CF 2 HCH 2, Pr, CF 3 CH 2], [RY986; CF 2 HCH 2, Pr, CF 3 CF 2], _{[RY987; CF 2 HCH 2,} Pr, CF 2 H], [RY988; CF 2 HCH 2, Pr, CF 2 HCH 2], [RY989; MeOCH 2, Pr, Pr], [RY990; MeOCH 2, Pr, i-Pr], [RY991; MeOCH 2, Pr, c-Pr], [RY992; MeOCH 2, Pr, t-Bu], [RY993; MeOCH 2, Pr, Bu], [RY994; MeOCH 2, Pr, t-Bu], [RY995; MeOCH 2, Pr, c-PrCH 2], [RY996; MeOCH 2, Pr, Ph], [RY997; MeOCH 2, Pr, Bn], [RY998; MeOCH 2, Pr, CF ₃ ], [RY 999; MeOCH ₂ , Pr, CF ₃ CH ₂ ], [RY 1000; MeOCH ₂ , Pr, CF ₃ CF ₂ ],

_{[RY1001; MeOCH 2, Pr,} CF 2 H], [RY1002; MeOCH 2, Pr, CF 2 HCH 2], [RY1003; EtOCH 2, Pr, Pr], [RY1004; EtOCH 2, Pr, i-Pr] _{, [RY1005; EtOCH 2, Pr} , c-Pr], [RY1006; EtOCH 2, Pr, t-Bu], [RY1007; EtOCH 2, Pr, Bu], [RY1008; EtOCH 2, Pr, t-Bu] _{, [RY1009; EtOCH 2, Pr} , c-PrCH 2], [RY1010; EtOCH 2, Pr, Ph], [RY1011; EtOCH 2, Pr, Bn], [RY1012; EtOCH 2, Pr, CF 3], [ _{RY1013; EtOCH 2, Pr, CF} 3 CH 2], [RY1014; EtOCH 2, Pr, CF 3 CF 2], [RY1015; EtOCH 2, Pr, CF 2 H], [RY1016; EtOCH 2, Pr, CF 2 _{HCH 2], [RY1017; MeSCH} 2, Pr, Pr], [RY1018; MeSCH 2, Pr, i-Pr], [RY1019; MeSCH 2, Pr, c-Pr], [RY1020; MeSCH 2, Pr, t _{-Bu], [RY1021; MeSCH 2} , Pr, Bu], [RY1022; MeSCH 2, Pr, t-Bu], [RY1023; MeSCH 2, Pr, c-PrCH 2], [RY1024; MeSCH 2, Pr, _{Ph], [RY1025; MeSCH 2} , Pr, Bn], [RY1026; MeSCH 2, Pr, CF 3], [RY1027; MeSCH 2, Pr, CF 3 CH 2], [RY1028; MeSCH 2, Pr, CF 3 _{CF 2], [RY1029; MeSCH} 2, Pr, CF 2 H], [RY1030; MeSCH 2, Pr, CF 2 HCH 2], [RY1031; EtSCH 2, Pr, Pr], [RY1032; EtSCH 2, Pr, i-Pr], [RY1033; EtSCH 2, Pr, c-Pr], [RY1034; EtSCH 2, Pr, t-Bu], [RY1035; EtSCH 2, Pr, Bu], [RY1036; EtSCH 2, Pr, t-Bu], [RY1037; EtSCH ₂ , Pr, c _{-PrCH 2], [RY1038; EtSCH} 2, Pr, Ph], [RY1039; EtSCH 2, Pr, Bn], [RY1040; EtSCH 2, Pr, CF 3], [RY1041; EtSCH 2, Pr, CF 3 CH _{2], [RY1042; EtSCH 2} , Pr, CF 3 CF 2], [RY1043; EtSCH 2, Pr, CF 2 H], [RY1044; EtSCH 2, Pr, CF 2 HCH 2], [RY1045; Ph, Pr , Pr], [RY1046; Ph, Pr, i-Pr], [RY1047; Ph, Pr, c-Pr], [RY1048; Ph, Pr, t-Bu], [RY1049; Ph, Pr, Bu], [RY1050; Ph, Pr, t -Bu], [RY1051; Ph, Pr, c-PrCH 2], [RY1052; Ph, Pr, Ph], [RY1053; Ph, Pr, Bn], [RY1054; Ph, _{Pr, CF 3], [RY1055} ; Ph, Pr, CF 3 CH 2], [RY1056; Ph, Pr, CF 3 CF 2], [RY1057; Ph, Pr, CF 2 H], [RY1058; Ph, Pr _{, CF 2 HCH 2], [} RY1059; Bn, Pr, Pr], [RY1060; Bn, Pr, i-Pr], [RY1061; Bn, Pr, c-Pr], [RY1062; Bn, Pr, t- Bu], [RY1063; Bn, Pr, Bu], [RY1064; Bn, Pr, t-Bu], [RY1065; Bn, Pr, c-PrCH 2], [RY1066; Bn, Pr, Ph], [RY1067 ; Bn, Pr, Bn], [RY1068; Bn, Pr, CF 3], [RY1069; Bn, Pr, CF 3 CH 2], [RY1070; Bn, Pr, CF 3 CF 2], [RY1071; Bn, _{Pr, CF 2 H], [} RY1072; Bn, Pr, CF 2 HCH 2], [RY1073; HCCCH 2, Pr, Pr], [RY1074; HCCCH 2, Pr, i-Pr], [RY1075; HCCCH 2, Pr, c-Pr], [ RY1076; HCCCH 2, Pr, t-Bu], [RY1077; HCCCH 2, Pr, Bu], [RY1078; HCCCH 2, Pr, t-Bu], [RY1079; HCCCH 2, Pr, c-PrCH ₂ ], [RY 1080; H _{CCCH 2, Pr, Ph],} [RY1081; HCCCH 2, Pr, Bn], [RY1082; HCCCH 2, Pr, CF 3], [RY1083; HCCCH 2, Pr, CF 3 CH 2], [RY1084; HCCCH 2 _{, Pr, CF 3 CF 2]} , [RY1085; HCCCH 2, Pr, CF 2 H], [RY1086; HCCCH 2, Pr, CF 2 HCH 2], [RY1087; CH 3 CCCH 2, Pr, Pr], [ _{RY1088; CH 3 CCCH 2, Pr} , i-Pr], [RY1089; CH 3 CCCH 2, Pr, c-Pr], [RY1090; CH 3 CCCH 2, Pr, t-Bu], [RY1091; CH 3 CCCH _{2, Pr, Bu], [} RY1092; CH 3 CCCH 2, Pr, t-Bu], [RY1093; CH 3 CCCH 2, Pr, c-PrCH 2], [RY1094; CH 3 CCCH 2, Pr, Ph] _{, [RY1095; CH 3 CCCH 2} , Pr, Bn], [RY1096; CH 3 CCCH 2, Pr, CF 3], [RY1097; CH 3 CCCH 2, Pr, CF 3 CH 2], [RY1098; CH 3 CCCH _{2, Pr, CF 3 CF 2} ], [RY1099; CH 3 CCCH 2, Pr, CF 2 H], [RY1100; CH 3 CCCH 2, Pr, CF 2 HCH 2], [RY1101; H, i-Pr, i-Pr], [RY 1102; H, i-Pr, c-Pr], [RY 1103; H, i-Pr, t-Bu], [RY 1104; H, i-Pr, Bu], [RY 1 105; H, i-Pr, t-Bu], [RY 1106; H, i-Pr, c-PrCH ₂ ], [RY 1107; H, i-Pr, Ph], [RY 1108; H, i-Pr, Bn], [RY 1109 H, i-Pr, CF ₃ ], [RY 1110; H, i-Pr, CF ₃ CH ₂ ], [RY 1111; H, i-Pr, CF ₃ CF ₂ ], [RY 1112; H, i-Pr, _{CF 2 H], [RY1113;} H, i-Pr, CF 2 HCH 2], [RY1114; Me, i-Pr, i-Pr], [RY1115; Me, i-Pr, c-Pr], [RY1116 Me, i-Pr, t-Bu], [RY 1117; Me , i-Pr, Bu], [RY 1118; Me, i-Pr, t-Bu], [RY 1119; Me, i-Pr, c-PrCH ₂ ], [RY 1 120; Me, i-Pr, Ph], [RY 1 120; RY1121; Me, i-Pr, Bn], [RY1122; Me, i-Pr, CF 3], [RY1123; Me, i-Pr, CF 3 CH 2], [RY1124; Me, i-Pr, CF 3 CF ₂ ], [RY 1125; Me, i-Pr, CF ₂ H], [RY 1 126; Me, i-Pr, CF ₂ HCH ₂ ], [RY 1127; Et, i-Pr, i-Pr], [RY 1 128; Et, i-Pr, c-Pr], [RY 1129; Et, i-Pr, t-Bu], [RY 1130; Et, i-Pr, Bu], [RY 1131; Et, i-Pr, t-Bu] , [RY 1132; Et, i-Pr, c-PrCH ₂ ], [RY 1 133; Et, i-Pr, Ph], [RY 1 134; Et, i-Pr, Bn], [RY 1 135; Et, i-Pr, CF _{3], [RY1136; Et,} i-Pr, CF 3 CH 2], [RY1137; Et, i-Pr, CF 3 CF 2], [RY1138; Et, i-Pr, CF 2 H], [RY1139; _{Et, i-Pr, CF 2} HCH 2], [RY1140; Pr, i-Pr, i-Pr], [RY1141; Pr, i-Pr, c-Pr], [RY1142; Pr, i-Pr, t -Bu], [RY1143; Pr, i-Pr, Bu], [RY 1144; Pr, i-Pr, t-Bu], [RY 1145; Pr, i-Pr, c-PrCH ₂ ], [RY 1146; Pr, i-Pr, Ph], [RY 1147; Pr, i-Pr, Bn], [RY 1148; Pr, i-Pr, CF ₃ ], [RY 1149; Pr, i-Pr, CF ₃ CH ₂ ], [RY 1 150; _{Pr, i-Pr, CF 3} CF 2], [RY1151; Pr, i-Pr, CF 2 H], [RY1152; Pr, i-Pr, CF 2 HCH 2], [RY1153; i-Pr, i- Pr, i-Pr], [RY1154; i-Pr, i-Pr, c-Pr], [RY1155; i-Pr, i-Pr, t-Bu], [RY1156; i-Pr, i-Pr, Bu], [RY 1157; i-Pr, i-Pr, t-Bu], [RY 1158; i-Pr, i-Pr, c-PrCH ₂ ], [RY 1 159; i-Pr, i-Pr, Ph], [RY1160; i-Pr, i-Pr, Bn], [RY1161; i-Pr, i-Pr, CF ₃ ], [RY1162; i-Pr, i-Pr , CF ₃ CH ₂ ], [RY 1163; i-Pr, i-Pr, CF ₃ CF ₂ ], [RY 1164; i-Pr, i-Pr, CF ₂ H], [RY 1165; i-Pr, i-Pr , CF ₂ HCH ₂ ], [RY 1166; c-Pr, i-Pr, i-Pr], [RY 1167; c-Pr, i-Pr, c-Pr], [RY 1 168; c-Pr, i-Pr, t-Bu], [RY 1169; c-Pr, i-Pr, Bu], [RY 1170; c-Pr, i-Pr, t-Bu], [RY 1171; c-Pr, i-Pr, c-PrCH ₂ ], [RY1172; c-Pr , i-Pr, Ph], [RY1173; c-Pr, i-Pr, Bn], [RY1174; c-Pr, i-Pr, CF 3], [RY1175; c- _{Pr, i-Pr, CF 3} CH 2], [RY1176; c-Pr, i-Pr, CF 3 CF 2], [RY1177; c-Pr, i-Pr, CF 2 H], [RY1178; c- _{Pr, i-Pr, CF 2} HCH 2], [RY1179; c-PrCH 2, i-Pr, i-Pr], [RY1180; c-PrCH 2, i-Pr, c-Pr], [RY1181; c _{-PrCH 2, i-Pr, t} -Bu], [RY1182; c-PrCH 2, i-Pr, Bu], [RY1183; c-PrCH 2, i-Pr, t-Bu], [RY1184; c- PrCH ₂ , i-Pr, c-PrCH ₂ ], [RY 1185; c-PrCH ₂ , i-Pr, Ph], [RY 1186; c-PrCH ₂ , i-Pr, Bn], [RY 1187; c-PrCH ₂ , i-Pr, CF ₃ ], [RY 1188; c-PrCH ₂ , i-Pr, CF ₃ CH ₂ ], [RY 1189; c-PrCH ₂ , i-Pr, CF ₃ CF ₂ ], [RY 1190; c- _{PrCH 2, i-Pr, CF} 2 H], [RY1191; c-PrCH 2, i-Pr, CF 2 HCH 2], [RY1192; i-Bu, i-Pr, i-Pr], [RY1193; i -Bu, i-Pr, c-Pr], [RY 1194; i-Bu, i-Pr, t-Bu], [RY 1195; i-Bu, i-Pr, B u], [RY 1196; i-Bu, i-Pr, t-Bu], [RY 1197; i-Bu, i-Pr, c-PrCH ₂ ], [RY 1198; i-Bu, i-Pr, Ph], [RY 1199; i-Bu, i-Pr, Bn], [RY 1200; i-Bu, i-Pr, CF ₃ ],

[RY1201; i-Bu, i -Pr, CF 3 CH 2], [RY1202; i-Bu, i-Pr, CF 3 CF 2], [RY1203; i-Bu, i-Pr, CF 2 H], [RY 1204; i-Bu, i-Pr, CF ₂ HCH ₂ ], [RY 1205; CF ₃ CH ₂ , i-Pr, i-Pr], [RY 1206; CF ₃ CH ₂ , i-Pr, c-Pr] _{, [RY1207; CF 3 CH 2} , i-Pr, t-Bu], [RY1208; CF 3 CH 2, i-Pr, Bu], [RY1209; CF 3 CH 2, i-Pr, t-Bu], _{[RY1210; CF 3 CH 2,} i-Pr, c-PrCH 2], [RY1211; CF 3 CH 2, i-Pr, Ph], [RY1212; CF 3 CH 2, i-Pr, Bn], [RY1213 CF ₃ CH ₂ , i-Pr, CF ₃ ], [RY 1214; CF ₃ CH ₂ , i-Pr, CF ₃ CH ₂ ], [RY 1215; CF ₃ CH ₂ , i-Pr, CF ₃ CF ₂ ], _{[RY1216; CF 3 CH 2,} i-Pr, CF 2 H], [RY1217; CF 3 CH 2, i-Pr, CF 2 HCH 2], [RY1218; CF 2 HCH 2, i-Pr, i-Pr _{], [RY1219; CF 2 HCH} 2, i-Pr, c-Pr], [RY1220; CF 2 HCH 2, i-Pr, t-Bu], [RY1221; CF 2 HCH 2, i-Pr, Bu] _{, [RY1222; CF 2 HCH 2} , i-Pr, t-Bu], [RY1223; CF 2 HCH 2, i-Pr, c-PrCH 2], [RY1224; CF 2 HCH 2, i-Pr, Ph] _{, [RY1225; CF 2 HCH 2} , i-Pr, Bn], [RY1226; CF 2 HCH 2, i-Pr, CF 3], [RY1227; CF 2 HCH 2, i-Pr, CF 3 CH 2], _{[RY1228; CF 2 HCH 2,} i-Pr, CF 3 CF 2], [RY1229; CF 2 HCH 2, i-Pr, CF 2 H], [RY1230; CF 2 HCH 2, i-Pr, CF 2 HCH _{2], [RY1231; MeOCH 2} , i-Pr, i-Pr], [RY1232; MeOCH 2, i-P r, c-Pr], [ RY1233; MeOCH 2, i-Pr, t-Bu], [RY1234; MeOCH 2, i-Pr, Bu], [RY1235; MeOCH 2, i-Pr, t-Bu], _{[RY1236; MeOCH 2, i-} Pr, c-PrCH 2], [RY1237; MeOCH 2, i-Pr, Ph], [RY1238; MeOCH 2, i-Pr, Bn], [RY1239; MeOCH 2, i- Pr, CF ₃ ], [RY 1240; MeOCH ₂ , i-Pr, CF ₃ CH ₂ ], [RY 1241; MeOCH ₂ , i-Pr, CF ₃ CF ₂ ], [RY 1242; MeOCH ₂ , i-Pr, CF _{2 H], [RY1243; MeOCH 2} , i-Pr, CF 2 HCH 2], [RY1244; EtOCH 2, i-Pr, i-Pr], [RY1245; EtOCH 2, i-Pr, c-Pr], [ RY 1246; EtOCH ₂ , i-Pr, t-Bu], [RY 1247; EtOCH ₂ , i-Pr, Bu], [RY 1248; EtOCH ₂ , i-Pr, t-Bu], [RY 1249; EtOCH ₂ , i- _{Pr, c-PrCH 2],} [RY1250; EtOCH 2, i-Pr, Ph], [RY1251; EtOCH 2, i-Pr, Bn], [RY1252; EtOCH 2, i-Pr, CF 3], [RY1253 EtOCH ₂ , i-Pr, CF ₃ CH ₂ ], [RY 1254; EtOCH ₂ , i-Pr, CF ₃ CF ₂ ], [RY 1 255; EtOCH ₂ , i-Pr, CF ₂ H], [RY 1 256; EtOCH _{2 , i-Pr, CF 2 HCH} 2], [RY1257; MeSCH 2, i-Pr, i-Pr], [RY1258; MeSCH 2, i-Pr, c-Pr], [RY1259; MeSCH 2, i-Pr , t-Bu], [RY 1260; MeSCH ₂ , i-Pr, Bu], [RY 1261; MeSCH ₂ , i-Pr, t-Bu], [RY 1262; MeSCH ₂ , i-Pr, c-PrCH ₂ ], [RY 1263; MeSCH ₂ , i-Pr, Ph], [RY 1264; MeSCH ₂ , i-Pr, Bn], [RY 1265; MeSCH ₂ , i-Pr, CF ₃ ], [RY 1266; MeSCH ₂ , i-Pr, CF _{3 CH 2], [RY1267; MeSCH} 2, i-Pr, CF 3 CF 2], [RY1268; MeSCH 2, i-Pr, CF 2 H], [RY1269; MeSCH 2, i-Pr, CF 2 HCH 2] , [RY 1270; EtSCH ₂ , i-Pr, i-Pr], [RY 1271; EtSCH ₂ , i-Pr, c-Pr], [RY 1272; EtSCH ₂ , i-Pr, t-Bu], [RY 1273; EtSCH _{2, i-Pr, Bu]} , [RY1274; EtSCH 2, i-Pr, t-Bu], [RY1275; EtSCH 2, i-Pr, c-PrCH 2], [RY1276; EtSCH 2, i-Pr, _{Ph], [RY1277; EtSCH 2} , i-Pr, Bn], [RY1278; EtSCH 2, i-Pr, CF 3], [RY1279; EtSCH 2, i-Pr, CF 3 CH 2], [RY1280; EtSCH _{2, i-Pr, CF 3} CF 2], [RY1281; EtSCH 2, i-Pr, CF 2 H], [RY1282; EtSCH 2, i-Pr, CF 2 HCH 2], [RY1283; Ph, i- Pr, i-Pr], [RY1284; Ph, i-Pr, c-Pr], [RY1285; Ph, i-Pr, t-Bu], [RY1286; Ph, i-Pr, Bu], [RY1287; Ph, i-Pr, t-Bu], [RY 1 288; Ph, i-Pr, c-PrCH ₂ ], [RY 1 289; Ph, i-Pr, Ph], [RY 1290; Ph, i-Pr, Bn], [RY1291; Ph, i-Pr , CF 3], [RY1292; Ph, i-Pr, CF 3 CH 2], [RY1293; Ph, i-Pr, CF 3 CF 2], [RY1294; Ph, i- _{Pr, CF 2 H], [} RY1295; Ph, i-Pr, CF 2 HCH 2], [RY1296; Bn, i-Pr, i-Pr], [RY1297; Bn, i-Pr, c-Pr], [RY1298; Bn, i-Pr, t-Bu], [RY 1299; Bn, i-Pr, Bu], [RY 1300; Bn, i-Pr, t-Bu], [RY1301; Bn, i-Pr, c _{-PrCH 2], [RY1302; Bn} , i-Pr, Ph], [RY1303; Bn, i-Pr, Bn], [RY1304; Bn, i-Pr, CF 3], [RY 1305; Bn, i-Pr, CF 3 CH 2], [RY1306; Bn, i-Pr, CF 3 CF 2], [RY1307; Bn, i-Pr, CF 2 H], [RY1308; Bn, i- _{Pr, CF 2 HCH 2],} [RY1309; HCCCH 2, i-Pr, i-Pr], [RY1310; HCCCH 2, i-Pr, c-Pr], [RY1311; HCCCH 2, i-Pr, t- _{Bu], [RY1312; HCCCH 2} , i-Pr, Bu], [RY1313; HCCCH 2, i-Pr, t-Bu], [RY1314; HCCCH 2, i-Pr, c-PrCH 2], [RY1315; _{HCCCH 2, i-Pr, Ph} ], [RY1316; HCCCH 2, i-Pr, Bn], [RY1317; HCCCH 2, i-Pr, CF 3], [RY1318; HCCCH 2, i-Pr, CF 3 CH _{2], [RY1319; HCCCH 2} , i-Pr, CF 3 CF 2], [RY1320; HCCCH 2, i-Pr, CF 2 H], [RY1321; HCCCH 2, i-Pr, CF 2 HCH 2], _{[RY1322; CH 3 CCCH 2,} i-Pr, i-Pr], [RY1323; CH 3 CCCH 2, i-Pr, c-Pr], [RY1324; CH 3 CCCH 2, i-Pr, t-Bu] , [RY 1325; CH ₃ CCCH ₂ , i-Pr, Bu], [RY 1326; CH ₃ CCCH ₂ , i-Pr, t-Bu], [RY 1327; CH ₃ CCCH ₂ , i-Pr, c-PrCH ₂ ] _{, [RY1328; CH 3 CCCH 2} , i-Pr, Ph], [RY1329; CH 3 CCCH 2, i-Pr, Bn], [RY1330; CH 3 CCCH 2, i-Pr, CF 3], [RY1331; _{CH 3 CCCH 2, i-Pr} , CF 3 CH 2], [RY1332; CH 3 CCCH 2, i-Pr, CF 3 CF 2], [RY1333; CH 3 CCCH 2, i-Pr, CF 2 H], _{[RY1334; CH 3 CCCH 2,} i-Pr, CF 2 HCH 2], [RY1335; H, c-Pr, c-Pr], [RY1336; H, c-Pr, t-Bu], [RY1337; H , c-Pr, Bu], [RY 1338; H, c -Pr, t-Bu], [ RY1339; H, c-Pr, c-PrCH 2], [RY1340; H, c-Pr, Ph], [RY1341; H, c-Pr, Bn], [RY1342; _{H, c-Pr, CF 3} ], [RY1343; H, c-Pr, CF 3 CH 2], [RY1344; H, c-Pr, CF 3 CF 2], [RY1345; H, c-Pr, CF ₂ H], [RY 1346; H, c-Pr, CF ₂ HCH ₂ ], [RY 1347; Me, c-Pr, c-Pr], [RY 1348; Me, c-Pr, t-Bu], [RY 1 349; Me, c-Pr, Bu], [RY 1350; Me, c-Pr, t-Bu], [RY 1351; Me, c-Pr, c-PrCH ₂ ], [RY 1352; Me, c-Pr, Ph], [RY1353; Me, c-Pr , Bn], [RY1354; Me, c-Pr, CF 3], [RY1355; Me, c-Pr, CF 3 CH 2], [RY1356; Me, c-Pr, CF ₃ CF ₂ ], [RY 1357; Me, c-Pr, CF ₂ H], [RY 1358; Me, c-Pr, CF ₂ HCH ₂ ], [RY 1359; Et, c-Pr, c-Pr], [RY 1 360 Et, c-Pr, t-Bu], [RY1361; Et, c-Pr, Bu], [RY1362; Et, c-Pr, t-Bu], [RY1363; Et, c-Pr, c-PrCH ₂ ], [RY 1364; Et, c-Pr, Ph], [RY 1365; Et, c-Pr, Bn], [RY 1366; Et, c-Pr, CF ₃ ], [RY 1367; Et, c-Pr, CF ₃ CH ₂ ], [RY 1368; Et, c-Pr, CF ₃ CF ₂ ], [RY 1369; Et, c-Pr, CF ₂ H], [RY 1370; Et, c-Pr, CF ₂ HCH ₂ ], [[ RY1371; Pr, c-Pr, c-Pr], [RY1372; Pr, c-Pr, t-Bu], [RY1373; Pr, c-Pr, Bu], [RY 1374; Pr, c-Pr, t- Bu], [RY 1375; Pr, c-Pr, c-PrCH ₂ ], [RY 1376; Pr, c-Pr, Ph], [RY 1377; Pr, c-Pr, Bn], [RY 1378; Pr, c-Pr , CF ₃ ], [RY 1379; Pr, c-Pr, CF ₃ CH ₂ ], [RY 1380; Pr, c-Pr, CF ₃ CF ₂ ], [RY1381; Pr, c -Pr, CF 2 H], [RY1382; Pr, c-Pr, CF 2 HCH 2], [RY1383; i-Pr, c-Pr, c-Pr], [RY1384; i-Pr, c-Pr, t-Bu], [RY 1385; i-Pr, c-Pr, Bu], [RY 1386; i-Pr, c-Pr, t-Bu], [RY 1387; i-Pr, c-Pr, c-PrCH ₂ ], [RY 1388; i-Pr, c-Pr, Ph], [RY 1389; i-Pr, c-Pr, Bn], [RY 1390; i-Pr, c-Pr, CF _{3], [RY1391; i-} Pr, c-Pr, CF 3 CH 2], [RY1392; i-Pr, c-Pr, CF 3 CF 2], [RY1393; i-Pr, c-Pr, CF 2 H], [RY1394; i-Pr, c-Pr, CF ₂ HCH ₂ ], [RY 1395; c-Pr, c-Pr, c-Pr], [RY 1396; c-Pr, c-Pr, t-Bu ], [RY 1397; c-Pr, c-Pr, Bu], [RY 1398; c-Pr, c-Pr, t-Bu], [RY 1399; c-Pr, c-Pr, c-PrCH ₂ ], [[ RY 1400; c-Pr, c-Pr, Ph],

[RY 1401; c-Pr, c-Pr, Bn], [RY 1402; c-Pr, c-Pr, CF ₃ ], [RY 1403; c-Pr, c-Pr, CF ₃ CH ₂ ], [RY 1404; c _{-Pr, c-Pr, CF 3} CF 2], [RY1405; c-Pr, c-Pr, CF 2 H], [RY1406; c-Pr, c-Pr, CF 2 HCH 2], [RY1407; c _{-PrCH 2, c-Pr, c} -Pr], [RY1408; c-PrCH 2, c-Pr, t-Bu], [RY1409; c-PrCH 2, c-Pr, Bu], [RY1410; c- PrCH ₂ , c-Pr, t-Bu], [RY 1411; c-PrCH ₂ , c-Pr, c-PrCH ₂ ], [RY 1412; c-PrCH ₂ , c-Pr, Ph], [RY 1413; c- _{PrCH 2, c-Pr, Bn} ], [RY1414; c-PrCH 2, c-Pr, CF 3], [RY1415; c-PrCH 2, c-Pr, CF 3 CH 2], [RY1416; c-PrCH _{2, c-Pr, CF 3} CF 2], [RY1417; c-PrCH 2, c-Pr, CF 2 H], [RY1418; c-PrCH 2, c-Pr, CF 2 HCH 2], [RY1419; i-Bu, c-Pr, c-Pr], [RY 1420; i-Bu, c-Pr, t-Bu], [RY 1421; i-Bu, c-Pr, Bu], [RY 1422; i-Bu, c-Pr, t-Bu], [RY 1423; i-Bu, c-Pr, c-PrCH ₂ ], [RY 1424; i-Bu, c-Pr, Ph], [RY 1425; i-Bu, c-Pr , Bn], [RY 1426; i-Bu, c-Pr, CF ₃ ], [RY 1427; i-Bu, c-Pr, CF ₃ CH ₂ ], [RY 1428; i-Bu, c-Pr, CF ₃ CF ₂ ], [RY 1429; i-Bu, c-Pr, CF ₂ H], [RY 1430; i-Bu, c-Pr, CF ₂ HCH ₂ ], [RY 1431; CF ₃ CH ₂ , c-Pr, c- _{Pr], [RY1432; CF 3} CH 2, c-Pr, t-Bu], [RY1433; CF 3 CH 2, c-Pr, Bu], [RY1434; CF 3 CH 2, c-Pr, t-Bu ], [RY 1435; CF ₃ CH ₂ , c-Pr, c-PrCH ₂ ], [RY 14 _{36; CF 3 CH 2, c} -Pr, Ph], [RY1437; CF 3 CH 2, c-Pr, Bn], [RY1438; CF 3 CH 2, c-Pr, CF 3], [RY1439; CF 3 _{CH 2, c-Pr, CF} 3 CH 2], [RY1440; CF 3 CH 2, c-Pr, CF 3 CF 2], [RY1441; CF 3 CH 2, c-Pr, CF 2 H], [RY1442 CF ₃ CH ₂ , c-Pr, CF ₂ HCH ₂ ], [RY 1443; CF ₂ HCH ₂ , c-Pr, c-Pr], [RY 1444; CF ₂ HCH ₂ , c-Pr, t-Bu], _{[RY1445; CF 2 HCH 2,} c-Pr, Bu], [RY1446; CF 2 HCH 2, c-Pr, t-Bu], [RY1447; CF 2 HCH 2, c-Pr, c-PrCH 2], _{[RY1448; CF 2 HCH 2,} c-Pr, Ph], [RY1449; CF 2 HCH 2, c-Pr, Bn], [RY1450; CF 2 HCH 2, c-Pr, CF 3], [RY1451; CF _{2 HCH 2, c-Pr,} CF 3 CH 2], [RY1452; CF 2 HCH 2, c-Pr, CF 3 CF 2], [RY1453; CF 2 HCH 2, c-Pr, CF 2 H], [ _{RY1454; CF 2 HCH 2, c} -Pr, CF 2 HCH 2], [RY1455; MeOCH 2, c-Pr, c-Pr], [RY1456; MeOCH 2, c-Pr, t-Bu], [RY1457; _{MeOCH 2, c-Pr, Bu} ], [RY1458; MeOCH 2, c-Pr, t-Bu], [RY1459; MeOCH 2, c-Pr, c-PrCH 2], [RY1460; MeOCH 2, c-Pr , Ph], [RY1461; MeOCH 2, c-Pr, Bn], [RY1462; MeOCH 2, c-Pr, CF 3], [RY1463; MeOCH 2, c-Pr, CF 3 CH 2], [RY1464; MeOCH ₂ , c-Pr, CF ₃ CF ₂ ], [RY1465; MeOCH ₂ , c-Pr, CF ₂ H], [RY 1466; MeOCH ₂ , c-Pr, CF ₂ HCH ₂ ], [RY 1467; EtOCH ₂ , c-Pr, c-Pr] , [RY 1468; EtOCH ₂ , c-Pr, t-Bu], [RY 1469; EtOCH ₂ , c-Pr, Bu], [RY 1470; EtOCH ₂ , c-Pr, t-Bu], [RY 1471; EtOCH ₂ , c-Pr, c-PrCH ₂ ], [RY1472; EtOCH ₂ , c-Pr, Ph], [RY 1473; EtOCH ₂ , c-Pr, Bn], [RY 1474; EtOCH ₂ , c-Pr, CF ₃ ], _{[RY1475; EtOCH 2, c-} Pr, CF 3 CH 2], [RY1476; EtOCH 2, c-Pr, CF 3 CF 2], [RY1477; EtOCH 2, c-Pr, CF 2 H], [RY1478; EtOCH ₂ , c-Pr, CF ₂ HCH ₂ ], [RY 1479; MeSCH ₂ , c-Pr, c-Pr], [RY 1480; MeSCH ₂ , c-Pr, t-Bu], [RY 1481; MeSCH ₂ , c -Pr, Bu], [RY1482; MeSCH 2, c-Pr, t-Bu], [RY1483; MeSCH 2, c-Pr, c-PrCH 2], [RY1484; MeSCH 2, c-Pr, Ph], _{[RY1485; MeSCH 2, c-} Pr, Bn], [RY1486; MeSCH 2, c-Pr, CF 3], [RY1487; MeSCH 2, c-Pr, CF 3 CH 2], [RY1488; MeSCH 2, c _{-Pr, CF 3 CF 2],} [RY1489; MeSCH 2, c-Pr, CF 2 H], [RY1490; MeSCH 2, c-Pr, CF 2 HCH 2], [RY1491; EtSCH 2, c-Pr, c-Pr], [RY1492; EtSCH 2, c-Pr, t-Bu], [RY1493; EtSCH 2, c-Pr, Bu], [RY1494; EtSCH 2, c-Pr, t-Bu], [RY1495 EtSCH ₂ , c-Pr, c-PrCH ₂ ], [RY 1496; EtSCH ₂ , c-Pr, Ph], [RY 1497; EtSCH ₂ , c-Pr, Bn], [RY 1498; EtSCH ₂ , c-Pr, CF ₃ ], [RY 1499; EtSCH ₂ , c-Pr, CF ₃ CH ₂ ], [RY 1500; EtSCH ₂ , c-Pr, CF ₃ CF ₂ ], [RY 1501; EtSCH ₂ , c-Pr , CF ₂ H], [RY 1502; EtSCH ₂ , c-Pr, CF ₂ HCH ₂ ], [RY 1503; Ph, c-Pr, c-Pr], [RY 1504; Ph, c-Pr, t-Bu], [RY1505; Ph, c-Pr , Bu], [RY1506; Ph, c-Pr, t-Bu], [RY1507; Ph, c-Pr, c-PrCH 2], [RY1508; Ph, c-Pr, Ph], [RY 1509; Ph, c-Pr, Bn], [RY 1510; Ph, c-Pr, CF ₃ ], [RY 1511; Ph, c-Pr, CF ₃ CH ₂ ], [RY 1512; Ph, c- _{Pr, CF 3 CF 2],} [RY1513; Ph, c-Pr, CF 2 H], [RY1514; Ph, c-Pr, CF 2 HCH 2], [RY1515; Bn, c-Pr, c-Pr] , [RY 1516; Bn, c-Pr, t-Bu], [RY 1517; Bn, c-Pr, Bu], [RY 1518; Bn, c-Pr, t-Bu], [RY 1519; Bn, c-Pr, _{c-PrCH 2], [RY1520} ; Bn, c-Pr, Ph], [RY1521; Bn, c-Pr, Bn], [RY1522; Bn, c-Pr, CF 3], [RY1523; Bn, c- _{Pr, CF 3 CH 2],} [RY1524; Bn, c-Pr, CF 3 CF 2], [RY1525; Bn, c-Pr, CF 2 H], [RY1526; Bn, c-Pr, CF 2 HCH 2 _{], [RY1527; HCCCH 2,} c-Pr, c-Pr], [RY1528; HCCCH 2, c-Pr, t-Bu], [RY1529; HCCCH 2, c-Pr, Bu], [RY1530; HCCCH 2 , c-Pr, t-Bu ], [RY1531; HCCCH 2, c-Pr, c-PrCH 2], [RY1532; HCCCH 2, c-Pr, Ph], [RY1533; HCCCH 2, c-Pr, Bn _{], [RY1534; HCCCH 2,} c-Pr, CF 3], [RY1535; HCCCH 2, c-Pr, CF 3 CH 2], [RY1536; HCCCH 2, c-Pr, CF 3 CF 2], [RY1537 _{; HCCCH 2, c-Pr,} CF 2 H], [RY1538; HCCCH 2, c-Pr, CF 2 HCH 2], [RY1539; CH 3 CCCH 2, c-Pr, c-P _{r], [RY1540; CH 3} CCCH 2, c-Pr, t-Bu], [RY1541; CH 3 CCCH 2, c-Pr, Bu], [RY1542; CH 3 CCCH 2, c-Pr, t-Bu _{], [RY1543; CH 3 CCCH} 2, c-Pr, c-PrCH 2], [RY1544; CH 3 CCCH 2, c-Pr, Ph], [RY1545; CH 3 CCCH 2, c-Pr, Bn], _{[RY1546; CH 3 CCCH 2,} c-Pr, CF 3], [RY1547; CH 3 CCCH 2, c-Pr, CF 3 CH 2], [RY1548; CH 3 CCCH 2, c-Pr, CF 3 CF 2 _{], [RY1549; CH 3 CCCH} 2, c-Pr, CF 2 H], [RY1550; CH 3 CCCH 2, c-Pr, CF 2 HCH 2]

  The compound RA of the present invention, the compound RB of the present invention, the compound RC of the present invention, the compound RE of the present invention, the compound RF of the present invention, the compound RG of the present invention, the compound RH of the present invention, the compound RI of the present invention The compound RK of the present invention, the compound RL of the present invention, the compound RM of the present invention, the compound RO of the present invention, the compound RP of the present invention, the compound RQ of the present invention, the compound RR of the present invention, the compound RS of the present invention, the compound RT of the present invention The compound RU of the invention, the compound RV of the invention, the compound RW of the invention, the compound RX of the invention and the compound RY of the invention are referred to as a compound A of the invention.

The compound of the present invention can be used in combination or in combination with a bactericidal agent, an insecticide, an acaricide, a nematode, a plant growth regulator or a synergist (hereinafter collectively referred to as the present component). Then, a plant or soil is treated with a composition containing one or more members selected from the group consisting of fungicides, insecticides, acaricides, nematocides, plant growth regulators and synergists, and the compound of the present invention. Thus, pests such as harmful arthropods, harmful linear animals, and plant pathogens can be controlled. Furthermore, pests can be controlled by separately applying the compound of the present invention and the component.
A bactericidal agent is a component used to protect plants from diseases caused by plant pathogens (filamentous fungi and bacteria), and is defined, for example, by the FRAC (Fungicide Resistance Action Committee) The thing is mentioned.
Examples of the insecticide, acaricide and nematocide include those specified by IRAC (Insecticide Resistance Action Committee: Insecticide Resistance Measures Committee) and the like.
The plant growth regulator means a component that regulates plant growth, such as promoting fruit set and rooting, and examples include indole butyric acid.
By a synergist is meant a component that enhances the efficacy of the agent when used in admixture with or in combination with other agents, such as piperonyl butoxide.

Below, the example of the combination of this invention compound and this component is described. For example, tebuconazole (tebuconazole) + SX means a combination of tebuconazole (tebuconazole) and SX. The abbreviation SX means any one compound selected from the compound A of the present invention. Also, numbers in parentheses indicate CAS registration numbers.
Tebuconazole (tebuconazole) + SX, prothioconazole (prothioconazole) + SX, metconazole (metconazole) + SX, ipconazole (ipconazole) + SX, triticonazole (triticonazole) + SX, difenoconazole (difenoconazole) + SX, imazalil (imazailil) + triadimenol + SX, tetraconazole (tetraconazole) + SX, flutriafol + SX, bromuconazole (bromuconazole) + SX, propiconazole + SX, mefentrifluconazole (mefentrifluconazole) + SX, Ipfentrifluconazole ( ipfentrifluconazole) + SX, epoxiconazole (Epoxiconazole) + SX, cyproconazole (cyproconazole) + SX, mandestorobin (mandestrobin) + SX, azoxystrobin (Saxoxystrobin) + SX, pyraclostrobin (pyraclostrobin) + SX, trifloxystrobin (Pyraclostrobin) trifloxystrobin) + SX, fluoxast Robin (fluoxastrobin) + SX, picoxystrobin (SX), fenamidone + SX, dimoxystrobin (DX) + SX, metominostrobin + SX, pyribencarb (Pyribencarb) + SX, sedaxane + SX, Penflufen + SX, fluxapyroxad + SX, fluopyram (+ flupyram) + SX, benzovindiflupyr + SX, boscalid + SX, carboxin + SX, penthiopyrad + SX, flutranyl (flutolanil) + SX, bixafen + SX, pydiflumetofen + SX, 3-difluoromethyl-N- (7-fluoro-1,1,3-trimethylindan-4-yl) -1-methylpyrazole -4-carboxamide (1383809-87-7) + SX, N-cyclopropyl-3- (difluoromethyl) -5 Fluoro-N- (5-chloro-2-isopropylbenzyl) -1-methyl-1H-pyrazole-4-carboxamide (1255734-28-1) + SX, 3-difluoromethyl-1-methyl-N- (1,1 3, 3-trimethylindan-4-yl) pyrazole-4-carboxamide (141573-94-6) + SX, 3-difluoromethyl-1-methyl-N-[(3R) -1,1,3-trimethylindan-4 -Yl] pyrazole-4-carboxamide (1352994-67-2) + SX, metalaxyl (metalaxyl) + SX, metalaxyl M (metalaxyl-M) + SX, metrafenone (Straight) + Siflufenamide (cyflufenamid) + SX, proquinazid + SX, 3-chloro-5-phenyl-6-methyl-4- (2,6-difluorophenyl) pyridazine (1358061-55-8) + SX, 1- (2-{[1- (4-chlorophenyl) -1H-pi] [Sol-3-yl] oxymethyl} -3-methylphenyl) -4-methyl-1,4-dihydrotetrazol-5-one (1472649-01-6) + SX, 4- (2-bromo-4-fluorophenyl) ) -N- (2-Chloro-6-fluorophenyl) -1,3-dimethyl-1H-pyrazol-5-amine (1362477-26-6) + SX, (3S, 6S, 7R, 8R) -8-benzyl -3-[({3-[(isobutyryloxy) methoxy] -4-methoxypyridin-2-yl} carbonyl) amino] -6-methyl-4,9-dioxo-1,5-dioxonan-7 Yl-2-methylpropanate (517875-34-2) + SX, N '-(2,5-dimethyl-4-phenoxyphenyl) -N-ethyl-N-methylmethanimidamide (1052688- 31-9) + SX , Isotianil (isotianil) + SX, oxolinic acid SX, ferrimzone + SX, phthalide + SX, kasugamycin (kasugamicin) + SX, tebufloquine + SX, quinofumelin + SX, fenpyrazamine + SX, procymidone (Sucymonone) + SX, fludioxil + Tolclofos-methyl (stoclofos-methyl) + SX, thiabendazole (thiabendazole) + SX, etaboxam (ethaboxam) + SX, picalbutrazox (picarbutrazox) + SX, oxathiapiprolin + SX, imintagazine acetate (iminoctadine triacetate) + SX Silicate (iminooctadine albesilate) + SX, fenpropimorph + SX, fenpropidin + SX, spiroxamine + SX, chlorothalonil + SX, folpet + SX, captan + SX, Thiuram (thiram) + SX, sill off (Silthiofam) + SX, mancozeb (mancozeb) + SX, cartap (cartap) + SX, clothianidin + SX, thiamethoxam + SX, imidacloprid + SX, thiacloprid (thiaclop) + SX, flupyrisulfurone (Sulfoxaflor) + SX, Triflumezopyrim + SX, Dichloromezotiaz (Dicloromezotiaz) + SX, Beta-cyfluthrin (beta-cyfluthrin) + SX, Tefluthrin (tefluthrin) + SX, Fipronil (fipronil) + SX, Chlorantraniliprol (chlorantranprole ) + SX, cyantraniliprole + SX, tetraniliprol (tetraniliprole) + SX, thiodicarb + thiocarb + SX, carbofuran + SX, fluxametamide + SX, afoxolaner + SX, fluralaner + Broflanilid e) + SX, abamectin + SX, fluensulfone + SX, fluazaindolizine + SX, tiozafafen + SX, (E) -N- {1-[(6-chloropyridine-3-) [Ill) methyl] pyridin-2 (1H) -ylidene} -2, 2, 2-trifluoroacetamide (1689566-03-7) + SX, Mycorrhizal Fungi + SX, Bacillus firmus (Bacillus firmus) + SX, Bacillus amyloliquefaciens + SX, Pasteuria nishizawae + SX, Pasteuria penetrans + SX.

The ratio of the compound of the present invention to the component is not particularly limited, but the weight ratio (the compound of the present invention: component) is from 1000: 1 to 1: 1000, 500: 1 to 1: 500, 100: 1. To 1: 100, 50: 1 to 1:50, 20: 1 to 1:20, 10: 1 to 1:10, 3: 1 to 1: 3, 1: 1 to 1: 500, 1: 1 to 1 : 100, 1: 1 to 1:50, 1: 1 to 1:20, 1: 1 to 1:10 and the like.

  By treating the compound of the present invention on plants, the seedling establishment rate, healthy leaf number increase, plant height increase, plant body weight increase, leaf area increase, number or weight of seeds or fruits, number of set flowers or number of fruits set The effect of promoting plant growth such as increase of root growth and increase of root growth can be obtained. Furthermore, by treating the compound of the present invention on plants, tolerance to temperature stress such as high temperature stress or low temperature stress, water stress such as drought stress or excessive humidity stress, or abiotic stress such as salt stress is improved.

  Next, formulation examples are shown. In the preparation examples, "part" means "part by weight".

Formulation Example 1 A formulation is obtained by thoroughly grinding and mixing 50 parts of any one compound of the present invention A, 3 parts of calcium lignin sulfonate, 2 parts of magnesium lauryl sulfate and 45 parts of synthetic hydrous silicon oxide.

Formulation Example 2 20 parts of any one compound of the present invention A and 1.5 parts of sorbitan trioleate are mixed with 28.5 parts of an aqueous solution containing 2 parts of polyvinyl alcohol and finely ground by a wet grinding method, Into this, 40 parts of an aqueous solution containing 0.05 part of xanthan gum and 0.1 part of aluminum magnesium silicate is added, and 10 parts of propylene glycol is further added thereto, followed by stirring and mixing to obtain a preparation.

Formulation Example 3 A formulation is obtained by thoroughly grinding and mixing 2 parts of any one compound of the present invention A, 88 parts of kaolin clay and 10 parts of talc.

Formulation Example 4 A formulation is obtained by thoroughly mixing 5 parts of any one compound of the present invention A, 14 parts of polyoxyethylene styryl phenyl ether, 6 parts of calcium dodecylbenzene sulfonate and 75 parts of xylene.

Formulation Example 5 2 parts of any one compound of the present invention A, 1 part of synthetic hydrous silicon oxide, 2 parts of calcium lignin sulfonate, 30 parts of bentonite and 65 parts of kaolin clay are well ground and mixed, then water is added and kneaded well The formulation is obtained by combining, granulating and drying.

Formulation Example 6 20 parts of any one compound of the present invention A; 35 parts of a mixture of white carbon and polyoxyethylene alkyl ether sulfate ammonium salt (weight ratio 1: 1) and water are mixed to make the total amount 100 parts, and ground The formulation is obtained by processing using a machine.

The following Test Examples show that the compounds of the present invention are useful for controlling pests.

Test Example 1 Control test against wheat leaf blight fungus (Septoria tritici) Dimethylsulfoxide so as to contain 1500 ppm of the present compound 3, 4, 5, 11, 13, 14, 21, 21, 45, 64, 79-82, 83 or 85 And diluted with 1 μL into a titer plate (96 wells), and then 150 μL of potato juice liquid medium (PDB medium) inoculated with spores of wheat leaf blight fungus in advance was dispensed. The plate was cultured at 18 ° C. for 5 days to grow wheat leaf blight, and then the absorbance at 550 nm of each well of the titer plate was measured, and the value was defined as the viability of wheat leaf blight. As a result, in the groups treated with the compounds of the present invention 3, 4, 5, 11, 13, 14, 21, 45, 64, 79-82, 83 or 85, the growth rate in any of the groups was 50 % Or less.

Test Example 2 Control Test against Tomato Leaf Mold Fungus (Cladosporium fulvum) Compounds of the Present Invention 1, 7, 13, 23, 25, 28, 31, 32, 34, 36, 39-45, 47, 54, 59, 61, 71 , Diluted with dimethyl sulfoxide so that it contains 1500 ppm of 74, 77, 79, 80-82, 86-88 or 89, and dispensed 1 μL to a titer plate (96 wells), Among the genes encoded, 150 μL of potato juice liquid medium (PDB medium) inoculated with spores of QoI resistant strain in which the nucleotide sequence is mutated so that the 129th amino acid residue of cytochrome b is substituted from phenylalanine to leucine I ordered. This plate was cultured at 18 ° C. for 5 days to grow tomato leaf mold fungus, and then the absorbance at 550 nm of each well of the titer plate was measured, and the value was taken as the viability of tomato leaf mold fungus. As a result, the compounds 1, 7, 13, 23, 25, 28, 31, 32, 34, 36, 39 to 45, 47, 54, 59, 61, 71, 74, 77, 79, 80 to 82, The degree of growth in the section treated with 86 to 88 or 89 was 50% or less of the degree of growth in the untreated section.

Test Example 3 Control Test for Soybean Rust (Phakopsora pachyrhizi) The soil is packed in a plastic pot, soya beans (variety: Kurosengoku) are sown, and grown in a greenhouse for 10 days, water containing Natsuspore of soybean rust fungus The suspension was spray inoculated. Present invention compound 1 formulated according to the method described in Formulation Example 6 after placing soybean under humid conditions in a greenhouse at daytime 23 ° C. and nighttime 20 ° C. after cultivation and then cultivating for 2 days in a greenhouse 16, 16, 18 to 37, 39, 40 to 48, 50 to 58, 60 to 77, 79 to 86, 88 to 91 or 92 are mixed with water to a concentration of 200 ppm, and the mixture is The foliage was sprayed so as to adhere well to the leaf surface. After spraying, the soybeans were air dried and cultivated for 8 days in a greenhouse, and then the lesion area was examined. As a result, as for the lesion area in the soybean which processed this invention compound 1-16, 18-37, 39, 40-48, 50-58, 60-77, 79-86, 88-91, or 92, all are none. It was less than 30% of the lesion area in treated soybean.

Test Example 4 Control Test for Soybean Rust (Phakopsora pachyrhizi) The soil was packed in a plastic pot, soya bean (variety: Kurosengoku) was sown and cultivated in a greenhouse for 13 days. Concentrations of the present compound 1, 3 to 16, 18 to 33, 35 to 48, 50 to 77, 79, 80, 82 to 86, 88 to 91, or 92 formulated according to the method described in Formulation Example 6 The mixture was mixed with water to 200 ppm, and the mixture was foliage-sprayed to adhere well to the leaf surface of the soybean. After spraying, the soybeans were air-dried, and 4 days later, they were spray-inoculated with a water suspension containing spores of soybean rust. After inoculation, soybeans were placed in a greenhouse at daytime 23 ° C. and nighttime at 20 ° C. under high humidity for 1 day, and then grown for 10 days in a greenhouse, and then the lesion area was examined. As a result, as for the lesion area in the soybean which processed this-invention compound 1, 3-16, 18-33, 35-48, 50-77, 79, 80, 82-86, 88-91 or 92, all are none. It was less than 30% of the lesion area in treated soybean.

Test Example 5 Control Test for Wheat Leaf Blight (Septoria tritici) A soil was packed in a plastic pot, and wheat (variety; apodie) was sown and cultivated in a greenhouse for 10 days. Invention compounds 1, 3 to 8, 10, 13 to 24, 29, 30, 32 to 35, 39, 40, 42, 44, 49, 51, 52 formulated according to the method described in Formulation Example 6. , 54-58, 60, 62-69, 71, 74, 77, 79-82, 84-86, 88 or 89 with water to a concentration of 500 ppm, the mixture being the leaf surface of the wheat The leaves and leaves were sprayed so as to adhere well to the After spraying, the wheat was air-dried, and 4 days later, it was spray-inoculated with an aqueous suspension containing spores of wheat leaf blight. After inoculation, wheat was placed at 18 ° C. for 3 days and then grown under illumination for 14 to 18 days, and then the lesion area was examined. As a result, the compounds of the present invention 1, 3 to 8, 10, 13 to 24, 29, 30, 32 to 35, 39, 40, 42, 44, 49, 51, 52, 54 to 58, 60, 62 to 69, The lesion area in wheat treated with 71, 74, 77, 79 to 82, 84 to 86, 88 or 89 was 30% or less of the lesion area in untreated wheat.

Test Example 6 Control Test for Wheat Leaf Blight (Septoria tritici) A soil was packed in a plastic pot, and wheat (variety; apodie) was sown and cultivated in a greenhouse for 10 days. Invention compounds 1, 3 to 8, 11 to 14, 16 to 31, 35 to 37, 39 to 44, 52 to 56, 58, 60 to 62, 64 formulated according to the method described in Formulation Example 6. ~ 71, 74, 77, 79-88 or 89 were mixed with water to a concentration of 200 ppm, and the mixture was sprayed with stem and leaf so as to adhere well to the leaf surface of the wheat. After spraying, the wheat was air-dried, and 4 days later, it was spray-inoculated with an aqueous suspension containing spores of wheat leaf blight. After inoculation, wheat was placed at 18 ° C. for 3 days and then grown under illumination for 14 to 18 days, and then the lesion area was examined. As a result, the compounds of the present invention 1, 3 to 8, 11 to 14, 16 to 31, 35 to 37, 39 to 44, 52 to 56, 58, 60 to 62, 64-71, 74, 77, 79 to 88 or The lesion area in each of the 89-treated wheat was 30% or less of that in the untreated wheat.

Test Example 7 Control Test for Wheat Rust (Puccinia recondita) A soil was packed in a plastic pot, and wheat (variety; Shirogane) was sown and cultivated in a greenhouse for 9 days. Invention compounds 1 to 8, 11, 13 to 25, 27, 29 to 36, 39, 40, 47 to 50, 52 to 69, 71, 74, 77 formulated according to the method described in Formulation Example 6. 79, 80 to 86, 88 or 89 were mixed with water to a concentration of 500 ppm, and the mixture was foliated to sufficiently adhere to the leaf surface of the wheat. After spraying, the wheat was air-dried, cultivated at 20 ° C. under illumination for 5 days, and then inoculated with spores of wheat rust fungus. After inoculation, wheat was placed at 23 ° C. in dark and humid for 1 day, and then grown at 20 ° C. in illumination for 8 days, and the lesion area was examined. As a result, the present compounds 1 to 8, 11, 13 to 25, 27, 29 to 36, 39, 40, 47 to 50, 52 to 69, 71, 74, 77, 79, 80 to 86, 88 or 89 can be obtained. The lesion area in the treated wheat was 30% or less of the lesion area in the untreated wheat.

Test Example 8 Control Test for Wheat Rust (Puccinia recondita) A soil was packed in a plastic pot, and wheat (variety; white ginseng) was sown and cultivated in a greenhouse for 9 days. Invention compounds 1, 3 to 8, 12 to 14, 16 to 25, 29, 30, 33, 35 to 37, 39 to 41, 43, 44, 51 formulated according to the method described in Formulation Example 6. 53, 55 to 58, 60 to 66, 71 to 74, 77, 79 to 88 or 89 are mixed with water to a concentration of 200 ppm, and the mixture is sufficiently adhered to the leaf surface of the wheat. The leaves were sprayed. After spraying, the wheat was air-dried, cultivated at 20 ° C. under illumination for 5 days, and then inoculated with spores of wheat rust fungus. After inoculation, wheat was placed at 23 ° C. in dark and humid for 1 day, and then grown at 20 ° C. in illumination for 8 days, and the lesion area was examined. As a result, the compounds of the present invention 1, 3 to 8, 12 to 14, 16 to 25, 29, 30, 33, 35, 37, 39 to 41, 43, 44, 51, 53, 55 to 58, 60 to 66, The lesion area in each of the wheats treated with 71 to 74, 77, 79 to 88, or 89 was 30% or less of the lesion area in untreated wheat.

Test Example 9 Control Test for Rice Blast (Magnaporthe grisea) The soil was packed in a plastic pot, and rice (variety; Hinohikari) was sown and cultivated in a greenhouse for 20 days. Thereafter, the compound of the present invention 1 to 4, 6, 7, 14, 17, 21, 21, 39, 51, 63, 66 to 68, 71 or 82 formulated according to the method described in Formulation Example 6 has a concentration of 500 ppm The mixture was mixed with water so as to give a mixture of the above-mentioned plants, and the mixture was sprayed with leaves and leaves so as to sufficiently adhere to the above-mentioned rice leaf surface. After spraying, the rice is air-dried and left for 6 days while contacting the sprayed rice and the rice seedling infected with rice blast fungus (cultivar: Hinohikari) in the daytime at 24 ° C and nightly at 20 ° C with high humidity. The lesion area was investigated. As a result, the lesion area in the rice treated with the compounds of the present invention 1 to 4, 6, 7, 14, 17, 21, 39, 51, 63, 66 to 68, 71 or 82 in any untreated rice. Less than 30% of the lesion area.

Test Example 10 Control Test for Rice Blast (Magnaporthe grisea) A soil was packed in a plastic pot, and rice (variety; Hinohikari) was sown and cultivated in a greenhouse for 20 days. Thereafter, the present compound 3, 4, 15, 20, 52, 55, 63, 66 to 69 or 71 formulated according to the method described in Formulation Example 6 is mixed with water to a concentration of 200 ppm. The mixture was foliated to sufficiently adhere to the leaf surface of the above rice. After spraying, the rice is air-dried and left for 6 days while contacting the sprayed rice and the rice seedling infected with rice blast fungus (cultivar: Hinohikari) in the daytime at 24 ° C and nightly at 20 ° C with high humidity. The lesion area was investigated. As a result, the lesion area in rice treated with the compound of the present invention 3, 4, 15, 20, 52, 55, 63, 66 to 69 or 71 is 30% or less of the lesion area in untreated rice. there were.

Test Example 11 Control Test against Cucumber Powdery Mildew (Sphaerotheca fuliginea) A plastic pot was filled with soil, and a cucumber (variety; Sagami Hankaku) was sown and cultivated in a greenhouse for 12 days. Thereafter, the compound of the present invention 4 or 43 formulated according to the method described in Formulation Example 6 is mixed with water to a concentration of 200 ppm, and the mixture is sufficiently adhered to the leaf surface of the cucumber. The leaves were sprayed. After spraying, the cucumbers were air-dried and placed in a greenhouse at daytime 24 ° C. and nighttime at 20 ° C. for 1 day, and then sporulated with spores of cucumber seedlings (variety; Sagami Hankaku) infected with cucumber powdery mildew. The cucumber was grown in a greenhouse at 24 ° C. in the daytime and at 20 ° C. in the night for 8 days, and then the lesion area was examined. As a result, the lesion area in the cucumber treated with the compound of the present invention 4 or 43 was 30% or less of the lesion area in the untreated cucumber.

Test Example 12 Control Test Against Barley Blotch (Pyrenophora teres) The soil was packed in a plastic pot, and barley (variety: Nishinohoshi) was sown and cultivated in a greenhouse for 7 days. The compound of the present invention 5, 8, 10, 15, 32, 50, 55, 61 or 71 formulated according to the method described in Formulation Example 6 is mixed with water to a concentration of 500 ppm, and the mixture Were sprayed so as to adhere sufficiently to the above-mentioned barley leaf surface. After spraying, the barley was air-dried, and two days later, it was spray-inoculated with an aqueous suspension of barley net blotch spores. After inoculation, barley was placed in a greenhouse at 23 ° C. and 20 ° C. at night under humid conditions for 3 days, and then grown for 7 days in a greenhouse, and then the lesion area was examined. As a result, the lesion area in the barley treated with the compound 5, 8, 10, 15, 32, 50, 55, 61 or 71 of the present invention was 30% or less of the lesion area in untreated barley.

Test Example 13
About 30 cotton aphids (Aphis gossypii, all stages) were inoculated to cucumber seedlings (the second true leaf development stage) planted in a container and allowed to stand for 1 day. The compound of the present invention 15, 64, 84 or 85 formulated according to the method described in Formulation Example 6 is adjusted with water to a concentration of 500 ppm, and the solution is adjusted to 10 mL / seedling of the above-mentioned seedlings Sprayed at a rate. After 5 days, the number of surviving insects was examined, and the control value was determined by the following equation.
Control value (%) = {1- (Cb × Tai) / (Cai × Tb)} × 100
The letters in the formula have the following meanings.
Cb: Number of tested insects in untreated area Cai: Number of surviving insects in survey in untreated area Tb: Number of tested insects in treated zone Tai: Number of surviving insects in survey in treated area Here, untreated group means It means a zone that performs the same operation as the treatment zone except that the compound of the present invention is not used.
As a result, the treated area of the compound of the present invention 15, 64, 84 or 85 showed a control value of 90% or more.

Comparative Test Example Control Test for Wheat Rust (Puccinia recondita) The soil was packed in a plastic pot, and wheat (variety; Shirogane) was sown and cultivated in a greenhouse for 9 days. N, N-Dimethyl-4- [5- (trifluoromethyl) -1,2,4-oxadi, described in WO 2013/008162, formulated according to the method described in Formulation Example 6 Azole-3-yl] benzenesulfonamide was mixed with water to a concentration of 200 ppm, and the mixture was foliage sprayed to adhere well to the wheat leaf surface. After spraying, the wheat was air-dried, cultivated at 20 ° C. under illumination for 5 days, and then inoculated with spores of wheat rust fungus. After inoculation, wheat was placed at 23 ° C. in dark and humid for 1 day, and then grown at 20 ° C. in illumination for 8 days, and the lesion area was examined. As a result, no lesion area was found in wheat treated with N, N-dimethyl-4- [5- (trifluoromethyl) -1,2,4-oxadiazol-3-yl] benzenesulfonamide. More than 70% of the lesion area in the treated wheat.

  The compound of the present invention has pesticidal activity against pests and is useful as an active ingredient of pest control agents.

Claims (11)

Formula (I)

[In the formula,
A represents a single bond, NR ¹ or an oxygen atom,
m represents any of 0 to 3;
R ¹ represents a C1-C6 alkyl group optionally having one or more halogen atoms or a hydrogen atom,
X represents a single bond, CR ⁴ R ⁵ , NR ⁶ or an oxygen atom,
R ² , R ³ , R ⁴ and R ⁵ are each independently a C 1 -C 6 alkyl group optionally having one or more substituents selected from group A, one or more substituents selected from group B A C1-C6 alkoxy group which may have a group, a phenyl group which may have one or more substituents selected from group D, and one or more substituents selected from group D A pyridyl group, a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, a hydrogen atom, a halogen atom, or a cyano group, or R ² and R ³ M may be taken together with the carbon atom to which it is attached to form a 3- to 6-membered ring (the 3- to 6-membered ring may have one or more substituents selected from Group D), m When is 2 or 3, the plurality of R ² and R ³ may be the same or different,
R ⁶ is a C 1 -C 6 alkyl group which may have one or more substituents selected from group A, a C 3 -C 6 alkenyl group which may have one or more halogen atoms, one or more halogen atoms C 3 -C 6 alkynyl group which may have one or more substituents, C 1 -C 6 alkoxy group which may have one or more halogen atoms, C 3-which may have one or more substituents selected from group D A C6 cycloalkyl group, a phenyl group optionally having one or more substituents selected from group D, a 5-membered aromatic heterocyclic group optionally having one or more substituents selected from group D, A 6-membered aromatic heterocyclic group or a hydrogen atom which may have one or more substituents selected from group D,
n represents 0, 1 or 2;
Q represents an oxygen atom, NR ⁷ , N-CN, N-NO ₂ , N-C (O) R ⁷ , N-C (O) OR ⁷ or N-S (O) ₂ R ⁷ (n is In the case of 2, two Q may be the same or different)
R ⁷ represents a C 1 -C 6 alkyl group optionally having one or more substituents selected from the group consisting of a halogen atom and a cyano group, or a hydrogen atom,
G is a thiophene ring, furan ring, imidazole ring, oxazole ring, isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine ring, pyrazine ring, pyridazine ring, pyrimidine ring or benzene ring {the thiophene ring, The furan ring, the imidazole ring, the oxazole ring, the isoxazole ring, the thiazole ring, the pyridine ring, the pyrazine ring, the pyridazine ring, and the pyrimidine ring have one or more substituents selected from group D. It may be done. In addition, when n is 0, the benzene ring may have one or more substituents selected from group I. When n is 1 or 2, the benzene ring is one or more selected from group D. Represents an optionally substituted substituent},
Y is a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, a phenyl group optionally having one or more substituents selected from group D, a group D 5-membered aromatic heterocyclic group optionally having one or more substituents selected, 6-membered aromatic heterocyclic group optionally having one or more substituents selected from group G, from group D Represents a 3- to 6-membered non-aromatic heterocyclic group optionally having one or more substituents, CR ⁸ R ⁹ R ¹⁰ , NR ¹¹ R ¹² or OR ¹³ ,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more substituents selected from the group consisting of Group A and Group F, and one or more halogen atoms C3-C6 alkenyl group which may have, C3-C6 alkynyl group which may have one or more halogen atoms, C1-C6 which may have one or more substituents selected from group B Alkoxy group, C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, phenyl group optionally having one or more substituents selected from group D, group D Represents a 5- to 6-membered aromatic heterocyclic group optionally having one or more substituents, a hydrogen atom, a halogen atom or a cyano group,
R ¹¹ and R ¹² each independently have a C 1 -C 6 alkyl group optionally having one or more substituents selected from the group consisting of Group E and Group F, and one or more halogen atoms A C3-C6 alkenyl group which may be, a C3-C6 alkynyl group which may have one or more halogen atoms, a C1-C6 alkoxy group which may have one or more halogen atoms, a group D C3-C6 cycloalkyl group which may have one or more substituents, phenyl group which may have one or more substituents selected from group D, one or more substituents selected from group D Represents a 5- to 6-membered aromatic heterocyclic group or hydrogen atom which may be possessed, or R ¹¹ and R ¹² are bonded to each other to form a 3- to 8-membered heterocyclic ring (the 3- to 8-membered heterocyclic ring is Form one or more substituents selected from group D) Even if well,
R ¹³ is a C1-C6 alkyl group optionally having one or more substituents selected from the group consisting of Group A and Group F, and a C3-C6 alkenyl group optionally having one or more halogen atoms A C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more substituents selected from group D, one or more selected from group D Or a substituted or unsubstituted phenyl group, a 5-6 membered aromatic heterocyclic group optionally having one or more substituents selected from group D, or a hydrogen atom,
When X is CR ⁴ R ⁵ and Y is CR ⁸ R ⁹ R ¹⁰ , R ⁴ and R ⁸ may be combined with each other to form a 5-7 membered heterocyclic ring (the 7-membered heterocyclic ring may have one or more substituents selected from group D),
When X is CR ⁴ R ⁵ and Y is NR ¹¹ R ¹² , R ⁴ and R ¹¹ may be combined with each other to form a 5-7 membered heterocyclic ring (the 5-7 membered member) The heterocycle may have one or more substituents selected from group D),
When X is CR ⁴ R ⁵ and Y is OR ¹³ , R ⁴ and R ¹³ may be bonded to each other to form a 5-7 membered hetero ring (the 5-7 membered hetero ring) The ring may have one or more substituents selected from group D),
When X is NR ⁶ and Y is CR ⁸ R ⁹ R ¹⁰ , R ⁶ and R ⁸ may be combined with each other to form a 5-7 membered heterocyclic ring (the 5-7 membered member) The heterocycle may have one or more substituents selected from group D),
When X is NR ⁶ and Y is NR ¹¹ R ¹² , R ⁶ and R ¹¹ may be bonded to each other to form a 5- to 7-membered heterocyclic ring (the 5- to 7-membered heterocyclic ring) And may have one or more substituents selected from group D),
When X is NR ⁶ and Y is OR ¹³ , R ⁶ and R ¹³ may be bonded to each other to form a 5-7 membered heterocycle (the 5-7 membered heterocycle is It may have one or more substituents selected from group D).
Group A: C1-C6 alkoxy group optionally having one or more halogen atoms, C1-C6 alkylthio group optionally having one or more halogen atoms, one or more substituents selected from group C A C3-C6 cycloalkyl group which may have, a phenyl group which may have one or more substituents selected from group H, and one or more substituents selected from group H A group consisting of a 5- to 6-membered aromatic heterocyclic group, a halogen atom, a nitro group and a cyano group.
Group B: C1-C6 alkylthio group optionally having one or more halogen atoms, phenyl group optionally having one or more substituents selected from group H, one or more substituents selected from group H A group comprising a 5- to 6-membered aromatic heterocyclic group which may have a group, a halogen atom, a nitro group and a cyano group.
Group C: a group consisting of a halogen atom, a nitro group, and a cyano group.
Group D: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3 optionally having one or more halogen atoms -C6 alkynyloxy group, C1-C6 alkylthio group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, halogen atom, cyano group, And a nitro group.
Group E: C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A C1-C6 alkylthio group which may have one or more substituents, a phenyl group which may have one or more substituents selected from group H, and one or more substituents selected from group H 5-6 membered aromatic heterocyclic group, C1-C6 alkylsulfonyl group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, and halogen A group of atoms.
Group F: C2 to C7 alkylcarbonylamino group optionally having one or more substituents selected from group C, C1 to C6 alkylamino optionally having one or more substituents selected from group C A carbonyl group, a di (C 1 -C 6 alkyl) aminocarbonyl group optionally having one or more substituents selected from group C, a C 1-optionally having one or more substituents selected from group C A C6 alkylsulfonylamino group, a C1-C6 alkylaminosulfonyl group optionally having one or more substituents selected from group C, and one or more substituents optionally selected from group C The group which consists of a C1-C6 alkyl) aminosulfonyl group.
Group G: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3 optionally having one or more halogen atoms -C6 alkynyloxy group, C1-C6 alkylthio group optionally having one or more halogen atoms, C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, halogen atom, and nitro group A group consisting of
Group H: a group consisting of a C1 to C6 alkyl group optionally having one or more halogen atoms, a C1 to C6 alkoxy group optionally having one or more halogen atoms, a halogen atom and a cyano group.
Group I: C1-C6 alkyl group optionally having one or more substituents selected from group C, C3-C6 cycloalkyl group optionally having one or more substituents selected from group C, C3-C6 alkenyloxy group optionally having one or more halogen atoms, C3-C6 alkynyloxy group optionally having one or more halogen atoms, optionally having one or more halogen atoms A group consisting of a C1-C6 alkylthio group, a C1-C6 alkylsulfonyloxy group optionally having one or more halogen atoms, a fluorine atom and a cyano group. ]
A compound represented by A is a single bond and m is 0,
G is a benzene ring or a pyridine ring (the benzene ring and the pyridine ring may have one or more fluorine atoms),
X is a single bond or NR ⁶ ,
Q is an oxygen atom, NH, N-CN, a N-C (O) R ⁷ or ^{N-C (O) OR 7} ,
R ⁷ is a C1-C6 alkyl group,
Y is a C3-C6 cycloalkyl group which may have one or more halogen atoms, a phenyl group which may have one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² ,
R ⁶ is a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is one or more selected from the group consisting of a halogen atom, a C 1 -C 6 alkoxy group, a C 1 -C 6 alkylthio group, a C 3 -C 6 cycloalkyl group and a phenyl group Optionally substituted), C3-C6 alkynyl group optionally having one or more halogen atoms, C3-C6 cycloalkyl group optionally having one or more halogen atoms, phenyl group (The phenyl group may have one or more substituents selected from the group consisting of a halogen atom, a C1-C6 alkyl group or a C1-C6 alkoxy group) or a hydrogen atom,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more halogen atoms, a phenyl group, a hydrogen atom or a halogen atom,
R ¹¹ and R ¹² are each independently a hydrogen atom or a C 1 -C 6 alkyl group,
The compound according to claim 1, wherein A is bonded on the benzene ring or pyridine ring corresponding to G in the para-position to the oxadiazole ring. A is a single bond and m is 0,
G is a benzene ring or a pyridine ring (the benzene ring and the pyridine ring may have one or more fluorine atoms),
X is a single bond or NR ⁶ ,
Q is an oxygen atom, NH or N-CN,
Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, CR ⁸ R ⁹ R ¹⁰ or NR ¹¹ R ¹² ,
R ⁶ is a C 1 -C 6 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
R ⁸ , R ⁹ and R ¹⁰ each independently represent a C1-C6 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
Each of R ¹¹ and R ¹² independently represents a C 1 -C 6 alkyl group (wherein the C 1 -C 6 alkyl group is a halogen atom, a C 3 -C 6 cycloalkyl group, and a C 1 -C 6 alkoxy group) A C3-C6 alkynyl group optionally having one or more halogen atoms, a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or a hydrogen atom Or R ¹¹ and R ¹² are bonded to each other to form a 3- to 6-membered heterocyclic ring (the 3- to 6-membered heterocyclic ring may have one or more halogen atoms),
A compound according to claim 1 or claim 2. G is a benzene ring which may have one or more fluorine atoms,
Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or CR ⁸ R ⁹ R ¹⁰ ,
A compound according to any of claims 1 to 3. G is a benzene ring which may have one or more fluorine atoms,
X is a single bond,
Y is CR ⁸ R ⁹ R ¹⁰ ,
The compound as described in any one of Claims 1-4. G is a benzene ring which may have one or more fluorine atoms,
X is NR ⁶ ,
n is 2 and
Q is an oxygen atom,
Y is a C3-C6 cycloalkyl group optionally having one or more halogen atoms, or CR ⁸ R ⁹ R ¹⁰ ,
The compound as described in any one of Claims 1-4. G is a benzene ring which may have one or more fluorine atoms,
X is a single bond,
n is 2 and
Q is an oxygen atom,
Y is NR ¹¹ R ¹² ,
A compound according to any of claims 1 to 3. A pest control agent containing the compound according to any one of claims 1 to 7. A method for controlling pests by treating plants or soil with an effective amount of the compound according to any one of claims 1 to 7. Use of a compound according to any of claims 1 to 7 for controlling pests. A compound according to any one of claims 1 to 7 which contains one or more selected from the group consisting of fungicides, insecticides, acaricides, nematocides, plant growth regulators and synergists. Composition.